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Summary	  
Background	  ⎯	  Malignant	  melanoma	  is	  an	  aggressive	  form	  of	  skin	  cancer	  with	  poor	  prognosis.	  Current	  
immunotherapies	   targeting	   melanoma	   using	   the	   patient’s	   immune	   system	   can	   achieve	   long-­‐term	  
melanoma	  clearance	  in	  some	  patients.	  T-­‐cells	  are	  the	  main	  effectors	  of	  this	  anti-­‐melanoma	  immunity	  
and	  can	  specifically	  recognise	  and	   lyse	  tumour	  cells.	  T-­‐cells	  express	  unique	  surface	  T-­‐cell	   receptors	  
(TCR)	  which	  recognise	  tumour-­‐derived	  peptide	  antigens	  bound	  to	  a	  Human	  Leukocyte	  Antigen	  (HLA)	  
molecule	  on	  melanoma	  cells.	  My	  research	  aimed	  at	  studying	  anti-­‐melanoma	  T-­‐cell	   responses	   from	  
both	  a	  molecular	  and	  cellular	  level.	  	  
Results	  ⎯	  Initially,	  I	  analysed	  the	  first	  crystallographic	  structure	  of	  a	  TCR	  in	  complex	  with	  a	  peptide	  
from	   the	  melanoma	   protein	   Glycoprotein(gp)100	   bound	   to	   HLA-­‐A2.	   I	   show	   that	   an	   unanticipated	  
molecular	  switch	  of	  the	  position(P)4-­‐5	  peptide	  bond	  by	  substitution	  of	  the	  P3	  residue	  could	  abrogate	  
recognition	  by	  host	  TCRs.	  I	  then	  dissected	  successful	  T-­‐cell	  responses,	  restricted	  to	  specific	  HLA	  alleles,	  
in	   melanoma	   infiltrates	   from	   two	   complete	   responder	   (CR)	   patients	   after	   Tumour	   Infiltrating	  
Lymphocyte	   (TIL)	   therapy.	   The	   antigen	   specificity	   and	   phenotype	   of	   anti-­‐melanoma	   TILs	   were	  
evaluated,	   and	   a	   panel	   of	   TIL	   clones	   capable	   of	   lysing	   autologous	   melanoma	   cell	   targets	   was	  
characterised.	   Interestingly,	   in	  each	  patient	   studied,	  melanoma-­‐specific	  clonotypes	  detected	   in	   the	  
TILs	  persist	  in	  the	  blood	  after	  TIL	  therapy	  and	  recognise	  T-­‐cell	  epitopes	  shared	  by	  other	  patients	  and	  
other	  tumour	  types.	  	  
Conclusions	  ⎯	  I	  demonstrate	  that	  structural	  studies	  should	  be	  considered	  when	  designing	  improved	  
peptide	  cancer	  vaccines	  as	  even	  single	  substitutions	  in	  residues	  not	  heavily	  engaged	  by	  the	  TCR	  can	  
have	  important,	  unpredictable	  knock-­‐on	  effects	  that	  impair	  T-­‐cell	  recognition.	  Understanding	  the	  key	  
antigen-­‐specificities	  of	   anti-­‐tumour	  TILs	   from	  CR	  patients,	  will	   improve	   the	  efficacy	  of	   T-­‐cell	   based	  
therapies.	   Validated	   antigens	   could	   be	   applied	   as	   biomarkers	   of,	   or	   targets	   for,	   cancer	  
immunotherapy.	  Dominant	  shared	  antigens	  targeted	  in	  CR	  patients	  may	  make	  promising	  candidates	  
for	  therapeutic	  vaccination.	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Abbreviations	  
β2m	  	   	   	   	   	   Beta2-­‐microglobulin	  
Ab	   	   	   	   	   Antibody	  
ACT	  	   	   	   	   	   Adoptive	  cell	  transfer	  
APC	   	   	   	   	   Allophycocyanin	  
ATCC	   	   	   	   	   American-­‐type	  culture	  collection	  
BSA	  	   	   	   	   	   Bovine	  serum	  albumin	  
C	  	   	   	   	   	   Celsius	  
CD	  	   	   	   	   	   Cluster	  of	  differentiation	  
cDNA	  	   	   	   	   	   Complementary	  deoxyribonucleic	  acid	  
CDR	  	   	   	   	   	   Complementarity	  determining	  region	  
CLIP	   	   	   	   	   Class	  II-­‐associated	  Invariant-­‐chain	  Peptide	  
CTL	  	   	   	   	   	   Cytotoxic	  T	  lymphocyte	  
Cr	   	   	   	   	   Chromium	  
CRISPR	   	   	   	   	   Clustered	  Regularly-­‐Interspaced	  Short	  Palindromic	  Repeats	  	  
DAMP	   	   	   	   	   Damage-­‐associated	  molecular	  pattern	  
DC	  	   	   	   	   	   Dendritic	  cell	  
DMEM	  	   	   	   	   	   Dulbecco	  modified	  eagle's	  minimal	  essential	  media	  
DMSO	  	   	   	   	   	   Dimethyl	  sulphoxide	  
DNA	  	   	   	   	   	   Deoxyribonucleic	  acid	  
E.	  coli	   	   	   	   	   Escherichia	  coli	  
EDTA	   	   	   	   	   Ethyl-­‐enediaminetetra	  acetic	  acid	  
ELISA	   	   	   	   	   Enzyme-­‐Linked	  Immunosorbent	  Assay	  
ELISpot	   	   	   	   	   Enzyme-­‐Linked	  ImmunoSpot	  
ER	  	   	   	   	   	   Endoplasmic	  reticulum	  
FACS	  	   	   	   	   	   Fluorescence-­‐activated	  cell	  sorting	  
FBS	  	   	   	   	   	   Foetal	  bovine	  serum	  
FDA	   	   	   	   	   Food	  and	  Drug	  Administration	  
FITC	  	   	   	   	   	   Fluorescein	  isothiocyante	  
FPLC	   	   	   	   	   Fast	  protein	  liquid	  chromatography	  
GEM	   	   	   	   	   Germline-­‐Encoded	  Mycolyl-­‐reactive	  cell	  
GF	   	   	   	   	   Gel	  filtration	  
HLA	  	   	   	   	   	   Human	  Leukocyte	  Antigen	  
HLA-­‐I	   	   	   	   	   Human	  Leukocyte	  Antigen	  class-­‐I	  
HLA-­‐II	   	   	   	   	   Human	  Leukocyte	  Antigen	  class-­‐II	  
HRP	  	   	   	   	   	   Horseradish	  peroxidise	  
IFN	  	   	   	   	   	   Interferon	  
IE	   	   	   	   	   Ion	  exchange	  
IL	  	   	   	   	   	   Interleukin	  
IPTG	   	   	   	   	   Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  
ITAM	   	   	   	   	   Immuno-­‐receptor	  tyrosine-­‐based	  activation	  motif	  
ITC	   	   	   	   	   Isothermal	  Titration	  Calorimetry	  
ITIM	  	   	   	   	   	   Immuno-­‐receptor	  tyrosine-­‐based	  inhibition	  motif	  
IU	   	   	   	   	   International	  Units	  
MAA	   	   	   	   	   Melanoma	  associated	  antigen	  
mAb	  	   	   	   	   	   Monoclonal	  antibody	  
MAIT	   	   	   	   	   Mucosal-­‐Associated	  Invariant	  T-­‐cell	  
MAPK	   	   	   	   	   Mitogen-­‐Activated	  Protein	  Kinase	  
MHC-­‐I	  	   	   	   	   	   Major	  Histocompatibility	  Complex	  class-­‐I	  
MHC-­‐II	  	   	   	   	   	   Major	  Histocompatibility	  Complex	  class-­‐II	  
MIP	   	   	   	   	   Macrophage	  Inflammatory	  Protein	   	  
mRNA	  	   	   	   	   	   Messenger	  Ribonucleic	  Acid	  
N	  	   	   	   	   	   Non-­‐germline	  
	  	   VII	  
NKT	   	   	   	   	   Natural	  Killer	  T-­‐cell	  
NGS	   	   	   	   	   Next	  Generation	  Sequencing	  
PBMC	   	   	   	   	   Peripheral	  blood	  mononuclear	  cell	  
PBS	  	   	   	   	   	   Phosphate	  buffered	  saline	  
PCR	   	   	   	   	   Polymerase	  Chain	  Reaction	  
PE	  	   	   	   	   	   Phycoerythrin	  
PFA	   	   	   	   	   Paraformaldehyde	  
PI	   	   	   	   	   Protease	  inhibitor	  
PKI	   	   	   	   	   Protein	  Kinase	  Inhibitor	  
RACE	   	   	   	   	   Rapid	  Amplification	  of	  cDNA	  Ends	  
RAG	  	   	   	   	   	   Recombinase-­‐Activating	  Gene	  
RNA	  	   	   	   	   	   Ribonucleic	  Acid	  
RT	   	   	   	   	   Reverse	  Transcriptase	  
SDS-­‐PAGE	  	   	   	   	   Sodium	  Dodecyl	  Dulphate-­‐Polyacrylamide	  Gel	  Electrophoresis	  
SPR	   	   	   	   	   Surface	  Plasmon	  Resonance	  
TAA	  	   	   	   	   	   Tumour-­‐Associated	  Antigen	  
TAP	  	   	   	   	   	   Transporter	  associated	  with	  antigen	  processing	  
TAPI	   	   	   	   	   TNF-­‐α	  Protease	  Inhibitor	  
TCR	  	   	   	   	   	   T-­‐cell	  receptor	  
TIL	  	   	   	   	   	   Tumour	  Infiltrating	  Lymphocyte	  
TNF	   	   	   	   	   Tumour	  Necrosis	  Factor	  
VDJ	  	   	   	   	   	   Variable,	  Diversity,	  Joining	  region	  
UV	   	   	   	   	   Ultraviolet	  
	  
	  
All	  units	  of	  measure	  and	  their	  abbreviations	  used	  in	  this	  thesis,	  follow	  the	  International	  System	  of	  Units,	  unless	  
otherwise	  specified.	  	  
Amino	  acids	  are	  designated	  by	  the	  single-­‐letter	  or	  three-­‐letter	  nomenclature.	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   1	  
1   Introduction	  
1.1   Cutaneous	  melanoma	  	  
Cutaneous	  melanoma,	  a	  cancer	  derived	  from	  the	  epidermal	  melanocytes	  of	  the	  skin,	  is	  a	  disease	  of	  
major	  public	  health	  significance.	  Although	  it	  is	  the	  least	  common	  form	  of	  skin	  cancer,	  melanoma	  is	  by	  
far	  the	  most	  lethal	  due	  to	  its	  tendency	  to	  metastasize	  to	  a	  number	  of	  vital	  organs	  (Leung	  et	  al.,	  2012).	  
Global	   estimates	   of	  mortality	   for	  melanoma	   show	   that	   the	   disease	   is	   responsible	   for	   over	   65,000	  
deaths	   annually	   (Berwick	   et	   al.,	   2016).	   Moreover,	   data	   collected	   by	   the	   Cancer	   Statistics	   Review	  
Program	  show	  that	  melanoma	   incidence	  rates	  have	  continued	  to	   increase	  over	   the	  past	  40	  years1.	  
Cutaneous	  melanoma	  incidence	  rates	  vary	  up	  to	  100-­‐fold	  throughout	  different	  populations,	  with	  the	  
highest	   rates	   reported	   in	   Australia	   and	   New	   Zealand	   (60	   cases	   per	   100,000	   inhabitants	   per	   year)	  
(Erdmann	  et	  al.,	  2012).	  In	  Europe,	  the	  rate	  is	  of	  approximately	  20	  cases	  per	  100,000	  per	  year	  (Garbe	  
et	  al.,	  2012).	  Clinically,	  melanoma	  occurs	  most	  commonly	  in	  individuals	  between	  the	  age	  of	  40	  and	  60,	  
but	   it	  can	  affect	  adolescents	  and	  the	  elderly	   (>	  80	  years).	  The	  median	  age	  at	  diagnosis	   is	  57	  years,	  
which	  is	  almost	  one	  decade	  before	  most	  solid	  tumours	  typically	  arise	  (Garbe	  et	  al.,	  2012).	  	  
Excessive	  sun	  exposure	  is	  the	  major	  risk	  factor	  for	  cutaneous	  melanoma	  (Lawrence	  et	  al.,	  2013).	  UV-­‐
mediated	   damage	   induces	   genetic	   transitions	   (C>T	   or	   G>T)	   that	   are	   frequently	   observed	   in	  
melanomas,	  leading	  to	  an	  extremely	  high	  mutation	  rate	  compared	  to	  other	  tumours	  (Alexandrov	  et	  
al.,	   2013;	   Hodis	   et	   al.,	   2012).	   Other	  major	   risk	   factors	   include	   a	   family	   history	   of	   melanoma,	   the	  
presence	  of	  atypical,	  large	  or	  numerous	  moles	  and	  sun	  sensitivity	  	  (Boniol	  et	  al.,	  2012;	  FitzGerald	  et	  
al.,	  1996;	  Gandini	  et	  al.,	  2005).	  
1.1.1   Melanocytes	  and	  melanoma	  progression	  
In	  the	  human	  skin,	  melanocytes	  are	  specialised	  pigmented	  cells	   in	  the	  basal	   layer	  of	  the	  epidermis,	  
where	   they	   form	   melanin-­‐producing	   units	   (Fitzpatrick	   et	   al.,	   1961).	   Mature	   melanocytes	   are	  
characterised	   by	   cytoplasmic	   organelles	   (i.e.	   melanosomes)	   which	   are	   responsible	   of	   melanin	  
synthesis	   (reviewed	   by	   Raposo	   and	   Marks,	   2007).	   The	   close	   network	   between	   neighbouring	  
keratinocytes	  and	  the	  dendritic	  processes	  of	  melanocytes	  is	  essential	  to	  transfer	  newly	  synthesised	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
1	   Howlader	   et	   al.	   (eds).	   SEER	   Cancer	   Statistics	   Review,	   1975-­‐2012,	   National	   Cancer	   Institute.	   Bethesda,	  
MD,	  http://seer.cancer.gov/csr/1975_2012/,	  based	  on	  November	  2014	  SEER	  data	  submission,	  posted	  to	  the	  SEER	  web	  site,	  April	  
2015.	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melanin	  into	  keratinocytes,	  and	  is	  involved	  in	  determining	  skin	  colour	  and	  photo-­‐protection	  (Plonka	  
et	  al.,	  2009).	  	  
The	   transformation	   of	   normal	   melanocytes	   into	   melanoma	   is	   a	   multistep	   process	   during	   which	  
pigmented	  cells	  acquire	  distinct	  phenotypic	  features,	  schematically	  illustrated	  in	  Figure	  1.1.	  The	  first	  
event	  in	  melanoma	  development	  is	  the	  formation	  of	  benign	  nevi	  (commonly	  known	  as	  moles)	  due	  to	  
the	  proliferation	  of	   structurally	  normal	  melanocytes	   (Alonso	  et	  al.,	  2004;	  Clark	  et	  al.,	  1984).	  These	  
primary	  lesions	  are	  flat	  or	  slightly	  raised,	  with	  a	  uniform	  pigmentation.	  The	  next	  step	  is	  the	  aberrant	  
growth	  of	  atypical	  cells	  within	  a	  pre-­‐existing	  nevus	  or	   in	  a	  new	  location.	  Changes	   in	  the	  symmetry,	  
diameter	  and	  colour	  of	  benign	  nevi,	  or	  the	  appearance	  of	  a	  new	  growth,	  are	  all	   important	  warning	  
signs	  of	  atypical	   lesions	  evolving	  (Boland	  and	  Gershenwald,	  2016).	  Due	  to	  the	  presence	  of	  melanin	  





During	  a	  later	  stage	  (i.e.	  radial-­‐growth	  phase),	  melanocytes	  become	  dysplastic	  and	  acquire	  the	  ability	  
to	  proliferate	   in	   small	   intra-­‐epidermal	  nests.	   Lesions	   that	  progress	   to	   the	   following	  vertical-­‐growth	  
phase,	   also	   acquire	   the	   ability	   to	   invade	   the	   dermis	   and	   form	   an	   expansive	   nodule,	  widening	   the	  
papillary	   dermis.	   The	   final	   step	   of	   melanoma	   transformation	   consists	   of	   the	   successful	   spread	   of	  
melanoma	  cells	  into	  other	  areas	  of	  the	  skin	  and/or	  vital	  organs	  (most	  commonly	  the	  brain,	  lungs	  and	  
liver),	  where	  tumour	  cells	  successfully	  proliferate	  and	  establish	  metastatic	  foci	  (Alonso	  et	  al.,	  2004;	  
Clark	  et	  al.,	  1984).	  Of	  note,	  metastatic	  spread	  can	  also	  be	  initiated	  at	  earlier	  stages	  even	  during	  primary	  
lesion	  formation	  (Damsky	  et	  al.,	  2014).	  
	  
	  
Figure	  1.1.	  Schematic	  representation	  of	  melanoma	  progression	  
Normal	  melanocytes	   progressively	   develop	   a	  malignant	   phenotype	   through	   the	   acquisition	   of	   various	   phenotypic	   features.	  
Clinical	  and	  histological	  features	  are	  shown	  in	  the	  insert.	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Cutaneous	   melanoma	   classification	   involves	   distinct	   stages	   that	   take	   into	   account	   the	   depth	   and	  
thickness	  of	  the	  lesion,	  and	  whether	  or	  not	  the	  tumour	  has	  spread	  to	  other	  sites2	  (Balch	  et	  al.,	  2009;	  
Gershenwald	  et	  al.,	  2010).	  Stages	  0	  and	  I	  tumours	  (early	  melanomas)	  are	  mostly	  in	  situ,	  meaning	  that	  
they	  are	  small,	  localised	  and	  non-­‐invasive.	  Stage	  II	  tumours	  (intermediate	  melanomas),	  although	  still	  
localised,	  are	  larger	  (>	  1	  mm),	  have	  penetrated	  below	  the	  surface	  of	  the	  skin	  and	  have	  a	  greater	  mitotic	  
rate.	  Once	  a	  melanoma	  has	  progressed	  beyond	  Stage	  II,	  it	  is	  likely	  to	  have	  spread	  beyond	  the	  original	  
site.	  More	  advanced	  melanomas	  metastasise	  to	  the	  regional	  lymph	  nodes	  (Stage	  III)	  and/or	  to	  other	  
parts	  of	  the	  body	  (Stage	  IV),	  through	  tissues,	  the	  lymphatic	  system	  or	  the	  blood.	  	  
1.1.2   Therapy	  options:	  past,	  present	  and	  future	  
The	  staging	  classification	  described	  above	   is	  also	  used	  to	  determine	  melanoma	  treatment.	  Surgical	  
resection	  is	  still	  considered	  the	  primary	  option	  at	  all	  stages,	  in	  particular	  early	  diagnosed	  benign	  or	  
localised	   melanoma	   lesions	   (Koshenkov	   et	   al.,	   2016).	   On	   the	   other	   hand,	   melanomas	   with	   deep	  
invasion	  or	   that	  have	  spread	   to	   lymph	  nodes	  may	  be	   treated	  with	  chemotherapy	  and/or	   radiation	  
therapy.	   Standard	   chemotherapy	   induces	   objective	   responses	   in	   less	   than	   20%,	   rarely	   leads	   to	  
complete	  remission,	  and	  benefits	  last	  only	  months	  (Howard	  and	  Mehnert,	  2016).	  Despite	  significant	  
breakthroughs	  in	  understanding	  the	  pathobiology	  of	  melanoma,	  which	  has	  resulted	  in	  new	  therapies,	  
metastatic	   (or	  Stage	   IV)	  melanoma,	  until	   recently,	  was	  still	  associated	  with	  a	  poor	  prognosis	  and	  a	  
median	  survival	  of	  6	  to	  12	  months.	  Because	  of	  the	  difficulty	  of	  targeting	  the	  disseminated	  phenotype,	  
advanced	  stages	  of	  the	  disease	  are	  less	  sensitive	  to	  conventional	  therapeutic	  regimens.	  Until	  2010,	  no	  
randomized	  clinical	  trial	  had	  shown	  evidence	  for	  improved	  survival	  for	  those	  with	  Stage	  IV	  melanoma.	  
Before	  then,	  the	  only	  two	  drugs	  that	  had	  been	  approved	  in	  the	  USA	  for	  the	  treatment	  of	  metastatic	  
melanoma	  patients	  were	  the	  chemotherapeutic	  agent	  dacarbazine	  and	  the	  immunomodulator	  IL-­‐2,	  
both	   of	   which	   did	   not	   increase	   the	  median	   overall	   survival.	   Dacarbazine	   treatment	   yielded	   a	   low	  
clinical	  response	  rate	  with	  short	  duration	  (Rosenberg	  et	  al.,	  1999;	  Serrone	  et	  al.,	  2000);	  high-­‐dose	  IL-­‐2	  
resulted	  in	  durable	  complete	  responses	  (6%)	  plus	  severe	  toxicity	  (Atkins	  et	  al.,	  1999;	  Phan	  et	  al.,	  2001).	  	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
2	  Revisions	  to	  the	  Melanoma	  Staging	  System	  were	  published	  in	  the	  7th	  edition	  of	  the	  American	  Joint	  Committee	  on	  Cancer	  (AJCC)	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The	  treatment	  of	  advanced	  melanoma	  has	  changed	  since	  2011	  with	  the	  Food	  and	  Drug	  Administration	  
(FDA)	  approval	  of	  new	  ‘targeted’	  drugs.	  These	  molecules	  were	  designed	  with	  the	  aim	  of	  interfering	  
with	  genetic	  mutations	   in	   specific	  enzymatic	  pathways	   that	  drive	  melanoma	  growth,	  while	   leaving	  
normal	   cells	   intact.	   In	   particular,	   Vemurafenib	   (Zelboraf®),	   Dabrafenib	   (Tafinlar®),	   and	   Trametinib	  
(Mekinist™)	  target	  specific	  mutations	  in	  genes	  encoding	  for	  the	  BRAF	  protein	  (shared	  by	  nearly	  50%	  
of	  melanomas)	  or	  MEK	  protein	  (Huang	  et	  al.,	  2013;	  Solit	  and	  Rosen,	  2011).	  BRAF	  and	  MEK	  are	  both	  
key	   proteins	   in	   the	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	   pathway,	   which	   helps	   promote	  
melanoma	  growth	  when	  defective	  (Davies	  et	  al.,	  2002).	  Even	  though	  BRAF	  inhibitors	  result	  in	  excellent	  
early	  disease	  control	  for	  patients	  with	  BRAF	  V600E/K	  mutations,	  duration	  of	  the	  responses	  is	  limited	  
to	   less	   than	   a	   year	   because	   of	   the	   development	   of	   multiple	  molecular	   mechanisms	   of	   resistance	  
(Emery	  et	  al.,	  2009;	  Nazarian	  et	  al.,	  2010).	  
	  
Against	  this	  background,	  in	  the	  past	  twenty	  years,	  melanoma	  has	  been	  the	  focus	  for	  the	  research	  and	  
application	  of	  new	  treatment	  options,	  with	  the	  help	  of	  European	  guidelines	  that	  recommended	  stage	  
IV	  melanoma	  patients	   to	  be	  preferentially	  enrolled	  on	  new	  trials	   (reviewed	  by	  Garbe	  et	  al.,	  2010).	  
Additional	  characteristics	  of	  cutaneous	  melanoma,	  such	  as	  the	  accessible	  location	  of	   lesions	  on	  the	  
skin	  and	  the	  adaptability	  of	  melanoma	  cells	  to	  in	  vitro	  culture	  conditions,	  have	  contributed	  to	  its	  role	  
as	   a	   ‘model	   tumour’	   for	   cutting-­‐edge	   immunotherapies.	   Immunotherapy	   refers	   to	   all	   those	  
approaches	  that	  aim	  to	  harness	  the	  patient’s	  own	  immune	  system	  to	  eliminate	  autologous	  tumour	  
cells.	  The	  underlying	  concept	  of	  immunotherapy	  is	  that	  tumours	  are	  characterised	  by	  several	  genetic	  
and	  epigenetic	   alterations	  which	  provide	   the	   immune	   system	  with	   a	   set	  of	   antigens	   to	  distinguish	  
transformed	  cells	  from	  their	  healthy	  counterparts	  (Burnet,	  1970;	  Thomas,	  1982).	  Of	  note,	  the	  journal	  
Science	  named	  cancer	  immunotherapy	  its	  2013	  Breakthrough	  of	  the	  Year	  (Couzin-­‐Frankel,	  2013),	  to	  
acknowledge	   this	   rising	   tide	  of	   treatments	   in	  melanoma,	  where	   they	  were	   first	   tested.	  My	  work	   is	  
focused	   around	   the	   current	   spectrum	   of	   immunotherapies	   that	   engage	   T-­‐cells	   to	   fight	  melanoma	  
(discussed	  in	  Section	  1.4);	  therefore,	  I	  will	  first	  introduce	  T-­‐cell	  immunity	  in	  the	  following	  section.	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1.2   αβ	  T-­‐cell	  immunity	  and	  cancer	  
Cells	  from	  both	  the	  innate	  arm	  (dendritic	  cells,	  natural	  killer	  cells,	  macrophages,	  mast	  cells,	  neutrophils	  
and	  myeloid	  derived	  suppressor	  cells)	  and	  the	  adaptive	  arm	  (B	  and	  T	   lymphocytes)	  of	   the	   immune	  
system	  are	  present	  within	  the	  tumour	  and	  interact	  with	  the	  malignant	  cells,	  either	  directly	  or	  through	  
the	  production	  of	  soluble	  factors,	  therefore	  shaping	  tumour	  progression	  and	  its	  response	  to	  therapy	  
(Janeway	   and	  Murphy,	   2011).	   As	  my	  work	   focuses	   on	   the	   adaptive	   immune	   response	   to	   tumours	  
mediated	  by	  T-­‐cells,	  the	  rest	  of	  my	  thesis	  will	  focus	  on	  these	  cells	  in	  particular.	  	  
	  
T-­‐cells	  are	  lymphocytes	  derived	  from	  the	  bone	  marrow	  which	  undergo	  maturation	  within	  the	  thymus.	  
The	   human	   T-­‐cell	   population	   consists	   of	   several	   heterogeneous	   subsets,	   which	   contribute	   to	   the	  
overall	  immune	  surveillance	  with	  distinct	  functions.	  Broadly	  speaking,	  T-­‐cells	  can	  be	  divided	  into	  αβ	  
and	  γδ	  T-­‐cells,	  according	  to	  the	  somatically	  rearranged	  TCR	  heterodimer	  expressed	  on	  their	  cell	  surface	  
(αβ	  or	  γδ	  TCR,	  respectively).	  αβ	  T-­‐cells	  are	  by	  far	  the	  most	  abundant	  and	  best	  characterised	  circulating	  
human	  T-­‐cells.	  Conventionally,	  the	  αβ	  TCR	  is	  ‘MHC-­‐restricted’,	  in	  that	  it	  recognises	  antigen	  in	  the	  form	  
of	   foreign	   (or	   self)	   peptide	   bound	   to	   a	  Major	   Histocompatibility	   Complex	   (MHC)	  molecule	   on	   the	  
surface	  of	  antigen-­‐presenting	  cells.	  However,	  a	  significant	  fraction	  of	  αβ	  T-­‐cells	  that	  can	  reside	  at	  high	  
frequencies	   in	   specific	   human	   tissues,	   does	   not	   fit	   this	   paradigm.	   These	   cells	   include:	   (i)	   invariant	  
natural	  killer	  T	  (NKT)	  cells,	  (ii)	  mucosal-­‐associated	  invariant	  T	  (MAIT)	  cells;	  and	  (iii)	  germline-­‐encoded	  
mycolyl-­‐reactive	  (GEM)	  T-­‐cells	   (reviewed	  by	  Godfrey	  et	  al.,	  2015).	  Collectively,	   these	  αβ	  T-­‐cells	  are	  
named	   'unconventional',	   because	   they	   are	   not	   MHC-­‐restricted	   and	   can	   recognise	   lipids,	   small-­‐
molecule	  metabolites	  or	  specially	  modified	  peptides.	  It	  is	  becoming	  clear	  that	  these	  subsets	  play	  a	  role	  
in	  recognising	  pathogens	  and	  orchestrating	  inflammatory	  responses	  (reviewed	  by	  Liuzzi	  et	  al.,	  2015).	  	  
γδ	  T-­‐cells,	  which	  represent	  1-­‐10%	  of	  circulating	  T-­‐cells,	  are	  also	  considered	  ‘unconventional’	  as	  they	  
are	  not	  MHC-­‐restricted	  and	  do	  not	  appear	  to	  recognise	  peptide	  antigens.	  Several	  studies	   in	  mouse	  
models	  have	  established	  the	  protective	  immune	  surveillance	  and	  antitumor	  activity	  of	  the	  γδ	  lineage	  
(Silva-­‐Santos	  et	  al.,	  2015).	  These	  aspects	  fall	  beyond	  the	  scope	  of	  this	  introduction,	  therefore,	  unless	  
otherwise	  stated,	  I	  will	  provide	  an	  overview	  of	  conventional	  αβ	  T-­‐cell	  immunity.	  	  
	  
αβ	  T-­‐cells	  can	  be	  divided	  into	  CD4+	  T-­‐cells	  and	  CD8+	  T-­‐cells	  and	  then	  further	  fall	  under	  specific	  subsets	  
depending	   on	   their	   effector	   functions.	   Broadly	   speaking,	   CD4+	   T-­‐cells	   are	   involved	   in	   helping	   and	  
regulating	   immune	   responses,	   while	   CD8+	   T-­‐cells	   are	   responsible	   for	   inducing	   targeted	   killing	   of	  
infected	  or	  transformed	  cells	  (Janeway	  and	  Murphy,	  2011).	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1.2.1   Antigen	  presentation	  to	  αβ	  T-­‐cells	  
MHC	  restriction	   is	  critical	  for	  αβ	  T-­‐cell	   function	  because	   it	  enables	  T	   lymphocytes	  to	   identify	  target	  
cells	  expressing	  intracellular,	  foreign	  proteins	  or	  genetic	  mutations	  in	  cancer	  cells	  (Cole	  et	  al.,	  2007;	  
Zinkernagel	  and	  Doherty,	  1997).	  In	  humans,	  MHC	  molecules	  are	  encoded	  within	  the	  Human	  Leukocyte	  
Antigen	   (HLA)	   locus,	  which	   is	   the	  most	  polymorphic	   region	  of	   the	  human	  genome	   (Potts	  and	  Slev,	  
1995).	  The	  HLA	  locus	  is	  located	  on	  the	  short	  arm	  of	  chromosome	  6	  and	  spans	  a	  region	  of	  about	  four	  
million	  bp.	  It	  encodes	  more	  than	  7,000	  allelic	  variants	  across	  the	  population,	  with	  a	  large	  number	  of	  
these	  variants	  present	  at	  appreciable	  frequencies	  (Robinson	  and	  Marsh,	  2003).	  	  
	  
The	  mhc	  genes	  encode	  two	  homologous	  types	  of	  proteins,	  MHC	  molecules	  of	  class-­‐I	  (MHC-­‐I)	  and	  class-­‐
II	  (MHC-­‐II),	  which	  are	  expressed	  differentially	  on	  human	  cells.	  MHC-­‐I	  molecules,	  generated	  from	  the	  
HLA-­‐A,	   -­‐B	   or	   -­‐C	   loci,	   are	   expressed	   by	   all	   nucleated	   cells	   and	   platelets	   (Germain,	   1994).	   However,	  
expression	  levels	  differ	  between	  tissues;	  high	  levels	  can	  be	  found	  in	  lymphocytes	  whereas	  cells	  in	  the	  
brain	  or	  kidney	  express	  lower	  levels.	  MHC-­‐II	  molecules,	  generated	  from	  the	  HLA-­‐DR,	  -­‐DP	  or	  -­‐DQ	  loci,	  
are	  expressed	  in	  a	  tissue-­‐specific	  manner;	  with	  constitutive	  expression	  normally	  restricted	  to	  cells	  of	  
the	  immune	  system	  (i.e.	  activated	  B	  cells,	  macrophages,	  and	  Langerhans-­‐dendritic	  cells	  of	  the	  skin	  and	  
lymphoid	  organs)	  and	  the	  thymus	  epithelium	  (Mendez	  et	  al.,	  2009;	  Radka	  et	  al.,	  1986;	  Reith	  et	  al.,	  
2005).	  Several	  cytokines,	  especially	  interferons,	  are	  known	  to	  upregulate	  MHC-­‐I	  and	  MHC-­‐II	  expression	  
(Steimle	  et	  al.,	  1994).	  MHC-­‐I	  molecules	  present	  peptide	  antigens	  to	  CD8+	  cytotoxic	  T-­‐cells,	  whereas	  
MHC-­‐II	  molecules	  present	  peptides	  to	  CD4+	  helper	  T-­‐cells.	  
1.2.1.1   MHC	  structure	  
MHC-­‐I	  molecules	   consist	   of	   two	   polypeptide	   chains:	   a	   highly-­‐variable	   44	   kDa	  membrane-­‐spanning	  
heavy	  chain	  associated	  with	  a	  conserved	  12	  kDa	  β2	  microglobulin	  (β2m)	  domain	  (Figure	  1.2).	  The	  heavy	  
chain	   is	   composed	   of	   three	   domains	   named	  α1,	   α2	  and	   α3.	  Only	   the	  membrane-­‐distal	   α1	  and	   α1	  
domains	  are	  polymorphic;	  these	  form	  the	  antigen-­‐binding	  grove,	  a	  group	  of	  eight	  β-­‐strands	  supporting	  
two	   α-­‐helices.	   The	   closed-­‐end	   conformation	   of	   the	   α1α2	   binding	   groove	   restricts	   the	   length	   of	  
peptides	  presented	   to	  8-­‐13	  amino	  acids.	  Most	  commonly,	  MHC-­‐I	  accommodates	  a	  9mer	  or	  10mer	  
peptide	  (Bouvier	  and	  Wiley,	  1994;	  Rammensee	  et	  al.,	  1995;	  Rudolph	  et	  al.,	  2006).	  It	  is	  known,	  however,	  
that	  longer	  peptides	  can	  also	  bind	  MHC-­‐I	  (Burrows	  et	  al.,	  2008;	  Probst-­‐Kepper	  et	  al.,	  2001);	  these	  will	  
be	  fixed	  at	  both	  termini	  and,	  as	  a	  result,	  adopt	  a	  bulging	  conformation	  out	  of	  the	  cleft	  (Speir	  et	  al.,	  
2001).	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MHC-­‐II	  are	  polypeptides	  of	  approximately	  35	  kDa,	   formed	  by	  an	  α-­‐	  and	  β-­‐chain,	  both	  of	  which	  are	  
anchored	   to	   the	  plasma	  membrane.	  Each	   chain	   folds	   into	  a	  membrane-­‐distal	  polymorphic	  domain	  
followed	   by	   an	   Ig-­‐like	   domain	   (Rudolph	   et	   al.,	   2006;	   Stern	   and	   Wiley,	   1994).	   Despite	   structural	  
similarities,	   the	   two	   MHC	   classes	   present	   peptides	   in	   a	   distinct	   manner	   that	   depends	   on	   the	  
composition	  of	  their	  binding	  groove	  (Figure	  1.2).	  Unlike	  MHC-­‐I,	   the	  α1β1	  binding	  groove	  of	  MHC-­‐II	  
molecules	  is	  characterised	  by	  an	  open-­‐end	  conformation,	  allowing	  longer	  peptides	  to	  bind	  (Lippolis	  et	  
al.,	   2002;	   Stern	   and	   Wiley,	   1994).	   The	   9mer	   peptide	   core	   contains	   the	   motif	   for	   binding	   to	   the	  
particular	   MHC-­‐II	   heterodimer,	   but	   eluted	   and	   sequenced	   peptides	   reveal	   families	   of	   processed	  
peptides	  12–20	  aa	  (namely,	  ‘nested’	  peptide	  sets)	  that	  share	  the	  core	  binding	  region	  (Carson	  et	  al.,	  
1997;	  Holland	  et	  al.,	  2013;	  Rudolph	  et	  al.,	  2006).	  The	  peptide	  flanking	  regions	  (i.e.	  the	  amino	  acids	  
outside	  of	  the	  peptide	  core)	  can	  also	  interact	  with	  the	  MHC-­‐II	  and	  influence	  peptide	  stability	  (Godkin	  
et	  al.,	  1997).	  It	  is	  becoming	  increasingly	  clear	  that	  these	  regions	  may	  have	  a	  more	  specific	  role	  in	  T-­‐cell	  




Figure	  1.2.	  Antigen	  presentation	  by	  MHC	  class-­‐I	  and	  MHC	  class-­‐II	  molecules	  
Combined	  ribbon	  and	  surface	  representation	  (blue)	  of	  the	  human	  MHC-­‐I	  molecule	  (PDB-­‐code:	  4WJ5)	  and	  MHC-­‐II	  molecule	  (PDB-­‐
code:	  4IS6)	  peptide	  binding	  groove.	  The	  peptide	  is	  shown	  in	  pink	  sticks.	  Schematic	  representations	  of	  MHC	  class-­‐I	  and	  class-­‐II	  
domains	  are	  also	  shown.	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1.2.1.2   Antigen	  processing	  
Two	  distinct	  intracellular	  pathways	  deliver	  the	  peptide	  ligands	  that	  are	  presented	  on	  MHC-­‐I	  or	  MHC-­‐II	  
molecules	  at	  the	  cell	  surface.	  Intracellular	  self	  and	  foreign	  peptides	  presented	  by	  MHC-­‐I	  are	  produced	  
from	  the	  degradation	  of	  intracellular	  proteins	  by	  the	  proteasome,	  a	  large	  proteolytic	  complex	  in	  the	  
cytosol	  (Kloetzel,	  2004;	  Vigneron	  and	  Van	  den	  Eynde,	  2014).	  Most	  cells	  in	  the	  steady	  state	  contain	  a	  
standard	   proteasome	  which	   includes	   constitutive	   catalytic	   subunits	   (β1,	   β2,	   and	   β5).	   In	   lymphoid	  
tissues	   and	   under	   inflammatory	   condition,	   the	   proteasome	   catalytic	   machinery	   is	   replaced	   by	  
inducible	   subunits	   (β1i,	   β2i,	   and	   β5i)	   which	   have	   different	   cleaving	   specificities	   (Aki	   et	   al.,	   1994;	  
Macagno	  et	  al.,	  1999).	  In	  addition,	  some	  tumour	  tissues	  process	  peptide	  antigens	  exclusively	  through	  
intermediate	  proteasomes	  made	  of	  a	  mixed	  assortment	  of	  catalytic	  subunits	  (Guillaume	  et	  al.,	  2010).	  
Peptide	  precursors	   produced	  by	   the	  proteasome	   can	  be	   further	   trimmed	   to	   an	  optimal	   length	   for	  
MHC-­‐I	   presentation	   by	   other	   peptidases,	   mainly	   in	   the	   ER	   by	   the	   endoplasmic	   reticulum	  
aminopeptidase	  ERAP1	  (Hammer	  et	  al.,	  2007;	  Serwold	  et	  al.,	  2002).	  Peptides	  are	  translocated	  to	  the	  
ER	  lumen	  by	  a	  transporter	  associated	  with	  antigen	  processing	  (TAP).	  In	  the	  ER,	  the	  assembly	  of	  a	  stable	  
pMHC	   complex	   is	   assisted	   by	   chaperone	   proteins.	   This	  MHC-­‐I	   complex	   finally	   exits	   the	   ER	   via	   the	  
constitutive	  secretory	  pathway	  to	  the	  cell	  surface	  for	  presentation	  (Harding	  and	  Unanue,	  1990;	  Pamer	  
and	  Cresswell,	  1998).	  	  
	  
MHC-­‐II	  molecules	  generally	  bind	  peptides	  generated	  by	   lysosomal	  proteolysis	   in	   the	  endocytic	  and	  
phagocytic	   pathways	   (Lechler	   et	   al.,	   1996;	   Théry	   et	   al.,	   1998).	   During	   their	   maturation,	   MHC-­‐II	  
molecules	   are	   prevented	   from	   binding	   to	   endogenous	   antigens	   in	   the	   ER	   by	   associating	   with	   an	  
invariant	  chain	  (Ii).	  MHC	  II–Ii	  complexes	  translocate	  through	  the	  Golgi	  to	  the	  MIIC/CIIV	  compartment	  
where	  the	  invariant	  chain	  is	  degraded	  to	  CLIP	  (Class	  II-­‐associated	  Invariant-­‐chain	  Peptide)	  (Riberdy	  et	  
al.,	   1992).	   Finally,	   the	   CLIP	   peptides	   is	   removed	   from	   the	  MHC-­‐II	   complex	   and	   exchanged	   for	   the	  
antigenic	  peptide	  which	  in	  presented	  on	  the	  cell	  surface. However,	  both	  MHC-­‐I	  and	  MHC-­‐II	  can	  present	  
peptides	  generated	  from	  endogenous	  and	  exogenous	  antigens.	  For	  example,	  MHC-­‐I	  can	  bind	  peptides	  
derived	   from	   exogenous	   proteins	   that	   have	   been	   internalised	   by	   endocytosis	   or	   phagocytosis,	   a	  
process	  known	  as	  ‘cross-­‐presentation’	  (reviewed	  by	  Heath	  and	  Carbone,	  2001).	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1.2.2   T-­‐cell	  receptor	  (TCR)	  
The	  αβTCR	  is	  a	  disulphide-­‐linked	  heterodimer	  consisting	  of	  an	  α-­‐	  and	  β-­‐chain	  (Figure	  1.3A).	  The	  two	  
chains	  are	  composed	  of	  an	  Ig-­‐like	  variable	  and	  constant	  domains,	  each	  with	  an	  intra-­‐chain	  disulphide	  
bond,	  joined	  by	  a	  hinge	  region	  (Chothia	  et	  al.,	  1988;	  Rudolph	  et	  al.,	  2006).	  The	  constant	  domains	  are	  
N-­‐terminal	  to	  the	  transmembrane	  region,	  while	  the	  hypervariable	   loops	  from	  the	  variable	  domains	  
(Vα	  and	  Vβ)	  are	  distal	  from	  the	  cell	  surface.	  The	  TCR	  binds	  the	  peptide-­‐MHC	  via	  six	  complementarity-­‐
determining	  regions	  (CDR)	  loops,	  three	  from	  the	  Vα	  domain	  and	  three	  from	  Vβ	  (Rudolph	  et	  al.,	  2006)	  
(Figure	  1.3B).	  CDR1	  and	  CDR2	  are	  germline-­‐encoded,	  while	  the	  hypervariable	  CDR3	  region	  consists	  of	  
both	  germline	  and	  non-­‐germline-­‐encoded	  segments	  (Chothia	  et	  al.,	  1988).	  
	  
X-­‐ray	  crystallographic	  studies	  of	  TCR–pMHC	  complexes	  (in	  their	  bound	  and/or	  free	  state)	  published	  to	  
date,	   show	   similarities	   in	   the	   overall	   binding	  mode	   of	   the	   TCR,	   independently	   of	  MHC-­‐restriction	  
(reviewed	  by	  Gras	  et	  al.,	  2012;	  Rudolph	  et	  al.,	  2006).	  Nevertheless,	  as	  the	  number	  of	  TCR	  structures	  
increases,	  it	  is	  now	  accepted	  that	  TCR-­‐peptide-­‐MHC	  interactions	  are	  not	  rigidly	  conserved	  but	  allow	  
for	  flexibility.	  TCRs	  are	  indeed	  intrinsically	  flexible	  and	  can	  undergo	  large	  conformational	  changes	  in	  
order	   to	  bind	   their	   ligands	   (Borbulevych	  et	  al.,	  2009).	  Apart	   from	  structural	   features	   (Garcia	  et	  al.,	  
2009;	   Marrack	   et	   al.,	   2008),	   other	   characteristics	   of	   the	   TCR-­‐pMHC	   interaction	   can	   be	   analysed,	  
including	   thermodynamic	  properties	   (Krogsgaard	  et	  al.,	   2003;	  Willcox	  et	   al.,	   1999),	   kinetic	  on-­‐/off-­‐
rates	  and	  affinity	  (Aleksic	  et	  al.,	  2012;	  Bridgeman	  et	  al.,	  2011).	   Interestingly,	  compared	  to	  antibody	  
recognition,	   the	   TCR-­‐pMHC	   interaction	   is	   of	   low	   affinity,	   with	   a	   dissociation	   constant	   in	   the	   low	  
micromolar	  range	  (van	  der	  Merwe	  and	  Davis,	  2003),	  and	  is	  characterised	  by	  slow	  association	  rates	  and	  




Figure	  1.3.	  The	  αβ	  TCR	  structure	  and	  CDR	  loops	  
A)	  MHC	  (purple),	  TCR	  (blue)	  and	  peptide	  (pink)	  structure	  schematic	  representation.	  Co-­‐receptor	  CD8	  binds	  the	  α3	  domain	  of	  
MHC	  class-­‐I,	  while	  CD4	  binds	   the	  β2	  domain	  of	  MHC-­‐class	   II.	   (B)	   Ribbon	  model	  of	   an	  αβ	  T-­‐cell	   receptor	   (TCR)	   showing	   the	  
positions	  of	  the	  six	  variable	  complementarity-­‐determining	  region	  (CDR)	  loops	  (PDB-­‐code:	  4QOK).	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1.2.3   Generation	  of	  diversity	  
Approximately	  4x1011	  T-­‐cells	  circulate	  in	  the	  adult	  human	  body.	  Many	  different	  TCRs	  are	  generated	  by	  
genetic	  recombination	  during	  T-­‐cell	  development,	  such	  that	  each	  T-­‐cell	  generally	  expresses	  a	  single	  
type	  of	  TCR	  (Janeway	  and	  Murphy,	  2011).	  The	  set	  of	  cells	  with	  a	  same	  TCR	  defines	  a	  T-­‐cell	  clonotype,	  
and	  the	  set	  of	  T-­‐cells	  in	  the	  body	  can	  be	  thought	  of	  as	  a	  repertoire	  of	  clonotypes.	  αβTCR	  diversification	  
mainly	   occurs	   in	   the	   thymus	   by	   stochastic	   V(D)J	   recombination	   of	   non-­‐contiguous	   gene	   segments	  
(Davis	   and	   Bjorkman,	   1988;	   Yui	   and	   Rothenberg,	   2014).	   Figure	   1.4A	   shows	   the	   gene	   segment	  
composition	  for	  both	  the	  α-­‐chain	  and	  β-­‐chain	  locus.	  During	  thymocyte	  development	  in	  the	  thymus,	  
the	  variable	  domains	  of	  tcra	  and	  tcrb	  genes	  are	  assembled	  following	  rearrangement	  of	  the	  variable	  
(V),	  diversity	  (D),	  and	  joining	  (J)	  gene	  segments	  by	  a	  multistep	  process	  called	  V(D)J	  recombination.	  The	  
enzyme	  pair	  RAG1	  and	  RAG2	  selectively	  targets	  recombination	  signal	  sequences	  that	  flank	  the	  V,	  D,	  
and	   J	   segments	   (Oettinger	  et	   al.,	   1990;	   Schatz	  et	   al.,	   1989).	  V(D)J	   recombination	  events	   first	  bring	  
together	  one	  of	  many	  V	  segments	  and	  a	  J	  segment	  to	  form	  the	  N-­‐terminal	  variable	  domain	  of	  the	  TCR	  
(Tonegawa,	  1983);	  an	  additional	  D	  segment	   is	   included	   in	   the	  case	  of	   the	  TCR	  β-­‐chain	   (Born	  et	  al.,	  
1985).	  	  The	  C	  gene	  contains	  separate	  exons	  encoding	  for	  the	  constant	  and	  hinge	  domains,	  and	  a	  single	  
exon	   for	   the	   transmembrane	   and	   cytoplasmic	   regions.	   The	   V(D)J	   process	   is	   such	   that	   TCR	  CDR1α,	  
CDR1β,	  CDR2α	  and	  CDR2β	  loops	  are	  entirely	  encoded	  by	  germline	  DNA	  segments.	  	  
In	   contrast,	   the	  CDR3	   loops	   are	   generated	   from	   the	   joining	  of	   recombined	  V,	   (D)	   and	   J	   segments.	  
Joining	  at	  these	  sites	  is	  imprecise	  and	  results	  in	  the	  CDR3	  loop	  hyper	  variability,	  in	  that	  template	  and	  
non-­‐template	   nucleotides	   can	   be	   randomly	   added	   and/or	   deleted	   by	   the	   DNA-­‐repair	   machinery	  
(Figure	  1.4B).	  Therefore,	  TCR	  diversity	  can	  be	  mainly	  attributed	  to	  the	  pairing	  of	  different	  TCR-­‐α	  and	  -­‐
β	  chains	  (i.e.	  combinatorial	  diversity),	  and	  is	  further	  enhanced	  by	  imprecise	  joining	  of	  coding	  nicked	  
gene	  segments	  (i.e.	  junctional	  diversity).	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Figure	  1.4.	  Human	  TCR	  α-­‐	  and	  β-­‐chain	  gene	  rearrangement	  and	  expression	  
(A)	  The	  germline	  organisation	  of	  the	  human	  TCRα	  locus	  (chromosome	  14)	  and	  TCRβ	  locus	  (chromosome	  7)	  is	  shown	  in	  the	  top	  
panel.	  The	  TCRα-­‐	  and	  β-­‐chain	  genes	  are	  composed	  of	  discrete	  segments	  that	  are	  joined	  by	  somatic	  recombination.	  The	  TCRα	  
locus	  consists	  of	  70–80	  Vα	  gene	  segments,	  each	  preceded	  by	  an	  exon	  encoding	  the	  leader	  sequence	  (L),	  a	  cluster	  of	  61	  Jα	  gene	  
segments,	  followed	  by	  a	  single	  C	  gene.	  The	  TCRβ	  locus	  consists	  of	  a	  cluster	  of	  52	  functional	  Vβ	  gene	  segments	  and	  two	  separate	  
clusters	  each	  containing	  a	  single	  D	  gene	  segment;	  6-­‐7	  J	  gene	  segments	  and	  a	  single	  C	  gene	  segment.	  Rearrangement	  of	  V(D)J	  
gene	  segments	  generates	  a	  functional	  V-­‐region	  exon	  for	  both	  chains,	  that	  is	  transcribed	  and	  spliced	  to	  join	  to	  the	  corresponding	  
C-­‐region.	  The	  resulting	  mature	  mRNA	  is	  translated	  to	  the	  T-­‐cell	  receptor	  α-­‐	  and	  β-­‐chain.	  (B)	  V(D)J	  recombination	  produces	  three	  
TCR	  CDR	  loops.	  CDR1	  and	  CDR2	  are	  entirely	  germline-­‐encoded	  and	  lie	  in	  the	  V	  region.	  The	  hypervariable	  CDR3	  loop	  is	  formed	  
at	  the	  junction	  between	  recombined	  V(D)J	  segments.	  Combinatorial	  diversity	  is	  further	  enhanced	  by	  addition	  and	  deletion	  of	  
nucleotides	  (N)	  at	  the	  junctions	  between	  segments.	  
	  
	  
The	   theoretical	   number	   of	   different	   αβ	   TCRs	   that	   could	   be	   generated,	   in	   principle,	   by	   the	   V(D)J	  
recombination	   system	   alone	   is	   around	   1018	   (Davis	   and	   Bjorkman,	   1988;	   Zarnitsyna	   et	   al.,	   2013).	  
However,	  these	  estimates	  are	   limited	  because	  each	   individual	  can	  only	  possess	  a	  smaller	  subset	  of	  
possible	  TCRs	  at	  one	  time,	  ∼1011	  at	  most.	  This	  number	  is	  sufficient	  to	  recognise	  at	  least	  one	  antigen	  
from	  any	  given	  pathogen.	  This	  also	  implies	  that	  TCRs	  must	  be	  able	  to	  respond	  to	  distinct	  pMHC	  ligands	  
(Mason,	  1998);	   the	  notion	  of	  TCR	   ‘cross-­‐reactivity’	   is	   consistent	  with	  a	   large	  body	  of	  experimental	  
evidence	   which	   includes	   studies	   of	   T-­‐cell	   clones	   responding	   to	   several	   distinct	   peptide	   antigens	  
(Sewell,	  2012;	  Wooldridge	  et	  al.,	  2012).	  Given	  the	  excess	  thymic	  TCR	  diversity	  described	  above,	  one	  
would	   also	   expect	   that	   individuals	   hardly	   ever	   share	   the	   same	   TCR	   recombination.	   Nevertheless,	  
several	  studies	  have	  shown	  that	   ‘public'	  TCRs	   (i.e.	   identical	  clonotypes)	   to	  defined	  antigens	  can	  be	  
found	  in	  different	  MHC-­‐matched	  individuals	  (Li	  et	  al.,	  2012;	  Venturi	  et	  al.,	  2008).	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1.2.4   T-­‐cell	  development	  and	  selection	  
In	  human	  adults,	  thymocyte	  development	  begins	  with	  the	  migration	  of	  multipotent	  precursors	  from	  
the	  bone	  marrow	  into	  the	  cortico-­‐medullary	  junction	  of	  the	  thymus	  via	  chemotactic	  attraction	  (Haynes	  
and	  Heinly,	  1995;	  Lind	  et	  al.,	  2001).	  T-­‐cell	  development	  and	  repertoire	  selection	  is	  a	  highly	  regulated	  
multi-­‐step	  process	   that	   requires	   the	   relocation	  of	   thymocytes	   (i.e.	  developing	   lymphocytes)	  within	  
microenvironments	  in	  the	  thymus	  (Bevan,	  1977;	  Miller,	  1961).	  The	  thymic	  stroma	  not	  only	  structurally	  
supports	  migrating	  thymocytes	  but	  also	  provides	  guidance	  through	  chemokines	  produced	  by	  distinct	  
subsets	   of	   cells	   in	   the	   stroma	   (Takahama,	   2006).	   Following	   their	   entry	   into	   the	   thymus,	   lymphoid	  
progenitor	   cells	   gradually	   lose	   multi-­‐potency	   which	   defines	   their	   T-­‐cell	   lineage	   commitment	  
(Rothenberg	  et	   al.,	   2008).	   The	  development	  of	   thymocytes	   is	   commonly	  divided	   into	  major	   stages	  
based	  on	  the	  expression	  of	  surface	  markers:	  the	  CD4-­‐	  CD8-­‐	  double	  negative	  (DN)	  stage;	  the	  CD4+	  CD8+	  
double	  positive	  (DP)	  stage	  and	  the	  CD4+	  CD8-­‐	  or	  CD8+	  CD4-­‐	  single	  positive	  (SP)	  stage	  (Figure	  1.5).	  For	  
most	  of	  the	  αβ	  T-­‐cell	  lineage,	  development	  is	  made	  of	  selection	  steps	  that	  are	  MHC-­‐induced	  and	  result	  
in	  the	  complete	  differentiation	  of	  (CD4+	  or	  CD8+)	  SP	  thymocytes	  that	  are	  direct	  precursors	  of	  mature	  





Figure	  1.5.	  Simplified	  diagram	  of	  T-­‐cell	  development	  and	  selection	  	  
On	  the	  basis	  of	  CD4	  and	  CD8	  co-­‐receptor	  surface	  expression,	  several	  stages	  of	  thymocyte	  differentiation	  can	  be	  distinguished.	  
In	  the	  thymus,	  double-­‐negative	  (DN)	  thymocytes	  progress	  to	  the	  double-­‐positive	  (DP)	  stage.	  During	  the	  DP	  to	  single-­‐positive	  
(SP)	  transition,	  the	  T-­‐cell	  repertoire	  is	  formed	  by	  a	  process	  known	  as	  positive	  selection.	  DP	  thymocytes	  that	  express	  a	  potentially	  
harmful	  (autoreactive)	  T-­‐cell	  receptor	  (TCR)	  are	  deleted	  by	  negative	  selection	  at	  this	  stage,	  whereas	  DP	  thymocytes	  that	  express	  
TCRs	  that	  do	  not	  recognize	  self-­‐peptide–MHC	  complexes	  are	  eliminated	  in	  a	  process	  that	  is	  known	  as	  'death	  by	  neglect'	  (not	  
shown).	  Positive	  selection	  correlates	  with	  commitment	  to	  the	  CD4+	  or	  CD8+	  T-­‐cell	  subsets.	  Decision	  checkpoints	  in	  the	  thymus	  
are	  shown	  in	  blue	  in	  the	  bottom	  panel.	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After	   T-­‐cell	   lineage	   commitment,	   multiple	   checkpoints	   during	   thymic	   development	   ensure	   that	  
thymocytes	  expressing	  a	  non-­‐functional	  (or	  autoreactive)	  TCR	  are	  deleted,	  and	  that	  a	  functional	  T-­‐cell	  
repertoire	  is	  generated	  and	  ready	  to	  translocate	  to	  the	  periphery.	  The	  first	  checkpoint	  for	  committed	  
thymocytes,	  known	  as	  β	  selection,	  verifies	  that	  a	  correct	  TCRβ	  gene	  rearrangement	  has	  occurred	  and	  
that	  a	  functional	  receptor	  is	  expressed	  on	  the	  T-­‐cell	  surface.	  β	  selection	  requires	  thymocytes	  to	  signal	  
through	  a	  pre-­‐TCR	  (i.e.	  a	  correctly	  rearranged	  TCR	  β-­‐chain,	  CD3	  chains	  and	  a	  pre-­‐Tα)	  (Boehmer,	  2005;	  
Yamasaki	  et	  al.,	  2006). The	  second	  checkpoint	  verifies	  the	  interaction	  of	  the	  αβTCR	  with	  self-­‐peptide-­‐
MHC	  complexes	  presented	  by	  thymic	  epithelial	  cells	  and	  dendritic	  cells,	  determining	  the	  fate	  of	  the	  
developing	  T-­‐cell	  (Anderson	  et	  al.,	  2000).	  T-­‐cells	  with	  TCRs	  that	  don’t	  bind	  self	  pMHC	  complexes,	  fail	  
to	   transduce	   signals	   required	   for	   survival	   and	  die	  by	  neglect.	   Thymocytes	  bearing	   interacting	  TCRs	  
result	  in	  positive	  selection	  and	  develop	  into	  single	  positive	  CD8+	  or	  CD4+	  T-­‐cells,	  which	  are	  capable	  of	  
recognising	  foreign	  antigens	  presented	  by	  self	  MHC-­‐I	  or	  MHC-­‐II	  molecules,	  respectively	  (Anderson	  et	  
al.,	  1994;	  Hogquist	  et	  al.,	  1994;	  Hu	  et	  al.,	  1997).	  However,	  those	  bearing	  a	  TCR	  that	  binds	  with	  high	  
affinity	  for	  the	  selecting	  pMHC	  ligand	  are	  eliminated	  (negative	  selection)	  through	  apoptotic	  cell	  death	  
(Rammensee	  et	  al.,	  1984).	  However,	  via	  a	  process	  known	  as	  receptor	  editing,	  thymocytes	  with	  a	  high-­‐
affinity	   TCR	   for	   self	   pMHC	   can	   avoid	   clonal	   deletion	   by	   undergoing	   a	   secondary	   TCRα	   gene	  
rearrangement,	   therefore	   changing	   their	   antigen	   specificity	   (McGargill	   et	   al.,	   2000).	   Overall,	   the	  
selection	   process	   in	   the	   thymus,	   known	   as	   ‘central	   tolerance’,	   has	   evolved	   to	   limit	   potential	   self-­‐
reactivity	  of	  the	  final	  T-­‐cell	  repertoire,	  by	  ensuring	  that	  only	  those	  T-­‐cells	  expressing	  a	  TCR	  within	  a	  
narrow	  affinity	  range	  for	  self	  peptide-­‐MHC	  are	  rescued	  from	  clonal	  deletion	  (Alam	  et	  al.,	  1996;	  Ashton-­‐
Rickardt	   and	   Tonegawa,	   1994).	   Although	   central	   tolerance	  mechanisms	   are	   efficient,	   they	   cannot	  
eliminate	  all	  potential	  self-­‐reactive	  T-­‐cells,	  in	  part	  because	  not	  all	  self-­‐antigens	  are	  expressed	  in	  the	  
thymus,	   the	   primary	   site	   of	   T-­‐cell	   development	   (Kyewski	   and	   Derbinski,	   2004).	   Therefore,	   various	  
mechanisms	   operate	   to	   ensure	   that	   self-­‐reactive	   T-­‐cells	   after	   thymic	   output	   become	   functionally	  
unresponsive	  or	  are	  deleted	  by	  apoptosis	  after	  self-­‐antigen	  encounter	  in	  peripheral	  tissues	  (Xing	  and	  
Hogquist,	  2012).	  
1.2.5   The	  production	  of	  effector	  T-­‐cells	  
Once	   completed	   their	  maturation	   in	   the	   thymus,	   naïve	   T-­‐cells	   enter	   the	   periphery	   and	   recirculate	  
throughout	  the	  secondary	  lymphoid	  compartment,	  moving	  between	  lymph	  nodes,	  blood	  and	  spleen	  
(Janeway,	  2011).	  For	  the	  T-­‐cell	  arm	  of	  the	  immune	  system	  to	  lead	  to	  the	  effective	  killing	  of	  tumour	  
cells,	   a	   series	   of	   steps	   must	   be	   initiated	   (schematically	   represented	   in	   Figure	   1.6).	   Signals	   with	  
immunogenic	  potential	  are	  exposed	  at	  the	  cell	  surface	  or	  released	  from	  stressed	  and	  damaged	  tumour	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Figure	  1.6.	  Schematic	  diagram	  of	  a	  successful	  anti-­‐tumour	  T-­‐cell	  immune	  response	  
The	  immune	  surveillance	  of	  cancer	  by	  T-­‐cells	  requires	  local	  uptake	  of	  tumour-­‐specific	  antigen	  followed	  by	  the	  activation	  and	  
expansion	  of	  tumour	  specific	  effector	  T-­‐cells,	  such	  as	  CTLs.	  Each	  step	  is	  described	  above,	  with	  the	  primary	  cell	  types	  involved	  
and	  the	  anatomic	  location	  of	  the	  activity	  listed.	  Adapted	  from	  Chen	  and	  Mellman	  et	  al.,	  2013.	  
	  
	  
Such	   damage-­‐associated	  molecular	   patterns	   (DAMPs)	   include	   a	   large	   range	   of	  molecules,	   such	   as	  
surface	  proteins	   (eg.	  heat	   shock	  proteins),	   secreted	  proteins	   (eg.	  HMGB1),	   as	  wells	  as	  nucleic	  acid	  
degradation	  products	  and	  lipids	  (eg.	  Phosphatidylserine	  residues	  exposed	  on	  the	  outer	   layer	  of	  the	  
plasma	  membrane)	  (reviewed	  by	  Kroemer	  et	  al.,	  2013;	  Li	  et	  al.,	  2003;	  Scaffidi	  et	  al.,	  2002).	  The	  release	  
of	   these	   molecules	   alerts	   the	   immune	   system	   to	   the	   presence	   of	   dying	   tumour	   cells,	   therefor	  
enhancing	  their	   immunogenicity.	  An	   increasing	  number	  of	  DAMPs	  are	  being	  reported	  as	  candidate	  
ligands	  of	  Toll-­‐like	  receptors	  (TLRs),	  in	  particular	  TLR4	  (Fang	  et	  al.,	  2011;	  Apetoh	  et	  al.,	  2007).	  DAMPs	  
can	  bind	   to	   the	  TLR,	  promoting	  an	   inflammatory	   response	  and	  providing	  dendritic	   cells	   (DCs)	  with	  
‘danger	  signals’	  (Fang	  et	  al.,	  2014).	  Overall,	  this	  immunogenic	  form	  of	  cancer	  cell	  death	  contributes	  to	  
the	  triggering	  of	  tumour-­‐specific	  T-­‐cell	  responses	  by	  assisting	  the	  activation	  and	  maturation	  of	  DCs,	  
the	   antigen	   processing	   and	   presentation	   on	   MHC-­‐I	   or	   MHC-­‐II	   molecules	   on	   mature	   DCs	   and,	  
eventually,	  T	  cell	  activation	  (Hernandez	  et	  al.,	  2016).	  	  
T-­‐cell	   activation	   is	   a	   finely	   regulated	  process	   that	   includes	  mobilisation	  of	  Ca2+,	  new	   transcription,	  
release	  of	  pre-­‐processed	  and	  retained	  surface	  receptors,	  internalisation	  of	  surface	  receptors	  and	  the	  
release	  of	  granules	  or	  cytokines	  (reviewed	  by	  Malissen	  et	  al.,	  2014).	  To	  achieve	  maximal	  expansion,	  
CD8+	   T	   cells	   need	   to	   integrate	   multiple	   signals,	   including	   the	   TCR,	   co-­‐stimulatory	   signals,	   and	  
inflammatory	  cytokines	  (Mescher	  et	  al.,	  2006;	  Parish	  and	  Kaech,	  2009).	  Activated	  T-­‐cells	  are	  induced	  
to	  proliferate	   and	  differentiate	   into	   armed	  CD4+	  or	   CD8+	  primed	  T-­‐cells;	   they	   leave	   the	   leave	   the	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lymph	   nodes	   via	   the	   circulation	   and	   are	   recruited	   to	   the	   tumour	   site,	   providing	   that	   the	   vascular	  
endothelium	  expresses	  the	  correct	  homing	  ligands.	  Finally,	  tumour-­‐specific	  T-­‐cells	  bind	  to	  the	  target	  
pMHC	  on	  malignant	  cells,	  and	  are	  able	  of	  clearing	  the	  autologous	  cancer	  cells	  through	  several	  effector	  
mechanisms,	   such	   as	   cell-­‐mediated	   cytotoxicity.	   Lysis	   of	   the	   tumour	   cells	   results	   in	   the	   release	   of	  
further	  tumour-­‐associated	  antigens	  which	  can	  be	  taken	  up	  by	  resident	  dendritic	  cells	  (Mellman	  et	  al.,	  
2011).	  In	  tumour	  patients	  with	  progressing	  disease,	  one	  or	  more	  steps	  described	  above	  fail	  to	  occur	  
correctly.	   For	   example,	   tumour-­‐associated	   antigens	   may	   not	   be	   detected	   because	   of	   a	   down-­‐
regulation	  of	  MHC	  molecules	  on	  tumour	  cells;	  T	  regulatory	  cell	  responses	  may	  be	  elicited	  rather	  than	  
effector	  responses,	  because	  of	  the	  self	  origin	  of	  tumour	  antigens;	  T-­‐cells	  may	  not	  home	  to	  the	  tumour	  
site	  and	  can	  be	  inhibited	  by	  an	  immunosuppressive	  tumour	  microenvironment	  (reviewed	  by	  Joyce	  and	  
Fearon,	  2015;	  Lanitis	  et	  al.,	  2015).	  
	  
1.2.5.1   CD8+	  cytotoxic	  T-­‐cells	  
Traditionally,	  effector	  cytotoxic	  CD8+	  T-­‐cells	  have	  been	  thought	  to	  be	  the	  major	  mediators	  of	  effective	  
anti	  tumour	  T-­‐cell	  responses.	  CD8+	  T-­‐cells	  represent	  a	  population	  of	  cytotoxic	  lymphocytes	  (CTLs)	  that	  
are	  able	  to	  induce	  targeted	  killing	  of	  both	  infected	  and	  malignant	  cells	  (Andersen	  et	  al.,	  2006;	  Henkart,	  
1994).	  They	  can	  contribute	  to	  promote	  tumour	  rejection	  also	  by	  changing	  the	  micro-­‐environment	  of	  
the	  tumour	  cells	  to	  inhibit	  further	  growth	  (Andersen	  et	  al.,	  2006;	  Barry	  and	  Bleackley,	  2002).	  Direct	  
killing	  is	  mediated	  by	  cytolytic	  factors	  that	  are	  compartmentalized	  into	  acidified	  secretory	  lysosomes	  
commonly	  known	  as	  ‘lytic	  granules’.	  Cytolytic	  factors	  include	  perforin	  (a	  toxin	  that	  forms	  pores	  in	  the	  
target	  cell	  plasma	  membrane),	   serine	  proteases	  such	  as	  granzymes	   (in	  particular	  granzyme	  B),	  and	  
chemokines	  (such	  as	  MIP-­‐1α,	  MIP-­‐1β	  and	  RANTES)	  which	  promote	  the	  recruitment	  of	  additional	  cells	  
to	  the	  immune	  response	  (Thiery	  et	  al.,	  2011;	  Voskoboinik	  et	  al.,	  2010).	  Granzymes	  enter	  the	  target	  cell	  
through	  newly	  formed	  pores	  and,	  by	  cleaving	  aspartate	  residues,	  activate	  the	  caspase	  cascade	  which	  
leads	   to	   apoptosis	   of	   the	   target	   tumour	   cell	   (Ewen	   et	   al.,	   2012).	   Advanced	   confocal	   and	   electron	  
microscopy	  have	  provided	  super	  high-­‐resolution	   images	  of	  secreting	  CTLs,	  showing	  how	  these	  cells	  
polarise	  the	  Golgi	  and	  microtubule	  apparatus	  in	  order	  to	  focus	  the	  lytic	  granules	  release	  only	  on	  the	  
point	  of	  contact	  with	  the	  target	  cell,	  therefore	  leaving	  the	  neighbouring	  cells	  intact	  (Ritter	  et	  al.,	  2015). 
CTLs	   can	   also	   secrete	   TNF-­‐α	   family	   members	   (such	   as	   TNF-­‐α,	   FasL	   and	   TRAIL)	   which	   induce	   the	  
multimerisation	  of	  the	  cognate	  receptors	  on	  the	  target	  cell	  and	  induce	  apoptosis	  (Ratner	  and	  Clark,	  
1993).	  IFN-­‐γ	  can	  enhance	  Fas	  levels	  on	  target	  cells,	  thus	  increasing	  the	  sensitivity	  to	  CD8+	  T-­‐cell	  killing	  
(Seliger	  et	  al.,	  2008).	  Whereas	  perforins	  and	  granzymes	  are	  produced	  constitutively	  in	  effector	  cells	  
delivering	   immediate	   cytotoxic	   effect,	   cytokines	   are	   produced	   upon	   relevant	   stimulation	   and	   are	  
released	  on	  a	  time	  scale	  of	  hours	   (Sanderson,	  1976;	  Slifka	  et	  al.,	  1999).	   In	   fact,	  unlike	   lytic	   factors,	  
cytokines	  are	  newly	  produced	  after	  TCR	  stimulation	  by	  either	  upregulation	  of	  gene	  transcription	  or	  
translation	   of	   pre-­‐existing	   mRNA	   transcripts.	   The	   lysosomal-­‐associated	   membrane	   glycoproteins	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(LAMPs),	  CD107a	  and	  CD107b	  are	  also	  transiently	  expressed	  on	  the	  T-­‐cell	  surface	  upon	  degranulation	  
of	  lytic	  granules	  (Betts	  et	  al.,	  2003).	  Finally,	  although	  IL-­‐2	  doesn’t	  have	  a	  direct	  cytolytic	  effect,	  antigen-­‐
specific	  CD8+	  T-­‐cells	  can	  use	  IL-­‐2	  secretion	  as	  an	  autocrine	  growth	  factor	  promoting	  their	  survival	  and	  
further	  proliferation	  after	  second	  antigen	  encounter	  (Cox	  et	  al.,	  2013).	  	  
	  
1.2.5.2   CD4+	  T-­‐cells	  
Although	  CD8+	  T	  cells	  are	   important	  mediators	  of	  anti-­‐tumour	   immunity,	   the	  contribution	  of	  CD4+	  
T	  cells	  has	  also	  been	  appreciated.	  CD4+	  T-­‐cells	  represent	  a	  heterogeneous	  population	  of	  lymphocytes	  
with	  effector	  and	  regulatory	  functions	  (Kim	  and	  Cantor,	  2014).	  Following	  antigen	  recognition,	  naïve	  
CD4+	  T-­‐cells	  have	  the	  potential	  to	  differentiate	  into	  a	  wide	  array	  of	  effector	  T	  helper	  (Th1,	  Th2,	  Th17,	  
Th22	   and	   Tfh)	   and	   regulatory	   cell	   types	   (Tregs),	   capable	   of	   differentially	   orchestrating	   immune	  
responses.	   The	   cytokine	   environment	   and	   the	   induction	   of	   specific	   transcription	   factors	   drive	   the	  
polarisation	  of	  recently	  activated	  CD4+	  T	  cells	  (Jiang	  and	  Dong,	  2013;	  Zhu	  and	  Paul,	  2008).	  	  
	  
CD4+	   T	   cells	   are	   mainly	   known	   for	   their	   ability	   to	   provide	   a	   helper	   function	   to	   tumour-­‐reactive	  
cytotoxic	  and	  memory	  CD8+	  T-­‐cells	  responses	  (Antony	  et	  al.,	  2005;	  Gao	  et	  al.,	  2002;	  Janssen	  et	  al.,	  
2003;	  Nishimura	  et	  al.,	  1999).	  A	  primary	  helper	  mechanism	  involves	  the	  ‘licensing’	  of	  DCs	  to	  induce	  
optimal	   expansion	   and	   activation	   of	   cytotoxic	   CD8+	   T	   cells	   (‘licence	   to	   kill’).	   Licensing	   of	   DCs	   is	  
mediated	   by	   the	   CD40–CD40L	   interaction	   between	   the	   DC	   and	   cognate	   CD4+	   T	   cell,	   respectively	  
(Bennett	  et	  al.,	  1998).	  DCs	  require	  antigen-­‐specific	  CD4+	  T-­‐helper	  cell	   to	  mature	  and	   increase	  their	  
antigen-­‐presenting	  and	  co-­‐stimulatory	  activity.	  Functionally	  mature	  DCs	  can	  subsequently	   induce	  a	  
robust	   CD8+	   effector	   T	   cell	   response,	   with	   both	   the	   CD8+	   and	   CD4+	   T	   cells	   binding	   an	   antigen	  
presented	  by	  the	  same	  DC	  (Bennett	  et	  al.,	  1997).	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1.3   T-­‐cells	  and	  melanoma	  
1.3.1   Melanoma	  cells	  are	  antigenic	  
Proteins	  expressed	  by	  melanoma	  cells	  may	  contain	  one	  or	  more	  peptide	  epitopes	  presented	  by	  MHC	  
molecules	   and	   bound	   by	   autologous	   T-­‐cells	   (Boon	   et	   al.,	   2006).	  Melanoma	  peptide	   antigens	  were	  
among	  the	  first	  tumour-­‐associated	  antigens	  to	  be	  identified	  in	  humans	  (Traversari	  et	  al.,	  1992;	  van	  der	  
Bruggen	  et	  al.,	  1991),	  leading	  to	  a	  wave	  of	  research	  in	  the	  identification	  of	  other	  T-­‐cell	  targets	  which	  
provided	  the	  basis	  for	  antigen-­‐specific	  cancer	   immunotherapy	  (Section	  1.4.1).	  Several	  melanosome	  
antigens,	   including	   tyrosinase	   (Brichard	   et	   al.,	   1993),	   MART-­‐1/Melan-­‐A	   (Kawakami	   et	   al.,	   1994c),	  
gp100	  (Kawakami	  et	  al.,	  1994b),	  TRP1	  (Wang	  et	  al.,	  1995)	  and	  TRP-­‐2	  (Bloom	  et	  al.,	  1997)	  have	  been	  
identiﬁed	  by	  screening	  cDNA	  libraries	  with	  tumour-­‐reactive	  CD8+	  T-­‐cells	  which	  exhibited	  antitumor	  
functions.	  Tumour-­‐associated	  peptide	  antigens	  that	  are	  expressed	  by	  melanoma	  cells	  are	  listed	  in	  an	  
online,	  open-­‐access	  database3,	  which	  is	  regularly	  updated  (Vigneron	  et	  al.,	  2013).	  Depending	  on	  their	  
tissue	   distribution,	   T-­‐cell	   defined	   melanoma	   associated	   antigens	   fall	   into	   the	   broad	   groups	   listed	  
below.	  
1.3.1.1   Differentiation	  antigens	  
The	   first	   group	   of	   tumour	   antigens	   includes	   those	   encoded	   by	   differentiation	   genes.	   After	  
transformation,	  melanoma	  cells	  generally	  continue	  to	  express	  antigens	  that	  are	  characteristic	  of	  their	  
tissue	  site	  of	  origin. Melanocyte	  differentiation	  antigens	  are	  usually	  overexpressed	  by	  most	  melanoma	  
tumours	  but	  are	  also	  expressed	  by	  normal	  melanocytes	  in	  the	  stratum	  basale	  of	  the	  skin,	  in	  the	  retinal	  
pigmented	   epithelium	   in	   the	   eyes,	   and	   in	   the	   inner	   ear,	   where	   they	   are	   associated	  with	  melanin	  
production	   in	   melanosomes	   (Overwijk	   and	   Restifo,	   2000;	   Overwijk	   et	   al.,	   1998).	   Prototypes	   of	  
melanoma	  differentiation	  antigens	  include	  proteins	  such	  as	  Glycoprotein	  (gp)100,	  MART-­‐1/Melan-­‐A,	  
tyrosinase,	  TYRP1	  and	  TYRP2.	  Gp100	  will	  be	  the	  focus	  of	  Chapter	  3.	  
1.3.1.2   Cancer-­‐testis	  antigens	  
MAGE-­‐l,	  MAGE-­‐3,	  BAGE,	  GAGE	  and	  NY-­‐ESO-­‐1	  belong	  to	  a	  second	  group	  of	  tumour-­‐speciﬁc	  antigens	  
(Gillespie	  et	  al.,	  1998;	  Jäger	  et	  al.,	  1998;	  van	  der	  Bruggen	  et	  al.,	  1991;	  1994).	  This	  group	  of	  antigens	  are	  
called	  cancer-­‐testis	  (CT)	  antigens	  because	  of	  their	  predominant	  expression	  in	  many	  tumours	  (including	  
melanomas)	  and	  male	  germline	  cells,	  but	  not	  in	  other	  normal	  adult	  tissues	  (Simpson	  et	  al.,	  2005).	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
3	   http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm (Peptide	   database:	   T	   cell-­‐defined	   tumour	  
antigens.	  Cancer	  Immunology)	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Male	  germline	  cells	  do	  not	  express	  MHC	  molecules	  on	   their	   surface,	  and	  therefore	  do	  not	  express	  
antigens	   that	   can	   be	   recognized	   by	   CT	   antigen-­‐specific	   T-­‐cells.	  Whereas	  melanoma	   differentiation	  
antigens	   are	   expressed	   at	   very	   high	   frequencies	   that	   do	   not	   differ	   between	   early	   and	   late	   stage	  
disease,	  several	  CT	  antigens	  are	  increasingly	  expressed	  with	  disease	  progression	  (Barrow	  et	  al.,	  2006;	  
Hodi,	  2006).	  	  
1.3.1.3   Over-­‐expressed	  antigens	  
In	  contrast	  to	  CT	  antigens,	  which	  have	  the	  potential	   to	  be	  strictly	  tumour-­‐specific,	  a	  third	  group	  of	  
cancer	   antigens,	   namely	   overexpressed	   antigens,	   are	   also	   present	   in	   many	   normal	   cells.	   Survivin	  
(Schmidt	   et	   al.,	   2003),	   PRAME	   (Ikeda	   et	   al.,	   1997)	   and	   telomerase	   (Vonderheide	   et	   al.,	   1999)	   are	  
prototypes	  of	  this	  category.	  	  Overexpressed	  antigens	  are	  heterogeneous	  in	  their	  distribution	  in	  normal	  
tissues	  and	  in	  terms	  of	  their	  biological	  function.	  In	  some	  cases,	  over-­‐expressed	  antigens	  are	  critical	  for	  
cancer	  cell	  survival	  (e.g.	  the	  anti-­‐apoptotic	  activity	  of	  Survivin),	  suggesting	  highly	  stable	  expression	  of	  
these	  antigens	  in	  tumour	  cells.	  Widespread	  expression	  of	  these	  antigens	  and	  the	  essential	  nature	  of	  
such	  gene	  expression	  for	  the	  survival	  of	  malignant	  neoplasms	  has	  made	  them	  particularly	  attractive	  
targets	  for	  immunotherapy.	  
1.3.1.4   Neo-­‐antigens	  
A	   fourth	   group	   of	   tumour-­‐associated	   antigens,	   known	   as	   ‘neo-­‐antigens’,	   has	   recently	   raised	  
considerable	   interest	   in	   the	   scientific	   community	   (McGranahan	   et	   al.,	   2016;	   Ophir	   et	   al.,	   2015;	  
Schumacher	  and	  Schreiber,	  2015).	  Neo-­‐antigens	  result	  from	  the	  large	  number	  of	  somatic	  mutations	  
found	  in	  human	  cancer	  cells	  and	  therefore	  are	  by	  definition	  tumour	  (and	  patient)	  speciﬁc.	  Such	  gene	  
mutations	  can	  produce	  new	  antigenic	  peptides	  by	  changing	  one	  amino	  acid,	  by	  altering	  the	  phase	  of	  
the	   reading	   frame	   or	   by	   extending	   the	   coding	   sequence	   beyond	   the	   normal	   stop	   codon.	  Massive	  
parallel	  sequencing	  can	  now	  reveal	  with	  precision	  the	  mutational	  spectrum	  of	  individual	  tumours	  (i.e.	  
the	   mutanome)	   (Figure	   1.7).	   Most	   human	   melanomas	   have	   a	   mutational	   load	   above	   10	   somatic	  
mutations	  per	  megabase	  (Mb)	  of	  coding	  DNA,	  and	  this	  is	  apparently	  sufficient	  to	  lead	  to	  the	  frequent	  
formation	  of	  neo-­‐antigens	  (Alexandrov	  et	  al.,	  2013;	  Vogelstein	  et	  al.,	  2013).	  Identification	  of	  tumour-­‐
associated	  antigens	  (TAA)	  peptides	  expressed	  by	  human	  melanomas	  provided	  the	  basis	  for	  antigen-­‐
specific	   active	   immunotherapy	   and	   facilitated	   the	   design	   of	   new	   vaccination	   clinical	   trials	   (section	  
1.4.1).	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Figure	  1.7.	  Signatures	  of	  mutational	  processes	  in	  melanoma	  compared	  to	  other	  human	  cancers	  (from	  Alexandrov	  et	  al.,	  2013)	  
Estimate	  of	  the	  neo-­‐antigen	  repertoire	  in	  human	  cancer.	  Data	  depict	  the	  number	  of	  somatic	  mutations	  in	  individual	  tumour	  
types.	  Every	  dot	  represents	  a	  sample	  whereas	  the	  red	  horizontal	  lines	  are	  the	  median	  numbers	  of	  mutations	  in	  the	  respective	  
cancer	  types.	  The	  y	  axis	  (log	  scaled)	  shows	  the	  number	  of	  mutations	  per	  megabase,	  whereas	  the	  different	  cancer	  types	  are	  
ordered	  on	  the	  x	  axis	  based	  on	  their	  median	  numbers	  of	  somatic	  mutations.	  A	  value	  of	  10	  somatic	  mutations	  per	  Mb	  of	  coding	  
DNA	  corresponds	  to	  ~150	  non-­‐synonymous	  mutations	  within	  expressed	  genes.	  
	  
1.3.2   CD8+	  T-­‐cell	  responses	  in	  melanoma	  
A	  number	  of	  studies	  regarding	  the	  role	  of	  the	  immune	  system	  in	  melanoma,	  provide	  evidence	  that	  
CD8+	  T-­‐cells	  can	  naturally	  recognise	  and	  help	  control	  melanoma,	  therefore	  justifying	  the	  use	  of	  T-­‐cell	  
based	   immunotherapies	   in	   the	   clinic.	   First,	   spontaneous	   regression,	   which	   occurs	   in	   13.8-­‐50%	   of	  
primary	  melanomas,	  is	  a	  result	  of	  a	  successful	  immune	  response	  against	  melanoma	  cells	  (Kalialis	  et	  
al.,	  2009),	  with	  infiltration	  of	  CD4+	  and	  CD8+	  T-­‐cells	  observed	  in	  melanomas	  samples	  (Wenzel	  et	  al.,	  
2005).	  	  One	  of	  the	  major	  goals	  was	  to	  demonstrate	  that	  melanoma	  patients	  harbour	  CD8+	  T-­‐cell	  clones	  
that	  could	  selectively	   recognise	  autologous	  melanoma	  cells	   in	  cytotoxicity	  assays	   (Kawakami	  et	  al.,	  
2000;	   Knuth	   et	   al.,	   1984;	   Mukherji	   and	   MacAlister,	   1983).	   These	   studies	   also	   reported	   that	   the	  
frequency	  of	  melanoma-­‐specific	  CTL	  precursors	  was	  higher	  in	  tumour	  infiltrates	  and	  affected	  lymph	  
nodes,	  compared	  to	  the	  circulating	  population	   (Mazzocchi	  et	  al.,	  1994;	  Romero	  et	  al.,	  1998).	  T-­‐cell	  
cloning	  techniques	  (from	  tumour	  tissues,	  draining	  lymph	  nodes	  or	  peripheral	  blood)	  allowed	  further	  
questions	   to	   be	   addressed	   regarding	   the	   effector	   functions	   and	   antigen	   specificity	   of	   melanoma-­‐
reactive	   T-­‐cells.	   Beside	   cytotoxicity,	   melanoma-­‐specific	   CTLs	   are	   known	   to	   produce	   a	   number	   of	  
cytokines	  such	  as	  TNF-­‐α,	  IFN-­‐γ	  and	  IL-­‐2	  (reviewed	  by	  Boon	  et	  al.,	  2006).	  T-­‐cell	  specificity	  is	  not	  always	  
restricted	  to	  autologous	  cell	  lines;	  many	  CD8+	  T-­‐cell	  clones	  recognise	  allogeneic	  cell	  lines,	  supporting	  
the	  notion	  that	  some	  melanoma	  peptides	  may	  represent	  shared	  antigens.	  Overall	  it	  seems	  that	  despite	  
the	  mechanisms	  of	  central	  and	  peripheral	  T-­‐cell	  tolerance	  against	  self-­‐antigens,	  spontaneous	  immune	  
responses	  against	  melanoma	  antigens	  are	  not	  uncommon.	  
The	  best	  studied	  CTL	  melanoma	  peptide	  target	  to	  date	  is	  Melan-­‐A/MART-­‐126−35	  (EAAGIGILTV),	  which	  
is	  recognized	  by	  CD8+	  T-­‐cells	  in	  the	  context	  of	  HLA-­‐A2	  (Romero	  et	  al.,	  2002).	  The	  EAAGIGILTV	  epitope	  
(EAA	  hereafter)	  is	  located	  within	  the	  putative	  transmembrane	  region	  of	  the	  Melan-­‐A	  protein	  (118	  aa),	  






	  	  	  	  	  	  
	   20	  
High	  frequencies	  (0.1%)	  of	  Melan-­‐A-­‐specific	  CD8+	  T-­‐cells	  are	  found	  in	  the	  blood	  and	  in	  invaded	  lymph	  
nodes	   of	  most	   HLA-­‐A2+	  melanoma	   patients	   (Romero	   et	   al.,	   1998).	   In	   particular,	   HLA-­‐A2+	   healthy	  
individuals	  show	  about	  0.07%	  of	  EAA-­‐specific	  CD8+	  T-­‐cells	   in	  their	  blood,	  a	   frequency	  which	   is	   two	  
orders	  higher	  than	  anti-­‐MAGE	  precursors	  (Marincola	  et	  al.,	  1996;	  Romero	  et	  al.,	  2002).	  An	  interesting	  
paper	   suggests	   the	   transcription	   of	   the	   protein	   in	   the	   thymus	   could	   explain	   the	   observed	   high	  
frequency	  of	   circulating	  anti-­‐Melan-­‐A	  T-­‐cells	   (Pinto	  et	   al.,	   2014).	   The	  authors	   show	   that	  medullary	  
thymic	  epithelial	  cells	  lack	  the	  immunodominant	  EAA	  epitope	  because	  they	  express	  a	  truncated	  form	  
of	   the	   Melan-­‐A	   transcript,	   therefore	   precluding	   central	   tolerance	   to	   this	   antigen.	   In	   contrast,	  
melanoma	  cells	  and	  normal	  melanocytes	  almost	  exclusively	  express	  a	  full-­‐length	  Melan-­‐A	  transcript,	  
providing	  the	  HLA-­‐A2	  restricted	  antigen	  for	  efficient	  recognition	  by	  CTLs.	  In	  addition,	  the	  recognition	  
of	  this	  peptide	  by	  germline-­‐encoded	  residues	  within	  the	  CDR1	  region	  of	  the	  TRAV12-­‐1	  gene	  segment,	  
is	  further	  thought	  to	  vastly	  increase	  the	  potential	  to	  generate	  T-­‐cells	  specific	  for	  this	  HLA-­‐A2-­‐restricted,	  
melanoma-­‐derived	  peptide	  (Cole	  et	  al.,	  2009;	  Trautmann	  et	  al.,	  2002;	  Wieckowski	  et	  al.,	  2009).	  
1.3.3   CD4+	  T-­‐cell	  responses	  in	  melanoma	  
Most	  tumour	  cells	  express	  only	  MHC-­‐I	  molecules	  ensuring	  that	  the	  majority	  of	  interest	  has	  focused	  on	  
CD8+	  T-­‐cell	  responses	  in	  cancer	  immunotherapy.	  	  However,	  melanoma	  cells	  commonly	  constitutively	  
express	  MHC-­‐II	  molecules	  de	  novo	  (Altomonte	  et	  al.,	  2003;	  Fossati	  et	  al.,	  1986;	  Mendez	  et	  al.,	  2009).	  
While	  melanocytes	  are	  usually	  MHC-­‐II	  negative,	  class-­‐II	  expression	  appears	  in	  early	  melanoma	  lesions	  
as	  a	  possible	  bystander	  effect	  of	  transformation	  and	  invasion	  (Moretti	  et	  al.,	  1990;	  Ruiter	  et	  al.,	  1984;	  
van	  Vreeswijk	  et	  al.,	  1988).	  MHC-­‐II	  expression	  in	  melanoma	  has	  been	  also	  linked	  to	  patient	  survival	  
(Anichini	  et	  al.,	  2006;	  van	  Duinen	  et	  al.,	  1988;	  Zaloudik	  et	  al.,	  1988).	  Expression	  of	  MHC-­‐II	  by	  melanoma	  
cells	  allows	  direct	  recognition	  by	  tumour-­‐antigen	  specific	  CD4+	  T-­‐cells	  (Donia	  et	  al.,	  2013;	  Friedman	  et	  
al.,	  2012).	  Initial	  studies	  using	  prediction	  algorithms	  identified	  an	  MHC-­‐DR4-­‐restricted	  epitope	  in	  the	  
Melan-­‐A	   protein	   (Zarour	   et	   al.,	   2000).	   Since	   these	   early	   findings,	   several	   other	   MHC-­‐II	   restricted	  
melanoma-­‐associated	  antigens	  have	  been	  characterised	  (Andersen	  et	  al.,	  2012;	  Ayyoub	  et	  al.,	  2010;	  
2005;	   Gnjatic	   et	   al.,	   2003).	   Several	   early	   studies	   demonstrated	   that	   T-­‐cell	   infiltrates	   of	  melanoma	  
lesions	   contained	   not	   only	   CD8+	   T-­‐cells,	   but	   also	   CD4+	   T-­‐cells,	   capable	   of	   recognising	  melanocyte	  
differentiation	  antigens	  (Robbins	  et	  al.,	  2002;	  Topalian	  et	  al.,	  1996).	  While	  direct	  cytotoxicity	  by	  CD4+	  
T-­‐cells	   may	   play	   a	   role	   in	   tumour	   clearance	   (Quezada	   et	   al.,	   2010),	   the	   more	   canonical	   effector	  
mechanism	  of	  producing	  cytokines	  such	  as	  IFN-­‐γ	  or	  TNF-­‐α	  that	  could	  mitigate	  the	  immune-­‐suppressive	  
tumour	  microenvironment	  might	   be	  more	   important	   (Brady	   et	   al.,	   2000;	   Braumüller	   et	   al.,	   2013).	  
Interestingly,	  a	  few	  examples	  of	  clinical	  tumour	  regression	  possibly	  associated	  with	  CD4+	  lymphocytes	  
have	  been	  reported	  (Friedman	  et	  al.,	  2012;	  Hunder	  et	  al.,	  2008).	  Is	  it	  important	  to	  underline	  though	  
that	  CD4+	  T-­‐cells	  can	  also	  downregulate	  immune	  responses	  to	  melanoma	  (Sakaguchi,	  2004).	  CD4+	  TILs	  
with	  a	  regulatory	  T-­‐cell	  phenotype	  have	  been	  isolated	  and	  expanded	  from	  melanoma	  tumours	  (Wang	  
et	  al.,	  2004;	  Wang,	  2006;	  Yao	  et	  al.,	  2012).	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1.4   T-­‐cell	  based	  immunotherapy	  approaches	  for	  metastatic	  melanoma	  
Melanoma	  has	  been	  the	  focus	  of	  extensive	  research	  in	  tumour	  immunotherapies	  for	  several	  decades.	  
Due	  to	  the	  breath	  and	  pace	  of	  development	  of	  this	  field,	  a	  truly	  exhaustive	  review	  of	  all	  this	  literature	  
is	   beyond	   the	   scope	   of	   this	   introduction.	   Here,	   I	   will	   instead	   introduce	   the	   main	   T-­‐cell	   based	  
immunotherapy	  approaches	  that	  are	  relevant	  to	  my	  own	  studies.	  Some	  expansion	  of	  this	  background	  
will	  be	  provided	  in	  the	  introduction	  to	  specific	  results	  chapters.	  In	  this	  respect,	  peptide	  vaccination	  for	  
melanoma	  treatment	  will	  be	  discussed	  in	  Chapter	  3	  while	  Tumour	  Infiltrating	  Lymphocyte	  (TIL)-­‐based	  
immunotherapy	  will	  be	  the	  focus	  of	  Chapters	  4	  and	  5.	  
1.4.1   Improving	  antigenic	  peptide	  vaccines	  
The	   field	   of	   tumour	   vaccination	   comprises	   a	   broad	   array	   of	   approaches	   that	   aim	   to	   generate	   and	  
amplify	   cancer-­‐specific	   immune	   responses.	   Cancer	   vaccines	   include	   full	   length	   proteins,	   short	  
peptides,	   DNA,	   pulsed	   dendritic	   cells,	   viruses,	   whole	   tumour	   cells	   and	   cell	   lysates	   (reviewed	   by	  
Blanchard	  et	   al.,	   2013).	   Peptide	   cancer	   vaccines	   are	   attractive	   compared	   to	  other	   immunotherapy	  
approaches	  because	  they	  have	  low	  production	  costs,	  are	  easy	  to	  use	  as	  an	  ‘off-­‐shelf’	  reagent	  and	  have	  
shown	  low	  toxicities	  in	  preclinical	  settings.	  Following	  the	  molecular	  identification	  of	  a	  large	  collection	  
of	  melanoma-­‐associated	  antigens,	  several	  peptide	  vaccines	  have	  been	  (and	  are	  being)	  used	  for	  the	  
immunisation	  of	  advanced	  melanoma	  patients.	  However,	  although	  cancer	  vaccines	  can	  extend	  survival	  
(by	  months,	  not	  years),	  broad	  reviews	  of	  clinical	  trials	  have	  shown	  that	  objective	  cancer	  regression	  is	  
achieved	  in	  less	  than	  4%	  of	  patients	  (Blanchard	  et	  al.,	  2013;	  Klebanoff	  et	  al.,	  2011;	  Rosenberg	  et	  al.,	  
2004).	  	  
	  
As	  shown	  in	  Figure	  1.8,	  an	  effective	  therapeutic	  peptide	  cancer	  vaccine	  delivers	  a	  target	  antigen	  to	  
both	  MHC-­‐I	   and	  MHC-­‐II	  molecules	   of	   antigen	   presenting	   cells	   at	   the	   site	   of	   intradermal	   injection,	  
promoting	  both	  CD4+	  and	  CD8+	  T-­‐cell	  responses.	  A	  non-­‐specific	  adjuvant	  component	  can	  be	  added	  to	  
activate	  dendritic	  cells	  and	  augment	  vaccine	  potency	  (Melief	  et	  al.,	  2015).	  Immunisation	  with	  peptide	  
epitopes	   can	   be	   quite	   effective	   in	   inducing	   tumour-­‐specific	   T-­‐cells	   that	   can	   be	   detected	   among	  
circulating	  lymphocytes	  of	  vaccinated	  patients	  (Cormier	  et	  al.,	  1997;	  Lee	  et	  al.,	  1999;	  Pittet	  et	  al.,	  2001;	  
Scheibenbogen	  et	  al.,	  2000).	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Figure	  1.8.	  Mechanism	  of	  action	  of	  an	  effective	  peptide	  cancer	  vaccine	  
Adjuvant	  molecules	  in	  the	  vaccine	  preparation	  activate	  dendritic	  cells	  (DCs),	  which	  respond	  by	  up-­‐regulating	  molecules	  needed	  
to	  interact	  with	  T-­‐cells	  in	  the	  lymph	  nodes.	  Activated	  DCs	  present	  antigen	  to	  T-­‐cells;	  if	  the	  T-­‐cell	  recognises	  its	  cognate	  antigen	  
in	  the	  proper	  context,	   it	   is	  activated.	  Upon	  activation,	  CD4+	  T	  cells	  produce	  cytokines	  that	  support	  CD8+	  T-­‐cells	  maturation	  
(Adapted	  from	  (Drake	  et	  al.,	  2014).	  
	  
Melanoma	  vaccination	  clinical	  trials	  have	  frequently	  shown	  that	  the	  detection	  of	  T-­‐cell	  responses	  in	  
patient	  blood	  may	  not	  correlate	  with	  outcome.	  These	  suboptimal	  clinical	  responses	  may	  relate	  to	  the	  
quality	  of	  the	  induced	  T-­‐cell	  response	  (for	  instance,	  TAA	  tolerance	  induced	  by	  a	  sub-­‐optimal	  antigen	  
presentation)	  or	  to	  melanoma	  escape	  mechanisms	  that	  might	  influence	  the	  tumour	  susceptibility	  to	  
treatment	  (Marincola	  et	  al.,	  2000).	  Among	  other	  reasons,	  the	  insufficient	  immune	  response	  to	  control	  
melanoma	  growth	  in	  vivo	  can	  be	  caused	  by	  the	  poor	  immunogenicity	  of	  natural	  epitopes	  expressed	  by	  
tumour	  cells.	  Many	  of	   these	  self-­‐antigens	  are	  expressed	   in	  the	  thymus,	  resulting	   in	  deletion	  of	   the	  
highly	  reactive	  T-­‐cell	  repertoire	  and	  development	  of	  suppressive	  T-­‐regulatory	  cells.	  With	  the	  exception	  
of	  the	   immunodominant	  melanoma	  antigens	  Melan-­‐A	  and	  gp100,	  which	  readily	  activate	  specific	  T-­‐
cells	  in	  vitro	  (Rivoltini	  et	  al.,	  1995)	  and	  in	  vivo	  (Cormier	  et	  al.,	  1997;	  Salgaller	  et	  al.,	  1996),	  generation	  
of	  most	  T-­‐cell	  responses	  requires	  repeated	  in	  vitro	  stimulation	  with	  TAA	  epitopes	  and	  shows	  limited	  
immunogenicity	  when	  used	  as	  vaccines	  for	  melanoma	  patients	  (Marchand	  et	  al.,	  1999;	  Weber	  et	  al.,	  
1999).	  Multiple	   strategies	  have	  been	  designed	  with	   the	  aim	  of	  enhancing	  peptide	   immunogenicity	  
(Berzofsky	  et	  al.,	  2015;	  Tsang	  et	  al.,	  2015).	  One	  approach	   involves	  the	  use	  of	  peptide	  substitutions	  
aimed	  at	   increasing	   the	  affinity	   for	   cognate	  TCRs	  or	  presenting	  MHC	  molecules.	  Such	  peptides	  are	  
referred	  to	  as	  ‘altered	  peptide	  ligands’	  (APL)	  or	  ‘heteroclitic	  peptides’	  (Figure	  1.9).	  	  
	  
Single	   amino	   acid	   modifications	   can	   improve	   the	   peptide	   stability	   in	   the	  MHC	   binding	   groove	   by	  
introducing	  higher	  affinity	  primary	  or	  secondary	  ‘anchor’	  residues	  (Rammensee	  et	  al.,	  1995;	  Ruppert	  
et	  al.,	  1993).	  Another	  strategy	  to	  improve	  immunogenicity	  involves	  modifing	  residues	  of	  the	  peptide	  
that	  protrude	  out	  of	  the	  binding	  groove	  and	  interact	  with	  the	  TCR	  CDR	  loops.	  The	  best-­‐studied	  system	  
in	   this	   respect	   is	   probably	   the	   HLA-­‐A2	   restricted	   immunodominant	   Melan-­‐A/MART-­‐1	   antigen	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Figure	  1.9.	  Examples	  of	  peptide	  enhancement	  strategies	  for	  melanoma	  vaccines	  
(A)	  A	  wild-­‐type	  tumour-­‐associated	  peptide	  antigen	  is	  presented	  on	  a	  MHC	  molecule	  and	  bound	  by	  a	  TCR.	  (B)	  The	  affinity	  for	  
binding	  to	  the	  MHC	  molecule	  can	  be	  increased	  by	  modifying	  the	  anchor	  peptide	  residues	  that	  affect	  the	  interaction	  with	  the	  
MHC	  binding	  groove.	  (C)	  The	  peptide	  affinity	  for	  a	  particular	  TCR	  can	  be	  increased	  by	  modifying	  those	  residues	  that	  interact	  
with	  the	  CDR	  loops	  of	  the	  TCR.	  Schematic	  representation	  of	  TCR	  and	  peptide-­‐MHC	  was	  adapted	  from	  Berzofsky	  et	  al.,	  2001.	  
Amino	  acid	  position	  is	  indicated	  in	  brackets;	  mutations	  are	  designated	  by	  the	  residue	  number	  in	  the	  the	  wild	  type	  sequence	  




The	   anchor-­‐modified	   ‘heteroclitic’	   version	   of	   this	   peptide,	   ELAGIGILTV	   (ELA	   hereafter),	   has	   been	  
shown	   to	   induce	   a	   far	   greater	   expansion	   of	   T-­‐cells	   compared	   to	   the	  wild	   type	   EAA,	  when	  used	   in	  
vaccine	  trials	   (Romero	  et	  al.,	  2002).	   It	  has	  been	  shown	  that	  APLs	  can	  strongly	  stimulate	  T-­‐cells	  and	  
achieve	  more	  potent	   immune	   responses	   than	  native	  peptide	  epitopes.	   It	   is	   critical	   that	   the	  T-­‐cells	  
elicited	  by	   the	   enhanced	   vaccine	   also	   recognise	   the	  wild-­‐type	   sequence	   actually	   expressed	  on	   the	  
melanoma	  cell	  surface.	  This	  was	  the	  main	  caveat	  of	  using	  ELA	  for	  therapeutic	  melanoma	  vaccination;	  
ELA-­‐based	  vaccines	  may	  prime	  T-­‐cells	  that	  do	  not	  optimally	  recognise	  the	  wild	  type	  EAA	  epitope	  (Cole	  
et	  al.,	  2010;	  Madura	  et	  al.,	  2015;	  Speiser	  et	  al.,	  2008).	  Preclinical	  studies	  have	  confirmed	  that,	  with	  
carefully	  design,	  heteroclitic	  peptides	  are	  indeed	  capable	  of	  inducing	  T-­‐cells	  with	  capacity	  of	  tumour	  
cell	  recognition	  and	  killing	  (Ayyoub	  et	  al.,	  2003;	  Parkhurst	  et	  al.,	  1996;	  Rivoltini	  et	  al.,	  1999;	  Speiser	  et	  
al.,	  2005;	  Valmori	  et	  al.,	  1998).	  Overall,	  these	  studies	  highlight	  that	  even	  when	  peptide	  modifications	  
are	   selected	   very	   conservatively	   to	   avoid	   changes	   in	   antigenic	   structure,	   APLs	   may	   prime	   T-­‐cells	  
bearing	  TCRs	  that	  are	  unable	  to	  recognize	  tumour	  cells	  (Clay	  et	  al.,	  1999;	  Pass	  et	  al.,	  1998;	  Tsang	  et	  al.,	  
2015).	  Therefore,	  use	  of	  APLs	  to	  break	  cancer	  tolerance	  requires	  careful	  evaluation	  for	  each	  specific	  
peptide-­‐MHC	   combination	   to	   reduce	   the	   risk	   of	   activating	   T-­‐cells	   that	   do	   not	   recognise	   tumour	  
(Berzofsky	  et	  al.,	  2015;	  Boon	  et	  al.,	  2006).	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1.4.2   Adoptive	  Cell	  Transfer	  (ACT)	  for	  the	  treatment	  of	  metastatic	  melanoma	  
Adoptive	   cell	   transfer	   (ACT)	   lies	   at	   the	   other	   end	   of	   the	   immunotherapy	   spectrum	   from	   peptide	  
vaccines.	  This	  cell-­‐based	  approach	  in	  which	  autologous	  T-­‐cells	  are	  expanded,	  manipulated	  ex	  vivo,	  and	  
then	   re-­‐infused	   into	   the	   patient	   to	   exert	   an	   anti-­‐tumour	   response	   involves	   multiple	   technical	  
challenges.	  
1.4.2.1   Tumour	  Infiltrating	  Lymphocyte	  (TIL)-­‐based	  therapy	  
Tumour	   Infiltrating	   Lymphocytes	   (TILs)	   represent	   a	   heterogeneous	   population	   of	   T-­‐cells	   within	   a	  
tumour	  and	  can	  be	  associated	  with	  killing	  malignant	   cells.	  The	   rationale	  of	  TIL-­‐based	   therapy	   is	   to	  
enhance	  the	  natural	  anti-­‐tumour	  immune	  response	  by	  removing	  cells	  with	  anti-­‐tumour	  potential	  from	  
an	  immunosuppressive	  tumour	  microenvironment,	  to	  an	  in	  vitro	  setting	  where	  autologous	  T-­‐cells	  can	  
be	  expanded	  and	  then	  re-­‐infused.	  TILs	  should	  be	  returned	  in	  high	  enough	  numbers	  to	  allow	  trafficking	  
to	   tumour	   sites	   and	   selective	   killing	   of	   tumour	   targets	   (possibly	   along	  with	   other	   cell	   targets	   that	  
sustain	   the	   tumour,	   such	   as	   vascular	   endothelial	   cells).	   In	   1988	   Rosenberg	   and	   colleagues,	   at	   the	  
Surgery	  Branch	  at	   the	  NIH,	  pioneered	   this	  new	  approach	  by	  publishing	   the	   first	  human	   study	   that	  
showed	   how	   TILs	   could	   induce	   cancer	   regression	   when	   administered	   to	   patients	   with	   metastatic	  
melanoma	  (Rosenberg	  et	  al.,	  1988).	  Since	  then,	  there	  has	  been	  considerable	  effort,	  at	  the	  NIH	  and	  
other	  institutions	  worldwide,	  towards	  the	  improvement	  of	  these	  first	  promising	  results	  by	  modifying	  
both	  the	  TIL	  generation	  and	  selection	  protocols,	  and	  the	  preparative	  regimens	  given	  prior	  to	  ACT	  that	  
allow	  TIL	  to	  engraft.	  
1.4.2.2   TIL	  isolation	  and	  production	  
TIL	  manufacturing	  is	  a	  technically	  complex	  and	  resource-­‐consuming	  process	  which	  needs	  to	  be	  carried	  
out	  following	  cGMP	  compliant	  rules.	  A	  general	  diagram	  of	  TIL	   isolation	  and	  production	   is	  shown	  in	  
Figure	  1.10,	  although	  protocols	  may	  vary	  between	  research	  institutes.	  Tran	  and	  colleagues	  established	  
a	  “Young	  TILs”	  protocol	  that	  shortened	  the	  time	  in	  culture	  and	  eliminated	  the	  step	  of	  screening	  for	  
tumour	  recognition	  (Tran	  et	  al.,	  2008).	  The	  first	  use	  of	  young	  TILs	  for	  patient	  treatment	  was	  reported	  
a	  few	  years	  later,	  resulting	  in	  15	  objective	  responders	  (48%)	  out	  of	  31	  treated	  patients	  (Itzhaki	  et	  al.,	  
2011).	  Other	  groups	  supported	  the	  notion	  that	  ‘young/unselected’	  TILs	  were	  simpler	  and	  more	  reliable	  
than	  selected	  TILs	  (Dudley	  et	  al.,	  2010).	  Svane	  and	  colleagues	  in	  Denmark	  performed	  a	  side-­‐by-­‐side	  
comparison	  of	  ‘standard’	  TIL	  and	  ‘young’	  TIL	  in	  2011	  and	  also	  found	  a	  higher	  expression	  of	  CD27+	  T-­‐
cells	  with	  longer	  telomeres	  (Donia	  et	  al.,	  2012).	  The	  introduction	  of	  the	  bioreactor	  (i.e.	  GMP	  compliant	  
closed	  systems)	  to	  TIL	  manufacture	  has	  allowed	  high-­‐density	  T-­‐cell	  expansions	  by	  more	  than	  5,000-­‐
fold	  at	  considerably	  reduced	  costs	  (Donia	  et	  al.,	  2014b;	  Somerville	  et	  al.,	  2012).	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Currently	  TIL	  therapy	  is	  being	  undertaken	  at	  several	  different	  institutions	  worldwide	  using	  a	  number	  
of	  varied	  protocols	  (Besser	  et	  al.,	  2009;	  Dudley	  et	  al.,	  2010;	  Goff	  et	  al.,	  2010;	  Joseph	  et	  al.,	  2011).	  The	  
use	  of	  ‘Young	  TIL’	  has	  reduced	  the	  time	  from	  tumour	  resection	  to	  TIL	  infusion	  to	  <5	  weeks	  and	  ensured	  





The	  addition	  of	  a	  lymphodepleting	  conditioning	  regimen	  has	  resulted	  in	  considerable	  improvement	  of	  
TIL-­‐based	  ACT.	  Creating	  a	  lymphopenic	  environment	  prior	  to	  TIL	  infusion	  is	  believed	  to	  eliminate	  other	  
lymphocytes	   (i.e.	   immunosuppressive	   regulatory	  T-­‐cells	   and	  myeloid	  derived	   suppressor	   cells)	   that	  
may	  compete	  for	  homeostatic	  cytokines	  IL-­‐7	  and	  IL-­‐15	  (Gattinoni,	  2005).	  Therefore,	  lymphodepletion	  
provides	  both	  a	  physical	  and	  biologic	  “space”	  for	  TILs	  and	  other	  potential	  effectors	  (such	  as	  NK	  cells)	  
to	  proliferate	  and	  survive.	  Total	  body	  irradiation	  contributes	  to	  lymphodepletion	  but	  also	  appears	  to	  
increase	  the	  function	  of	  antigen-­‐presenting	  cells	  by	  activating	  the	  innate	  immune	  system,	  in	  part	  due	  
to	   bacterial	   translocation	   from	   gut	  mucosal	   damage,	   which	   provides	   activation	   signals	   to	   antigen	  
presenting	  cells	  through	  their	  Toll-­‐Like	  Receptors	  (Paulos	  et	  al.,	  2007).	  	  
	  
Figure	  1.10.	  Schematic	  diagram	  of	  TIL	  isolation	  and	  expansion	  for	  ACT	  
Melanoma	  lesions,	  which	  often	  contain	  diverse	  cell	  types,	  can	  be	  surgically	  resected	  and	  fragmented;	  the	  cells	  can	  be	  placed	  in	  
wells	  into	  which	  a	  T-­‐cell	  growth	  factor,	  such	  as	  interleukin-­‐2	  (IL-­‐2),	  is	  added.	  T-­‐cell	  populations	  can	  be	  isolated	  and	  expanded,	  
and	   then	   adoptively	   transferred	   into	   patients.	   Prior	   to	   T-­‐cell	   adoptive	   transfer,	   hosts	   are	   immunodepleted	   by	   either	  
chemotherapy	  alone	  or	  in	  combination	  with	  total-­‐body	  irradiation.	  The	  combination	  of	  a	  lymphodepleting	  preparative	  regimen,	  
adoptive	   cell	   transfer	   and	   a	   T-­‐cell	   growth	   factor	   (such	   as	   IL-­‐2)	   can	   lead	   to	   prolonged	   tumour	   eradication	   in	   patients	  with	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In	  2008,	  Dudley	  et	  al	  presented	  an	  interesting	  analysis	  which	  described	  three	  sequential	  trials	  with	  
increasing	  intensities	  of	  myeloablation	  prior	  to	  TIL	  infusion	  (Dudley	  et	  al.,	  2008).	  Results	  suggest	  that	  
the	  overall	  response	  rates	  and	  complete	  response	  rates	  were	  progressively	  higher	  with	  the	  greater	  
intensity	   of	   lympho-­‐	   and	   myeloablation.	   Building	   on	   this	   success,	   ACT	   with	   tumour	   infiltrating	  
lymphocytes,	  T-­‐cells	  grown	  from	  resected	  metastatic	  tumour	  deposits,	  has	  resulted	  in	  high	  response	  
rates	  and	  reproducible	  complete	  and	  durable	  responses	  in	  metastatic	  melanoma.	  As	  shown	  in	  Table	  
1.1,	  most	  TIL-­‐based	   clinical	   trials	   achieved	  overall	   response	   rates	  and	   complete	   response	   rates	   for	  
metastatic	  melanoma	  were	  around	  50%	  and	  20%	  respectively,	  independent	  of	  the	  cancer	  centre.	  95%	  
of	  complete	  responses	  are	  ongoing,	  all	  at	   least	  with	  5	  years	  of	   follow-­‐up.	   In	  Europe,	  TIL	   therapy	   is	  
currently	   performed	   in	   three	   European	   research	   institutions:	   CCIT,	   Denmark;	   Netherlands	   Cancer	  
Institute–Anthoni	  van	  Leeuwenhoek	  Hospital,	  Amsterdam,	  The	  Netherlands.	  In	  the	  United	  Kingdom,	  
a	   GMP	   compliant	   TIL	   production	   process	   has	   been	   established	   in	  Manchester	   in	   partnership	  with	  




Table	  1.1.	  Treatment	  protocols	  and	  clinical	  results	  in	  TIL-­‐based	  ACT	  trials	  
NMA,	  non	  myeloablative;	  TILs,	  tumour-­‐infiltrating	  lymphocytes;	  TBI.	  Total	  body	  irradiation	  




CR	  rate	   Reference	  
Unselected	  TILs	  +	  high-­‐dose	  
IL-­‐2	  
NCI	   86	   34%	   6%	   (Rosenberg	  et	  al.,	  1994)	  
NMA	  +	  selected	  TILs	  +	  high-­‐
dose	  IL-­‐2	  
NCI	   43	   49%	   12%	   (Dudley,	  2005;	  Rosenberg	  
et	  al.,	  2011)	  
NMA	  +	  	  2-­‐Gy	  TBI	  +	  selected	  
TILs	  +	  high-­‐dose	  IL-­‐2	  
NCI	   25	   52%	   20%	   (Dudley	  et	  al.,	  2008;	  
Rosenberg	  et	  al.,	  2011)	  
NMA	  +	  	  12-­‐Gy	  TBI	  +	  selected	  
TILs	  +	  high-­‐dose	  IL-­‐2	  
NCI	   25	   72%	   40%	   (Dudley	  et	  al.,	  2008;	  
Rosenberg	  et	  al.,	  2011)	  




42	   40%	   10%	   (Itzhaki	  et	  al.,	  2011)	  
NMA	  +	  CD8+	  enriched	  young	  
TILs	  +	  high-­‐dose	  IL-­‐2	  
NCI	   33	   58%	   9%	   (Dudley	  et	  al.,	  2010)	  
NMA	  +	  6-­‐Gy	  TBI	  +	  CD8+	  
enriched	  young	  TILs	  +	  high-­‐
dose	  IL-­‐2	  
NCI	   23	   48%	   9%	   (Dudley	  et	  al.,	  2010)	  
NMA	  +	  modified	  young	  TILs	  +	  
two	  cycles	  high-­‐dose	  IL-­‐2	  
MD	  Anderson	   31	   42%	   6%	   (Radvanyi	  et	  al.,	  2012)	  
NMA	  +	  selected	  TILs	  +	  high-­‐
dose	  IL-­‐2	  
H	  Lee	  Moffitt	   13	   38%	   15%	   (Pilon-­‐Thomas	  et	  al.,	  
2012)	  
NMA	  +	  modified	  selected	  TILs	  
+	  14	  days	  low-­‐dose	  IL-­‐2	  
Herlev	  
Hospital	  
6	   33%	   33%	   (Ellebæk	  et	  al.,	  2012)	  
NMA	  +	  selected	  TILs	  +	  
prolonged	  low-­‐dose	  IL-­‐2	  
Uppsala	  
University	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1.4.2.3   Lessons	  from	  using	  genetically	  redirected	  T-­‐cells	  
T-­‐cells	  that	  are	  reactive	  against	  melanoma	  cells	  can	  also	  be	  generated	  ex	  vivo	  prior	  to	  infusion	  using	  
genetic	   engineering	   approaches,	   which	   involve	   the	   transduction	   of	   TAA-­‐specific	   surface	   receptor	  
genes.	   The	   rationale	   of	   infusing	   genetically-­‐modified	   T-­‐cells	   in	   melanoma	   patients,	   is	   that	   the	  
endogenous	  repertoire	  of	  potent	  tumour-­‐specific	  T-­‐cells	  has	  been	  compromised	  as	  a	  consequence	  of	  
central	   tolerance.	   Comparative	   analyses	   have	   demonstrated	   that	   tumour-­‐specific	   TCRs	   have	  
substantially	   lower	   antigen	   affinity	   compared	   with	   those	   directed	   against	   virus-­‐derived	   antigens	  
(Bridgeman	  et	  al.,	  2011),	  therefore	  partially	  explaining	  the	  lack	  of	  clinical	  efficacy	  of	  some	  approaches.	  
	  
There	  are	  two	  main	  types	  of	  antigen	  surface	  receptors	  used	  in	  genetic	  redirection	  of	  autologous	  T-­‐
cells	  (reviewed	  by	  Hinrichs	  and	  Rosenberg,	  2013).	  The	  first	  uses	  the	  native	  α-­‐	  and	  β-­‐chains	  of	  a	  TAA-­‐
specific	   TCR;	   the	   second,	   termed	   a	   chimeric	   antigen	   receptor	   (CAR),	   is	   usually	   composed	   of	   an	  
extracellular	   TAA-­‐specific	   single-­‐chain	   antibody	   variable	   fragment	   (scFv)	   linked	   to	   an	   intracellular	  
signalling	  domain	  via	  a	  hinge	  and	  transmembrane	  domains.	  Of	  note,	  because	  CARs	  are	  derived	  from	  
antibodies,	   their	   TAAs	   recognition	   is	   not	  MHC-­‐restricted;	   CAR-­‐based	   redirection	   represents	   a	   near	  
universal	  ‘off-­‐the-­‐shelf’	  method	  to	  generate	  large	  numbers	  of	  antigen-­‐specific	  helper	  and	  cytotoxic	  T-­‐
cells.	   Following	   the	   achievements	   in	   preclinical	   settings,	   in	   which	   established	   melanomas	   were	  
eradicated	   using	   genetically	   engineered	   T-­‐cells,	   these	   approaches	   have	   been	   tested	   in	   patients	  




Table	  1.2.	  Published	  reports	  of	  genetically	  redirected	  T-­‐cells	  in	  melanoma	  
(HMW-­‐MAA,	  high	  molecular	  weight	  melanoma-­‐associated	  antigen).	  	  
Clinical	  trial	  ID	  number	  and	  phase	  in	  brackets	  
	  










Willemsen	  et	  al.,	  2005	  
Morgan	  et	  al.,	  2013	  (I/II;	  NCT01273181)	  	  
Burns	  et	  al.,	  2010	  
Johnson	  et	  al.,	  2009	  (II;	  NCT00509496)	  
Rosenberg	  et	  al.,	  2010	  (I;	  NCT01176461)	  
Morgan	  et	  al.,	  2006;	  Burns	  et	  al.,	  2009	  (II;	  NCT00706992)	  
Johnson	  et	  al.,	  2009	  (II;	  NCT00509288)	  
Robbins	  et	  al.,	  2011	  (II;	  NCT00670748)	  
Davis	  et	  al.,	  2010	  (II;	  NCT00393029)	  	  
Antigens	  targeted	  by	  CARs	   Ref	  
Ganglioside	  GD2	  	  
VEGFR2	  
(Gargett	  et	  al.,	  2015)	  (I;	  NCT02107963)	  	  
(Chinnasamy	  et	  al.,	  2010)	  (I/II;	  NCT01218867)	  
	  
	   	  
	  	  	  	  	  	  
	   28	  
Genetically	  modified	  T-­‐cells	  expressing	  melanoma-­‐specific	  TCRs	  can	  be	  applicable	  to	  a	  wider	  range	  of	  
patients	  when	  suitable	  TILs	  cannot	  be	  isolated	  or	  grown,	  but	  they	  can	  be	  less	  effective	  than	  TIL-­‐based	  
therapy	   (Johnson	   et	   al.,	   2009;	   Morgan	   et	   al.,	   2006).	   Efforts	   have	   been	   made	   to	   increase	   the	  
effectiveness	  by	  generating	  modified	  high-­‐affinity	  TCRs	  for	  clinical	  studies	  (Chinnasamy	  et	  al.,	  2011;	  
Robbins	  et	  al.,	  2008;	  2011).	  However,	  the	  correlation	  between	  TCR	  affinity	  and	  anti-­‐tumour	  activity	  is	  
still	  controversial:	  high-­‐affinity	  TCRs	  have	  been	  shown	  to	  lead	  to	  stronger	  (Varela-­‐Rohena	  et	  al.,	  2008),	  
plateaued	   (Schmid	   et	   al.,	   2010),	   or	   even	   attenuated	   (Irving	   et	   al.,	   2012;	   McMahan,	   2006)	   T-­‐cell	  
responses.	  A	  recent	  study	  from	  my	  own	  laboratory	  compared	  a	  range	  of	  enhanced	  TCRs	  specific	  for	  
three	  different	   tumour	   antigens	   in	   an	   attempt	   to	   reconcile	   previous	  disparate	   findings	   (Tan	  et	   al.,	  
2015).	  This	  study	  showed	  that	  responses	  could	  be	  improved	  in	  all	  systems	  by	  modest	  enhancement	  of	  
anti-­‐tumour	   TCR	   affinity	   (~10-­‐fold).	   Greater	   enhancements	   reduced	   tumour	   recognition	   and/or	  
resulted	  in	  target	  recognition	  without	  the	  need	  for	  cognate	  antigen.	  Further	  unpublished	  studies	  have	  
demonstrated	  that	  the	  optimal	  affinity	  of	  MHC-­‐I-­‐restricted	  anti-­‐tumour	  TCRs	  is	  higher	  in	  CD4+	  T-­‐cells	  
than	   in	   CD8+	   T-­‐cells.	   This	   difference	   is	   presumed	   to	   be	   due	   to	   the	   lack	   of	   help	   from	   the	   CD8	   co-­‐
receptor,	  which	  binds	  to	   invariant	  parts	  of	  MHC-­‐I	   to	  aid	  TCR	  stability	  and	   intracellular	  signalling,	   in	  
CD4+	  T-­‐cells	  (Tan	  et	  al.,	  unpublished).	  
	  
An	  important	  issue	  with	  TCR-­‐	  or	  CAR-­‐modified	  T-­‐cells	  is	  that	  the	  receptor	  antigen	  specificity	  has	  to	  be	  
chosen	  so	  that	  the	  transduced	  T-­‐cells	  selectively	  target	  tumour	  cells	  and	  not	  healthy	  tissues.	  Despite	  
the	  promising	  results	  emerging	  from	  early	  phase	  clinical	  trials,	  a	  couple	  of	  studies	  targeting	  members	  
of	  the	  MAGE	  family	  have	  reported	  safety	  concerns	  associated	  with	  the	  potency	  of	  TCR-­‐engineered	  T-­‐
cell	  therapy	  (van	  den	  Berg	  et	  al.,	  2015).	  In	  one	  trial,	  T-­‐cells	  were	  engineered	  to	  express	  a	  TCR	  generated	  
in	   HLA-­‐A2	   transgenic	  mice	   that	   recognized	   an	   epitope	   shared	   between	  MAGE-­‐A3,	  MAGE-­‐A9,	   and	  
MAGE–A12.	  Five	  out	  of	  nine	  patients	  showed	  objective	  clinical	  responses,	  but	  three	  reported	  neural	  
toxicities,	   including	   two	   deaths	   (Morgan	   et	   al.,	   2013).	   Post-­‐mortem	   analysis	   revealed	   rare	   and	  
previously	  unknown	  expression	  of	  MAGE-­‐A12	  in	  brain	  tissues.	  	  A	  second	  trial,	  which	  evaluated	  the	  use	  
of	   the	   affinity	   enhanced	   MHC-­‐A*01-­‐restricted	   TCR,	   specific	   for	   MAGE-­‐A3,	   was	   aborted	   due	   to	  
unexpected	   toxicity	   (Linette	   et	   al.,	   2013).	   A	   patient	   experienced	   encephalopathy	   associated	   with	  
cardio-­‐toxicity	   and	   died	   within	   7	   days	   after	   T-­‐cell	   infusion.	   Extensive	   and	   detailed	   retrospective	  
analysis	  demonstrated	  that	  the	  affinity	  enhancement	  of	  the	  TCR	  resulted	  in	  the	  off-­‐target	  recognition	  
of	  a	  related	  epitope	  from	  the	  protein	  titin,	  which	  is	  expressed	  in	  cardiomyocytes	  (Linette	  et	  al.,	  2013;	  
van	  den	  Berg	  et	  al.,	  2015).	  My	  own	  laboratory	  have	  recently	  visualised	  the	  interaction	  between	  this	  
TCR	  and	  the	  titin	  and	  MAGE-­‐A3	  peptides	  (Raman	  et	  al.,	  2016)	  and	  shown	  that	  it	  is	  possibly	  to	  reverse	  
engineer	  out	  the	  dangerous	  cross-­‐reaction	  with	  titin.	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1.4.3   T-­‐cell	  checkpoint	  inhibitors	  	  
Immune	  checkpoint	   inhibitors	  have	  also	  been	   successfully	  used	   to	   treat	  advanced	  melanoma.	  This	  
form	  of	  immunotherapy	  exploits	  a	  naturally	  occurring	  feedback	  mechanism	  that	  prevents	  excess	  T-­‐
cell	  activation	  through	  the	  expression	  of	  negative	  costimulatory	  molecules.	  T-­‐cell	  negative	  regulatory	  
signals	  can	  be	  initiated	  through	  membrane	  receptors,	  following	  the	  binding	  of	  cognate	  ligands,	  either	  
soluble	  or	  membrane-­‐bound	  (Janeway,	  2011).	  These	  inhibitory	  receptors,	  also	  known	  as	  ‘checkpoints’,	  
such	   as	   cytotoxic	   T-­‐lymphocyte	   antigen	   4	   (CTLA-­‐4),	   programmed	   death	   1	   (PD-­‐1),	   T-­‐cell	  
immunoglobulin	   3	   (TIM-­‐3)	   and	   lymphocyte-­‐activation	   gene	   3	   (LAG-­‐3),	   act	   as	   ‘brakes’	   on	   T-­‐cell	  
activation	   (reviewed	   in	   Pardoll,	   2012).	   In	   patients	   with	   advanced	   cancer,	   inhibitory	   ligands	   and	  
receptors	  that	  regulate	  T-­‐cell	   tissue	  effector	  functions	  are	  often	  overexpressed	  on	  tumour	  cells	   (or	  
non-­‐malignant	   cells	   in	   the	   tumour	  microenvironment).	   This	   can	   allow	   the	  development	  of	   tumour	  
resistance	  and	   immune	  escape,	  which	  prevents	   the	   induction	  of	  an	  optimal	  anti-­‐tumour	   response.	  
Therefore,	  membrane-­‐bound	  T-­‐cell	  immune	  checkpoints	  are	  considered	  attractive	  drug	  targets	  using	  
inhibitory	  monoclonal	  antibodies	  (Pardoll,	  2012).	  Of	  note,	  unlike	  most	  antibodies	  approved	  for	  cancer	  
therapies	   which	   target	   tumour	   cells	   directly,	   mAbs	   blocking	   T-­‐cell	   immune	   checkpoints	   target	  
inhibitory	  receptors	  (or	  their	  ligands)	  in	  order	  to	  enhance	  endogenous	  anti-­‐tumour	  activity.	  As	  of	  2010,	  
three	   new	   mAbs	   have	   been	   approved	   for	   advanced	   melanoma	   by	   the	   US	   Food	   and	   Drug	  
Administration	   (FDA),	   which	   target	   T-­‐cell	   checkpoints	   PD-­‐1	   and	   CTLA-­‐4.	   Figure	   1.11	   schematically	  





Figure	  1.11.	  Checkpoint	  blockade	  antibodies	  
This	  approach	  to	  immunotherapy	  is	  exemplified	  by	  antibodies	  
directed	  against	  CTLA-­‐4,	  which	  block	  the	  immune	  suppression	  
mediated	  by	   the	   interaction	  between	  B7	   family	  members	   (on	  
antigen	  presenting	  cells)	  and	  CTLA-­‐4	  (on	  CD8+	  and	  CD4+	  T	  cells).	  
A	   second	   major	   checkpoint,	   mediated	   by	   the	   interaction	  
between	   PD-­‐1	   (on	   T-­‐cells)	   and	   its	   ligand	   PD-­‐L1	   (on	   antigen	  
presenting	   cells	   or	   tumours),	   has	   been	   the	   subject	   of	   several	  
recent	   clinical	   trials	   (adapted	   from	  Drake	   et	   al.,	   2014).	  Other	  
inhibitory	  receptors	  on	  T-­‐cells	  are	  TIM3	  and	  LAG3.	  The	  bottom	  
panel	   shows	   a	   few	   example	   of	   commercially	   available	  
antibodies.	  Commercial	  names	  are	  indicated	  in	  brackets. 	  







Ipilimumab	  (Yervoy)	   antibody	   CTLA-­‐4	   Hodi	  et	  al.,	  2010	  
Pembrolizumab	  (Keytruda)	   antibody	   PD-­‐L1	   Robert	  et	  al.,	  2014	  
Nivolumab	  (Opdivo)	   antibody	   PD-­‐1	   Weber	  et	  al.,	  2015	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CTLA-­‐4	  was	  the	  first	  immune-­‐checkpoint	  receptor	  to	  be	  clinically	  targeted	  in	  melanoma.	  Its	  expression	  
is	  primarily	  restricted	  to	  T-­‐cells	  where	  it	  mainly	  regulates	  the	  amplitude	  of	  the	  early	  stages	  of	  T-­‐cell	  
activation	  (Brunet	  et	  al.,	  1987;	  McCoy	  and	  Le	  Gros,	  1999).	  In	  a	  milestone	  publication,	  more	  than	  600	  
stage	   III	  or	   IV	  melanoma	  patients	  were	   treated	  with	   Ipilimumab	   (anti-­‐CTLA-­‐4	  mAb),	  gp100	  peptide	  
vaccine	  or	  a	  combination	  of	  both;	  the	  best	  overall	  response	  rate	  (10.9%)	  was	  achieved	  by	  Ipilimumab	  
alone,	  and	  long-­‐term	  responses	  (>2	  years)	  were	  reported	  in	  60%	  of	  patients	  (Hodi	  et	  al.,	  2010).	  
	  
PD-­‐1	  has	  a	  broader	  expression	  compared	  to	  CTLA-­‐4;	  it	  is	  minimally	  expressed	  in	  resting	  immune	  cells,	  
however,	  upon	  activation,	  it	  can	  be	  induced	  in	  other	  immune	  cells	  (including	  B	  and	  NK	  cells)	  where	  it	  
limits	  their	  lytic	  functions	  (Ishida	  et	  al.,	  1992;	  Keir	  et	  al.,	  2008).	  In	  activated	  and	  ‘exhausted’	  T-­‐cells,	  
the	  interaction	  between	  PD-­‐1	  and	  its	  ligands,	  PD-­‐L1	  or	  PD-­‐L2,	  dampens	  T-­‐cell	  function	  in	  non-­‐lymphoid	  
organs	  and	  lymphoid	  organs,	  respectively	  (Keir	  et	  al.,	  2008).	  PD-­‐L1	  is	  expressed	  by	  several	  tumour	  cell	  
types,	   including	   melanoma;	   PD-­‐L1	   can	   engage	   PD-­‐1	   on	   tumour	   infiltrating	   cells	   and	   inhibit	   their	  
function,	  therefore	  shielding	  the	  tumour	  from	  immune-­‐mediated	  killing.	  Results	  from	  a	  large	  phase	  I	  
clinical	   trial	   led	   to	   the	   FDA	   approval	   of	   Pembrolizumab	   (anti-­‐PD-­‐1)	   in	   September	   2014	   for	   the	  
treatment	  of	  patients	  with	  metastatic	  or	  unresectable	  melanoma	  (Robert	  et	  al.,	  2014).	  Nivolumab,	  
another	  anti-­‐PD-­‐1,	  was	  approved	  in	  December	  2014	  with	  the	  same	  indication	  (Weber	  et	  al.,	  2015).	  
More	  recently,	  another	  molecule,	  V-­‐domain	  Immunoglobulin	  Suppressor	  of	  T-­‐cell	  Activation	  (VISTA),	  
has	  been	  characterised	  as	  a	  potential	  T-­‐cell	  immune	  checkpoint	  target	  (Márquez-­‐Rodas	  et	  al.,	  2015;	  
Wang	  et	  al.,	  2011).	  VISTA	  and	  PD-­‐1/PD-­‐L1	  share	  expression	  profiles	  in	  haematopoietic	  cells,	  but	  their	  
immune-­‐regulatory	   pathways	   are	   non-­‐redundant,	   therefore	   VISTA	   and	   PD-­‐1	   can	   be	   targeted	   in	  
synergy	   (Lines	  et	   al.,	   2014;	   Liu	   et	   al.,	   2015).	   Preclinical	   studies	   in	  murine	   cancer	  models	  have	  also	  
shown	  that	  VISTA	  blockade	  leads	  to	  inhibition	  of	  melanoma	  growth	  and	  (Liu	  et	  al,	  2015).	  	  
	  
Overall,	  treatment	  with	  T-­‐cell	  checkpoint	  inhibitors	  produces	  long-­‐term	  responses,	  but	  in	  a	  minority	  
of	  patients.	  Treatment	  response	  and	  improved	  survival	  is	  often	  also	  associated	  with	  autoimmune	  side	  
effects	   (Hodi	   et	   al.,	   2010;	   Robert	   et	   al.,	   2011;	   Topalian	   et	   al.,	   2012).	   In	   addition	   to	   their	   use	   in	  
monotherapy,	   a	   few	   T-­‐cell	   checkpoint	   inhibitors	   are	   now	   being	   tested	   in	   combination	   with	   other	  
treatments	  (such	  as	  TIL-­‐based	  therapy)	  in	  clinical	  trials,	  which	  showed	  promising	  response	  rates	  (Kim	  
et	  al.,	  2014).	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1.4.4   Towards	  personalised	  approaches	  
Although	  a	  number	  of	  studies	  provided	  early	  evidence	  for	  the	  immunogenicity	  of	  mutation-­‐derived	  
neo-­‐antigens,	  the	  technology	  to	  analyse	  T-­‐cell	  reactivity	  against	  these	  antigens	  only	  became	  available	  
very	   recently.	   Identification	   of	   neo-­‐antigens	   can	   be	   achieved	   by	   eluting	   the	   peptides	   from	   MHC	  
molecules	  derived	  from	  the	  tumour	  tissue	  of	  a	  patient	   (i.e.	  MHC	   ligandome),	   followed	  by	  reversed	  
phase	  HPLC	  fractionation	  and	  mass	  spectrometry	  (MS).	  Results	  are	   integrated	  with	  cancer	  genome	  
data	  in	  order	  to	  identify	  mutations	  that	  may	  lead	  to	  candidate	  peptides	  (Haen	  and	  Rammensee,	  2013;	  
Trajanoski	   et	   al.,	   2015).	   Sahin	   and	   colleagues	   were	   the	   first	   to	   demonstrate	   how	   whole-­‐exome	  
sequencing	   data	   could	   be	   used	   to	   identify	   neo-­‐antigens	   recognized	  by	   CD8+	   T-­‐cells	   in	   the	  B16F10	  
murine	   melanoma	   models	   (Castle	   et	   al.,	   2012).	   In	   recent	   promising	   case	   studies,	   cancer	   exome	  
information	   was	   used	   to	   identify	   mutations	   in	   human	   melanomas,	   and	   T-­‐cell	   reactivities	   against	  
melanoma	  neo-­‐antigens	  was	  demonstrated	  in	  both	  CD8+	  and	  CD4+	  T-­‐cell	  compartments	  (Kreiter	  et	  
al.,	  2015;	  Linnemann	  et	  al.,	  2014;	  Tran	  et	  al.,	  2014).	  Robbins	  and	  colleagues	  have	  shown	  responses	  in	  
melanoma	  patients	  that	  correlated	  with	  neo-­‐antigen	  speciﬁc	  T-­‐cells	  in	  in	  vitro	  expanded	  and	  infused	  
TILs	   (Robbins	   et	   al.,	   2013).	   Another	   study	   presented	   the	   case	   of	   a	  melanoma	   patient	  with	   partial	  
tumour	  regression	  following	  anti-­‐CTLA-­‐4	  antibody	  treatment,	  which	  correlated	  with	  expansion	  of	  neo-­‐
antigen	  speciﬁc	  T-­‐cells	  after	  treatment	  (van	  Rooij	  et	  al.,	  2013).	  Durable	  complete	  tumour	  regression	  
was	  achieved	  infusing	  T-­‐cells	  specific	  for	  the	  mutated	  PP1R3B	  protein	  in	  a	  further	  patient	  (Lu	  et	  al.,	  
2013).	  Finally,	  three	  patients	  were	  recently	  treated	  with	  autologous	  DC	  pulsed	  with	  a	  pool	  of	  7	  private	  
peptides,	   showing	   a	   robust	   increase	   in	   the	   frequency	   of	   neo-­‐antigens-­‐speciﬁc	   T-­‐cells	   following	  
vaccination	   (Carreno	   et	   al.,	   2015).	   T-­‐cells	   speciﬁc	   for	   neo-­‐antigens	   were	   also	   shown	   to	   possess	  
functional	  sensitivity	  equivalent	  to	  that	  of	  anti-­‐viral	  T-­‐cells	   (Lennerz	  et	  al.,	  2005).	   In	  contrast,	  T-­‐cell	  
reactivity	   toward	  self-­‐antigens	   is	   lower	  by	  deﬁnition	  and	   is	  achieved	  only	  when	   tolerance	   to	   these	  
antigens	  is	  not	  fully	  developed.	  The	  identification	  of	  neo-­‐antigens	  on	  a	  patient-­‐specific	  basis	  could	  be	  
the	   way	   forward	   to	   design	   personalised	   immunotherapy	   programs	   aimed	   to	   induce	   (or	   boost)	  
melanoma-­‐specific	  adaptive	  immunity.	  However,	  such	  personalised	  approaches	  are	  highly	  expensive	  
and	  it	  is	  unlikely	  that	  they	  will	  become	  routine	  for	  the	  majority	  of	  patients.	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1.5   Project	  aims	  	  
Melanoma	  is	  generally	  accepted	  as	  being	  an	  antigenic	  tumour	  capable	  of	  eliciting	  T-­‐cell	   responses.	  
However,	  in	  most	  cases	  immune	  surveillance	  is	  suboptimal	  and	  fails	  to	  control	  melanoma	  growth.	  As	  
a	  result,	  several	  T-­‐cell	  based	  immunotherapy	  approaches,	  which	  aim	  at	  harnessing	  the	  patient’s	  own	  
anti-­‐melanoma	  adaptive	  immune	  response	  are	  being	  developed.	  My	  thesis	  mainly	  focuses	  on	  two	  of	  
these	  therapeutic	  approaches:	  cancer	  peptide	  vaccines	  and	  TIL-­‐based	  therapy.	  In	  particular,	  I	  aimed	  
to	  analyse	  human	  anti-­‐melanoma	  T-­‐cell	  responses	  from	  both	  a	  molecular	  and	  cellular	  point	  of	  view.	  	  
	  
•   In	  Chapter	  3	  my	  studies	  focus	  on	  the	  melanoma	  differentiation	  antigen	  gp100,	  which	  encodes	  
for	   several	   T-­‐cell	   peptide	   epitopes	   that	   have	   been	   extensively	   tested	   in	   cancer	   vaccination.	  
Despite	   the	   interest	   in	   these	   antigens,	   they	   have	   never	   before	   been	   viewed	   by	   X-­‐ray	  
crystallography.	  My	  main	  goal	  was	  therefore	  to	  build	  a	  molecular	  picture	  of	  how	  a	  gp100-­‐specific	  
TCR	   interacted	   with	   its	   cognate	   antigen	   and	   to	   provide	   a	   detailed	   binding	   analysis	   of	   this	  
important	  anti-­‐melanoma	  molecular	  interaction.	  	  
	  
•   In	  Chapters	  4	  and	  5,	  I	  focus	  on	  successful	  T-­‐cell	  responses	  against	  melanoma	  and,	  in	  particular,	  I	  
aimed	   to	   dissect	   the	   tumour	   reactivity	   of	   human	   TIL	   cultures	   associated	  with	   in	   vivo	   tumour	  
clearance.	   I	   was	   fortunate	   to	   be	   given	   privileged	   access	   to	   samples	   from	   patients	   who	   had	  
undergone	   successful	   TIL-­‐based	   therapy	   for	   metastatic	   melanoma	   at	   the	   Centre	   for	   Cancer	  
Immune	   Therapy	   (CCIT)	   in	   Copenhagen,	   Denmark.	   Having	   access	   to	   T-­‐cell	   infiltrates	   and	  
autologous	  melanoma	  cells	  from	  cured	  melanoma	  patients	  after	  TIL-­‐therapy,	  the	  main	  goal	  was	  
to	  provide	  cellular	  profiling	  of	  anti-­‐melanoma	  TILs	  in	  both	  an	  HLA-­‐A2+	  (Chapter	  4)	  and	  an	  HLA-­‐
A2-­‐	  patient	  (Chapter	  5).	  Both	  studies	  aim	  to	  examine	  the	  phenotype	  and	  antigen	  specificity	  of	  
the	  tumour-­‐reactive	  populations.	  In	  addition,	  I	  hypothesised	  that	  the	  dominant	  anti-­‐melanoma	  
responses	  in	  the	  patient’s	  blood	  following	  successful	  TIL	  therapy,	  could	  be	  those	  contributing	  to	  
in	  vivo	  tumour	  clearance.	  I	  therefore	  investigated	  whether	  anti-­‐melanoma	  T-­‐cell	  clones	  persist	  in	  
both	  patient’s	  blood	  after	  TIL	  therapy	  and	  attempted	  to	  map	  the	  antigen	  specificity.
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2   Materials	  and	  Methods	  
2.1   Protein	  expression,	  refolding	  and	  purification	  
2.1.1   Vectors	  for	  protein	  expression	  
The	  pGMT7	  expression	  plasmid	  (Banham	  and	  Smith,	  1993;	  Studier	  et	  al.,	  1990)	  was	  used	  as	  a	  vector	  
for	   bacterial	   protein	   expression,	   conferring	   a	   resistance	   to	   carbenicillin.	   It	   contains	   a	   sequence	  
encoding	  the	  protein	  of	   interest	   inducible	  with	   IPTG	  (Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside)	  under	  
the	  control	  of	  the	  T7	  RNA	  polymerase	  promoter,	  the	  sequence	  being	  cloned	  between	  BamHI	  and	  EcoRI	  
restriction	  sites.	  pGMT7	  expression	  were	  used	  to	  produce	  the	  extracellular	  domain	  of	  α-­‐chain	  and	  the	  
β-­‐chain	   soluble	  domains	  of	   the	  gp100-­‐specific	  TCRs,	  and	  HLA-­‐A*0201	   (HLA-­‐A2	   from	  hereon)	  heavy	  
chain.	  Human	  β2m	  was	  also	  expressed	  from	  pGMT7.	  The	  sequences	  that	  encode	  for	  the	  α-­‐chain	  of	  
HLA-­‐A2	   and	   β2m	   chain	   were	   designed	   according	   to	   previous	   work	   performed	   by	   Boulter	   and	  
colleagues	  (Boulter	  et	  al.,	  2003).	  The	  N-­‐terminus	  of	  the	  α-­‐chain	  of	  HLA-­‐A2	  was	  tagged	  with	  a	  15	  aa	  
biotinylation	   sequence	   (GLNDIFEAQKIEWHE)	   (AviTag™,	   Avidity)	   allowing	   tetramerisation	   of	   pMHC	  
monomer	  or	  adherence	  to	  streptavidin	  BIAcore	  chips	  (see	  section	  below).	  Proteins	  were	  expressed	  
without	  the	  biotinylation	  tag	  for	  crystallisation	  studies.	  A	  cysteine	  residue	  was	  added	  to	  the	  TCR	  α-­‐	  
and	  β-­‐chain	  extracellular	  domains	  in	  order	  to	  introduce	  potential	  for	  a	  non-­‐native	  disulphide	  bond	  to	  
enhance	  potential	  for	  αβ	  chain-­‐pairing	  during	  the	  refolding	  process	  (Boulter	  et	  al.,	  2003)	  as	  described	  
below.	  	  
2.1.2   Protein	  sequences	  
Expression	  constructs	  were	  used	  that	  expressed	  the	  following	  sequences:	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2.1.3   Culture	  media	  and	  buffers	  used	  for	  protein	  expression,	  refolding	  and	  purification	  
Buffer	   Composition	  
LB	  medium	   10	  g/L	  tryptone	  (Fisher	  Scientific),	  5	  g/L	  yeast	  extract	  (Fisher	  Scientific),	  5	  g/L	  NaCl	  (Fisher	  Scientific)	  and	  supplemented	  with	  50	  mg/L	  carbenicillin	  (Carbenicillin	  Direct)	  
LB	  agar	  plate	  medium	  
15	  g/L	  agar	  bacteriological	   (Oxoid),	  10	  g/L	   tryptone	   (Fisher	  Scientific),	  5	  g/L	  yeast	  
extract	   (Fisher	  Scientific),	  5	  g/L	  NaCl	   (Fisher	  Scientific)	  and	  supplemented	  with	  50	  
mg/L	  carbenicillin	  	  
TYP	  medium	   16	   g/L	   tryptone,	   16	   g/L	   yeast	   extract,	   5	   g/L	   potassium	   phosphate	   dibasic	   (Acros	  Organics)	  
Lysis	  buffer	   10	  mM	  Tris	  pH	  8.1	  (Fisher	  Scientific),	  10	  mM	  MgCl2,	  150	  mM	  NaCl,	  10%	  glycerol.	  
Triton	  wash	  buffer	   0.5%	  Triton	  X,	  50	  mM	  Tris	  pH	  8.1,	  100	  mM	  NaCl,	  2	  mM	  EDTA	  (Fisher	  Scientific).	  
Resuspension	  buffer	   50	  mM	  Tris	  pH	  8.1,	  100	  mM	  NaCl,	  2	  mM	  EDTA.	  
Guanidine	  buffer	   6	  M	  guanidine,	  50	  mM	  Tris	  pH	  8.1,	  100	  mM	  NaCl,	  2	  mM	  EDTA.	  
pMHC	  I	  refold	  buffer	   50	  mM	  Tris	  pH	  8,	  2	  mM	  EDTA	  pH	  8	  400	  mM	  L-­‐arginine	  (SAFC),	  0.74	  g/L	  cysteamine	  and	  0.83	  g/L	  cystamine	  
TCR	  refold	  buffer	   50	  mM	  Tris	  pH	  8,	  2	  mM	  EDTA	  pH	  8,	  2.5	  M	  Urea	  (Fisher	  scientific),	  0.74	  g/L	  cysteamine	  and	  0.83	  g/L	  cystamine	  
Ion	  exchange	  buffer	  A	   10	  mM	  Tris	  
Ion	  exchange	  buffer	  B	   10	  mM	  Tris,	  1	  M	  NaCl	  
Biomix	  A	   0.5	  M	  Bicine	  buffer	  pH	  8.3	  
Biomix	  B	   100	  mM	  ATP,	  100	  mM	  MgO(Ac)2,	  500	  μM	  Biotin.	  
Biacore	  buffer-­‐HPS	   10	  mM	  HEPES	  pH7.4,	  150	  nM	  NaCl,	  3	  mM	  EDTA	  and	  0.005%	  (v/v)	  Surfactant	  P20	  (GE	  Healthcare)	  
Crystal	  buffer	   10	  mM	  Tris	  pH	  8.1	  and	  10	  mM	  NaCl.	  
ITC	  buffer	   20	  mM	  Hepes	  pH	  7.4,	  150	  mM	  NaCl	  
Reducing	  sample	  buffer	   125	  mM	  Tris	  pH	  6.8,	  4%	  SDS,	  20%	  glycerol,	  20	  μg/mL	  bromophenol	  blue,	  10%	  DTT	  
Non-­‐reducing	  sample	  
buffer	   125	  mM	  Tris	  pH	  6.8,	  4%	  SDS,	  20%	  glycerol,	  20	  μg/mL	  bromophenol	  blue	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2.1.4   Transformation	  of	  competent	  E.	  coli	  cells	  
Competent	  Rosetta	  (DE3)	  pLysS	  E.coli	  cells	  (Invitrogen)	  were	  used	  to	  produce	  TCR	  α-­‐	  and	  β-­‐chains,	  and	  
MHC-­‐I	  α	  and	  β2m	  chains	  in	  the	  form	  of	  inclusion	  bodies.	  Transformation	  of	  competent	  Rosetta	  E.coli	  
cells	  was	  performed	  by	  thawing	  20	  μL	  of	  competent	  cells	  on	  ice	  for	  5	  min.	  50-­‐100	  ng	  of	  plasmid	  DNA	  
were	  added	  to	  the	  bacterial	  aliquot	  and	  incubated	  for	  5min	  on	  ice.	  The	  cells	  were	  then	  heat-­‐shocked	  
at	  42	  °C	  for	  2min	  and	  placed	  directly	  on	  ice	  for	  a	  5min	  recovery	  period.	  Cells	  were	  then	  plated	  onto	  a	  
LB	  agar	  medium	  plate	  (supplemented	  with	  50μg/mL	  carbenicillin)	  and	  grown	  overnight	  at	  37	  °C.	  	  
2.1.5   Expression	  of	  inclusion	  bodies	  in	  Rosetta	  E.	  Coli	  
A	  starter	  culture	  was	  set	  up	  to	  verify	  the	  expression	  of	  the	  protein	  by	  picking	  and	  culturing	  a	  single	  
colony	  in	  30	  mL	  of	  TYP	  media	  supplemented	  with	  50	  μg/mL	  of	  carbenicillin.	  The	  starter	  culture	  was	  
grown	  at	  37	  °C	  and	  shaken	  at	  220	  rpm	  (Sanyo,	  Leics,	  UK;	  MIR-­‐222U)	  until	  the	  suspension	  reached	  an	  
optical	  density	  (OD600nm)	  approx.	  0.5.	  The	  starter	  culture	  was	  then	  inoculated	  in	  1	  L	  carbenicillin	  (50	  
μg/mL)	  supplemented	  TYP	  medium	  and	  incubated	  in	  a	  shaker	  at	  37	  °C,	  220	  rpm	  (Sanyo,	  Leics,	  UK)	  for	  
3h	  (or	  until	  OD600nm	  was	  approx.	  0.5).	  Protein	  expression	  was	  induced	  by	  adding	  0.5	  mL	  of	  1	  M	  IPTG	  
and	  incubating	  at	  37	  °C	  for	  3h	  in	  an	  orbital	  shaking	  incubator.	  A	  0.5	  mL	  sample	  was	  taken	  before	  and	  
after	  IPTG	  induction	  to	  record	  the	  OD600nm	  and	  run	  on	  a	  SDS-­‐PAGE	  gel	  (Section	  2.1.7)	  in	  order	  to	  verify	  
the	  quality	  and	  quantity	  of	  protein	  expression.	  Cells	  were	  harvested	  and	  centrifuged	  at	  3450	  xg	  for	  20	  
min.	  The	  cell	  pellet	  was	  resuspended	  in	  40	  mL	  of	  lysis	  buffer	  and	  sonicated	  on	  ice	  at	  20%	  power	  for	  20	  
min	  using	  2	  sec	  intervals	  using	  a	  MS73	  probe	  (Bandelin).	  The	  sonicated	  pellet	  was	  incubated	  with	  200	  
μL	  of	  20	  mg/mL	  DNAase	  (Sigma)	  for	  over	  30	  min	  RT,	  resuspended	  with	  100	  mL	  of	  Triton	  wash	  buffer	  
and	  centrifuged	  for	  20	  min	  at	  15,180	  xg.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  scraped	  
and	   resuspended	   into	   100	   mL	   of	   triton	   wash	   buffer	   following	   homogenization	   (VWR	   VD25,	  
17,500/min).	  Pellets	  were	  then	  resuspended	  in	  10	  mL	  resuspension	  buffer	  and	  centrifuged	  for	  20	  min	  
at	  15,180	  xg.	  Finally,	  pellets	  were	  dissolved	  in	  the	  smallest	  volume	  possible	  (e.g.	  5-­‐10	  mL)	  of	  guanidine	  
buffer	  and	  stored	  in	  15	  mL	  tubes	  at	  -­‐20°C.	  The	  concentration	  of	  inclusion	  bodies	  was	  determined	  using	  
1-­‐3	  μL	  of	  each	  sample	  and	  guanidine	  buffer	  as	  a	  blank	  (Section	  2.1.6).	  
2.1.6   Estimating	  protein	  concentration	  by	  spectrophotometry	  
To	  determine	  the	  concentration	  of	  pMHC-­‐I	  and	  TCR	  proteins,	  samples	  were	  diluted	  1/100	  in	  PBS	  or	  
appropriate	  buffer.	  Using	  a	  spectrophotometer	  (NanoPhotometer®,	  Geneflow)	  the	  machine	  was	  blank	  
referenced	  using	  appropriate	  buffer	  (e.g.	  guanidine	  buffer	  for	  inclusion	  bodies).	  Readings	  at	  280	  nm	  
wavelength	  were	  recorded	  and	  the	  protein	  concentration	  was	  calculated	  using	  the	  dilution	  factor	  and	  
extinction	   co-­‐efficient	   (calculated	   from	   the	   amino	   acid	   sequence	   using	   ProtParam	   tool,	  
http://web.expasy.org/protparam/)	  following	  Beer’s	  Law	  formula:	  A280nm	  =	  ε*l*C.	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2.1.7   Sodium	  Dodecyl	  Sulphate-­‐Polyacrylamide	  Gel	  Electrophoresis	  (SDS-­‐PAGE)	  
SDS-­‐PAGE	   (Life	   Technologies	   X-­‐Cell	   SureLock™	   system)	   was	   used	   to	   verify	   purity	   and	   quantity	   of	  
proteins.	  Each	  sample	  was	  centrifuged	  at	  15.7	  xg	  for	  1	  min,	  prepared	  by	  diluting	  1:4	  in	  5X	  non-­‐reducing	  
sample	  buffer	  (or	  5X	  reducing	  buffer	  with	  the	  addition	  of	  10%	  DTT)	  and	  then	  incubated	  at	  90	  °C	  for	  
5min.	  20	  μL	  of	   each	   sample	  were	  analysed	  by	   loading	  onto	  a	  pre-­‐cast	  10%	  Bis/Tris	   gel	   (NuPAGE®,	  
Invitrogen).	  The	  running	  chamber	  was	  filled	  using	  1X	  running	  buffer	  (NuPAGE®,	  Invitrogen).	  The	  pre-­‐
stained	  protein	  ladder	  (BLUeye,	  10-­‐245	  kDa	  range,	  Geneflow	  Ltd.)	  was	  loaded	  in	  a	  separate	  lane.	  Gels	  
were	  run	  at	  180	  V	  for	  45	  min	  at	  200	  mA,	  stained	  with	  Quick	  Coomassie	  stain	  (Generon)	  and	  de-­‐stained	  
in	  dH2O	  for	  band	  visualisation.	  
2.1.8   Soluble	  pMHC-­‐I	  and	  TCR	  	  
For	  a	  1	  L	  refold,	  30	  mg	  of	  TCR	  α-­‐chain	  inclusion	  bodies	  were	  incubated	  at	  37	  °C	  for	  15	  min	  with	  10	  mM	  
DTT	  and	  added	  to	  cold	  refold	  buffer.	  After	  15	  min,	  30	  mg	  of	  TCR	  β-­‐chain,	  incubated	  for	  15	  min	  at	  37	  
°C	  with	  10	  mM	  DTT,	  were	  added.	  For	  a	  1	  L	  pMHC-­‐I	  refold,	  30	  mg	  of	  HLA-­‐A2	  α-­‐chain	  inclusion	  bodies	  
was	  mixed	  with	  30	  mg	  of	  β2m	  and	  4	  mg	  of	  synthetic	  peptide	  at	  37°C	  for	  15	  min,	  and	  then	  added	  to	  
cold	  refold	  buffer.	  Refolds	  were	  mixed	  at	  4°C	  for	  >1h.	  Dialysis	  was	  conducted	  twice	  using	  against	  10	  
mM	  Tris	  pH	  8.1	  until	  the	  conductivity	  of	  the	  refolds	  was	  <2	  mS/cm.	  All	  buffers	  and	  refolds	  were	  filtered,	  
firstly	  through	  a	  0.22	  μm	  filter	  (Fisher	  Scientific)	  and	  then	  a	  0.45	  μm	  (Sartorius)	  filter,	  before	  further	  
FPLC	  purification	  steps.	  	  
2.1.9   Fast	  Protein	  Liquid	  Chromatography	  (FPLC)	  
The	   refolded	   proteins	  were	   purified	   initially	   using	   an	   anion	   exchange	   column	   (POROS®	   50HQ,	   Life	  
Technologies),	   previously	   equilibrated	   in	   buffer	   A	   and	   washed	   with	   buffer	   B.	   Protein	   sample	   was	  
loaded	  at	  a	  flow	  rate	  of	  20	  mL/min	  (5	  MPa	  pressure)	  and	  eluted	  using	  buffer	  A	  into	  FPLC	  tubes	  (Greiner	  
Bio-­‐One)	   on	   a	   Frac-­‐920	   rack.	   Fractions	  were	   analysed	   for	   protein	   purity	   by	   SDS-­‐PAGE,	   pooled	   and	  
concentrated	  at	  3000	  xg	  until	  sample	  volume	  <1	  mL	  (approx.	  10-­‐15	  min)	  using	  a	  4	  mL	  Vivaspin®	  (10	  
kDa	   molecular	   weight	   cut-­‐off,	   Sartorius)	   concentrator	   tube.	   Buffer	   exchange	   and	   removal	   of	  
aggregates	  was	  achieved	  by	  gel	  filtration	  using	  a	  SuperdexTM	  HR	  200	  size-­‐exclusion	  column	  (Amersham	  
Pharmacia),	   previously	   equilibrated	  with	   appropriate	   buffer	   (i.e.	   crystal	   buffer,	   BIAcore	   buffer,	   ITC	  
buffer	  or	  PBS).	  Samples	  were	  carefully	  loaded	  with	  a	  1	  mL	  syringe	  to	  avoid	  air	  bubbles,	  and	  eluted	  into	  
FPLC	   tubes	   (Greiner	  Bio-­‐One).	   	   Fractions	   containing	   correctly	   folded	  TCR	  or	   pMHC-­‐I	   proteins	  were	  
identified	  by	  SDS-­‐PAGE,	  pooled,	  concentrated	  as	  described	  above,	  and	  stored	  at	  -­‐20	  °C.	  	  For	  BIAcore	  
experiments,	  refolded	  and	  purified	  pMHC-­‐I	  were	  biotinylated	  (section	  2.1.10)	  before	  gel-­‐filtration.	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2.1.10   Biotinylation	  of	  pMHC	  
Refolded	   and	   purified	   pMHC-­‐I	   proteins	   were	   concentrated	   to	   a	   volume	   of	   700	   µL	   using	   a	   20	  mL	  
Vivaspin®	  concentrator	  tube	  (10	  kDa	  molecular	  weight	  cut-­‐off,	  Sartorius).	  The	  biotinylation	  process	  
included	  the	  addition	  of	  100	  µL	  Biomix	  A,	  100	  µL	  Biomix	  B,	  100	  µL	  	  d-­‐Biotin	  500	  µM	  (Avadin)	  and	  2	  µL	  
BirA	  enzyme	  (Avadin)	  to	  the	  concentrated	  pMHC-­‐I	  at	  37	  °C	  for	  4	  h	  (or	  overnight	  at	  RT).	  Excess	  biotin	  
was	  removed	  by	  following	  gel	  filtration	  purification	  step.	  
2.2   Surface	  Plasmon	  Resonance	  (SPR)	  analysis	  
The	  binding	  analysis	  was	  performed	  using	  a	  BIAcore™	  3000	  or	  BIAcore™	  T100	  equipped	  with	  a	  CM5	  
sensor	  chip	  as	  previously	  reported	  (Wyer	  et	  al.,	  1999).	  Figure	  2.1	  illustrates	  a	  schematic	  representation	  
of	  the	  SPR	  system	  used.	  Briefly,	  biotinylated	  pMHC	  complexes	  were	  immobilized	  to	  streptavidin	  (500-­‐
600	  response	  units	   [RUs]),	  which	  was	  chemically	   linked	  to	  the	  chip	  surface	  by	  amine	  coupling.	  The	  
pMHC	  was	  injected	  at	  a	  slow	  flow	  rate	  (10	  μL/min)	  to	  ensure	  a	  uniform	  distribution	  of	  pMHC	  on	  the	  




Figure	  2.1.	  Schematic	  representation	  of	  the	  SPR	  system	  
A	  typical	  SPR	  immunoassay	  setup	  uses	  microfluids	  to	  flow	  controlled	  amounts	  of	  purified	  TCR	  protein	  across	  the	  sensor	  chip	  
surface	  to	  which	  the	  pMHC	  is	  immobilised.	  The	  system	  includes	  a	  light	  source,	  a	  prism	  and	  an	  optical	  detection	  unit,	  all	  coupled	  
to	  a	  gold-­‐coated	  sensor	  microfluidic	  chip.	  SPR	  detection	  monitors	  the	  variations	  in	  refractive	  index	  close	  to	  the	  gold	  layer	  of	  the	  
sensor	  chip	  surface.	  The	  intensity	  of	  the	  reflective	  light	  is	  measured	  to	  determine	  the	  occurrence	  of	  binding	  between	  the	  two	  
interacting	  proteins.	  Left	  panel)	  The	  surface	  of	  the	  sensor	  chip	  carries	  a	  dextran	  matrix	  to	  which	  streptavidin	  has	  been	  covalently	  
attached.	   The	   biotinylated	   pMHC	   protein	   is	   captured	   to	   the	   surface	   of	   the	   chip	   through	   the	   high	   affinity	   binding	   with	  
streptavidin.	  Right	  panel)	  Schematic	  illustration	  of	  an	  SPR	  sensorgram,	  which	  plots	  the	  response	  against	  time.	  A	  sensorgram	  
shows	  in	  real-­‐time	  the	  progress	  (association	  and	  dissociation)	  of	  the	  interaction	  between	  the	  TCR	  and	  pMHC	  proteins.	  
	  
	  
A	  flow	  cell	  with	  an	  irrelevant	  pMHC	  was	  used	  for	  each	  chip	  for	  background	  correction.	  Combined	  with	  
the	  small	  amount	  of	  pMHC	  bound	  to	  the	  chip	  surface,	  this	  reduced	  the	   likelihood	  of	  mass	  transfer	  
being	  in	  effect	  during	  these	  experiments.	  TCRs	  were	  purified	  and	  concentrated	  to	  100	  μM	  on	  the	  same	  
day	  of	  SPR	  analysis	  to	  reduce	  the	  likelihood	  of	  TCR	  aggregation	  affecting	  the	  results.	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For	  equilibrium	  analysis,	  10	  serial	  TCR	  dilutions	  were	  carefully	  prepared	  in	  triplicate	  for	  each	  sample	  
and	  injected	  over	  the	  relevant	  sensor	  chip	  at	  25	  °C.	  The	  maximum	  concentration	  for	  all	  soluble	  TCR	  
dilution	  series	  was	   in	   the	  range	  of	  200-­‐250	  µM.	  The	  equilibrium-­‐binding	  constant	   (KD)	  values	  were	  
calculated	  using	  a	  nonlinear	  curve	  fit	  (y	  =	  (P1x)/(P2	  +	  x)).	  For	  thermodynamic	  experiments,	  the	  above-­‐
mentioned	  method	  was	  repeated	  at	  the	  following	  temperatures:	  5	  °C,	  12	  °C,	  18	  °C,	  25	  °C,	  and	  37	  °C.	  
The	  thermodynamic	  parameters	  were	  calculated	  according	  to	  the	  Gibbs-­‐Helmholtz	  equation	  (ΔG	  =	  ΔH	  
-­‐	  TΔS).	  The	  binding	  free	  energies,	  ΔG	  (ΔG	  =	  -­‐RTlnKD)	  were	  plotted	  against	  temperature	  (K,	  Kelvin)	  using	  
nonlinear	  regression	  to	  fit	  the	  three-­‐parameter	  equation	  (y=dH+dCp*(x-­‐298)-­‐x*dS-­‐x*dCp*ln(x/298)).	  
Results	  were	  analysed	  using	  BIAevaluation	  3.1™,	  Microsoft	  Excel™	  and	  Origin	  6.0™.	  	  
2.3   Isothermal	  Titration	  Calorimetry	  (ITC)	  
ITC	   experiments	  were	   performed	   using	   a	  Microcal	   VP-­‐ITC	   (GE	  Healthcare)	   as	   previously	   described	  
(Armstrong	  and	  Baker,	  2007),	  with	  30	  μM	  pMHC-­‐I	  in	  the	  calorimeter	  cell	  and	  210	  μM	  soluble	  PMEL17	  
TCR	  in	  the	  syringe.	  ITC	  buffer	  was	  used	  and	  twenty	  2	  μL-­‐volume	  injections	  were	  performed.	  Results	  
were	  processed	  and	  integrated	  with	  the	  Origin	  6.0™	  software	  distributed	  with	  the	  instrument.	  	  
2.4   Crystallisation,	  diffraction	  data	  collection	  and	  model	  refinement	  
All	  protein	  crystals	  were	  grown	  at	  18	  °C	  by	  vapour	  diffusion	  via	  the	  hanging	  drop	  technique.	  200	  nL	  of	  
1:1	  molar	  ratio	  TCR	  and	  pMHC-­‐I	  (10	  mg/mL)	  in	  crystallization	  buffer	  was	  added	  to	  200	  nL	  of	  reservoir	  
solution.	  PMEL17	  TCR/A2-­‐YLE-­‐9V	  crystals	  were	  grown	  in	  0.2	  M	  sodium	  sulphate,	  0.1M	  Bis/Tris	  propane	  
pH	  6.5,	  20%	  w/v	  PEG	  3350	  (Bulek	  et	  al.,	  2012).	    Crystals	  of	  pMHC	  complexes	  were	  grown	  at	  18	  °C	  by	  
seeding	  into	  hanging	  drops	  of	  0.5	  µL	  of	  seeding	  solution,	  1	  µL	  of	  complex	  and	  1	  µL	  of	  reservoir	  solution.	  
In	  particular,	  0.1	  M	  Hepes	  pH	  7.5,	  0.2	  M	  Ammonium	  Sulphate,	  25%	  PEG	  4000	  was	  used	  for	  A2-­‐YLE	  and	  
A2-­‐YLE-­‐5A;	  0.1	  M	  Tris	  pH	  8.0,	  15%	  Glycerol,	  20%	  PEG	  4000	  for	  A2-­‐YLE-­‐3A	  (Bulek	  et	  al.,	  2012).	  	  
	  
Data	  were	   collected	   at	   -­‐180	   °C	   	   at	   the	  Diamond	   Light	   Source	   (Oxfordshire,	  UK).	   All	   datasets	  were	  
collected	  at	  a	  wavelength	  of	  0.976Å	  using	  an	  ADSC	  Q315	  CCD	  detector.	  Reflection	   intensities	  were	  
estimated	  with	  the	  XIA2	  package	  (Winter,	  2010)	  and	  the	  data	  were	  scaled,	  reduced	  and	  analysed	  with	  
SCALA	  and	  the	  CCP4	  package	  (Bailey,	  1994).	  Structures	  were	  solved	  by	  molecular	  replacement	  using	  
PHASER	  (McCoy	  et	  al.,	  2007).	  Sequences	  were	  adjusted	  with	  COOT	  (Emsley	  and	  Cowtan,	  2004)	  and	  
the	  models	  refined	  with	  REFMAC5	  (Murshudov	  et	  al.,	  1997).	  Graphical	  representations	  were	  prepared	  
with	  PYMOL	  (DeLano	  Scientific,	  LLC).	  Data	  reduction	  and	  refinement	  statistics	  are	  shown	  in	  Table	  2.1.	  
X-­‐ray	  structures	  were	  deposited	  in	  the	  Protein	  Data	  Bank	  (PDB)	  (http://www.rcsb.org/pdb/).	  
	   	  
	  	   39	  
Table	  2.1.	  Data	  collection	  and	  refinement	  statistics	  (molecular	  replacement)	  
One	  crystal	  was	  used	  for	  solving	  each	  structure.	  Values	  in	  parentheses	  are	  for	  the	  highest	  resolution	  shell.	  
	  
	  
Parameters	   PMEL17	  TCR-­‐A2-­‐
YLE-­‐9V	  
A2-­‐YLE	   A2-­‐YLE-­‐3A	   A2-­‐YLE-­‐5A	  
PDB	  code	   5EU6	   5EU3	   5EU4	   5EU5	  
Dataset	  statistics	   	  	   	  	   	  	   	  	  
Space	  group	   P1	   P1	  21	  1	   P1	   P1	  21	  1	  
Unit	  cell	  parameters	  (Å)	   a=	  45.5,	  b=	  54.4,	  
c=	  112.1	  
a=	  52.8,	  b=	  80.4,	  
c=	  56.1	  
a=	  56.1,	  b=	  57.6,	  
c=	  79.9	  
a=	  56.3,	  b=	  79.6,	  
c=	  57.7	  
Radiation	  source	   DIAMOND	  I03	   DIAMOND	  I03	   DIAMOND	  I02	   DIAMOND	  I02	  
Wavelength	  (Å)	   0.9763	   0.9999	   0.9763	   0.9763	  
Measured	  resolution	  range	  (Å)	   51.87	  –	  2.02	   45.25	  –	  1.97	   43.39	  –	  2.12	   43.42	  –	  1.54	  
Reflection	  observed	   128191	   99442	   99386	   244577	  
Unique	  reflections	   64983	   30103	   49667	   67308	  
Completeness	  (%)	   97.3	   98.5	   97.4	   99.6	  
Multiplicity	   2	   3.3	   2	   3.6	  
I/Sigma(I)	   5.5	   7.2	   6.7	   13	  
R
merge
	  (%)	   7.8	   9.8	   8.7	   5	  
Refinement	  statistics	   	  	   	  	   	  	   	  	  
Resolution	  (Å)	   2.02	   1.97	   2.12	   1.54	  
No	  reflections	  used	   61688	   28557	   47153	   63875	  
No	  reflection	  in	  Rfree	  set	   3294	   1526	   2514	   3406	  
R
cryst
	  (no	  cut-­‐off)	  (%)	   18.1	   19.7	   17.2	   17.0	  
R
free
	   22.2	   25.5	   21.1	   20.1	  
Root	  mean	  square	  deviation	  
from	  ideal	  geometry	  
	  	   	  	   	  	   	  	  
Bond	  lengths	  (Å)	   0.018	  (0.019)	   0.019	  (0.019)	   0.021	  (0.019)	   0.018	  (0.019)	  
Bond	  angles	  (°)	   1.964	  	  (1.939)	   1.961	  (1.926)	   2.067	  (1.927)	   1.914	  (1.936)	  
Overall	  coordinate	  error	  (Å)	   0.122	   0.153	   0.147	   .055	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2.5   TCR	  lentiviral	  transduction	  of	  primary	  human	  CD8+	  T-­‐cells	  
2.5.1   293T	  cells	  CaCl2	  transfection	  for	  lentivirus	  particles	  production	  
Prior	   to	   transfection,	   2×107	   293T	   cells	   (ATCC®)	   were	   plated	   in	   a	   T175	   flask	   in	   50	  mL	   transfection	  
medium,	  and	  incubated	  overnight	  at	  37	  °C,	  5%	  CO2	  until	  80%	  confluent.	  	  
The	  following	  media	  were	  prepared	  and	  0.2	  μm	  filtered:	  
	  
Medium	   Composition	  
transfection	  medium	  
(TFM)	  
DMEM	  (Life	  Technologies),	  100U/mL	  Penicillin,	  100μg/mL	  
Streptomycin,	  2mM	  L-­‐Glutamine,	  10%	  FBS	  
pH	  7.1	  medium	   DMEM,	  25mL	  HEPES,	  pH	  7.1	  	  
pH	  7.9	  medium	   TFM,	  25mL	  HEPES,	  pH	  7.9	  
	  
Lentivirus	  particles	  were	  generated	  using	  a	  3rd	  generation	  plasmid	  biosafe	  system.	  The	  lentiviral	  vector	  
plasmid	  (15	  μg)	  bearing	  the	  IMC	  TCR	  construct	  (Immunocore	  Ltd.,	  UK)	  was	  combined	  in	  pH	  7.1	  medium	  
with	  packaging	  plasmids	  pMDL	  (18	  μg),	  pVSV-­‐G	  (7	  μg)	  and	  pRSV	  (18	  μg)	  in	  a	  15mL	  tube	  (final	  volume	  
2.85	  mL).	  150	  μL	  of	  1	  M	  CaCl2	  solution	  were	  added	  to	  the	  DNA	  transfection	  mix.	  The	  transfection	  mix	  
was	   incubated	  at	   room	  temperature	   for	  30	  min	  to	  allow	  precipitates	   to	   form,	  briefly	  vortexed	  and	  
added	  dropwise	  to	  the	  flask.	  293T	  cells	  were	  incubated	  overnight.	  at	  37	  °C,	  5%	  CO2.	  Supernatant	  was	  
replaced	  16	  hours	  post	   transduction	   and	   collected	   after	   48	   and	  72h	   incubations,	   kept	   at	   4	   °C	   and	  
filtered	  through	  a	  0.45	  μm	  filter.	  The	  48h	  and	  72h	  lentivirus	  particle	  collections	  were	  concentrated	  as	  
a	  pool	  by	  ultracentrifugation	  (150,000	  xg	  for	  2	  hours)	  in	  sterilised	  pollyallomer	  ultracentrifuge	  tubes	  
(Beckham	   Coulter).	   After	   centrifugation,	   the	   medium	   was	   discarded	   and	   the	   lentiviral	   pellet	   was	  
resuspended	  in	  300	  μL	  of	  complete	  T-­‐cell	  media.	  The	  lentiviral	  aliquots	  were	  snap	  frozen	  on	  dry	  ice	  
into	  cryovials	  and	  stored	  at	  -­‐80	  °C.	  
2.5.2   Lentiviral	  transduction	  of	  primary	  CD8+	  T-­‐cells	  
Lymphocytes	  were	  isolated	  from	  PBMCs	  by	  standard	  density	  gradient	  as	  described	  in	  section	  2.9.1.	  
CD8+	   T	   cells	   were	   positively	   selected	   using	   human	   CD8	   MicroBeads	   (Miltenyi	   Biotec)	   following	  
manufacturer’s	   instructions.	   Briefly,	  magnetically	   labelled	   CD8+	   cells	  were	   eluted	   from	   a	  MACS	   L-­‐
column	  as	  the	  positively	  selected	  cell	  fraction,	  and	  resuspended	  in	  T-­‐cell	  complete	  medium.	  Cells	  were	  
activated	  overnight	  with	  anti-­‐CD3/CD28	  Human	  T	  cell	  activator	  Dynabeads®	  (Invitrogen)	  at	  a	  bead	  to	  
cell	  ratio	  of	  1:1	  before	  lentiviral	  transduction.	  Activated	  primary	  CD8+	  T	  cells	  (1x106	  in	  100	  μL)	  were	  
transduced	   with	   lentiviral	   constructs	   (100	   μL)	   expressing	   the	   IMC	   TCR	   specific	   for	   the	   HLA-­‐A2-­‐
restricted	  melanoma	  differentiation	  antigen	  gp100	  (YLEPGPVTA).	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Polybrene®	  (Santa	  Cruz	  Biotechnology,	  CA)	  was	  added	  at	  a	  final	  concentration	  of	  500	  μg/mL	  in	  order to 
increase	  binding	  between	  the	  viral	  particle	  and	  the	  cellular	  membrane	  and	  plates	  were	  incubated	  at	  
37	  °C,	  5%	  CO2.	  After	  72	  hours,	  transduction	  efficiency	  was	  determined	  by	  flow	  cytometry	  after	  staining	  
with	  the	  relevant	  pMHC-­‐I	  tetramer	  (as	  described	  in	  section	  2.11.4)	  or	  anti-­‐Vβ17	  TCR	  (FITC-­‐conjugated)	  
antibody.	   Dynabeads®	   were	   removed	   by	   magnet	   separation	   five	   days	   after	   transduction.	   Non	  
transduced	  cells	  and	  MEL5	  TCR	  transduced	  cells	   (kindly	  provided	  by	  Angharad	  Lloyd)	  were	  used	  as	  
controls.	  
2.6   Cell	  culture	  media	  and	  buffers	  
All	  reagents	  and	  buffers,	  with	  the	  exception	  of	  those	  supplied	  as	  part	  of	  commercial	  kits,	  used	  for	  T-­‐
cell	  culture	  are	  listed	  below.	  
	  
Media	  and	  reagents	   Composition	  
R0	  
RPMI-­‐1640	  (Life	  Technologies)	  	  
100	  U/mL	  Penicillin	  (Life	  Technologies),	  100	  μg/mL	  Streptomycin	  (Life	  
Technologies)	  	  
2	  mM	  L-­‐Glutamine	  (Life	  Technologies)	  
R5	   R0	  	  with	  5%	  Heat-­‐Inactivated	  Fetal	  Bovine	  Serum	  (FBS)	  (Life	  Technologies)	  
R10	   R0	  with	  10%	  FBS	  
T-­‐cell	  culture	  medium	  	  
R10	  
10	  mM	  HEPES	  (Life	  Technologies)	  
1	  mM	  Sodium	  Piruvate	  (Life	  Technologies)	  
1X	  MEM	  Non-­‐essential	  amino	  acids	  (NEAA)	  solution	  (Life	  Technologies)	  
25	  ng/mL	  IL-­‐15	  (PeproTech)	  




10	  mM	  HEPES	  
1	  mM	  Sodium	  Piruvate	  
1X	  MEM	  Non-­‐essential	  amino	  acids	  (NEAA)	  solution	  
25	  ng/mL	  IL-­‐15	  	  
20	  IU/mL	  IL-­‐2	  
1	  μg/mL	  purified	  PHA	  (Phytohemagglutinin)	  (Alere)	  
Freezing	  buffer	   90%	  FBS	  10%	  DMSO	  (Dimethyl	  sulfoxide)	  (Sigma	  Aldrich)	  
RBC	  lysis	  buffer	   155	  mM	  NH4Cl,	  10	  mM	  KHCO3,	  0.1	  mM	  EDTA	  (pH	  7.2-­‐7.4)	  
PBS-­‐EDTA	   PBS,	  2	  mM	  EDTA	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All	  media	  and	  buffers	  used	  for	  tissue	  culture	  were	  filtered	  using	  0.2	  μm	  syringe	  or	  filter	  bottle	  filters	  
(Stericup®,	  Merck	  Millipore).	  T25,	  T75	  and	  T175	  flasks	  (Greiner	  Bio-­‐One)	  and	  24-­‐,	  48-­‐,	  96-­‐multi	  well	  
plates	  (Greiner	  Bio-­‐One)	  were	  used	  for	  tissue	  culture,	  unless	  otherwise	  stated.	  Cell	  lines	  were	  regularly	  
screened	   for	  Mycoplasma	   infection	   (MycoAlert™	   kit,	   Lonza)	   following	  manufacturer’s	   instructions.	  
Cells	  were	  washed	  in	  serum-­‐free	  media	  (R0	  medium)	  and	  adherent	  cell	  cultures	  were	  detached	  with	  
PBS-­‐EDTA.	  R5	  medium	  was	  used	  to	  rest	  T	  cells	  overnight	  and	  to	  perform	  most	  of	  the	  in	  vitro	  assays	  
(ELISA,	  ELISPOT,	  etc).	  	  
2.7   Cell	  culture	  
Cell	  lines	  were	  grown	  at	  37	  °C	  with	  5%	  CO2	  in	  R10	  medium,	  unless	  otherwise	  stated.	  Every	  2	  to	  3	  days,	  
cells	  were	  split	  and	  a	  portion	  thereof	  seeded	  into	  fresh	  media.	  Care	  was	  taken	  to	  ensure	  the	  cells	  did	  
not	  exceed	  80-­‐90%	  confluence	  and/or	  turned	  the	  media	  yellow,	  indicating	  a	  decrease	  in	  pH	  level	  due	  
to	  the	  accumulation	  of	  waste	  products.	  	  For	  adherent	  cell	  lines,	  the	  whole	  content	  of	  the	  tissue	  culture	  
flask	  was	  transferred	  into	  a	  50	  mL	  centrifuge	  tube	  and	  the	  flask	  washed	  with	  PBS	  to	  remove	  all	  remains	  
of	  the	  media.	  PBS-­‐EDTA	  was	  added	  to	  detach	  the	  cells	  from	  the	  inner	  surface	  of	  the	  flask.	  The	  flask	  
was	  then	  incubated	  at	  37	  °C	  for	  2	  min	  and	  then	  rinsed	  with	  an	  equal	  volume	  of	  R10	  media.	  The	  bulk	  
cell	   suspension	  was	   transferred	   to	   the	  50	  mL	  centrifuge	   tube,	  centrifuged	  at	  400	  xg	   for	  5	  min	  and	  
resuspended	   in	  R10	  medium	  for	  counting.	  Cells	  were	  plated	   into	  a	  new	  flask	  at	   the	  recommended	  
seeding	  density.	  For	  suspension	  cultures,	  cells	  were	  resuspended	  thoroughly	  and	  counted	  if	  required.	  
Cells	  were	  then	  split	  into	  fresh	  R10	  medium	  in	  a	  new	  flask.	  	  
	  
The	  following	  cell	  lines	  were	  used	  throughout	  my	  studies:	  
Cell	  line:	   	  	   Grown	  in:	   	  Used	  as:	  
melanoma	  cell	  lines	   adherent	   R10	   target	  cells	  
T2	  (HLA-­‐A2+)	   suspension	   R10	   antigen	  presenting	  cells	  
C1R-­‐A2	  (HLA-­‐A2+)	   suspension	   R10	   antigen	  presenting	  cells	  
	  
2.7.1   Cell	  count	  
Cells	  were	   thoroughly	   resuspended,	  10	  μL	  of	  cell	   suspension	  was	  mixed	  1:1	  with	   trypan	  blue	  0.4%	  
solution	  (Sigma-­‐Aldrich)	  in	  a	  single	  well	  of	  a	  96-­‐well	  round	  bottomed	  plate.	  10	  μL	  were	  loaded	  onto	  a	  
counting	   chamber	   and	   live	   cells	   were	   counted	   based	   on	   trypan	   blue	   exclusion	   according	   to	   the	  
following	  formula:	  (number	  of	  cells	   in	  one	  section)	  x	  (trypan	  blue	  dilution	  factor)	  x104	  =	  number	  of	  
cells/mL.	  
	   	  
	  	   43	  
2.7.2   Cryopreservation	  and	  thawing	  of	  cell	  lines	  
Cells	  were	   centrifuged	  at	   400	   xg	   for	   5	  min	   to	   remove	   culture	  media,	   and	   resuspended	   in	   freezing	  
buffer.	  Viable	  cell	  numbers	  were	  enumerated	  by	  trypan	  blue	  exclusion	  and	  1	  mL	  aliquots	  (typically	  
from	  1	  to	  1x107	  cells)	  were	  frozen	  in	  internal	  thread	  cryovials	  (Nunc)	  at	  -­‐80	  °C	  using	  a	  controlled-­‐rate	  
freezing	  device	  (either	  Mr.	  Frosty®	  freezing	  pot,	  Nalgene,	  or	  CoolCell	  freezing	  pot,	  Biocision)	  following	  
manufacturer’s	  instructions.	  Once	  frozen,	  cells	  were	  stored	  short-­‐	  or	  long-­‐term	  in	  liquid	  nitrogen.	  Vials	  
of	  cryopreserved	  cells	  were	  removed	  from	  liquid	  nitrogen	  storage	  and	  thawed	  at	  37	  °C	  in	  a	  water	  bath.	  
Immediately	  upon	  thawing,	  cells	  were	  transferred	  into	  a	  15	  mL	  centrifuge	  tube	  containing	  10	  mL	  pre-­‐
warmed	  R10	  medium.	  Cells	  were	  centrifuged	  at	  400	  xg	  for	  5	  min	  and	  the	  supernatant	  discarded.	  The	  
cell	  pellet	  was	  resuspended	  in	  1	  mL	  R10	  media,	  counted	  and	  transferred	  to	  flasks	  or	  plates.	  
2.8   Generation	  of	  TILs	  and	  melanoma	  cell	  lines	  
Expanded	  TILs	  and	  autologous	  melanoma	  cell	  lines	  used	  in	  this	  study	  were	  generated	  by	  collaborators	  
at	   the	   Center	   for	   Cancer	   Immune	   Therapy	   (CCIT)	   Herlev	   Hospital,	   Copenhagen,	   Denmark)	   with	  
protocols	  extensively	  described	  in	  other	  studies	  (Donia	  et	  al.,	  2012;	  Ellebæk	  et	  al.,	  2012). Briefly,	  TILs	  
were	   initially	   isolated	   from	   surgically	   resected	   tumour	   fragments	   and	  minimally	   expanded	   in	   high	  
doses	  of	   IL-­‐2	  (6000	  IU/mL	  IL-­‐2,	  Proleukin;	  Novartis).	  When	  a	  minimum	  of	  5x107	  TILs	  were	  obtained	  
(typically	  about	  14-­‐28	  days	  after	  surgical	  resection),	  expansion	  was	  further	  achieved	  by	  a	  standard	  14-­‐
days	   Rapid	   Expansion	   Protocol	   (REP),	   in	   which	   TILs	   are	   non-­‐specifically	   expanded	  with	   a	   200-­‐fold	  
excess	  of	  allogeneic	  irradiated	  PBMCs	  from	  at	  least	  three	  different	  healthy	  donors	  and	  30	  ng/mL	  anti-­‐
CD3	   antibodies.	   Autologous	  melanoma	   cell	   lines	  were	   generated	   separately	   from	   TILs	   either	   from	  
tumour	  fragments	  or	  from	  a	  combination	  of	  cells	  recovered	  from	  suspension	  in	  transport	  medium	  or	  
after	  mincing,	  as	  previously	  described	  (Donia	  et	  al.,	  2012).	  
2.8.1   Patient	  samples	  
All	   the	   procedures	   were	   approved	   by	   the	   Scientific	   Ethics	   Committee	   for	   the	   Capital	   Region	   of	  
Denmark.	  Written	  informed	  consent	  was	  obtained	  from	  patients	  before	  any	  procedure	  according	  to	  
the	  Declaration	  of	  Helsinki.	   Tumour	   specimens	  of	   at	   least	   1	   cm	  were	  obtained	   from	  patients	  with	  
melanoma	  stage	  III	  or	  IV	  undergoing	  standard-­‐of-­‐care	  surgical	  procedures	  or	  specimen	  collection	  for	  
enrolment	  in	  a	  clinical	  trial	  (phase	  II	  identifier:	  NCT00937625).	  Throughout	  the	  text,	  patients	  sample	  
ID	  is	  referred	  to	  as	  MM909.24,	  MM909.11	  and	  MM909.154.	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2.8.2   HLA	  typing	  
HLA	   typing	   of	   TIL	   samples	  was	   performed	   by	   either	   Pure	   Transplant	   Solutions,	   LLC	   (Oklahoma)	   or	  
Welsh	  Transplantation	  and	  Immunogenetics	  Laboratory	  (UK).	  
2.9   Maintenance	  and	  expansion	  of	  T-­‐cell	  cultures	  
2.9.1   Isolation	  of	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  
Fresh	  blood	  samples	  were	  obtained	  from	  (EDTA-­‐treated)	  buffy	  coats	  via	  the	  Welsh	  Blood	  Service	  (WBS,	  
Cardiff)	   in	  accordance	  with	  the	  appropriate	  ethical	  approval.	  Samples	  were	  confirmed	  seronegative	  
for	   HIV-­‐1,	   HBV	   and	   HCV.	   PBMCs	   were	   isolated	   from	   whole	   blood	   by	   Lymphoprep™	   (Stemcell™	  
Technologies	   Inc.)	   density	   gradient	   centrifugation.	   Tubes	   were	   centrifuged	   at	   900	   xg	   for	   20	   min	  
without	  brake	  at	  RT.	  Using	  a	  sterile	  pasteur	  pipette,	  the	  mononuclear	  interface	  layer	  was	  removed,	  
transferred	  into	  a	  new	  50	  mL	  tube	  and	  washed	  in	  R10	  (700	  xg	  for	  10	  min).	  The	  pellet	  was	  resuspended	  
in	  25	  mL	  red	  blood	  cell	  lysis	  buffer	  and	  incubated	  at	  37°C	  for	  10	  min.	  A	  further	  wash	  was	  performed	  at	  
200	  xg	  for	  10	  min	  to	  remove	  platelets.	  PBMC	  were	  finally	  resuspended	  in	  R10	  medium,	  counted	  and	  
kept	  in	  the	  incubator	  at	  37	  °C,	  5%	  CO2	  for	  further	  processing.	  
2.9.2   Expansion	  and	  culture	  of	  T	  cells	  
The	  following	  antigen-­‐independent	  expansion	  protocol	  was	  used	  to	  generate	  large	  numbers	  of	  T-­‐cell	  
lines	  and	  clones.	  Up	  to	  1x106	  T	  cells	  were	  seeded	  into	  a	  T25	  tissue	  culture	  flask	  with	  15	  mL	  of	  T-­‐cell	  
expansion	  medium	  and	  15x106	  irradiated	  (3000	  rad)	  PBMC	  feeders	  (from	  3	  pooled	  donors	  as	  described	  
in	  section	  2.9.1).	  The	  flask	  was	  placed	  at	  37	  °C,	  5%	  CO2	  tilted	  at	  approx.	  45°,	  so	  as	  to	  enhance	  cell-­‐to-­‐
cell	  contact.	  On	  day	  5	  of	  the	  expansion,	  half	  the	  medium	  was	  replaced	  with	  the	  same	  volume	  of	  T-­‐cell	  
expansion	  medium.	  Cells	  were	  resuspended	  and	   incubated	  for	  a	   further	  2	  days	   in	  upright	  position.	  
Cells	  were	  then	  harvested	  on	  day	  7	  of	  the	  expansion,	  counted	  and	  plated	  in	  fresh	  T-­‐cell	  culture	  medium	  
at	  3-­‐4x106	  cells/well	  in	  24	  well	  plates	  (2	  mL/well)	  or	  1-­‐2x106	  cells/well	  in	  48	  well	  plates	  (1	  mL/well).	  
The	  plate	  was	  incubated	  at	  37	  °C,	  5%	  CO2	  and	  left	  until	  the	  wells	  were	  confluent.	  Every	  2-­‐3	  days	  half	  
the	  media	  was	  replaced,	  when	  media	  turned	  yellow,	  with	  fresh	  T-­‐cell	  complete	  medium.	  After	  14	  days	  
from	  expansion,	  T-­‐cells	  could	  be	  used	   for	  experiments,	  maintained	   for	  up	   to	  4	  weeks	   in	  culture	  or	  
frozen	  until	  further	  use.	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2.10   Functional	  T-­‐cell	  assays	  
2.10.1   Peptides	  
Crude	  (50-­‐60%	  purity)	  and	  pure	  (>	  90%	  purity)	  peptides	  used	  throughout	  this	  study	  were	  synthesized	  
by	  GL	  Biochem	  Ltd.	  (Shanghai,	  China)	  and	  Peptide	  Protein	  Research	  Ltd.	  (Hampshire,	  UK),	  respectively.	  
Lyophilised	  peptides	  (4	  mg)	  were	  reconstituted	  in	  DMSO	  to	  a	  final	  stock	  concentration	  of	  20	  mg/mL	  
and	  stored	  at	  -­‐80	  °C.	  Reconstituted	  peptides	  were	  thawed	  last	  minute	  on	  ice	  and	  a	  working	  dilution	  
was	   prepared	   in	   R0	   medium.	   HLA-­‐A2-­‐restricted	   viral	   peptides	   used	   as	   controls	   in	   this	   thesis	   are:	  
GILGFVFTL	  (designated	  as	  GIL)	  from	  Influenza	  viruses	  M1	  matrix	  protein	  (Bednarek	  et	  al.,	  1991)	  and	  
NLVPMVATV	   (designated	   as	   NLV)	   from	   CMV	   virus	   (Diamond	   et	   al.,	   1997).	   The	   full	   list	   of	   tumour-­‐
associated	  antigens	  used	  is	  provided	  in	  the	  Appendix.	  
2.10.2   IFN-­‐γ	  Enzyme-­‐Linked	  ImmunoSpot	  (ELISpot)	  assay	  
Mouse	  anti-­‐human	  IFN-­‐γ	  antibody	  1-­‐DIK	  (Mabtech)	  was	  diluted	  to	  10	  μg/mL	  with	  PBS,	  and	  50	  μL	  were	  
added	  to	  each	  well	  of	  an	  ELISpot	  plate	  (PVDF-­‐backed	  plate,	  Millipore).	  Coated	  plates	  were	  incubated	  
for	  4	  h	  at	  37	  °C	  wrapped	  in	  cling	  film,	  washed	  thoroughly	  5	  times	  with	  250	  μL	  PBS/well,	  and	  blocked	  
with	  100	  μL	  of	  R10	  medium	  for	  1	  h	  at	  RT.	  Rested	  T	  cells	  (overnight	  at	  37°C	  in	  R5)	  were	  added	  to	  the	  
wells	  (105	  cells)	  in	  100	  μL	  of	  R5	  medium.	  The	  peptide	  was	  added	  at	  the	  desired	  concentration	  (10-­‐5	  M)	  
to	  appropriate	  wells	  in	  20	  μL	  of	  R0	  medium.	  The	  final	  volume	  (200	  μL/well)	  was	  made	  up	  in	  R5	  medium.	  
Phytohaemagglutinin	  (PHA)	  (Sigma	  Aldrich)	  2	  pg/mL	  was	  added	  to	  the	  positive	  control	  wells;	  T	  cells	  
only	  were	  added	  to	  the	  negative	  control	  wells.	  ELISpot	  wells	  were	  set	  up	  in	  duplicate.	  Control	  wells	  
that	  did	  not	  require	  peptide	  received	  media	  alone,	  so	  that	  the	  total	  volume	  is	  200	  μL.	  The	  plate	  was	  
then	  wrapped	  in	  silver	  foil	  and	  incubated	  at	  37	  °C	  for	  16-­‐18	  hours.	  Plates	  were	  washed	  3	  times	  with	  
150	  μL	  PBS	  and	  incubated	  with	  100	  μL	  sterile	  water	  for	  10	  min	  at	  room	  temperature	  (therefore	  lysing	  
the	   remaining	   bound	   cells).	   The	   plate	  was	   further	  washed	   twice	  with	   150	  μL/well	   PBS.	   Secondary	  
biotinylated	  antibody	  7-­‐B6-­‐1-­‐Biotin	  (Mabtech)	  (1:1000	  in	  PBS)	  was	  added	  at	  50	  μL/well	  and	  incubated	  
in	  the	  dark	  at	  room	  temperature	  for	  2	  hours.	  The	  plate	  was	  washed	  5	  times	  with	  PBS,	  and	  50	  μL	  of	  
Streptavadin-­‐Alkaline	  phosphatase	  (1:1000	  in	  PBS)	  was	  added	  to	  each	  well.	  The	  plates	  were	  incubated	  
for	  2	  hours	  in	  the	  dark	  at	  RT,	  followed	  by	  5	  washes	  with	  150	  μL	  PBS.	  Developing	  solution	  was	  made	  
fresh	  using	  25X	  AP	  colour	  development	  buffer	   (Bio-­‐Rad),	  AP-­‐conjugate	  substrate	  A	  and	  B	  solutions	  
(Bio-­‐Rad),	   and	   sterile	  water.	  The	   solution	  was	  added	  at	  50	  μL/well	   and	   left	   to	  develop	   in	   the	  dark	  
between	  10	  to	  20	  min,	  until	  spots	  were	  clearly	  visible.	  Developing	  reaction	  was	  stopped	  by	  washing	  
plates	  with	  tap	  water;	  plates	  where	  then	  air	  dried	  in	  the	  dark	  before	  spot	  counting	  using	  an	  automated	  
ELISpot	  counting	  system	  (AID	  ELISpot	  reader,	  Cadama	  Medical).	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2.10.3   51Chromium	  (51Cr)	  release	  cytotoxicity	  assay	  
Functional	  assays	  to	  determine	  specific	  T-­‐cell	  killing	  of	   target	  cells	  were	  carried	  out	  by	  51Cr	  release	  
cytotoxicity	  assay.	  Effector	  T	  cells	  were	  rested	  overnight	  in	  R5	  when	  supernatant	  was	  harvested	  for	  
ELISA	   the	   following	   day.	   Assays	  were	   performed	   in	   duplicate	   for	   each	   sample	   in	   a	   96-­‐well	   round-­‐
bottomed	  plate.	  Briefly,	   target	   cells	   (2000/well)	  were	   labelled	   for	  1	  hour	  at	  37	   °C	  with	  30	  µCi	   51Cr	  
(sodium	  chromate	  in	  normal	  saline,	  Perkin	  Elmer)	  per	  1x106	  cells,	  washed	  with	  R10	  and	  allowed	  to	  
leach	  for	  a	  further	  hour	  at	  37	  °C	  in	  R10	  to	  remove	  any	  excess	  51Cr	  from	  the	  cells.	  After	  51Cr	  labelling,	  
target	  cells	  were	  washed,	  resuspended	  in	  R5,	  and	  plated	  with	  effector	  T	  cells	  at	  the	  desired	  effector-­‐
to-­‐target	  (E/T)	  ratio	  in	  a	  final	  volume	  of	  150	  µL	  of	  R10.	  Target	  cells	  were	  also	  incubated	  with	  5%	  Triton	  
X-­‐100	   detergent	   or	   alone	   to	   give	   the	   total	   and	   spontaneous	   51Cr	   released	   from	   the	   target	   cells	  
respectively.	  After	  a	  5-­‐	  and/or	  18-­‐hour	  incubation	  at	  37	  °C,	  5%	  CO2,	  the	  supernatants	  were	  harvested	  
(15	   μL),	   mixed	   with	   150	   μL	   of	   Optipahse	   Supermix	   Scintillation	   Cocktail	   (Perkin	   Elmer)	   in	   96-­‐well	  
polyethylene	   terephthalate	   plates	   (Perkin	   Elmer)	   and	   sealed.	   The	   amount	   of	   released	   51Cr	   was	  
measured	   indirectly	  on	  a	  1450-­‐MicrobetaTM	  counter	  (Perkin	  Elmer). The	  percent-­‐specific	  target	  cell	  
lysis	  by	  T	  cells	  was	  calculated	  according	  to	  the	  following	  formula:	  (experimental	  release	  –	  spontaneous	  
release)	  /	  (maximal	  release	  –	  spontaneous	  release)	  *100	  =	  %	  specific	  lysis.	  
2.10.4   Peptide	  activation	  assay	  by	  Enzyme	  Linked	  Immunosorbent	  Assay	  (ELISA)	  
T-­‐cells	  were	  washed	  with	  R0	  medium	  and	   rested	   in	  R5	  medium	  overnight	  before	  being	  used	   in	  an	  
activation	  assay.	  In	  a	  single	  well	  of	  a	  96	  round	  bottom-­‐well	  plate,	  3x104	  T-­‐cells	  were	  primed	  with	  6x104	  
antigen	  presenting	  cells	  per	  100	  μL	  of	  R5	  medium	  and	  a	  titration	  of	  peptide	  from	  10-­‐5	  to	  10-­‐12	  M	  for	  13	  
h	  at	  37	  °C,	  5%CO2.	  The	  plate	  was	  centrifuged	  at	  300	  xg	  3	  min	  to	  sediment	  cells	  to	  the	  bottom	  of	  the	  
well.	  50	  μL/well	  of	  supernatant	  was	  harvested	  and	  diluted	  with	  70	  μL	  of	  R0	  medium.	  Supernatants	  
were	  analysed	  by	  ELISA	  (described	  in	  section	  2.10.5).	  
2.10.5   MIP-­‐1β/TNF-­‐α	  ELISA	  	  
MIP-­‐1β/TNF-­‐α	   ELISA	   were	   performed	   using	   DuoSet®	   human	   ELISA	   kit	   following	   manufacturer’s	  
instructions	  (R&D	  Systems).	  All	  washes	  were	  performed	  with	  190	  μL	  of	  0.05%	  Tween	  20-­‐PBS	  (wash	  
buffer)	   using	   an	   automated	   microplate	   washer.	   Briefly,	   a	   half-­‐well	   flat	   bottom	   ELISA	   microplate	  
(Corning	  Costar)	  was	  coated	  with	  50	  μL	  of	  mouse	  anti-­‐human	  MIP-­‐1β/TNF-­‐	  α	  capture	  antibody	  (1.5	  
μg/mL)	  and	  incubated	  overnight	  at	  RT.	  The	  plate	  was	  washed	  3	  times,	  150	  μL	  of	  1%	  BSA-­‐PBS	  (reagent	  
diluent)	  solution	  was	  added	  to	  each	  well	  and	  the	  plate	  was	  incubated	  for	  1	  h	  at	  RT.	  Following	  3	  washes,	  
50	  μL	  of	  cell	  supernatant	  collected	  from	  an	  activation	  assay	  was	  added	  to	  each	  well	  and	  incubated	  1	  h	  
and	  15	  min	  at	  RT.	  A	  recombinant	  human	  MIP-­‐1β	  (or	  TNF-­‐α)	  standard	  (R&D	  Systems)	  was	  titrated	  from	  
1,000	  to	  15.6	  pg/mL	  in	  reagent	  diluent	  and	  plated	  50	  μL	  to	  produce	  a	  standard	  curve	  (Figure	  2.2).	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Figure	  2.2.	  Example	  of	  MIP-­‐1β	  standard	  curve	  
The	  linear	  regression	  line	  equation	  (y=	  m*x)	  was	  calculated	  and	  used	  to	  interpolate	  MIP-­‐1B	  concentrations	  for	  each	  sample.	  
	  
	  
The	  plate	  was	  washed	  3	  times	  and	  coated	  with	  50	  μL	  biotinylated	  goat	  anti-­‐human	  MIP-­‐1β	  (or	  TNF-­‐α)	  
(50	  ng/mL)	  detection	  antibody.	  After	  1h	  and	  15	  min	  incubation	  at	  RT,	  the	  plate	  was	  washed	  3	  times	  
and	  HRP-­‐conjugated	  streptavidin	  (50	  µL)	  was	  added	  to	  the	  wells.	  The	  plate	  was	  incubated	  in	  the	  dark	  
for	  20	  min	  at	  room	  temperature	  followed	  by	  3	  final	  washes.	  50	  μL	  of	  a	  1:1	  ratio	  colour	  reagents	  A	  and	  
B	  (R&D	  Systems)	  were	  added	  to	  each	  well	  and	  incubated	  for	  a	  maximum	  of	  15	  min	  at	  RT.	  The	  reaction	  
was	  blocked	  by	  adding	  25	  μL	  of	  stop	  solution	  (R&D	  Systems).	  The	  OD450nm	  of	  each	  well	  was	  read	  using	  
a	  Bio-­‐rad	  iMark	  microplate	  reader	  with	  correction	  set	  to	  570	  nm.	  
2.10.6   Combinatorial	  peptide	  library	  (CPL)	  scans	  
T	  cells	  were	  challenged	  with	  either	  a	  9-­‐mer	  or	  10-­‐mer	  combinatorial	  peptide	  library	  (CPL)	  in	  positional	  
scanning	  format	  (Pepscan	  Presto	  Ltd)	  and	  their	  activation	  towards	  each	  mixture	  was	  evaluated	  by	  the	  
release	  of	  MIP-­‐1β	  chemokine	  by	  ELISA	  (described	  in	  section	  2.10.5).	  The	  decamer	  CPL	  contains	  a	  total	  
of	  9.36	  x1012	  (=	  (10+19)	  x199)	  different	  decamer	  peptides	  and	  is	  divided	  into	  200	  different	  peptide	  mix.	  
In	  every	  peptide	  mixture,	  one	  position	  has	  a	   fixed	  L-­‐amino	  acid	  residue	  and	  all	  other	  positions	  are	  
degenerate,	  with	  the	  possibility	  of	  any	  one	  of	  19	  natural	  L-­‐amino	  acids	  being	   incorporated	   in	  each	  
individual	  position.	  The	  cysteine	  residue	  was	  omitted	  from	  the	  random	  positions	  to	  avoid	  formation	  
of	  disulphide	  bonds	  between	  peptides	  within	  the	  mixture	  and	  peptide	  aggregation.	  Each	  peptide	  mix	  
consists	   of	   3.2	   x1011	   (199)	   different	   decamer	   peptides	   in	   approximately	   equimolar	   concentrations.	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Figure	  2.3.	  Schematic	  diagram	  of	  a	  10mer	  combinatorial	  peptide	  library	  
Each	  of	  the	  20	  natural	  proteogenic	  amino	  acids	  at	  each	  position	  and	  all	  possible	  combinations	  of	  the	  other	  amino	  acids	  in	  
the	  other	  positions.	  For	  instance,	  sub-­‐library	  1	  has	  an	  Alanine	  at	  P1	  and	  an	  equimolar	  mix	  of	  amino	  acids	  at	  all	  the	  other	  




CD8+	  T	  cells	  were	  washed	  with	  R0	  medium	  and	  rested	  in	  R5	  medium	  overnight.	  Antigen	  presenting	  
cells	  were	  plated	  in	  single	  well	  of	  a	  96	  round	  bottom-­‐well	  plate	  at	  a	  concentration	  of	  6x104	  cells	  per	  
45	  μL	  and	  pulsed	  with	  5	  μL	  of	  peptide	  mixture	  from	  a	  decamer	  peptide	  library	  at	  a	  final	  concentration	  
of	   100	  μM	   for	   1	   hour	   at	   37	   °C,	   5%	  CO2;	   3x104	  CD8+	   T	   cells	   (50	  μL)	  were	   added	   to	   pulsed	   antigen	  
presenting	  cells.	  Plates	  were	  incubated	  overnight	  at	  37	  °C,	  5%	  CO2	  and	  centrifuged	  at	  300	  xg	  for	  5	  min.	  
Subsequently,	  the	  supernatant	  (50	  µL)	  was	  harvested	  and	  assayed	  for	  MIP-­‐1β	  by	  ELISA	  according	  to	  
the	  manufacturer's	  instructions	  (R&D	  Systems)	  (Section	  2.10.5).	  	  
2.10.6.1   Epitope	  identification	  
A	  novel	  webtool	  (PI	  CPL)	  developed	  by	  Dr	  Barbara	  Szomolay	  in	  Cardiff,	  was	  used	  to	  link	  the	  raw	  data	  
of	  CPL	  scans	  to	  the	  likelihood	  of	  the	  peptide	  to	  bind	  the	  cognate	  T-­‐cell	  clone	  (Szomolay	  et	  al.,	  2016).	  
The	   webtool	   is	   integrated	   into	   the	   WSBC	   webtools	   and	   is	   accessible	   at	  
http://wsbc.warwick.ac.uk/wsbcToolsWebpage.	  Human	  self	  databases	  were	  compiled	  on	  the	  basis	  of	  
public	   available	   protein	   sequence	   databases	   provided	   by	  NCBI	   (National	   Center	   for	   Biotechnology	  
Information),	  UniProt	  (Universal	  Protein	  Resource),	  and	  PDB	  (Protein	  Data	  Bank).	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2.11   Flow	  cytometric	  analysis	  
Samples	  were	  acquired	  on	  a	  BD	  FACSCanto™	  II	  flow	  cytometer	  (BD	  Biosciences)	  using	  the	  FACSDiva	  
software	  (BD	  Biosciences).	  Data	  analysis	  was	  performed	  on	  FlowJo	  version	  5.7	  (Tree	  Star	  Inc,	  US).	  	  Anti-­‐
mouse	   Igκ	  antibody	  capture	  beads	  (BD	  Biosciences)	  were	  used	  to	  prepare	   individual	  compensation	  
tubes	  for	  each	  mAb	  used	  in	  the	  experiment.	  	  
2.11.1   Labelling	  cells	  with	  fluorescence	  conjugated	  antibodies	  
Cells	  were	  washed	  in	  FACS	  buffer	  (700	  xg	  3	  min),	  counted	  by	  trypan	  blue	  exclusion	  and	  transferred	  to	  
either	  a	  96	  well	  plate	  or	  5mL	  FACS	  tube	  (Elkay	  Laboratory	  Products	  Ltd,	  UK)	  and	  washed	  in	  FACS	  buffer	  
(700	  xg	  for	  3	  min).	  	  Cells	  were	  washed	  in	  PBS	  and	  stained	  5min	  at	  room	  temperature	  with	  LIVE/DEAD®	  
Violet	  (Life	  Technologies)	  (diluted	  1:40	  in	  PBS)	  for	  dead	  cell	  exclusion	  before	  surface	  staining	  (20	  min	  
on	  ice	  and	  in	  the	  dark)	  with	  relevant	  mouse	  anti-­‐human	  mAb.	  
	  
The	  following	  mouse-­‐anti	  human	  mAbs	  were	  used	  depending	  on	  each	  experiment:	  
	  
mAb	  specificity	   Fluorochrome	   Clone	   Supplier	  
CD3	   PerCP	   BW264/56	   Miltenyi	  Biotec	  
CD8	   APC-­‐Vio770	  
APC	  
PE	  
BW135/80	   Miltenyi	  Biotec	  
CD4	   PE-­‐Vio770	  
FITC	  
APC	  
VIT4	   Miltenyi	  Biotec	  	  
αβ	  TCR	  	   PE	  
FITC	  
APC	  
IP26	   Biolegend	  
INF-­‐γ	   APC	   45-­‐15	   Miltenyi	  Biotec	  	  
CD107a	   PE	   H4A3	   BD	  Bioscence	  
TNF-­‐α	   PE-­‐Vio770	   MAb11	   Bioscence	  
CD19	   Pacific	  Blue	   HIB19	  	   Biolegend	  
	  
The	  following	  mouse-­‐anti	  human	  TCRBV	  mAbs	  (Beckman	  Coulter),	  PE-­‐	  or	  FITC-­‐conjugated,	  were	  used	  
for	  TCR	  β-­‐chain	  scanning:	  (Arden	  et	  al.,	  1995;	  Folch	  and	  Lefranc,	  2000)	  
	  
Vβ	   IMGT	  nomenclature	   Clone	   Fluorochrome	  
1	   TRBV9	   BL37.2	   FITC	  
2	   TRBV20-­‐1	   MPB2D5	   FITC/PE	  
3	   TRBV28	   CH92	   FITC	  
4	   TRBV29-­‐1	   WJF24	   PE	  
5.1	   TRBV5-­‐1	   IMMU	  157	   FITC	  
5.2	   TRBV5-­‐6	   36213	   FITC	  
5.3	   TRBV5-­‐5	   3D11	   PE	  
7.1	   TRBV4-­‐1	   ZOE	   FITC	  
	  	   50	  
7.2	   TRBV4-­‐3	   ZIZOU4	   PE	  
8	   TRBV12	   56C5.2	   FITC	  
9	   TRBV3	   FIN9	   PE	  
11	   TRBV25	   C21	   FITC	  
12	   TRBV10	   VER2.32.1	   FITC	  
13.1	   TRBV6-­‐5	   IMMU	  222	   FITC	  
13.2	   TRBV6-­‐2	   H132	   PE	  
13.6	   TRBV6-­‐6	   JU74.3	   FITC	  
14	   TRBV27	   CAS1.1.3	   FITC	  
16	   TRBV14	   TAMAYA1.2	   FITC	  
17	   TRBV19	   E17.5F3.15.13	   FITC	  
18	   TRBV18	   BA62.6	   PE	  
20	   TRBV30	   ELL1.4	   PE	  
21.3	   TRBV11-­‐2	   IG125	   FITC	  
22	   TRBV2	   IMMU	  546	   FITC	  
23	   TRBV13	   AF23	   PE	  
	  
Cells	  were	  washed	  twice	  in	  FACS	  buffer	  and	  finally	  resuspended	  in	  100-­‐200	  µL	  of	  PBS.	  
Cells	  were	  kept	  on	  ice	  in	  the	  dark	  (or	  fixed	  in	  2%	  PFA)	  until	  flow	  cytometric	  analysis.	  	  
2.11.2   Intracellular	  cytokine	  staining	  (ICS)	  assay	  
Cells	  were	  washed	  from	  culture	  medium	  and	  rested	  overnight	  in	  R5	  prior	  to	  activation.	  Subsequently,	  
cells	  were	   incubated	   at	   37	   °C,	   5%	  CO2	   for	   4	   h,	  with	   and	  without	   target	   cells,	   at	   a	   1:1	   ratio,	   in	   R5	  
containing	   GolgiStop™	   and	   GolgiPlug™	   (BD	   Biosciences),	   according	   to	  manufacturer’s	   instructions.	  
Cells	  were	  then	  stained	  with	  LIVE/DEAD®	  Violet	  (Life	  Technologies)	  and	  Abs	  against	  desired	  cell	  surface	  
markers.	   Cells	   were	   prepared	   for	   ICS	   by	   incubation	   with	   Cytofix/Cytoperm™	   (BD	   Biosciences)	  
according	  to	  manufacturer’s	   instructions,	  before	  staining	  for	  20	  min	  on	  ice	  with	  mouse	  anti-­‐human	  
IFNγ-­‐APC	  mAb	   (Miltenyi	   Biotec).	   Cells	  were	   resuspended	   in	   PBS	   (or	   fixed	  with	   2%	  PFA	   and	   stored	  
overnight	  at	  4	  °C	  in	  the	  dark)	  before	  flow	  cytometry	  and	  data	  analysis.	  
2.11.3   Blocking	  antibody	  assay	  
HLA-­‐restriction	   of	   CTL-­‐mediated	   killing	   was	   achieved	   by	   pre-­‐incubating	   the	   target	   cells	   with	   HLA	  
specific	  antibodies	  for	  1	  h	  at	  37	  °C,	  5%	  CO2	  before	  addition	  of	  effector	  cells.	  The	  following	  monoclonal	  
antibodies	  were	  used	  for	  blocking	  assays:	  anti-­‐HLA-­‐A,	  B,	  C	  (clone	  W6/32,	  Biolegend)	  and	  anti-­‐HLA-­‐DR,	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2.11.4   pMHC	  tetramer	  staining	  
Soluble	  biotinylated	  pMHC-­‐I	  were	  produced	  as	  previously	  described	  in	  Section	  2.1.8.	  Peptide-­‐MHC-­‐I	  
tetramers	  were	  assembled	  over	  ﬁve	  separate	  20	  min	  steps	  with	  the	  successive	  addition	  of	  streptavidin,	  
APC	  or	  PE	  conjugates	   (Life	  Technologies)	   to	  monomeric	  pMHC	  at	  a	  molar	   ratio	  of	  1:4.	  The	  desired	  
number	  of	  cells,	  typically	  0.5–1x105	  of	  a	  T-­‐cell	  clone	  or	  1–3x106	  TILs,	  was	  transferred	  to	  ﬂow	  cytometry	  
tubes	  and	  cells	  washed	  with	  FACS	  buffer	  (700xg	  3	  min).	  Cells	  were	  treated	  with	  the	  PKI	  (protein	  kinase	  
inhibitor)	  (Dasatinib,	  Axon	  Medchem,	  Reston)	  at	  a	  ﬁnal	  concentration	  of	  50	  nM	  for	  30	  min	  at	  37	  °C	  
and	   then	   stained	  with	   tetramer	  without	  washing.	   Treatment	  with	  PKI	   prevents	   TCR	   triggering	   and	  
internalization	  of	  the	  TCR	  and	  any	  pMHC	  tetramer	  bound	  to	  it.	  PKI	  is	  unstable	  when	  stored	  at	  4	  °C,	  so	  
1	  mM	  DMSO	  aliquots	  of	  PKI	  were	  stored	  at	  -­‐80	  °C	  and	  working	  aliquots	  of	  100	  nM	  were	  prepared	  in	  
PBS	  for	  each	  experiment.	  Tetramer	  concentrations	  ranged	  from	  0.02	  to	  2.4	  mg	  (0.4–48	  mg/mL	  with	  
respect	  to	  the	  monomeric	  pMHC	  concentration)	  per	  stain	  in	  50	  μL	  FACS	  buffer,	  and	  typically	  0.5mg	  
was	   used.	   Following	   tetramer	   addition,	   cells	   were	   placed	   on	   ice	   and	   in	   the	   dark	   for	   30	   min.	   All	  
subsequent	  Ab	  staining	  of	  the	  cells	  was	  performed	  for	  20	  min	  on	  ice	  and	  in	  the	  dark.	  Cells	  were	  washed	  
first	  in	  FACS	  buffer	  and	  then	  PBS	  before	  LIVE/DEAD®	  Violet	  stain	  (Life	  Technologies).	  Following	  a	  5	  min	  
incubation	  at	  room	  temperature	  in	  the	  dark,	  mAbs	  against	  cell-­‐surface	  markers	  were	  added	  directly	  
without	   washing	   and	   incubated	   on	   ice	   for	   20	   min	   in	   the	   dark.	   Samples	   were	   prepared	   for	   ﬂow	  
cytometry	  by	  washing	  twice	  in	  FACS	  buffer	  and	  resuspended	  in	  PBS	  or	  2%	  PFA.	  
2.11.4.1   “Boosted”	  pMHC	  tetramer	  staining	  	  
A	  “boosted”	  protocol	  was	  used	  to	  enhance	  tetramer	  staining	  intensity	  of	  T-­‐cell	  populations	  and	  T-­‐cell	  




Figure	  2.4.	  Schematic	  representation	  of	  the	  ‘boosted’	  pMHC	  
tetramer	  staining	  protocol	  used	  	  
(adapted	  from	  Tungatt	  et	  al.,	  2015).	  
Alongside	  a	  standard	  pMHC	  tetramer,	  the	  staining	  protocol	  
includes	   the	   binding	   of	   a	   mouse	   anti-­‐fluorochrome	  
unconjugated	  primary	   (1	  ̊)	  antibody	   to	   the	  pMHC	  multimer	  
associated	   fluorochrome,	   followed	   by	   a	   goat	   anti-­‐mouse	  
conjugated	  secondary	  (2	  ̊)	  Ab.	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Briefly,	  post–pMHC	  tetramer	  staining,	  the	  cells	  were	  washed	  in	  FACS	  buffer	  (700	  xg	  3	  min)	  and	  labelled	  
with	  anti-­‐ﬂuorochrome	  unconjugated	  primary	  Ab	  for	  20	  min	  on	  ice	  in	  the	  dark.	  Following	  two	  washes	  
in	  FACS	  buffer,	  the	  anti-­‐Ab	  conjugated	  secondary	  Ab	  was	  added	  and	  incubated	  for	  20	  min	  on	  ice	  in	  the	  
dark.	  Primary	  (1°)	  unconjugated	  mAbs	  were	  used	  at	  a	  concentration	  of	  10	  mg/mL	  (0.5	  mg/test).	  A	  goat	  
anti-­‐mouse	   conjugated	   secondary	   (2°)	   Ab	   was	   used	   at	   2	   mg/mL	   (0.1	   mg/test).	   The	   ﬂuorochrome	  
conjugated	  to	  the	  2°	  Ab	  was	  matched	  to	  the	  one	  used	  for	  the	  initial	  pMHC	  multimer	  staining.	  Both	  
anti-­‐ﬂuorochrome	  and	  anti-­‐Ab	  antibodies	  were	  spun	  at	  maximum	  speed	  in	  a	  micro-­‐centrifuge	  for	  1	  
min	  to	  remove	  any	  aggregates	  before	  staining	  cells.	  	  
The	  following	  primary	  and	  secondary	  antibodies	  were	  used	  in	  Chapter	  4:	  
	  
Primary	  (1˚)	  unconjugated	  	   Fluorochrome	   Clone	   Supplier	  
Mouse	  anti-­‐PE	  
Mouse	  anti-­‐APC	  





Secondary	  (2˚)	  conjugated	  	  
	   	   	  
Goat	  anti-­‐mouse	   PE	  
APC	  




2.11.5   Viable	  sorting	  of	  tumour	  reactive	  T	  cells	  
Autologous	  tumour	  cells	  were	  plated	  1x106/well	  in	  a	  24	  multi-­‐well	  plate	  in	  R10	  the	  day	  before	  sorting.	  
TIL	  samples	  or	  autologous	  PBMC	  were	  rested	  overnight	  in	  R5	  medium.	  Cells	  were	  then	  stimulated	  with	  
autologous	  tumour	  (1:1)	  in	  the	  presence	  of	  15	  µL	  of	  anti-­‐TNF-­‐α	  PE-­‐Cy7	  (clone	  Mab11,	  BD	  Biosciences),	  
15	  µL	  CD107a	  PE	  (clone	  H4A3,	  BD	  Biosciences)	  and	  10	  µM	  of	  TAPI-­‐0	  (Calbiochem)	  for	  4h	  at	  37	  °C,	  5%	  
CO2.	  Note	  that	  following	  the	  5-­‐hour	  incubation	  period	  with	  anti-­‐TNF-­‐α	  mAb,	  cells	  were	  not	  re-­‐stained	  
with	  anti-­‐TNF-­‐α	  in	  any	  subsequent	  steps.	  Following	  incubation,	  cells	  were	  LIVE/DEAD®	  Violet	  stained	  
and	   surface	   stained	  with	   anti-­‐CD3	   PerCP	   (clone	   BW264/56,	  Miltenyi	   Biotec),	   anti-­‐CD8	  APC	  Vio770	  
(clone	  BW135/80,	  Miltenyi	  Biotec),	  anti-­‐αβTCR	  FITC	  (clone	  IP26,	  Biolegend)	  and	  anti-­‐γδTCR	  APC	  (clone	  
11F2,	  Miltenyi	  Biotec)	  mAbs.	  Cells	  from	  each	  experimental	  condition	  were	  washed	  and	  sorted	  directly	  
into	  microfuge	  tubes	  containing	  350	  µL	  lysis	  buffer	  (Qiagen)	  and	  stored	  at	  −80	  °C	  until	  RNA	  extraction.  
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2.12  Analysis	  of	  human	  TCR	  Vβ	  CDR3	  repertoire	  
2.12.1   Total	  RNA	  extraction	  
RNA	  from	  reactive	  TILs	  and	  PBMC	  was	  extracted	  using	  the	  RNeasy	  Micro	  Kit	  (Qiagen),	  following	  the	  
manufacturer’s	   instructions.	   Briefly,	   samples	  were	   first	   lysed	   and	   then	   homogenized.	   Ethanol	  was	  
added	  to	  the	  lysates	  to	  provide	  ideal	  binding	  conditions.	  The	  lysates	  were	  then	  loaded	  onto	  a	  RNeasy	  
silica	   membrane,	   to	   which	   RNA	   binds	   while	   all	   contaminants	   are	   efficiently	   washed	   away.	   Pure,	  
concentrated	  RNA	  were	  eluted	  in	  14	  µL	  water.	  Isolation	  of	  total	  RNA	  was	  performed	  shortly	  after	  cell	  
sorting,	  in	  order	  to	  minimize	  loss	  of	  RNA.	  Standard	  RNA	  sample	  handling	  precautions	  (i.e.	  filtered	  tips	  
and	  certified	  RNAase	   free	   reagents)	  were	  used	   to	  avoid	  RNA	  degradation.	  All	  RNA	   isolation,	   cDNA	  
synthesis	   and	   PCR	   preparation	   steps	   were	   carried	   out	   in	   a	   clean	   RNAase	   free	   room	   to	   prevent	  
contamination.	  RNA	  samples	  were	  stored	  at	  -­‐80	  °C.	  
2.12.2   SMARTer™	  RACE	  cDNA	  amplification	  
SMARTer™	   (Switching	  Mechanism	  At	  5'	  end	  of	  RNA	  Transcript)	  RACE	   (Rapid	  Amplification	  of	  cDNA	  
Ends)	   kit	   (Clontech)	  was	  used	   for	   generating	   full-­‐length	   cDNAs	   from	  TCR-­‐β	   RNA	   (Zhu	  et	   al.,	   2001).	  
Figure	  2.5	  provides	  a	  schematic	  representation	  of	  the	  experimental	  workflow	  described	  in	  this	  section.	  	  
2.12.2.1   First	  strand	  cDNA	  synthesis	  
Samples	  and	  reagents	  were	  kept	  on	  ice	  at	  all	  times.	  RNA	  samples	  were	  thawed	  at	  room	  temperature.	  	  
The	  following	  mix	  was	  prepared	  for	  each	  sample:	  
Reagent	   Amount	  
RNA	   10	  µL	  
Oligo-­‐dT	   1	  µL	  
Final	  volume	   11	  µL	  
	  
The	  reaction	  tubes	  were	  placed	  in	  a	  thermal	  cycler	  and	  incubated	  at	  72	  °C	  for	  3	  min,	  then	  at	  42	  °C	  for	  
2	  min	  to	  anneal	  the	  synthesis	  primer.	  After	  incubation,	  tubes	  were	  spun	  briefly.	  The	  following	  master	  
mix	  for	  n	  reactions	  was	  prepared	  and	  8	  μL	  added	  to	  each	  tube:	  
Reagent	   Amount	  
5X	  First	  Strand	  buffer	   4	  µL	  
DTT	  (100	  mM)	   0.5	  µL	  
dNTP	  (20	  mM)	   1	  µL	  
RNase	  Inhibitor	  (20	  U)	   0.5	  µL	  
SMARTScribe	  RT	  (100	  U)	   2	  µL	  
Final	  volume	   8	  µL	  
	  
1	  μl	  of	  SMARTer	  II	  oligo	  A	  was	  added	  to	  each	  tube.	  In	  a	  thermal	  cycler,	  the	  tubes	  were	  incubated	  at	  42	  
°C	   for	  90	  min,	   then	  70	   °C	   for	  10	  min	   cDNA	  samples	  were	  directly	   stored	  at	   -­‐20	   °C	  or	  used	   for	   the	  
following	  PCR	  amplification	  step.	  
	  





Figure	  2.5.	  Experimental	  workflow	  of	  the	  SMARTer	  RACE	  approach	  to	  TCR-­‐β	  profiling	  	  
Abbreviations:	  Ss,	  single-­‐stranded;	  ds,	  double-­‐stranded;	  F,	  forward	  primer;	  R,	  reverse	  primer;	  RT,	  reverse	  transcriptase.	  	  
(A)	  Schematic	  diagram	  of	  the	  reverse	  transcription	  and	  PCR	  amplification	  of	  TCR-­‐β	  chain	  mRNA	  sequences	  (adapted	  from	  
Clontech	  Laboratories	  Inc.	  website).	  Single-­‐stranded	  cDNA	  from	  a	  mRNA	  template	  was	  generated	  by	  reverse	  transcription	  
using	  an	  oligo	  dT	  primer	  (located	  in	  the	  constant	  gene	  of	  the	  TCR-­‐β	  chain)	  and	  a	  MMLV-­‐derived	  RT.	  When	  the	  RT	  reaches	  
the	  end	  of	  the	  mRNA	  template,	  it	  adds	  several	  non-­‐templated	  nucleotides	  (indicated	  as	  “xxx”).	  The	  universal	  primer	  anneals	  
to	  the	  tail	  of	  the	  cDNA	  and	  serves	  as	  an	  extended	  template	  for	  the	  RT.	  The	  “universal	  anchor”	  appended	  to	  the	  target	  during	  
cDNA	  synthesis,	  allows	  subsequent	  PCR	  amplification	  steps	  (PCR	  1	  and	  2)	  using	  a	  5’universal	  primer	  (forward)	  and	  a	  3’	  Cβ	  -­‐
specific	  primer.	  The	  final	  product	  was	  cloned	  into	  a	  commercial	  vector	  and	  transformed	  into	  bacterial	  cells.	  (B)	  Semi-­‐nested	  
PCR	  approach	  for	  amplification	  of	  TCR-­‐β	  subunits.	  The	  primer	  pair	  (orange)	  used	  for	  the	  first	  PCR	  captures	  the	  entire	  variable	  
region	  and	  some	  of	  the	  constant	  region	  of	  the	  TCR-­‐β	  cDNA.	  The	  primer	  pair	  (green)	  used	  in	  the	  second	  PCR	  retains	  the	  entire	  
TCR-­‐β	  cDNA	  variable	  region	  and	  a	  smaller	  portion	  of	  the	  constant	  region.	  The	  expected	  size	  of	  final	  TCR-­‐β	  library	  cDNA	  (which	  
include	  the	  inserts	  and	  the	  universal	  adapters)	  is	  of	  approximately	  600	  bp.	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2.12.2.2   First	  PCR	  amplification	  
The	  first	  PCR	  amplification	  captures	  the	  entire	  variable	  region	  and	  some	  of	  the	  constant	  region	  of	  the	  
TCR-­‐β	  cDNA.	  A	  PCR	  mastermix	  was	  prepared	  as	  shown	  below:	  
	  
Reagent	   Amount	  
Phusion®	  5X	  Green	  buffer	   10	  µL	  
DMSO	  (100	  mM)	   0.5	  µL	  
dNTPs	  (20	  mM)	   1	  µL	  
10X	  Universal	  Primer	  A	  (F)	   5	  µL	  
Primer	  Cβ-­‐R1	  (R)	   1	  µL	  
Phusion®	  HF	  DNA	  polymerase	   0.25	  µL	  
H2O	  	   29.75	  µL	  
cDNA	  sample	   2.5	  µL	  
Final	  volume	   50	  µL	  
	  
The	  following	  cycling	  conditions	  were	  used:	  	  
4°C;	  initial	  denaturation	   	  
94°C;	  30	  s	  
30	  cycles	  63°C;	  30	  s	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
72°C;	  3	  m	  
72°C;	  final	  extension	   	  
	  
2.12.2.3   Second	  PCR	  amplification	  
The	   second	   PCR	   amplification	   used	   the	   DNA	   from	   the	   first	   round	   of	   amplification	   as	   template.	   It	  
captures	  the	  entire	  variable	  region	  and	  a	  smaller	  region	  of	  the	  constant	  TCR-­‐β	  cDNA.	  A	  PCR	  mastermix	  
was	  prepared	  as	  shown	  below:	  
	  
Reagent	   Amount	  
Phusion®	  5X	  Green	  buffer	   10	  µL	  
DMSO	  (100	  mM)	   0.5	  µL	  
dNTPs	  (20	  mM)	   1	  µL	  
Primer	  A	  Short	  (F)	   1	  µL	  
Primer	  Cβ-­‐R2	  (R)	   1	  µL	  
Phusion®	  HF	  DNA	  polymerase	   0.25	  µL	  
H2O	  	   33.75	  µL	  
DNA	  sample	   2.5	  µL	  
Final	  volume	   50	  µL	  
	  
The	  following	  cycling	  conditions	  were	  used:	  	  
94°C;	  initial	  denaturation	   	  
94°C;	  30	  s	  
30	  cycles	  66°C;	  30	  s	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
72°C;	  3	  m	  
72°C;	  final	  extension	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2.12.2.4   Agarose	  gel	  electrophoresis	  
Electrophoresis	  gels	  were	  prepared	  with	  1%	  agarose	  powder	   (Invitrogen)	  dissolved	   in	   (Tris-­‐acetate	  
EDTA)	 TAE	  buffer.	  For	  DNA	  visualisation,	  Midori	  Green	  nucleic	  acid	  staining	  solution	  (GeneFlow)	  was	  
added	  before	  allowing	  the	  gels	  to	  set.	  Samples	  were	  allowed	  to	  run	  at	  80V	  for	  45	  min	  on	  the	  gel,	  along	  
with	  5	  μL	  of	  1	  Kb	  DNA	  HyperLadder™	  (Bioline).	  Gels	  were	  visualised	  under	  a	  LED-­‐based	   illuminator	  




Figure	  2.6.	  Agarose	  gel	  analysis	  of	  SMARTer	  RACE	  cDNA	  
products	  
Representative	  gel	  of	  PCR	  amplified	  TCR-­‐β	  cDNA	  products	  from	  
PBMC	   samples	   of	   three	   melanoma	   patients	   (plus	   and	   minus	  
stands	   for	   the	   tumour-­‐reactive	   or	   non-­‐tumour	   reactive	  
population,	   respectively).	   Lane	   1:	   molecular	   weight	   ladder	  
(MW).	  An	  empty	  lane	  was	  kept	  between	  samples	  to	  avoid	  cross-­‐
contamination	   during	   gel	   loading	   and	   electrophoretic	   run.	  
Water	  was	  used	  as	  a	  negative	  control.	  Arrow	  heads	  indicate	  the	  
expected	  TCR-­‐β	  band	  of	  approx.	  600	  bp.	  
	  
2.12.2.5   DNA	  extraction	  from	  gel	  bands	  and	  purification	  for	  cloning	  
Amplified	  products	  were	  extracted	  from	  the	  agarose	  gel	  and	  purified	  for	  subsequent	  cloning	  steps.	  
The	   NucleoSpin®	   Gel	   and	   PCR	   Clean-­‐up	   kit	   (Clontech)	   was	   used	   to	   extract	   DNA	   from	   gel	   bands,	  
following	  manufacturer’s	  instructions.	  Briefly,	  the	  cut-­‐out	  gel	  band	  was	  mixed	  with	  Binding	  Buffer	  NTI	  
(200	  µL/100	  mg)	  and	  heated	  at	  50	  °C	  for	  10	  min	  to	  dissolve	  the	  agarose.	  In	  the	  presence	  of	  chaotropic	  
salt,	  the	  DNA	  sample	  was	  bound	  to	  the	  silica	  membrane	  of	  a	  NucleoSpin®	  column.	  Contaminations	  
were	  removed	  by	  washing	  steps	  with	  ethanolic	  Wash	  Buffer	  NT3.	  Finally,	  pure	  DNA	  was	  eluted	  under	  
low	  salt	  conditions	  with	  slightly	  alkaline	  Elution	  Buffer	  NE	  (5	  mM	  Tris/HCl,	  pH	  8.5).	  
	  
2.12.3   Molecular	  cloning	  and	  bacterial	  transformation	  
2.12.3.1   Zero	  Blunt®	  TOPO®	  PCR	  Cloning	  
Blunt-­‐end	  PCR	  products	  were	  cloned	  into	  a	  pCR™-­‐Blunt	  II-­‐TOPO®	  vector	  using	  a	  Zero	  Blunt®	  TOPO®	  
PCR	  Cloning	  Kit	  (Invitrogen),	  following	  manufacturer’s	  instructions.	  Briefly,	  a	  topoisomerase	  I–based	  
10-­‐minute	   ligation	  was	   performed	   in	   order	   to	   directly	   insert	   the	   blunt-­‐ended	   PCR	   products	   into	   a	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The	  following	  6	  µL	  TOPO®	  Cloning	  reaction	  was	  set	  up	  for	  each	  sample:	  
	  
Reagent	   Amount	  
Fresh	  PCR	  product	   4	  µL	  
Salt	  solution	   1	  µL	  
pCR™-­‐Blunt	  II-­‐TOPO®	   1	  µL	  
Final	  volume	   6	  µL	  
	  
The	  tubes	  were	  incubated	  for	  10	  min	  at	  room	  temperature,	  then	  placed	  on	  ice	  to	  stop	  the	  reaction.	  
TOPO®	  Cloning	  reactions	  were	  then	  transformed	  into	  chemically	  competent	  One	  Shot®	  TOP10	  E.	  coli	  
cells	  (Invitrogen).	  
2.12.3.2   Transformation	  of	  One	  Shot®	  TOP10	   	  
Chemically	  competent	  E.	  coli	  cells	  (One	  Shot®	  TOP10)	  were	  transformed	  following	  the	  manufacturer’s	  
instructions	   (Invitrogen).	   Briefly,	   one	   vial	   of	   One	   Shot®	   E.	   coli	   cells	   was	   thawed	   on	   ice	   for	   each	  
transformation.	  2	  µL	  of	  the	  TOPO®	  Cloning	  reaction	  were	  added	  to	  each	  vial	  of	  cells	  to	  be	  transformed,	  
and	  mixed	  gently.	  The	  vials	  were	  incubated	  on	  ice	  for	  30	  min	  and	  then	  heat-­‐shocked	  for	  30	  sec	  at	  42	  
°C	  without	  shaking.	  250	  µL	  of	   room	  temperature	  S.O.C.	  medium	  (supplied	  with	   the	  kit,	   Invitrogen)	  
were	   added	   to	   the	   cells.	   The	   tubes	   were	   capped	   and	   shaken	   at	   37	   °C	   for	   1h.	   150	   µL	   from	   each	  
transformation	  were	  spread	  on	  pre-­‐warmed	  LB-­‐Agar	  plates	  containing	  50	  µg/mL	  kanamycin	  selective	  
antibiotic.	   Plates	   were	   incubated	   overnight	   at	   37	   °C.	   An	   efficient	   TOPO®	   Cloning	   reaction	   would	  
produce	   several	   hundred	   colonies.	   Approximately	   96	   colonies	   were	   picked	   for	   analysis	   of	  
transformants.	  Each	  colony	  consists	  of	  bacteria	  transformed	  with	  one	  (and	  only	  one)	  tr	  sequence.	  
2.12.3.3   Colony	  PCR	  
Colonies	  containing	  the	   insert	  were	  screened	  and	  selected	  for	  amplification	  and	  sequencing.	  Single	  
bacterial	  colony	  plasmid	  inserts	  were	  amplified	  in	  a	  sealed	  96-­‐well	  plate	  format	  (Applied	  Biosystems)	  
using	   primers	   flanking	   the	   insertion	   site	   (M13F:	   5'-­‐TTTTCCCAGTCACGAC-­‐3';	   M13R:	   5'-­‐
CAGGAAACAGCTATGAC-­‐3’). Care	  was	  taken	  in	  order	  to	  pick	  only	  single	  colonies	  and	  to	  avoid	  cross-­‐
contamination	  between	  wells.	  Colony	  PCR	  reactions	  were	  prepared	  as	  follows: 
	  
Reagent	   Amount	  
Primer	  M13F	   1	  µL	  
Primer	  M13R	   1	  µL	  
DreemTaq	  Green	  master	  mix	   23	  µL	  
Final	  volume	   25	  µL	  
	  
Colony	  PCR	  reactions	  were	  run	  in	  a	  thermocycler	  as	  follows:	  	  
5	  µl	  of	  several	  individual	  products	  from	  plate	  were	  run	  on	  an	  agarose	  gel.	  Positive	  colonies	  were	  sent	  
for	  sequencing	  (Eurofins	  Genomics,	  Ebersburg,	  Germany).	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2.12.4   Sequence	  analysis	  
TCR-­‐β	   sequences	   were	   visualized	   in	   the	   analysis	   software	   BioEdit	  
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html)	   (Hall,	   1999)	   and	   analysed	   using	   IMGT/V-­‐QUEST	  
(http://www.imgt.org/IMGT_vquest),	   in	  order	  to	  identify	  the	  V,	  D	  and	  J	  segments	  for	  human	  TCR-­‐β	  
(Giudicelli	  et	  al.,	  2011).	  Grouped	  sequences	   for	  TIL	  and	  PBMC	  samples	  were	  ranked	   in	  a	  Microsoft	  
OfficeTM	   Excel	   spreadsheet	   according	   to	   their	   frequency.	   Unless	   otherwise	   stated,	   all	   tr	   and	   gene	  
segments	   are	   described	   using	   the	   ImMunoGeneTics	   (IMGT)	   nomenclature	   (Lefranc	   et	   al.,	   1999).	  
Accordingly,	  TCR	  α-­‐	  and	  β-­‐	  chain	  segments	  are	  designated	  TRA	  and	  TRB	  respectively,	  followed	  by	  the	  
letter	  V,	  D	  or	  J.	  	  
	  
2.13   Figures	  and	  data	  analysis	  
Unless	  otherwise	  stated,	  figures	  were	  made	  using	  GraphPad	  Prism	  5	  (GraphPad	  Software	  Inc.,	  La	  Jolla,	  
USA)	  or	  Microsoft	  OfficeTM	  Excel.	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3   A	  molecular	  switch	   in	  a	  gp100	  human	  melanoma	  antigen	  
abrogates	  T-­‐cell	  recognition	  
3.1   Background	  
Glycoprotein	  100	  (gp100)	  has	  been	  a	  widely	  studied	  target	  for	  melanoma	  peptide-­‐based	  vaccines.	  	  
This	  661	  amino	  acid	  long	  melanoma	  differentiation	  antigen	  is	  a	  melanosome	  matrix	  protein	  involved	  
in	  melanosome	  maturation	  and	  melanin	  synthesis	  (Raposo	  and	  Marks,	  2007).	  The	  gp100	  protein	  has	  
a	  significantly	  differential	  expression	  between	  tumour	  cells,	  being	  often	  over-­‐expressed	  in	  all	  stages	  
of	  melanoma	  progression,	  compared	  to	  normal	  melanocytes	  (Wagner	  et	  al.,	  1997).	  It	  was	  originally	  
identified	  by	  its	  reactivity	  with	  a	  melanocyte	  lineage-­‐specific	  monoclonal	  antibody	  used	  for	  diagnosis	  
of	  human	  melanoma	  (Kawakami	  et	  al.,	  1994b).	  Several	  studies	  showed	  that	  gp100	  encoded	  epitopes	  
can	  be	  recognised	  by	  tumour-­‐infiltrating	  and	  circulating	  T-­‐cells	  associated	  with	  tumour	  regression	  in	  
metastatic	  melanoma	  patients	  after	  TIL	  therapy	  (Kawakami	  et	  al.,	  1994b;	  1995;	  Salgaller	  et	  al.,	  1996).	  
Among	   these	  epitopes,	   the	  nonamer	  peptide	  gp100280-­‐288	   (YLEPGPVTA)	  was	  originally	   shown	   to	  be	  
recognized	  by	  HLA-­‐A*0201+	  TILs	  from	  melanoma	  patients	  (Kawakami	  et	  al.,	  1994a),	  and	  subsequently	  
eluted	   from	   HLA-­‐A*0201	   molecules	   on	   melanoma	   cells	   (Skipper	   et	   al.,	   1999).	   Immunization	   with	  
YLEPGPVTA	  peptide	  (YLE	  hereafter)	  has	  been	  shown	  to	  stimulate	  an	  in	  vitro	  polyclonal	  T-­‐cell	  response	  
in	  the	  context	  of	  HLA-­‐A*0201,	  present	  in	  49%	  of	  Caucasian	  individuals	  (Parkhurst	  et	  al.,	  1996).	  	  
	  
Collectively,	   the	   above	   findings	   renewed	   the	   interest	   in	   the	   development	   of	   gp100-­‐based	   anti-­‐
melanoma	   vaccines.	   However,	   our	   group	   and	   others,	   have	   previously	   shown	   through	   direct	  
biophysical	   measurements	   that	   anti-­‐cancer	   TCRs	   bind	   to	   their	   cognate	   peptide-­‐Human	   Leukocyte	  
Antigen	  (pHLA)	  with	  affinities	  ~5-­‐fold	  weaker	  than	  pathogen	  specific	  TCR	  (Aleksic	  et	  al.,	  2012;	  Cole	  et	  
al.,	  2007).	  TCR	  affinity	  is	  crucial	  for	  T-­‐cell	  activation	  and	  a	  5-­‐fold	  difference	  in	  TCR	  affinity	  can	  result	  in	  
a	  marked	  difference	  in	  recognition	  of	  tumour	  epitopes	  which	  are	  often	  present	  at	  low	  copy	  number	  
(Tan	  et	  al.,	  2015).	  Several	  strategies	  have	  been	  attempted	  to	  increase	  the	  immunogenicity	  of	  tumour	  
antigens.	  Many	  tumour-­‐associated	  epitopes	  possess	  suboptimal	  sequences	  for	  HLA	  anchoring	  (Cole	  et	  
al.,	  2010).	   Since	   the	  binding	  preferences	  of	   common	  HLA	  are	  known,	   improvements	   in	   suboptimal	  
primary	   HLA	   anchoring	   positions	   are	   easily	   made.	   Altered	   peptide	   ligands	   (APL),	   with	   improved	  
primary	  HLA	  anchor	  residues,	  have	  been	  designed	  for	  some	  melanoma-­‐associated	  antigens	  (Parkhurst	  
et	  al.,	  1996;	  Salgaller	  et	  al.,	  1996).	  Among	  these,	  the	  YLE-­‐9V	  modified	  version	  of	  YLE,	  in	  which	  a	  Valine	  
replaces	  Alanine	  at	  anchor	  position	  9	  to	  improve	  binding	  to	  HLA-­‐A*0201	  (HLA-­‐A2,	  hereafter)	  (Miles	  et	  
al.,	  2011b),	  enhanced	  the	  induction	  of	  melanoma	  reactive	  CTLs	  in	  vitro	  and	  has	  been	  successfully	  used	  
in	  clinical	  trials	  (Lesterhuis	  et	  al.,	  2011).	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However,	   studies	   using	   another	   HLA-­‐A2-­‐restricted	  melanoma-­‐derived	   epitope	   have	   demonstrated	  
that	   even	   minor	   changes	   in	   peptide	   anchor	   residues	   can	   substantially	   alter	   T-­‐cell	   recognition	  
unpredictably	  by	  altering	  TCR	  binding	  (Cole	  et	  al.,	  2010;	  Madura	  et	  al.,	  2015).	  Thus,	  a	  more	  complete	  
understanding	   of	   the	   molecular	   mechanisms	   underlying	   gp100280-­‐288	   targeting	   by	   specific	   TCRs	   is	  
needed	  to	  direct	  the	  design	  of	  improved	  APLs	  for	  use	  in	  therapeutic	  vaccination	  strategies.	  	  
3.1.1   Aims	  
The	  gp100280-­‐288	  epitope	  YLE	  presented	  on	  the	  surface	  of	  HLA-­‐A2+	  melanoma	  cells	  offers	  an	  attractive	  
target	   for	   immunotherapy.	  The	  YLE-­‐9V	  APL	   induces	  melanoma	   reactive	  CTLs	   in	   vitro	   and	  has	  been	  
successfully	  used	  in	  clinical	  trials	  (Lesterhuis	  et	  al.,	  2011),	  but	  no	  structural	  analysis	  of	  T-­‐cell	  recognition	  
of	   this	   peptide	   has	   been	   published	   to	   date.	   Previous	   studies	   from	   my	   own	   laboratory	   have	  
demonstrated	  that	  such	  HLA	  anchor	  residue	  alterations	  can	  unpredictably	  alter	  the	  way	  a	  peptide	  is	  
viewed	  by	  the	  TCR	  on	  cognate	  T-­‐cells	  (Cole	  et	  al.,	  2010)	  and	  show	  that	  increased	  HLA	  binding	  does	  not	  
necessarily	  produce	  a	  more	  potent	  antigen	  for	  tumour-­‐specific	  TCRs	  (Madura	  et	  al.,	  2015).	  	  
	  
The	  overall	  aim	  of	  this	  project	  was	  to	  understand	  the	  molecular	  recognition	  of	  gp100280-­‐288,	  by	  using	  a	  
combination	  of	  structural	  and	  biophysical	  approaches.	  In	  particular,	  my	  aims	  were	  to:	  
•   Solve	  the	  first	  ternary	  crystal	  structure	  of	  a	  natural	  cognate	  TCR	  in	  complex	  with	  the	  YLE-­‐9V	  
epitope	  
•   Complement	   structural	   information	   with	   a	   thermodynamic	   analysis	   of	   the	   TCR-­‐pMHC	  
interaction	  
•   Perform	   an	   alanine	   scan	   mutagenesis	   across	   the	   wild	   type	   YLE	   peptide	   backbone	   and	  
investigate	  TCR	  binding	  hotspots	  by	  Surface	  Plasmon	  Resonance	  (SPR)	  
	  
The	  results	  presented	   in	   this	  chapter	   formed	  the	  basis	  of	  a	  publication	   in	  The	   Journal	  of	  Biological	  
Chemistry	   entitled	   “A	   molecular	   switch	   abrogates	   gp100	   TCR-­‐targeting	   of	   a	   human	   melanoma	  
antigen”	  (Bianchi	  et	  al.,	  2016).	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3.2   Results	  
3.2.1   Production	  of	  soluble	  TCR	  and	  pHLA	  ectodomains	  
Two	  distinct	  YLE-­‐specific	  αβ	  TCRs	  were	  used	  in	  this	  project.	  The	  PMEL17	  TCR	  (TRAV21,	  TRBV7-­‐3)	  was	  
provided	  by	  Thymed	  and	  was	   isolated	  from	  a	  melanoma	  patient	  (Cole	  et	  al.,	  2007);	  the	  gp100	  TCR	  
(TRAV17,	  TRBV19)	  was	  provided	  by	  Immunocore	  Ltd	  (Oxfordshire,	  UK)	  and	  was	  isolated	  from	  a	  healthy	  
donor	   (Aleksic	   et	   al.,	   2012).	   Structural	   and	   biophysical	   experiments	   for	   this	   study	   required	   the	  
manufacture	  of	  considerable	  amounts	  of	  soluble,	  refolded	  and	  pure	  pHLA	  and	  TCR	  proteins.	  Briefly,	  
the	   process	   involved:	   (i)	   the	   expression	   of	   the	   ectodomain	   of	   each	   protein	   chain	   in	   the	   form	   of	  
inclusion	  bodies	  in	  E.	  coli	  bacteria;	  (ii)	  the	  purification	  of	  inclusion	  bodies	  and	  refolding	  by	  dilution	  of	  
denaturing	  conditions;	  (iii)	  anion	  exchange	  chromatography	  as	  a	  first	  purification	  step	  and	  (iv)	  several	  
gel	  filtration	  chromatography	  steps	  in	  order	  to	  obtain	  enough	  pure	  protein	  to	  perform	  the	  different	  
experiments.	  For	  biophysical	  analysis	  using	  BIAcore®	  technology,	  pHLA	  proteins	  were	  biotin-­‐tagged	  
prior	   to	   gel	   filtration	   (Figure	   4.3).	   The	   biotin	   group	   allowed	   coupling	   of	   the	   pHLA	   protein	   to	   a	  
streptavidin-­‐coated	   sensor	   chip	   (BIAcore®).	   Figure	   3.1	   and	   3.2	   provide	   an	   example	   of	   the	   final	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Figure	  3.1.	  PMEL17	  TCR	  protein	  purification	  	  
(A)	  Representative	  anion-­‐exchange	  chromatography	  of	  in	  vitro	  refolded	  PMEL17	  TCR	  on	  an	  8	  ml	  POROS	  50HQ	  column	  eluted	  
with	  a	  gradient	  of	  NaCl.	  The	  protein	  elutes	  as	  a	  single	  major	  peak.	  Fractions	  corresponding	  to	  the	  main	  peak	  were	  collected	  and	  
analysed	  by	  SDS-­‐PAGE.	  (B)	  Selected	  eluted	  fractions	  from	  A	  were	  analysed	  by	  Coomassie-­‐stained	  SDS	  PAGE	  under	  non-­‐reducing	  
and	  reducing	  conditions.	  A	  single	  band	  corresponding	  to	  the	  αβTCR	  ectodomain	  can	  be	  seen	  ~45	  kDa,	  which	  runs	  as	  distinct	  
chains	  of	  ~23	  kDa	  and	  ~28	  kDa,	  under	  reducing	  conditions.	  Lane	  1,	  molecular	  weight	  ladder	  (MW);	  lanes	  2-­‐7,	  fractions	  #26,	  #28	  
and	  #30	  analysed	  under	  both	  non-­‐reducing	  and	  reducing	  conditions.	  (C)	  Gel-­‐filtration	  chromatography	  (Superdex	  S200	  column)	  
of	  peak	  fraction	  from	  A,	  eluted	  with	  BIAcore	  buffer.	  (D)	  Coomassie-­‐stained	  SDS-­‐PAGE	  of	  pooled	  fractions	  from	  C,	  to	  evaluate	  
protein	  quality.	  Lane	  1,	  molecular	  weight	  ladder	  (MW);	  Lane	  2-­‐3,	  fraction	  #13	  (non-­‐reducing	  and	  reducing	  buffer).	  Fractions	  
were	  pooled	  and	  the	  TCR	  was	  concentrated	  to	  10.3	  mg/mL	  on	  the	  same	  day	  of	  SPR	  analysis	  to	  reduce	  the	  likelihood	  of	  TCR	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Figure	  3.2.	  HLA-­‐A2-­‐YLE	  protein	  purification	  	  
(A)	  Representative	  anion-­‐exchange	  chromatography	  of	  500	  mL	  refold	  of	  HLA-­‐A2-­‐YLE	  complex	  on	  an	  8	  ml	  POROS	  50HQ	  column	  
eluted	  with	  a	  gradient	  of	  NaCl.	  The	  protein	  elutes	  as	  two	  peaks	  (indicated	  by	  the	  arrows).	  Fractions	  corresponding	  to	  both	  peaks	  
were	  collected,	  analysed	  by	  SDS-­‐PAGE	  and	  pooled.	  (B)	  Coomassie-­‐stained	  SDS-­‐PAGE	  of	  fractions	  to	  evaluate	  protein	  quality.	  
Two	  distinct	  bands	  of	  ~35	  kDa	  (α-­‐chain)	  and	  ~10	  kDa	  (β2m	  chain)	  can	  be	  seen	  in	  both	  non/reducing	  conditions.	  Lane	  1,	  molecular	  
weight	  ladder	  (MW);	  Lane	  2-­‐7,	  fractions	  from	  A	  analysed	  under	  both	  non-­‐reducing	  and	  reducing	  conditions.	  (C)	  Gel-­‐filtration	  
chromatography	  of	  pooled	  peaks	  from	  A,	  on	  a	  Superdex	  S200	  column	  eluted	  with	  BIAcore	  buffer.	  (D)	  Coomassie-­‐stained	  SDS-­‐
PAGE	  of	  fraction	  #A14	  from	  C.	  Positive	  A2-­‐YLE	  fractions	  were	  pooled	  and	  concentrated	  to	  400	  μL	  (1.042	  mg/mL).	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3.2.2   Two	  distinct	  anti-­‐gp100	  TCRs	  share	  similar	  binding	  hotspots	  	  
In	   order	   to	   study	   the	   individual	   contribution	   of	   the	   YLE	   peptide	   residues	   to	   TCR-­‐pHLA	  binding,	   an	  
“alanine	   scan”	  mutagenesis	  was	  performed	  across	   the	  peptide	  backbone.	  Briefly,	   each	  amino	  acid	  
residue	  of	  the	  peptide	  was	  sequentially	  substituted	  with	  an	  Ala	  residue,	  based	  on	  the	  concept	  that	  the	  
Ala	  side	  chain	   is	  a	  small	  and	  uncharged	  methyl	  group.	  Residues	  P2	  and	  P9,	  which	  are	  known	  to	  be	  
important	  for	  HLA-­‐A2	  binding	  (Parker	  et	  al.,	  1992),	  were	  not	  assessed;	  in	  addition,	  P9	  residue	  was	  an	  
Alanine	   in	   the	   native	   sequence.	   The	   ability	   of	   the	   pHLA	   mutants	   to	   bind	   a	   YLE-­‐specific	   TCR	   was	  
evaluated	  by	  Surface	  Plasmon	  Resonance	  (SPR)	  experiments	  (Figure	  3.1).	  The	  altered	  peptide	  ligand	  
YLE-­‐9V,	  which	  has	  been	  shown	  to	  be	  a	  more	  potent	  agonist	  than	  the	  wild	  type	  sequence	  (Salgaller	  et	  
al.,	  1996),	  was	  also	   included	   in	  the	  experiment.	  SPR	  experiments	  were	   initially	  performed	  with	  the	  
human	  YLE-­‐specific	  PMEL17	  TCR	  (TRAV21	  TRBV7-­‐3).	  PMEL17	  TCR	  bound	  both	  A2-­‐YLE	  and	  A2-­‐YLE-­‐9V	  
with	  similar	  affinities	   (KD	  =	  7.6	  μM	  and	  6.3	  μM,	   respectively),	   consistent	  with	   the	   fact	   that	  YLE-­‐9V	  
variant	  was	  originally	  designed	   in	   such	  a	  way	   to	   increase	  HLA	  binding	  affinity	  without	   significantly	  
altering	   TCR	   recognition	   of	   the	   pHLA	   complex	   (Parkhurst	   et	   al.,	   1996)	   (Table	   3.1).	   Interestingly,	  
replacement	  of	  Glu	  by	  Ala	  in	  position	  3	  completely	  abrogated	  binding	  by	  PMEL17	  TCR.	  
	  
To	  support	  the	  results	  obtained	  on	  PMEL17	  TCR,	  the	  same	  experiment	  was	  also	  performed	  using	  a	  
previously	  published	  anti-­‐cancer	  TCR	  specific	  for	  the	  same	  nonamer	  (Aleksic	  et	  al.,	  2012).	  Alanine	  Scan	  
results	  on	  the	  gp100	  TCR	  (TRAV17,	  TRBV19),	  showed	  a	  similar	  pattern	  to	  those	  of	  PMEL17,	  although	  
at	   weaker	   affinities	   (of	   KD	   =	   26.5	   μM	   and	   21.9	   μM,	   for	   A2-­‐YLE	   and	   A2-­‐YLE-­‐9V,	   respectively).	  
Interestingly,	  no	  measurable	  binding	  could	  again	  be	  observed	  with	  A2-­‐YLE-­‐3A	  mutant	  and	  YLE-­‐5A	  was	  
confirmed	   as	   a	   very	   poor	   ligand,	   suggesting	   the	   importance	   of	   these	   residues	   for	   TCR	   specificity.	  
Overall,	  these	  data	  indicated	  that	  both	  PMEL17	  and	  gp100	  TCRs	  used	  a	  similar	  overall	  binding	  mode,	  






	  	  	  	  	  	  
	  
	   65	  
	  
Figure	  3.3.	  Binding	  affinity	  analysis	  (25°C)	  of	  A2-­‐YLE	  variants	  
PMEL17	   TCR	   equilibrium-­‐binding	   responses	   to	   A2-­‐YLE	   and	   altered	   peptide	   ligands	   are	   shown.	   Eight	   serial	   dilutions	   were	  
conducted	   for	   each	   equilibrium	   experiment.	   Sensorgrams	   (insert	   panels)	   were	   obtained	   using	   BIAevaluation	   3.1.	   The	  
equilibrium-­‐binding	  constant	  (KD)	  values	  were	  plotted	  using	  a	  nonlinear	  curve	  fit	  using	  Origin	  6.0.	  Sensorgrams	  and	  equilibrium-­‐




Table	  3.1.	  Alanin	  scan	  mutagenesis	  




YLEPGPVTA	   YLE	   7.6	  μM	   26.5	  μM	  
YLEPGPVTV	   YLE-­‐9V	   6.3	  μM	   21.9	  μM	  
ALEPGPVTA	   YLE-­‐1A	   15.9	  μM	  	   60.6	  μM	  
YLAPGPVTA	   YLE-­‐3A	   No	  binding	   No	  binding	  
YLEAGPVTA	   YLE-­‐4A	   19.7	  μM	   144.1	  μM	  
YLEPAPVTA	   YLE-­‐5A	   >	  1mM	   >	  1mM	  
YLEPGAVTA	   YLE-­‐6A	   11.4	  μM	   954.9	  μM	  
YLEPGPATA	   YLE-­‐7A	   31.1	  μM	   102.0	  μM	  
YLEPGPVAA	   YLE-­‐8A	   38.1	  μM	   121.0	  μM	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3.2.3   The	  PMEL17	  TCR	  utilizes	  a	  peptide-­‐centric	  binding	  mode	  to	  engage	  A2-­‐YLE-­‐9V	  	  
To	  understand	  why	  TCR	  recognition	  of	  YLE	  was	  highly	  sensitive	   to	  some	  of	   the	  substitutions	   in	   the	  
native	  peptide	  sequence,	  the	  crystal	  structure	  of	  the	  PMEL17	  TCR	  was	  determined	  in	  complex	  with	  
A2-­‐YLE-­‐9V	  at	  2.02	  Å	  resolution.	  Data	  collection	  and	  refinement	  statistics	  (molecular	  replacement)	  are	  
shown	  in	  Chapter	  2	  (Table	  2.1).	  Crystallographic	  Rwork/Rfree	  ratios	  were	  within	  accepted	  limits,	  as	  shown	  
in	  the	  theoretically	  expected	  distribution	  (Tickle	  et	  al.,	  2000).	  	  
	  
Figure	   3.4	   provides	   an	   overview	   of	   the	   PMEL17	   TCR/A2-­‐YLE-­‐9V	   complex.	   The	   PMEL17	   TCR	   was	  
centrally	  positioned	  over	  the	  exposed	  residues	  of	  the	  peptide	  (Figure	  3.4A)	  and	  used	  a	  conventional	  
diagonal	  orientation	  (crossing	  angle	  =	  46.15°),	  with	  the	  α-­‐chain	  positioned	  over	  the	  α2	  helix	  of	  the	  
HLA-­‐I	   binding	   groove,	   and	   the	  β-­‐chain	  over	   the	  α1	  helix.	  All	   but	   the	  CDR2α	   loop	  were	   involved	   in	  
contacting	  A2-­‐YLE-­‐9V,	  with	  the	  CDR3α	  and	  CDR3β	  “sitting”	  on	  the	  central	  axis	  of	  the	  antigen-­‐binding	  
cleft,	  making	  contacts	  with	  both	  the	  peptide	  and	  α-­‐helices	  of	  the	  HLA	  (Figure	  3.4B-­‐C).	  	  	  
The	  PMEL17	  TCR	  made	  approximately	  the	  same	  number	  of	  peptide-­‐mediated	  contacts	  and	  HLA-­‐A2	  
interactions;	  forming	  53	  of	  125	  (42.4%)	  van	  der	  Waals	  contacts	  and	  3	  of	  8	  (37.5%)	  hydrogen	  bonds	  
between	  the	  TCR	  and	  the	  peptide	  (Table	  3.2).	  The	  HLA	  helices	  were	  contacted	  by	  residues	  within	  the	  
CDR3α,	  CDR3β	  and	  CDR2β	  loops	  (with	  additional	  support	  of	  CDR1α	  residue	  Tyr32),	  which	  focused	  on	  
Arg65,	  Ala69,	  Gln72	  and	  Gln155	  (Figure	  3.4D).	  HLA	  residues	  at	  positions	  65,	  69	  and	  155	  are	  conserved	  
TCR-­‐mediated	  contact	  points	  in	  several	  TCR-­‐pHLA-­‐I	  structures	  determined	  so	  far,	  and	  are	  referred	  to	  
as	  “restriction	  triad”	  (Tynan	  et	  al.,	  2005).	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Figure	  3.4.	  Overview	  of	  the	  PMEL17	  TCR/A2-­‐YLE	  complex	  
(A)	  Cartoon	  representation	  of	  the	  PMEL17	  TCR-­‐A2-­‐YLE-­‐9V	  complex.	  The	  TCR	  α-­‐chain	  and	  TCR	  β-­‐chain	  are	  dark	  grey	  and	  black,	  
respectively;	  TCR	  CDR	  loops	  are	  shown	  (red,	  CDR1α;	  dark	  green,	  CDR2α;	  blue,	  CDR3α;	  yellow,	  CDR1β;	  aqua,	  CDR2β;	  orange,	  
CDR3β);	  the	  HLA-­‐A*0201	  is	  depicted	  in	  grey.	  The	  YLE-­‐9V	  peptide	  is	  represented	  in	  green	  sticks.	  The	  bottom	  panel	  shows	  the	  
TCR	  α-­‐	  and	  β-­‐chain	  CDR	  loops	  sequences	  and	  gene	  usage.	  N;	  nucleotide	  addition.	  (B)	  Close-­‐up	  view	  of	  the	  PMEL17	  TCR-­‐A2-­‐YLE-­‐
9V	  interface	  (colour-­‐coded	  as	  in	  A).	  The	  overall	  position	  of	  the	  PMEL17	  TCR	  CDR	  loops	  over	  both	  the	  peptide	  and	  the	  HLA-­‐A2	  
helices	  can	  be	  observed.	  (C) Surface	  and	  stick	  representation	  of	  residues	  of	  the	  PMEL17	  TCR	  CDR	  loops	  (colour-­‐coded	  as	  in	  A)	  
that	  contact	  the	  A2-­‐YLE	  surface	  (A2,	  grey;	  YLE-­‐9V,	  green	  sticks).	  Black	  diagonal	  line	  indicated	  the	  crossing	  angle	  of	  the	  TCR	  with	  
respect	  to	  the	  long	  axis	  of	  the	  YLE-­‐9V	  peptide	  (46.15°).	  Crossing	  angle	  was	  calculated	  as	  described	  in	  Rudolph	  et	  al,	  2006.	  (D)	  
Contact	  footprint	  of	  the	  PMEL17	  TCR	  on	  the	  A2-­‐YLE-­‐9V	  surface	  (A2,	  grey);	  purple	  and	  green	  (surface	  and	  sticks)	  indicate	  HLA-­‐
A*0201	  and	  YLE	  residues,	  respectively,	  contacted	  by	  the	  gp100	  TCR.	  Cut-­‐off	  of	  3.4Å	  for	  hydrogen	  bonds	  and	  4Å	  for	  van	  der	  
Waals	  contacts. 
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Table	  3.2.	  PMEL17	  TCR-­‐A2-­‐YLE-­‐9V	  contact	  table	  
HLA/peptide	  residue	   TCR	  residue	   No.	  vdW	  (≤4Å)	   No.	  H-­‐‑bonds	  (≤3.4Å)	  
Gly62	   αGly98	   3	   	  
	   αSer99	   1	   	  
Arg65	   αSer99	   2	   	  
Arg65	  O	   αAsn100	  Nδ2	   2	   1	  
Arg65	  NH1	   βAsp58	  Oδ2	   	   1	  
	   βSer59	   8	   	  
Lys66	   αGly98	   1	   	  
	   αSer99	   4	   	  
	   αAsn100	   4	   	  
Ala69	   αAsn100	   2	   	  
	   βAla56	   2	   	  
Gln72	  Nε2	   βGln51	  O	   3	   1	  
	   βGly54	   7	   	  
	   βAla55	   1	   	  
Thr73	   βGln51	   1	   	  
Val76	   βGln51	   3	   	  
	   βGly52	   2	   	  
Lys146	   βPhe97	   3	   	  
	   βIle98	   3	   	  
Ala150	   βIle98	   1	   	  
	   βAsp102	   3	   	  
Val152	   βIle98	   1	   	  
Glu154	   αTyr32	   1	   	  
Gln155	  N	   αTyr32	  OH	   4	   1	  
Gln155	  Oε1	   βThr101	  N	   10	   1	  
Tyr1OH	   αGly97	  O	   1	   1	  
	   αGly98	   1	   	  
	   αSer96	   1	   	  
Glu3	   αTyr101	   1	   	  
Pro4	   αSer96	   1	   	  
	   αSer99	   1	   	  
	   αAsn100	   4	   	  
Pro4	  O	   αTyr101N	   14	   1	  
Gly5	   αTyr101	   3	   	  
	   βGly100	   2	   	  
Val7	   βIle98	   7	   	  
	   βGly99	   2	   	  
	   βGly100	   2	   	  
Thr8	   βThr31	   5	   	  
	   βGln51	   1	   	  
	   βPhe97	   1	   	  
Thr8	  N	   βIle98	  O	   6	   1	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3.2.4   The	  PMEL17	  CDR	  loops	  focus	  on	  YLE	  residues	  Pro4,	  Val7	  and	  Thr8	  
The	  central	  positioning	  of	  the	  PMEL17	  TCR	  enabled	  contacts	  with	  6	  out	  of	  9	  amino	  acids	  in	  the	  peptide	  
(Figure	  3.5A).	  Peptide	  residues	  Pro4,	  Val7	  and	  Thr8	  represented	  the	  focal	  points	  of	  the	  PMEL17	  TCR.	  
Pro4	  made	  a	  sizeable	  network	  of	  interactions	  (1	  hydrogen	  bond	  and	  14	  van	  der	  Waal	  contacts)	  (Figure	  
3.5B).	   Interestingly,	   Pro6	  was	   the	   only	   central	   residue	   that	   did	   not	   interact	  with	   the	   PMEL17	   TCR	  
because	  of	   its	  reduced	  surface	  exposure.	  Therefore,	  the	  relative	  insensitivity	  of	  the	  PMEL17	  TCR	  to	  
alanine	  substitution	  at	  position	  6	  is	  consistent	  with	  its	  lack	  of	  involvement	  in	  TCR	  binding.	  In	  contrast,	  
the	  gp100	  TCR	  seemed	  to	  be	  more	  sensitive	  to	  position	  6	  mutation,	  causing	  a	  ~40–fold	  drop	  in	  binding	  
affinity	  compared	  to	  the	  unaltered	  peptide	  (Table	  3.1).	  This	  might	  be	  explained	  by	  the	  different	  TRAV	  
and	  TRBV	  gene	  usage	  of	  the	  two	  gp100-­‐specific	  TCRs	  and	  the	  very	  different	  residues	  of	  the	  CDR3	  loops	  
possibly	  contacting	  the	  central	  part	  of	  the	  gp100280-­‐288	  peptide.	  However,	  the	  PMEL17	  TCR	  complex	  
structure	  did	  not	  provide	  any	  clear	  mechanisms	  to	  explain	  the	  reduction	  in	  binding	  observed	  when	  
peptide	  residues	  3	  and	  5	  were	  mutated	  to	  alanine.	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Figure	  3.5.	  The	  PMEL17	  CDR	  loops	  focus	  on	  peptide	  residues	  Pro4,	  Val7	  and	  Thr8	  	  
(A)	  Schematic	  representation	  of	  contacts	  between	  YLE-­‐9V	  peptide	  and	  PMEL17	  CDR	  loop	  residues	  (colour	  coded	  as	  in	  Figure	  
2A).	  Number	  at	  the	  bottom	  of	  the	  panel	  show	  total	  contacts	  between	  the	  TCR	  and	  peptide.	  (B)	  Contacts	  between	  the	  PMEL17	  
TCR	  and	  the	  YLE	  peptide	  (green	  sticks),	  showing	  the	  van	  der	  Waals	  contacts	  (black	  dashed	  lines)	  and	  hydrogen	  bonds	  (red	  
dashed	  lines)	  made	  by	  the	  TCR	  CDR3α	  (blue),	  CDR1β	  (yellow),	  CDR2β	  (aqua)	  and	  CDR3β	  (orange)	  loops.	  In	  the	  lower	  panel,	  
close	  view	  of	  contacts	  between	  YLE	  Pro4,	  Val7	  and	  Thr8,	  respectively,	  and	  TCR	  CDR	  loops	  residues	  (sticks	  colour	  coded	  as	  in	  
Figure	  1A).	  Cut-­‐off	  of	  3.4Å	  for	  hydrogen	  bonds	  and	  a	  cut-­‐off	  of	  4Å	  for	  van	  der	  Waals	  contacts.	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3.2.5   Binding	  thermodynamics	  and	  affinity	  of	  the	  GP100	  TCR/A2-­‐YLE	  complex	  
To	   complement	   information	   gained	   from	   the	   crystal	   structure,	   the	   affinity	   and	   thermodynamic	  
parameters	  of	  the	  PMEL17	  TCR	  were	  studied.	  Affinity	  data	  collected	  from	  kinetic	  studies	  is	  helpful	  in	  
understanding	  the	  free	  energy	  (ΔG)	  of	  the	  TCR-­‐pMHC	  binding,	  while	  thermodynamic	  parameters	  (ΔH°,	  
ΔS°)	   help	   understanding	   the	  molecular	   forces	   driving	   the	   TCR-­‐pMHC	   interaction.	   SPR	   experiments	  
were	   performed	   with	   purified	   soluble	   gp100-­‐specific	   TCR	   and	   immobilized	   A2-­‐YLE	   complex.	   The	  
binding	  strength	  of	  the	  complex	  was	  then	  measured	  at	  5,	  12,	  18,	  25	  and	  37	  °C	  (Figure	  3.6).	  At	  25	  °C	  
(the	  standard	  temperature	  for	  binding	  measurements),	  the	  KD	  of	  the	  complex	  was	  3.2	  μM.	  The	  PMEL17	  
TCR-­‐A2-­‐YLE	  interaction	  at	  25	  °C	  was	  characterized	  by	  a	  binding	  ΔG	  of	  -­‐7.5	  kcal/mol,	  which	  was	  within	  
the	  normal	  range	  of	  TCR/pHLA	  interactions.	  PMEL17	  TCR-­‐A2-­‐YLE	  binding	  was	  characterized	  by	  a	  very	  
small,	  favourable	  enthalpy	  change	  (ΔH=	  -­‐0.6	  kcal/mol)	  and	  a	  larger,	  positive	  entropy	  change	  (TΔS=	  6.9	  
cal/mol);	   thus,	  order	   to	  disorder	  drove	   the	   interaction,	  probably	   through	   the	  expulsion	  of	  ordered	  
water	  molecules	  at	  the	  interface	  (i.e.	  solvation	  effects)	  (Figure	  3.7A).	  The	  thermodynamic	  properties	  
of	  the	  complex	  at	  the	  physiologically	  relevant	  temperature	  of	  37	  °C	  were	  also	  studied.	  The	  binding	  
free	  energy	  (ΔG	  =	  -­‐7.7	  kcal/mol)	  was	  very	  similar	  to	  the	  one	  observed	  at	  25	  °C	  (ΔG=	  -­‐7.5	  kcal/mol).	  
Interestingly	  though,	  at	  37	  °C,	  the	  parameters	  were	  reversed;	  the	  interaction	  was	  driven	  mostly	  by	  
enthalpy,	  thus	  probably	  by	  the	  formation	  of	  non-­‐covalent	  bonds.	  	  
	  
Isothermal	  calorimetric	  titration	  (ITC)	  was	  also	  performed	  as	  it	  provides	  a	  direct	  measure	  of	  enthalpy	  
and	   is	   therefore	   considered	   more	   accurate	   than	   SPR	   in	   determining	   thermodynamic	   parameters	  
(Armstrong	  and	  Baker,	  2007).	  ITC	  is	  based	  on	  the	  measurement	  of	  heat	  released	  or	  absorbed	  upon	  the	  
binding	  of	  the	  TCR	  to	  the	  pHLA.	  ITC	  measurements	  (ΔH=	  -­‐0.3	  kcal/mol	  and	  TΔS=	  5.6	  cal/mol)	  confirmed	  
observation	  made	  with	  SPR	  thermodynamics	  (Figure	  3.7B).	  The	  favourable	  enthalpy	  of	  this	  TCR/pHLA	  
system	  shows	  that	  the	  overall	  number	  of	  formed	  bonds	  is	  equal	  to	  number	  of	  disrupted	  ones	  upon	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Figure	  3.6.	  PMEL17	  TCR	  equilibrium-­‐binding	  responses	  to	  A2-­‐YLE	  at	  5,	  12,	  18,	  25	  and	  37°C	  
PMEL17	  TCR	  equilibrium-­‐binding	  responses	  to	  A2-­‐YLE	  at	  5,	  12,	  18,	  25	  and	  37°C,	  respectively.	  Nine	  serial	  dilutions	  of	  the	  PMEL17	  
TCR	  were	  measured	  at	  each	  temperature.	  The	  equilibrium	  binding	  constant	  (KD,	  μM)	  values	  were	  calculated	  in	  each	  case	  using	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Figure	  3.7.	  Thermodynamic	  analysis	  of	  the	  PMEL17	  TCR/A2-­‐YLE	  interaction	  
(A)	  The	  thermodynamic	  parameters	  were	  calculated	  first	  by	  SPR,	  according	  to	  the	  Gibbs-­‐Helmholtz	  equation	  (ΔG° = ΔH	  −	  
TΔS°),	  at	  25°C	  and	  37°C,	  respectively.	  The	  binding	  free	  energies,	  ΔG°	  (ΔG° = -­‐RTlnKD),	  were	  plotted	  against	  temperature	  (K)	  
using	  nonlinear	  regression	  to	  fit	  the	  three-­‐parameter	  equation,	  (y = dH+dCp*(x-­‐298)-­‐x*dS-­‐x*dCp*ln(x/298)).	  Enthalpy	  (ΔH°)	  
and	  entropy	  (TΔS°)	  at	  25°C	  and	  37°C,	  are	  shown	  in	  kcal/mol,	  and	  were	  calculated	  by	  a	  non-­‐linear	  regression	  of	  temperature	  
(K)	  plotted	  against	  the	  free	  energy	  (ΔG°).	  (B)	  Isothermal	  calorimetric	  titration	  (ITC)	  measurements	  for	  PMEL17	  TCR/A2-­‐YLE	  
interaction.	  Enthalpy	  (ΔH°)	  and	  entropy	  (TΔS°)	  at	  298K	  (25°C),	  are	  shown	  in	  kcal/mol	  
	  
3.2.6   Peptide	   substitutions	   can	   induce	   perturbation	   at	   adjacent	   peptide	   residues	  
abrogating	  T-­‐cell	  recognition	  	  
The	  alanine	  scan	  results	  regarding	  position	  3	  and	  5	  were	  quite	  unexpected,	  considering	  that	  the	  Glu3	  
and	  Gly5	  residues	  in	  the	  ternary	  complex	  structure	  were	  only	  involved	  in	  weak	  bonds	  with	  the	  PMEL17	  
TCR	   (Table	   3.2).	   In	   order	   to	   understand	   the	   structural	   basis	   underlying	   the	   substantial	   changes	   in	  
affinity	   of	   PMEL17	   TCR-­‐A2-­‐YLE-­‐9V	   binding	   resulting	   from	   Glu3>Ala	   and	   Gly5>Ala	   substitutions,	   I	  
decided	  to	  solve	  the	  unbound	  structures	  of	  YLE-­‐3A	  and	  YLE-­‐5A	  alanine	  mutant	  peptides	  in	  complex	  
with	  HLA-­‐A2.	  Data	  collection	  and	  refinement	  statistics	  for	  individual	  structures	  are	  shown	  in	  Chapter	  
2	   (Table	   2.1).	   The	   structures	   were	   solved	   between	   1.54	   –	   2.12	   Å	   resolution	  with	   crystallographic	  
Rwork/Rfree	   ratios	   within	   accepted	   limits.	   Electron	   density	   around	   the	   peptide	   was	   unambiguous	  
(Appendix,	   Figure	   7.1).	   Comparison	   of	   the	   crystallographic	   structure	   of	   A2-­‐YLE	   and	   A2-­‐YLE-­‐3A	  
complexes	  surprisingly	  did	  not	  show	  an	  overall	  change	  in	  the	  peptide	  backbone	  conformation	  (Figure	  
3.9).	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Figure	  3.8.	  Conformational	  comparison	  of	  YLE,	  YLE-­‐3A	  and	  A2-­‐YLE-­‐5A	  peptides	  presented	  by	  HLA-­‐A*0201	  	  
(A)	   YLE	   (dark	   green	   sticks)	   and	   YLE-­‐3A	   (orange	   sticks)	   peptide	   alignment	   by	   superimposition	   of	   HLA-­‐A2	   α1	   helix	   (grey	  
cartoon).	  Boxed	  residues	   indicate	  the	  mutation	  of	  Glu3	   into	  an	  Alanine.	  The	   insets	  show	  how	  the	  Glu3>Ala	  substitution,	  
causes	   a	   shift	   in	   position	   (black	   arrow)	   of	   neighbour	   residue	   Pro4	   in	   the	   A2-­‐YLE-­‐3A	   structure	   compared	   to	   the	   A2-­‐YLE	  
structure.	  (B)	  YLE	  (dark	  green	  sticks)	  and	  YLE-­‐5A	  (pink	  sticks)	  peptide	  alignment	  by	  superimposition	  of	  HLA-­‐A2	  α1	  helix	  (grey	  
cartoon).	  Boxed	  residues	  indicate	  the	  mutation	  of	  Glycine	  5	  into	  an	  Alanine.	  
	  
	  
Nonetheless,	   in	   the	   A2-­‐YLE	   structure,	   Glu3	   bridges	   across	   to	   the	   main	   chain	   at	   position	   4-­‐5;	   the	  
mutation	  of	  Glu3	  into	  a	  shorter	  side	  chain	  (i.e.	  alanine),	  which	  is	  no	  longer	  able	  to	  bridge	  across	  the	  
void,	  caused	  an	  unusual	  “knock-­‐on	  effect”	  on	  the	  central	  Pro4	  residue	  (Figure	  3.8A).	  The	  Pro4	  in	  the	  
A2-­‐YLE-­‐3A	  structure	  lost	  restraint,	  causing	  the	  oxygen	  atom	  to	  flip	  in	  the	  opposite	  direction.	  Because	  
of	  this	  unanticipated	  displacement	  of	  the	  Pro4	  oxygen,	  the	  outward	  facing	  side	  of	  the	  Pro4	  residue	  
was	  no	  longer	  in	  an	  optimal	  position	  to	  be	  contacted	  by	  the	  TCR,	  therefore	  potentially	  losing	  a	  network	  
of	  interactions.	  These	  findings	  are	  consistent	  with	  the	  complete	  absence	  of	  measurable	  binding	  of	  the	  
YLE-­‐3A	  mutant	  in	  the	  alanine	  scan	  (Table	  3.1).	  	  Gly5	  was	  the	  only	  gp100	  peptide	  residue	  contacted	  by	  
both	  CDR3	  loops	  through	  αTyr101	  and	  βGly100	  in	  the	  PMEL17	  TCR/A2-­‐YLE	  structure.	  Upon	  mutation	  
of	  Gly5	  with	  an	  alanine	  residue	  in	  A2-­‐YLE-­‐5A	  structure,	  steric	  hindrance	  in	  the	  centre	  of	  the	  peptide	  
may	  explain	  the	  significant	  fold-­‐increase	  in	  binding	  affinity	  observed	  in	  the	  alanine	  scan	  (Figure	  3.8B).	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3.2.7   Alanine	  substitutions	  in	  YLE	  positions	  3	  and	  5	  abrogate	  T-­‐cell	  activation	  
To	  determine	  the	  effect	  of	  YLE	  altered	  peptide	  ligands	  on	  the	  activation	  of	  T-­‐cells,	  the	  ability	  of	  these	  
mutants	  to	  induce	  MIP-­‐1β,	  TNF-­‐α	  production	  and	  specific	  cytotoxicity	  was	  determined.	  These	  are	  key	  
effector	   functions	  of	  activated	  CD8+	  T-­‐cells,	  which	  can	  be	  measured	  over	  a	  wide	   range	  of	  peptide	  
concentrations.	  Human	  primary	  CD8+	  T-­‐cells	  were	  transduced	  with	  a	  lentiviral	  construct	  carrying	  the	  
gp100	  TCR	  and	  enriched	  for	  high	  and	  equal	  levels	  of	  TCR	  expression.	  Flow	  cytometry	  analysis	  with	  mAb	  
anti-­‐Vβ17	  TCR	  (i.e.	  TRBV19)	  showed	  that	  gp100	  TCR	  expression	  levels	  were	  ≥	  30%	  of	  total	  CD3+	  T-­‐cells	  
in	   three	   independent	   donors	   (Figure	   3.9).	   Transduced	   CD8+	   T-­‐cells	  were	   stimulated	  with	   peptide-­‐
pulsed	   HLA-­‐A2+	   T2	   target	   cells,	   across	   a	   range	   of	   different	   concentrations	   of	   YLE	   altered	   peptide	  
ligands.	  	  
	  
Antigen-­‐specific	  responses	  of	  gp100	  TCR-­‐engineered	  T-­‐cells	  were	  validated	  at	  the	  level	  of	  production	  
of	  MIP-­‐1β	  and	  specific	  lysis	  of	  pulsed	  targets.	  Non-­‐transduced	  CD8+	  T-­‐cells	  were	  used	  to	  control	  for	  
non-­‐specific	  activation	  through	  the	  endogenous	  TCR;	  T-­‐cells	  transduced	  with	  the	  MEL5	  TCR	  (specific	  
for	  the	  HLA-­‐A2	  restricted	  cancer	  epitope	  ELA	  from	  the	  Melan-­‐A	  protein)	  were	  used	  as	  an	  irrelevant	  
control	  in	  all	  experiments.	  Peptide	  titration	  experiments	  showed	  marked	  differences	  in	  the	  ability	  to	  
sensitize	  target	  cells	  for	  MIP-­‐1β	  production	  by	  CD8+	  gp100-­‐specific	  T-­‐cells	  (Figure	  3.11A).	  In	  particular,	  
target	  cells	  pulsed	  with	  YLE	  and	  YLE-­‐9V	  were	  recognized	  more	  efficiently	  than	  those	  pulsed	  with	  YLE-­‐
1A,	  YLE-­‐8A,	  YLE-­‐4A	  and	  YLE-­‐7A.	  No	  MIP-­‐1β	  production	  was	  measured	  with	  YLE-­‐3A	  and	  YLE-­‐5A	  peptide	  
ligands,	  even	  at	  higher	  peptide	  concentrations.	  TNF-­‐α	  production	  was	  measured	  by	  ELISA	  from	  the	  
same	  supernatants	  (Figure	  3.11C)	  and	  low	  levels	  of	  this	  cytokine	  were	  only	  detected	  when	  cells	  were	  
pulsed	  with	  YLE,	  YLE-­‐9V,	  YLE-­‐8A	  or	  YLE-­‐6A.	  Figure	  3.11B	  shows	  specific	  lysis	  of	  target	  cells	  pulsed	  with	  
the	   same	   range	   of	   peptides	   and	  measured	   by	   51Cr	   release	   assay.	   Similar	   to	   the	  MIP-­‐1β	   response	  
curves,	  the	  specific	  lysis	  induced	  by	  these	  altered	  YLE	  ligands	  was	  variable.	  Most	  importantly,	  no	  CTL-­‐
mediated	  lysis	  was	  observed	  when	  peptides	  YLE-­‐3A	  or	  YLE-­‐5A	  were	  used.	  Taken	  together,	  these	  data	  
are	   consistent	   with	   the	   molecular	   analysis	   demonstrating	   that	   the	   structural	   and	   biophysical	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Figure	  3.9.	  Gp100	  TCR	  expression	  by	  transduced	  primary	  CD8+	  human	  T-­‐cells	  
Activated	  primary	  CD8+	  T	  cells	  were	  transduced	  with	  lentiviral	  constructs	  expressing	  the	  gp100	  TCR	  specific	  for	  the	  HLA-­‐A2-­‐
restricted	   melanoma	   differentiation	   antigen	   gp100	   (YLEPGPVTA,	   280-­‐288).	   After	   72	   hours,	   transduction	   efficiency	   was	  
determined	  by	  flow	  cytometry	  after	  staining	  with	  anti-­‐Vβ17	  TCR	  (i.e.	  TRBV19)	  FITC-­‐conjugated	  antibody.	  Anti-­‐FITC	  microbeads	  
(MACS)	  were	  used	  to	  enrich	  the	  TRBV+	  population	  before	  staining.	  Dot	  plots	  show	  surface	  expression	  of	  gp100	  TCR	  (TRBV19)	  
on	  primary	  CD8+	  cells	  (gated	  on	  live	  CD3+	  T	  cells)	  in	  three	  different	  blood	  donors	  (A,	  B	  and	  C).	  Untransduced	  (UT)	  cells	  or	  MEL5	  
TCR	  (irrelevant)	  transduced	  cells	  were	  used	  as	  controls.	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Figure	  3.10.	  Production	  of	  MIP-­‐1β,	  TNFα	  and	  cytotoxicity	  by	  gp100	  TCR	  transduced	  CD8+	  T-­‐cells	  in	  response	  to	  stimulation	  
with	  YLE	  peptide	  ligands	  
A)	   gp100	   TCR	   transduced	   CD8+	   T-­‐cells	   were	   stimulated	  with	   peptide-­‐pulsed	   target	   cells	   as	   indicated.	   Supernatant	  was	  
assayed	  for	  MIP-­‐1β	  by	  ELISA.	  Negative	  control	  (no	  peptide)	  was	  subtracted	  from	  each	  stimulated	  condition.	  (B)	  gp100	  TCR	  
transduced	  CD8+	  T-­‐cells	  were	  tested	  in	  a	  standard	  4	  h	  51Cr-­‐release	  assay	  against	  peptide-­‐pulsed	  targets.	  Negative	  control	  
(no	  peptide)	  was	  subtracted	  from	  each	  stimulated	  condition.	  	  (C)	  gp100	  TCR	  transduced	  CD8+	  T-­‐cells	  were	  stimulated	  with	  
peptide-­‐pulsed	  target	  cells	  (10-­‐5	  M	  peptide)	  as	  indicated.	  Supernatant	  was	  assayed	  for	  TNF-­‐α	  by	  ELISA.	  Negative	  control	  (no	  
peptide)	  was	  subtracted	  from	  each	  stimulated	  condition.	  ELA	  (Melan-­‐A/MART-­‐1)	  9mer	  peptide	  was	  used	  as	  an	  irrelevant	  
control	  in	  all	  experiments.	  Results	  of	  one	  (out	  of	  three)	  donor	  are	  shown.	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3.3   Discussion	  
TCRs	  specific	  for	  cancer	  epitopes	  are	  generally	  characterised	  by	  low	  binding	  affinities	  (binding	  KDs	  high	  
micromolar	   range)	   (Bridgeman	  et	  al.,	  2011).	  This	   lower	  binding	  affinity	   is	   thought	   to	  be	  a	   result	  of	  
negative	  selection	  of	  T-­‐cells	  that	  bear	  TCRs	  with	  higher	  affinity	  for	  self-­‐ligands	  in	  the	  thymus.	  Since	  
TCR	  affinity	  plays	  an	  important	  role	  in	  T-­‐cell	  activation,	  the	  TCR	  affinity	  gap	  between	  anti-­‐pathogen	  
and	  anti-­‐cancer	  T-­‐cells	  leaves	  the	  latter	  at	  a	  distinct	  disadvantage	  and	  makes	  it	  more	  difficult	  to	  break	  
self-­‐tolerance	   to	   such	   antigens.	  One	   approach	   to	   enhance	   the	   T-­‐cell	   response	   to	   tumour	   antigen-­‐
derived	   peptides	   has	   been	   to	   immunize	   patients	  with	   altered	   peptide	   ligands	   that	   differ	   from	   the	  
native	  sequence	  by	  a	  single,	  or	  multiple,	  amino	  acid	  residues	  (Lesterhuis	  et	  al.,	  2011).	  However,	  such	  
‘heteroclitic’	  peptides	  with	  even	  single	  amino	  acid	  substitutions	  that	  are	  predicted	  to	  only	  contact	  the	  
HLA	   can	   have	   unpredictable,	   yet	   important,	   effects	   on	   TCR	   engagement.	   Despite	   their	   extensive	  
application	  in	  clinical	  trials	  as	  cancer	  vaccines,	  to	  date	  only	  a	  few	  X-­‐ray	  structures	  of	  TCRs	  bound	  to	  
cognate	  tumour	  antigens	  have	  been	  determined	  (Borbulevych	  et	  al.,	  2011;	  Chen,	  2005;	  Deng	  et	  al.,	  
2007;	  Madura	   et	   al.,	   2015).	   I	   have	   solved	   the	   first	   crystal	   structure	   of	   a	   HLA-­‐A2	   restricted	   gp100	  
peptide	  antigen	  bound	  to	  a	  cognate	  αβ	  TCR.	  In	  this	  chapter,	  I	  show	  how	  the	  PMEL17	  TCR	  bound	  with	  
a	  typical	  diagonal	  orientation	  over	  the	  central	  peptide	  residues,	  and	  mainly	  contacted	  residues	  4,	  7	  
and	  8	  of	   the	  YLE-­‐9V	  peptide	  which	  protruded	  out	  of	   the	  HLA-­‐A2	  binding	  groove.	   Interestingly,	   the	  
PMEL17	  TCR	  was	  characterized	  by	  a	  binding	  affinity	  (KD)	  of	  7.6	  μM,	  a	  value	  that	  falls	  in	  the	  very	  high	  
end	  of	  affinity	  ranges	  described	  so	  far	  for	  cancer	  TCR	  and	  pHLA	  interactions	  (Bridgeman	  et	  al.,	  2011;	  
Aleksic	   et	   al.,	   2012).	   These	   observations	   suggest	   that	   healthy	   donors	   or	   melanoma	   patients	   may	  
harbour	  T-­‐cells	  bearing	  TCRs	  with	  reasonable	  affinity	  for	  some	  tumour	  associated	  antigens,	  which	  can	  
be	  preferentially	  chosen	  for	  TCR-­‐based	  applications.	  For	  example,	  gp100-­‐specific	  ImmTACs	  (Immune-­‐
mobilising	  monoclonal	  TCRs	  against	  cancer)	  are	  a	  new	  class	  of	  soluble	  bi-­‐specific	  anti-­‐tumour	  agents	  
that	   combine	   a	   high-­‐affinity	   TCR-­‐based	   gp100	   recognition	   domain	  with	   a	   T	   cell	   activation	   domain	  
(Liddy	  et	  al.,	  2012;	  Bossi	  et	  al.,	  2014).	  IMCgp100	  is	  being	  tested	  as	  a	  soluble	  drug	  and	  is	  showing	  partial	  
or	  complete	  durable	  responses	  in	  Phase	  I/IIa	  trial	  in	  patients	  with	  advanced	  melanoma	  (Middleton	  et	  
al.,	  2015).	  
	  
In	   this	   chapter	   I	   also	   provide	   insight	   into	   YLE	   single	   amino	   acid	   contribution	   to	   TCR	   binding	   by	  
performing	  an	  alanine	  scan	  mutagenesis	  across	  the	  peptide	  backbone	  with	  two	  different	  YLE-­‐specific	  
αβTCRs.	  Interestingly,	  both	  PMEL17	  TCR	  and	  gp100	  TCR	  were	  most	  sensitive	  to	  mutations	  at	  position	  
3	   or	   5	   of	   the	   native	   YLE	   peptide	   sequence	   despite	   these	   TCRs	   being	   constructed	   from	   completely	  
different	  Vα	  and	  Vβ	  genes.	  These	  results	  are	  supported	  by	  a	  recent	  study	  of	  YLE	  altered	  peptide	  ligands	  
which	  described	  YLE-­‐3A	  as	  a	  null	  agonist	  for	  a	  different	  TCR	  (Shaft	  et	  al.,	  2003;	  2013).	  Overall,	  along	  
with	  the	  two	  TCRs	  studied	  here,	  the	  sequences	  of	   further	  two	  distinct	  YLE-­‐specific	  TCRs	  have	  been	  
published,	  demonstrating	  diverse	  gene	  usage	  and	  different	  CDR3	  loop	  sequences	  (Table	  3.3).	  	  
No	  structural	  data	  supporting	  these	  observations	  have	  been	  published	  to	  date.	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Table	  3.3.	  Alignment	  of	  TCR	  CDR3	  regions	  of	  four	  gp100-­‐specific	  TCRs	  
PMEL17,	  gp100,	  MPD	  (Schaft	  et	  al.,	  2003)	  and	  296	  (Schaft	  et	  al.,	  2003)	  gp100-­‐specific	  TCR.	  
TCR	   CDR1α	   CDR2α	   CDR3α	   CDR1β	   CDR1β	   CDR1β	  
PMEL17	   DSAIYN IQSSQRE CAVLSSGGSNYKLTFG SGHTA FQGTGA CASSFIGGTDTQYFG 
gp100	   TSINN IRSNERE CATDGDTPLVFG LNHDA SQIVND CASSIGGPYEQYFG 
MPD	   KALYS LLKGGEQ CGTETNTGNQFYFG SGHDY FNNNVP CASSLGRYNEQFFG 




Interestingly,	  mutation	  in	  position	  3	  in	  the	  YLE	  peptide	  did	  not	  alter	  the	  conformation	  of	  the	  peptide	  
backbone	  itself,	  but	  resulted	  in	  a	  ‘knock-­‐on’	  effect	  on	  the	  neighbouring	  residue	  Pro4	  that	  completely	  
abolished	  TCR	  binding	  and	  T-­‐cell	  recognition.	  This	  can	  be	  explained	  by	  the	  fact	  that	  Pro4	  was	  at	  the	  
centre	  of	  a	  sizeable	  network	  of	  interactions	  (both	  vdW	  and	  hydrogen	  bonds)	  in	  the	  PMEL17-­‐A2-­‐YLE-­‐
9V	  structure.	  In	  addition,	  Position	  3	  in	  HLA-­‐A2	  restricted	  peptides	  is	  known	  to	  be	  a	  secondary	  anchor	  
residue	  (Ruppert	  et	  al.,	  1993),	  in	  that	  it	  supports	  the	  exposed	  peptide	  bulge	  that	  is	  normally	  involved	  
in	  TCR	  binding.	  By	  mutating	   the	  residue	   in	  position	  3	  with	  a	  smaller	  side	  chain,	   this	  support	   is	   lost	  
causing	  a	  ‘molecular	  switch	  in	  the	  neighbour	  Pro4.	  A	  similar	  mechanism	  in	  an	  HIV-­‐1	  derived	  peptide,	  
has	  recently	  been	  described	  by	  our	  group,	  with	  important	  implications	  for	  the	  immune	  control	  of	  HIV	  
infection	  and	  patterns	  of	  viral	  escape	  mutants	  (Kløverpris	  et	  al.,	  2015).	  Additionally,	  the	  existence	  of	  a	  
novel	  mode	  of	  flexible	  peptide	  presentation	  in	  a	  diabetes	  model	  has	  been	  demonstrated,	  showing	  the	  
potential	   dynamic	   nature	   of	   the	   region	   surrounding	   the	   HLA	   F-­‐pocket	   (Motozono	   et	   al.,	   2015;	  
Borbulevych	   et	   al.,	   2009).	   Taken	   together,	   these	   studies	   support	   the	   notion	   that	   peptide-­‐HLA	  
interactions	  are	  more	  plastic	  and	  dynamic	  than	  previously	  appreciated,	  with	  obvious	  implications	  for	  
immune	  recognition,	  epitope	  prediction	  and	  structural	  modelling.	  
	  	  
Overall,	   the	   results	  presented	  here	   represent	   the	   first	   structural	   insight	   into	  TCR	   recognition	  of	  an	  
important	  tumour	  antigen,	  targeted	  by	  many	  clinical	  therapies.	  They	  reveal	  that	  two	  very	  different	  
TCRs	  share	  a	  similar	  pattern	  of	  specificity,	  demonstrated	  by	  their	  near	  identical	  sensitivity	  to	  different	  
peptide	  modifications.	  Finally,	   I’ve	  shown	  that	  modification	  to	  peptide	  residues	  outside	  of	   the	  TCR	  
binding	  motif	  can	  have	  unpredictable	  knock-­‐on	  effects	  on	  adjacent	  peptide	  residues	  that	  abrogate	  TCR	  
binding	   and	   T-­‐cell	   recognition,	   highlighting	   that	   even	   conservative	   peptide	   substitutions	   can	   have	  
unexpected	  consequences	  for	  T-­‐cell	  recognition	  by	  different	  antigen-­‐specific	  TCRs	  due	  to	  ‘knock-­‐on’	  
structural	  changes	  in	  the	  HLA-­‐bound	  peptide.	  Such	  ‘transmitted’	  structural	  changes	  need	  to	  be	  taken	  
into	   consideration	   when	   designing	   improved	   peptides	   for	   cancer	   vaccination.	   Given	   the	   growing	  
evidence	  that	  plasticity	  at	  the	  TCR-­‐pHLA	  interface	  can	  influence	  immune	  recognition,	  structural	  and	  
biophysical	  studies	  of	  binding	  should	  be	  taken	  into	  account	  when	  attempting	  to	  design	  altered	  peptide	  
ligands	  with	  improved	  immunogenicity.	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4   Dissection	   of	   T-­‐cell	   responses	   in	   an	   HLA-­‐A2+	   remission	  
melanoma	  patient	  after	  TIL-­‐therapy	  
4.1   Background	  
4.1.1   TIL-­‐therapy	  at	  the	  CCIT	  (Copenhagen,	  Denmark)	  
Tumour	  infiltrating	  lymphocytes	  (TILs)	  represent	  a	  heterogeneous	  population	  of	  lymphocytes	  that	  are	  
found	  within	  a	  tumour.	  TIL-­‐based	  Adoptive	  T	  cell	  therapy	  (ACT)	  is	  emerging	  as	  a	  promising	  option	  to	  
cure	  treatment-­‐refractory	  metastatic	  melanoma.	  More	  than	  30	  patients	  (between	  the	  age	  of	  18	  and	  
70)	   with	   progressive	   metastatic	   (or	   locally	   advanced)	   cutaneous	   malignant	   melanoma	   have	   been	  
treated	  with	  TIL	  therapy	  in	  a	  phase	  I/II	  clinical	  trial	   (identifier:	  NCT00937625,	  directed	  by	  Professor	  
Inge	  Marie	   Svane)	   at	   the	   CCIT	   and	  Herlev	  Hospital	   (Copenhagen,	  Denmark)	   (Ellebæk	  et	   al.,	   2012).	  
Durable	  complete	  tumour	  regressions	  (>1	  year)	  and	  an	  overall	  response	  rate	  of	  42%	  were	  achieved	  
(Andersen	   et	   al.,	   2016;	   Ellebæk	   et	   al.,	   2012).	   A	   schematic	   representation	   of	   the	   TIL	   isolation	   and	  
expansion	  process	   is	   shown	   in	   Figure	   1.9	   (Chapter	   1).	   Briefly,	   TIL	   isolation	   starts	  with	   the	   surgical	  
resection	  of	  suitable	  melanoma	  lesions,	  which	  are	  cut	  into	  1-­‐3	  mm3	  fragments	  and	  grown	  in	  culture	  
plates	  with	  IL-­‐2	  supplemented	  medium.	  The	  process	  involves	  an	  initial	  in	  vitro	  expansion	  step	  of	  the	  
patient’s	  autologous	  TILs	   for	  a	  period	  of	  2-­‐4	  weeks	   to	  at	   least	  5x107	  cells,	  after	  which	  cells	   can	  be	  
cryopreserved	   for	   future	  use.	   TILs	   are	   then	   subjected	   to	  a	  Rapid	  Expansion	  Protocol	   (REP)	   and	   re-­‐
infused	  into	  the	  patient	  with	  intravenous	  moderate	  dose	  of	  IL-­‐2,	  following	  a	  lympho-­‐depleting	  regimen	  
(Donia	  et	  al.,	  2012;	  Elleabak	  et	  al.,	  2012).	  	  
	  	  
Although	  the	  clinical	  efficacy	  of	  these	  TIL-­‐based	  trials	  is	  promising,	  the	  characterisation	  of	  the	  T-­‐cell	  
responses	  that	  mediate	  tumour	  recognition	  and	  regression	  in	  vivo	  has	  been	  limited.	  Previous	  work	  has	  
shown	  that	  the	  absolute	  number	  of	  TILs	  infused,	  and	  in	  particular	  the	  number	  of	  CD8+	  TILs,	  is	  a	  critical	  
factor	   influencing	   the	   outcome	  of	  ACT	   (Itzhaki	   et	   al.,	   2011;	   Radvanyi	   et	   al.,	   2012).	   Analysis	   of	   the	  
composition	  of	  melanoma-­‐restricted	  T-­‐cell	  responses	  among	  TILs	  revealed	  that	  only	  small	  percentages	  
of	   TILs	   recognise	   shared	   self-­‐antigens	   (Andersen	   et	   al.,	   2012).	  Most	   of	   the	   antigen	   specificities	   in	  
melanoma	  TILs	  associated	  with	  long-­‐term	  complete	  regressions	  remain	  elusive.	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4.1.2   Aims	  
The	  overall	  aim	  of	  this	  study,	  which	  was	  carried	  out	  in	  collaboration	  with	  the	  CCIT	  research	  team	  in	  
Denmark,	  was	  to	  dissect	  melanoma	  T-­‐cell	  responses	  in	  TIL	  infiltrates	  associated	  with	  complete	  in	  vivo	  
tumour	  regression.	  I	  had	  privileged	  access	  to	  samples	  (TIL	  infusion	  products,	  autologous	  melanoma	  
cell	   lines	  and	  blood	  samples)	  of	  metastatic	  melanoma	  patients	   from	  the	  Danish	  trial	  who	  achieved	  
complete	   remission	   after	   TIL-­‐based	   therapy	   (Ellebaek	   et	   al.,	   2012;	   Andersen	   et	   al.,	   2016).	   In	   this	  
chapter,	   I	  have	  focused	  on	  an	  HLA-­‐A2+	  complete	  responder	  patient,	   identified	  hereafter	  as	  patient	  
MM909.24.	  In	  the	  next	  chapter,	  I	  took	  a	  similar	  approach	  using	  TILs	  from	  a	  patient	  that	  did	  not	  express	  
HLA-­‐A2	  and	  the	  biases	  associated	  with	  this	  HLA.	  The	  HLA-­‐A2	  allele	  is	  the	  most	  common	  in	  Northern	  
Asia	  and	  North	  America	  populations,	  and	  is	  the	  restricting	  element	  that	  presents	  the	  majority	  of	  the	  
T-­‐cell	  epitopes	  described	  to	  date	  (Andersen	  et	  al.,	  2012).	  
	  
At	  the	  outset,	  I	  aimed	  to	  address	  the	  following	  research	  questions:	  
•   Which	  T-­‐cell	  subsets	  contribute	  to	  T-­‐cell	  tumour	  reactivity?	  
•   To	  what	  degree	  is	  the	  autologous	  tumour	  targeted	  through	  HLA-­‐A2?	  
•   Is	  the	  antigen	  specificity	  of	  TILs	  directed	  towards	  known	  shared	  melanoma	  antigens?	  
•   How	  many	  clonotypes	  constitute	  tumour	  reactive	  TILs	  and	  do	  dominant	  clones	  persist	  in	  the	  
patient’s	  blood	  after	  treatment?	  	  
•   What	  is	  the	  antigen	  specificity	  of	  the	  dominant	  anti-­‐tumour	  T-­‐cell	  clonotype(s)?	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4.2   Results	  
4.2.1   Patient	  characteristics	  and	  experimental	  approach	  
Details	  of	  the	  patient	  MM909.24	  clinical	  outcome	  and	  characteristics	  of	  the	  infused	  TILs	  are	  shown	  in	  
Figure	   4.1A.	   The	   TIL	   infusion	   product	   was	   defrosted	   and	   cultured	   in	   complete	   T-­‐cell	   medium,	  
supplemented	  with	  200	  IU/mL	  IL-­‐2	  (see	  section	  2.9	  of	  Materials	  and	  Methods	  for	  details	  regarding	  TIL	  
culture	  maintenance	  and	  expansion).	  The	  limited	  sample	  availability	  (approximately	  2-­‐3	  x106	  of	  cells	  
from	  the	  original	  TIL	  infusion	  product)	  required	  the	  expansion	  of	  TILs	  to	  the	  minimum	  cell	  numbers	  
for	  functional	  experiments.	  Repeated	  in	  vitro	  expansion	  and	  long-­‐term	  culture	  of	  TILs	  was	  a	  potential	  
concern	  as	  it	  could	  result	  in	  a	  bias	  toward	  certain	  clonotypes	  that	  were	  adapted	  to	  growth	   in	  vitro.	  
Therefore,	   all	   the	   experiments	   shown	   in	   this	   chapter	   were	   performed	   on	   TIL	   cultures	   that	   were	  
expanded	   for	  a	  maximum	  of	  2-­‐3	  passages.	  Where	  possible,	   the	  original	   infusion	  product	   itself	  was	  
studied.	  
	  
The	   presence	   of	   distinct	   TCR	   Vβ	   families	   in	   TIL	   cultures	   was	   initially	   analysed	   by	   staining	   with	  
conjugated	  antibodies	  directed	  against	   individual	  TRBV	  gene	  products.	  TRBV20-­‐1	  and	  TRBV12	  were	  
the	  most	  frequent	  in	  MM909.24	  TILs	  (26.7%	  and	  9.5%	  of	  total	  CD8+	  TILs,	  respectively)	  (Figure	  4.1B).	  
However,	   commercially	   available	   TRBV	   antibodies	   cover	   only	   about	   half	   of	   the	   whole	   TCR	   Vβ	  
repertoire,	   and	   therefore	   sometimes	   fail	   to	   label	   cognate	   TRBV+	   T-­‐cell	   populations.	   Furthermore,	  
distinct	  T-­‐cell	  clones	  may	  share	  the	  same	  TCRVβ	  but	  have	  a	  different	  CDR3	  sequence	  (i.e.	  the	  region	  
that	   interacts	   with	   the	   cognate	   peptide-­‐HLA	   ligand)	   and	   therefore	   different	   peptide	   specificities.	  
Therefore,	  to	  overcome	  these	  limitations	  and	  to	  provide	  a	  more	  complete	  analysis	  of	  the	  TCRβ	  V	  gene	  
usage	  of	  tumour	  reactive	  T-­‐cells	  in	  the	  patient’s	  TIL	  population,	  I	  opted	  for	  TCRβ	  clonotyping,	  which	  
will	  be	  discussed	  in	  more	  detail	  in	  section	  4.2.5	  of	  this	  chapter.	  	  
	  
The	  HLA	  expression	  of	  the	  autologous	  tumour	  cell	   line	  was	  tested	  by	  flow	  cytometry	  (Figure	  4.1C).	  
MM909.24	  melanoma	  cells	  express	  high	  levels	  of	  HLA-­‐I	  molecules,	  while	  HLA-­‐II	  expression	  could	  only	  
be	   induced	   after	   a	   72-­‐hour	   treatment	   with	   a	   low	   dose	   of	   IFN-­‐γ.	   These	   expression	   profiles	   are	   in	  
accordance	   with	   studies	   from	   our	   collaborators	   and	   others	   groups,	   which	   have	   shown	   a	  
heterogeneous	   pattern	   of	   constitutive	   or	   IFN-­‐γ	   induced	   HLA-­‐II	   surface	   expression	   in	   hundreds	   of	  










Figure	  4.1.	  Patient	  MM909.24	  characteristics,	  TIL	  composition	  and	  autologous	  tumour	  HLA	  expression	  
(A)	   Patient	   characteristics,	   treatment	   details	   and	   clinical	   outcome.	   M1a	   stage	   (AJCC)	   (Balch	   et	   al.,	   2009)	   involves	   distant	  
metastasis	  in	  the	  skin,	  subcutaneous	  tissue,	  or	  distant	  lymph	  nodes.	  A	  complete	  response	  (CR)	  is	  defined	  by	  RECIST	  guidelines	  
as	  the	  “disappearance	  of	  all	  target	  lesions	  and	  any	  pathological	  lymph	  nodes	  must	  have	  reduction	  to	  <10	  mm	  (Eisenhauer	  et	  al.,	  
2009).	  (B)	  TRBV	  antibody	  surface	  staining	  of	  MM909.24,	  gated	  on	  total	  CD3+	  CD8+	  viable	  T-­‐cells.	  (C)	  Left	  panel	  shows	  the	  flow	  
cytometric	  analysis	  of	  HLA-­‐I	  and	  HLA-­‐II	  expression	  of	  autologous	  melanoma	  cells.	  Cells	  were	  untreated	  or	  treated	  with	  low	  dose	  
IFN-­‐γ	  (100	  IU/mL)	  for	  72	  hours.	  Right	  panel	  shows	  full	  HLA-­‐I	  and	  HLA-­‐II	  typing.	  HLA-­‐I	  typing	  is	  shown	  at	  the	  2-­‐digit	  level,	  which	  
distinguishes	  the	  protein	  family,	  whereas	  HLA-­‐II	  was	  performed	  to	  the	  4-­‐digit	  level	  and	  distinguishes	  different	  proteins	  within	  a	  
family.	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4.2.2   Anti-­‐melanoma	  reactivity	  of	  TILs	  MM909.24	  
IFN-­‐γ	  and	  TNF-­‐α	  are	  among	  the	  secreted	  cytokines	  that	  mediate	  the	  anti-­‐tumour	  activity	  of	  effector	  
CD8+	  T-­‐cells.	  During	  the	  killing	  process	  of	  the	  target	  tumour	  cell	  the	  lysosomal-­‐associated	  membrane	  
protein,	  CD107a,	  is	  also	  transiently	  mobilised	  to	  the	  surface	  membrane	  of	  effector	  CD8+	  cells	  (Betts	  
et	  al.,	  2003).	  The	  reactivity	  of	  cultured	  MM909.24	  TILs	  against	  autologous	  tumour	  cells	  was	  analysed	  
by	  measuring	  IFN-­‐γ,	  CD107a	  and	  TNF-­‐α	  T-­‐cell	  production	  by	  flow	  cytometry	  (Figure	  4.2B).	  The	  CD8+	  
subset	   of	   TILs	  MM909.24	   (which	   represents	   96.9%	  of	   total	   CD3+	   TILs)	   produced	   IFN-­‐γ,	   TNF-­‐α	   and	  
CD107a	  upon	  stimulation	  with	  autologous	  tumour	  cells	  (14.4%,	  21.7%	  and	  28%,	  respectively).	  When	  
gated	  on	  CD4+	  TILs	  (2.49%	  of	  total	  CD3+	  cells),	  only	  0.2%	  of	  CD4+	  CD107a+	  cells	  could	  be	  detected	  
(Figure	  4.2C)	  and	  as	  the	  number	  of	  events	  acquired	  for	  this	  population	  is	  very	  low,	  it	  may	  not	  be	  a	  true	  
representation	  of	  activity.	  The	  assay	  would	  need	  to	  be	  repeated	  to	  validate	  CD4+	  activity	  using	  more	  
cells	  per	  condition.	  Alternatively,	  the	  CD4+	  cells	  could	  be	  cloned	  and	  tumour	  reactivity	  assessed	  at	  the	  
clonal	  level.	  Collectively,	  these	  data	  suggest	  that	  there	  is	  a	  functional	  heterogeneity	  among	  tumour	  
reactive	   TILs.	   The	   hierarchy	   seen	   for	   the	   outputs	   used	   here	  may	   be	   attributable	   to	   T-­‐cell	   peptide	  
sensitivity	  (La	  Gruta	  et	  al.,	  2004;	  Laugel	  et	  al.,	  2007;	  Price	  et	  al.,	  1998).	  
	  
My	   first	   attempt	   at	   investigating	   the	   HLA-­‐restriction	   of	   tumour-­‐reactive	   TILs	   involved	   the	   use	   of	  
blocking	   antibodies.	   Incubation	   of	   target	   melanoma	   cells	   with	   an	   anti-­‐HLA-­‐I	   mAb	   resulted	   in	   the	  
inhibition	  of	  IFN-­‐γ,	  TNF-­‐α	  and	  CD107a	  expression,	  which	  decreased	  in	  turn	  to	  1.02%,	  1.15%	  and	  3.04%	  
(Figure	  4.2B),	  from	  14.4%,	  21.7%	  and	  28%	  respectively.	  Incubation	  with	  an	  anti-­‐HLA-­‐II	  mAb	  resulted	  
in	  a	  less	  marked	  reduction	  in	  IFN-­‐y,	  TNFα	  and	  CD107a,	  with	  a	  drop	  of	  3.9%,	  1.7%	  and	  0.4%	  respectively.	  
Taken	  together,	   these	   initial	   results	  suggest	  that	  the	  major	  reactivity	  against	  autologous	  tumour	   in	  
MM909.24	  TILs	  is	  mediated	  by	  the	  CD8+	  TIL	  subset	  and	  expected	  to	  be	  HLA-­‐I	  restricted.	  
	  
	  





Figure	  4.2.	  MM909.24	  TILs	  reactivity	  to	  autologous	  tumour	  is	  mediated	  by	  CD8+	  T-­‐cells	  and	  is	  HLA	  class-­‐I	  restricted	  
(A)	  TILs	  were	  gated	  on	  live	  CD3+	  T-­‐cells	  and	  CD8+	  and	  CD4+	  subsets	  analysed	  separately.	  (B)	  FACS	  plots	  of	   ICS	  of	  CD8+	  TILs	  
expressing	  IFN-­‐γ,	  TNF-­‐α	  and	  CD107a	  after	  5	  hour	  stimulation	  with	  autologous	  tumour	  cells	  (E:T	  ratio	  2:1).	  TILS	  alone	  were	  used	  
as	  control.	  Target	  melanoma	  cells	  were	  also	  incubated	  with	  either	  an	  anti-­‐HLA-­‐I	  or	  HLA-­‐II	  mAb	  to	  explore	  HLA-­‐restriction.	  Gates	  
were	  set	  based	  on	  Fluorescence	  Minus	  One	  (FMO)	  sample	  (i.e.	  unstimulated	  TILs	  stained	  with	  surface	  markers	  only).	  (C)	  ICS	  
FACS	  plots	  of	  CD4+	  TILs	  expressing	  IFN-­‐γ,	  TNF-­‐α	  and	  CD107a	  upon	  activation	  with	  autologous	  tumour	  cells.	  TILS	  alone	  were	  
used	  as	  control.	  
	  
	  
Given	   the	   fact	   that	   patient	  MM909.24	   is	   HLA-­‐A2+	   (HLA-­‐A30	   at	   the	   second	   HLA-­‐A	   allele),	   another	  
blocking	  experiment	  using	  an	  anti–HLA-­‐A2	  mAb	  (BB7.2	  clone)	  was	  performed	  and	  the	  production	  of	  
IFN-­‐γ	  by	  CD8+	  TILs	  was	  measured.	  As	  shown	  in	  Figure	  4.3A,	   incubation	  of	  melanoma	  cells	  with	  the	  
antibody	   resulted	   in	   a	   3-­‐fold	   reduction	   of	   TILs	   IFN-­‐γ	   expression,	   but	   did	   not	   completely	   inhibit	  
autologous	  melanoma	  recognition.	  An	  anti-­‐HLA-­‐A1	  blocking	  antibody	  was	  used	  as	  a	  negative	  control	  
and	  had	  no	  effect	  on	  tumour	  recognition	  as	  expected.	  These	  data	  suggest	  that	  at	   least	  30%	  of	  the	  

































Figure	  4.3.	  MM909.24	  TIL	  tumour	  reactivity	  is	  predominantly	  HLA-­‐A2	  restricted	  
(A)	  ICS	  FACS	  plots	  show	  the	  percentage	  of	  CD8+	  IFN-­‐γ+	  TILs	  upon	  5	  hour	  stimulation	  with	  autologous	  tumour	  cells	  (E:T	  ratio	  
2:1).	  Unstimulated	  TILs	  were	  used	  as	  negative	  control.	  Cells	  were	  gated	  on	  live	  CD3+	  TILs.	  Target	  melanoma	  cells	  were	  also	  
incubated	  with	  either	  an	  anti-­‐HLA-­‐A2	  or	  anti-­‐HLA-­‐A1	  (irrelevant	  control)	  mAb	  to	  explore	  HLA-­‐A2	  restriction.	  (B)	  Bar	  chart	  shows	  
the	  percentage	  of	  CD107a+	  TNF-­‐α+	  TILs	  upon	  stimulation	  with	  melanoma	  cell	  lines,	  of	  which	  several	  share	  the	  HLA-­‐A2	  allele	  
(blue)	  or	  HLA-­‐B40	  allele	  (aqua)	  with	  the	  autologous	  tumour.	  Stimulation	  with	  autologous	  tumour	  (black	  bar)	  and	  PHA	  (3	  µg/mL)	  
(grey	   bar)	   were	   used	   as	   positive	   controls.	   Reactivity	   against	   the	   autologous	   tumour	   was	   lower	   than	   seen	   in	   previous	  
experiments.	  Gates	  were	  set	  on	  unstimulated	  TILs	  samples	  (negative	  control).	  Representative	  FACS	  plots	  are	  shown	  in	  Appendix	  




Blocking	  antibodies	  might	  not	  be	  the	  optimal	  tool	  to	  inhibit	  effector	  T-­‐cell	  activity,	  as	  they	  can	  fail	  to	  
saturate	   all	   the	   available	   surface	   HLA	   molecules.	   To	   further	   explore	   TILs	   HLA-­‐A2	   restriction	   and	  
overcome	  the	  limitations	  of	  using	  blocking	  antibodies,	  I	  decided	  to	  evaluate	  TILs	  MM909.24	  reactivity	  
against	  a	  panel	  of	  partially	  HLA	  matched	  (for	  HLA-­‐A2	  or	  HLA-­‐B40)	  or	  mismatched	  melanoma	  cells	  lines,	  
kindly	  provided	  by	  Marco	  Donia	  (CCIT,	  Copenhagen)	  (Appendix,	  Table	  7.1A).	  As	  shown	  in	  Figure	  4.3B,	  
TIL	  reactivity	  against	  target	  cell	  lines	  was	  defined	  as	  the	  percentage	  of	  CD107a+	  and	  TNF-­‐α+	  cells	  gated	  
on	   total	   CD8+	   TILs.	   	   All	   13	   melanoma	   cell	   lines	   recognised	   by	   MM909.24	   TILs	   express	   HLA-­‐A2,	  
supporting	   the	   results	  previously	  obtained	  with	   the	  BB7.2	  blocking	  antibody.	   This	   experiment	  also	  
suggests	  that	  the	  HLA-­‐A2-­‐restricted	  T-­‐cell	  epitope(s)	  recognised	  by	  MM909.24	  TILs	  are	  not	  exclusively	  
displayed	  by	  the	  autologous	  tumour	  cells	  but	  are	  shared	  by	  other	  HLA-­‐A2	  tumours.	  Shared	  antigens	  
are	   particularly	   interesting	   for	   immunotherapy	   as	   they	   are	   relevant	   to	  many	   patients,	   I	   therefore	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4.2.3   Multiple	   clonotypes	  mediate	   an	  HLA-­‐A2-­‐restricted	  Melan-­‐A	   specific	   anti-­‐tumour	  
response	  in	  patient	  MM909.24	  	  
TIL	   reactivity	   against	   melanoma	   can	   be	   mediated	   by	   shared	   antigens	   (such	   as	   differentiation,	  
overexpressed	  or	  cancer	  testis	  antigens)	  and/or	  neo-­‐antigens	  derived	  from	  private	  point	  mutations	  
(Boon	  et	  al.,	  2006).	  In	  order	  to	  explore	  peptide	  dominant	  specificities	  in	  MM909.24	  TILs,	  I	  decided	  to	  
examine	   the	   TILs	   at	   the	   polyclonal	   level	   and	   also	   to	   grow	   tumour	   specific	   T-­‐cell	   clones.	  My	   initial	  





Figure	  4.4.	  Schematic	  outline	  of	  the	  experimental	  strategy	  used	  to	  dissect	  anti-­‐melanoma	  TILs	  from	  patient	  MM909.24	  
MM909.24	  TILs	  are	  associated	  with	  in	  vivo	  long-­‐term	  tumour	  clearance.	  TILs	  as	  a	  bulk	  population	  were	  screened	  against	  a	  panel	  
of	   known	   HLA-­‐A2	   restricted	   melanoma	   T-­‐cell	   epitopes.	   Individual	   T-­‐cell	   clones	   were	   also	   isolated	   and	   selected	   based	   on	  
reactivity	  against	  the	  autologous	  melanoma	  cell	  line.	  HLA-­‐A2	  restricted	  antigen	  specificity	  was	  dissected	  by	  screening	  against	  a	  
panel	   of	   known	  melanoma	   T-­‐cell	   epitopes.	   T-­‐cell	   clones	  with	   known	   antigen	   specificities	  were	   validated	   through	   tetramer	  
staining	  and	  peptide	  sensitivity	  experiments.	  T-­‐cell	  clones	  with	  unknown	  antigen	  specificity	  (‘orphan’	  clones)	  were	  screened	  
against	  a	  panel	  of	  melanoma	  cell	  lines.	  The	  specificity	  of	  orphan	  clones	  can	  be	  further	  explored	  by	  using	  Combinatorial	  Peptide	  
Library	  scans	  (CPL)	  with	  a	  positional	  scanning	  format,	  in	  order	  to	  obtain	  detailed	  picture	  of	  the	  amino	  acid	  landscape	  preferred	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Firstly,	   I	   assessed	   whether	   known	   A2-­‐restricted	   melanoma	   T-­‐cell	   responses	   were	   present	   within	  
MM909.24	  TILs.	  To	  address	  this	  question,	  I	  selected	  a	  large	  panel	  of	  published	  melanoma-­‐associated	  
T-­‐cell	   epitopes	   (Andersen	   et	   al.,	   2012),	   encoded	  by	   proteins	   that	   are	   either	   exclusively	  melanoma	  
specific	  (such	  as	  gp100,	  Melan-­‐A,	  tyrosinase	  antigens)	  or	  shared	  with	  other	  tumours	  types	  (such	  as	  
p53,	   Survivin,	  NY-­‐ESO	   and	   the	  MAGE	   antigens).	   The	  Andersen	   et	   al.	   study	   (Andersen	   et	   al.,	   2012)	  
combined	  data	  from	  available	  literature	  with	  the	  Cancer	  Immunity	  database	  (Van	  den	  Eynde	  and	  van	  
der	  Bruggen,	  1997),	  the	  CTpedia	  database	  (Almeida	  et	  al.,	  2009)	  and	  a	  previously	  published	  antigen	  
list	  (Novellino	  et	  al.,	  2005).	  The	  study	  was	  more	  rigorous	  than	  those	  that	  preceded	  it	  and	  only	  included	  
T-­‐cell	   epitopes	   with:	   (i)	   a	   defined	  minimal	   epitope	   sequence;	   (ii)	   known	   HLA	   restriction;	   and,	   (iii)	  
evidence	  that	  the	  peptide	  is	  processed	  and	  presented	  on	  tumour	  cells.	  A	  full	  list	  of	  the	  145	  peptides	  is	  
provided	   in	   the	   Appendix	   (Table	   7.2).	   Peptide	   specific	   T-­‐cell	   responses	   in	   MM909.24	   TILs	   were	  






Figure	  4.5.	  Melan-­‐A	  T-­‐cell	  epitope	  (ELAGIGILTV)	  recognition	  by	  TILs	  MM909.24	  
(A)	   IFN-­‐γ	  ELISpot	  performed	  on	  5x105	  MM909.24	  TILs	  stimulated	  in	  duplicate	  with	  145	  known	  HLA-­‐A2	  restricted	  melanoma-­‐
associated	  peptides	  (10-­‐6	  M)	  for	  24	  hours.	  Data	  for	  wells	  that	  gave	  a	  response	  above	  background	  are	  shown.	  Viral	  peptides	  
NLVPMATV	  (CMV	  pp65	  protein)	  and	  GILGFVFTL	  (Influenza	  M1	  protein)	  were	  also	  tested.	  PHA	  (3	  µg/mL)	  was	  used	  as	  a	  positive	  
control.	  The	  number	  of	  IFN-­‐γ	  secreting	  cells	  per	  5	  x105	  TILs	  is	  displayed	  on	  the	  X	  axis;	  peptide	  sequence	  and	  protein	  of	  origin	  (in	  
brackets)	  are	  displayed	  on	  the	  Y	  axis.	  Each	  bar	  represents	  the	  mean	  spot	  count	  per	  well	  (±	  SD).	  Representative	  images	  of	  ELISpot	  
wells	  are	  shown	  in	  the	  bottom	  panel.	  (B)	  Supernatants	  from	  A)	  were	  used	  to	  detect	  MIP-­‐1β	  release	  (ELISA).	  Background	  (T-­‐cells	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Of	   the	   145	   known	   peptides	   tested,	   the	   Melan-­‐A	   decamer	   heteroclitic	   peptide	   ELAGIGILTV	   (ELA	  
hereafter)	  elicited	  the	  highest	  response	  within	  M909.24	  TIL	  (173	  ±	  37	  IFN-­‐γ	  SFU	  /	  5x105	  TILs;	  Figure	  
4.5A).	   This	   result	   is	   consistent	   with	   prior	   data	   on	   melanoma	   TILs	   reactivity,	   showing	   that	   T-­‐cell	  
responses	   against	   the	   melanocyte	   differentiation	   antigen	   Melan-­‐A	   are	   dominant	   in	   HLA-­‐A2+	  
individuals	  (Boon	  et	  al.,	  2006;	  Romero	  et	  al.,	  2006).	  Other	  known	  tumour-­‐associated	  antigens	  were	  
not	  detected	  or	  only	  elicited	  specific	  T-­‐cell	  responses	  in	  the	  range	  of	  10-­‐12	  IFN-­‐γ	  SFU.	  In	  concordance	  
with	  these	  results,	  our	  collaborators	  showed	  that	  1.8%	  of	  the	  MM909.24	  TIL	  infusion	  product	  stained	  
with	   an	   A2-­‐ELA	   tetramer	   and	   produced	   IFN-­‐γ	   (data	   not	   shown;	   Marco	   Donia,	   personal	  
communication).	  Interestingly,	  a	  CMV-­‐derived	  T-­‐cell	  epitope	  also	  produced	  a	  positive	  result	  (46	  ±	  16	  
IFN-­‐γ	  SFU)	   in	  ELISpot.	  There	  was	  also	  a	  smaller	  response	  to	  an	  immunodominant	  HLA-­‐A2-­‐restricted	  
influenza-­‐derived	  epitope.	  The	  occurrence	  of	  anti-­‐viral	  T-­‐cells	  within	  TIL	  populations	  is	  supported	  by	  
previous	  studies	  in	  which	  low	  frequency	  virus-­‐specific	  T-­‐cells	  were	  detected	  in	  melanoma	  TIL	  cultures	  
(Andersen	   et	   al.,	   2012;	   Kvistborg	   et	   al.,	   2012).	   Supernatants	   were	   also	   tested	   by	   MIP-­‐1β	   ELISA,	  
confirming	  the	  immunodominance	  of	  the	  Melan-­‐A	  epitope	  (Figure	  4.5B).	  	  
	  
I	  next	  decided	  to	   further	  explore	  the	  dominant	  ELA	  T-­‐cell	   reactivity	   in	  MM909.24	  TILs.	  TIL	  cultures	  
were	   stained	  with	  an	  A2-­‐ELA	   tetramer	   to	  measure	  Melan-­‐A	   reactivity	   at	   the	  population	   level,	   and	  
cloning	  plates	  were	  also	  set	  up	   to	   isolate	   tumour-­‐specific	  T-­‐cell	   clones	   from	  these	  TILs.	  During	   the	  
course	  of	  my	  PhD,	  our	  research	  group	  has	  developed	  an	  improved	  pHLA	  tetramer	  staining	  protocol	  
that	  allows	  the	  detection	  of	   low-­‐affinity	  or	  rare	  T-­‐cells	  otherwise	  undetected	  by	  standard	  tetramer	  
staining	   (Dolton	  et	  al.,	  2015;	  Tungatt	  et	  al.,	  2015).	  We	  showed	  that	  the	  addition	  of	  a	  primary	  anti-­‐
fluorochrome	  Ab	  followed	  by	  a	  secondary	  anti-­‐Ab	  conjugated	  secondary	  Ab	  substantially	   improved	  
tetramer	  staining	  intensity	  and	  flow	  cytometry	  detection	  (Tungatt	  et	  al.,	  2015).	  This	  ‘boosted’	  protocol	  
(A2-­‐ELA	  tetramer	  +	  primary	  Ab	  +	  secondary	  Ab)	  was	  used	  to	  stain	  ELA	  T-­‐cell	  responses	  in	  MM909.24	  
TIL	  cultures	  (Figure	  4.6).	  Baseline	  A2-­‐ELA	  tetramer	  staining	  of	  unstimulated	  TILs	  showed	  that	  5%	  of	  
CD8+	  T-­‐cells	  were	  tetramer	  positive.	  TILs	  were	  then	  co-­‐cultured	  with	  autologous	  melanoma	  cells	  for	  7	  
days.	  Long-­‐term	  stimulation	  with	  autologous	  melanoma	  resulted	   in	  the	  enrichment	  of	  the	  A2-­‐ELA+	  
population	  (19.6%	  of	  total	  CD8+	  TILs	  by	  day	  7).	  No	  tumour	  cells	  were	  visible	  in	  culture	  or	  on	  FACS	  after	  
48	  hours	  (data	  now	  shown).	  Overall,	  these	  results	  show	  that	  in	  vitro	  exposure	  to	  autologous	  melanoma	  
leads	  to	  a	  significant	  expansion	  of	  ELA-­‐specific	  T-­‐cells.	  Although	  Melan-­‐A-­‐specific	  T-­‐cell	  responses	  in	  
TILs	   have	   been	   relatively	  well	   described,	   given	   the	   dominance	   of	   the	   response	   shown	  here,	   I	  was	  
interested	   in	   studying	   the	   clonotypic	   composition	   of	   ELA-­‐specific	   T-­‐cells	   in	  MM909.24	   TILs	   and	   in	  
dissection	  of	  their	  anti-­‐tumour	  function	  at	  the	  clonal	  level.	  I	  successfully	  grew	  ELA	  specific	  clones	  as	  
part	  of	  my	  strategy	  as	  outlined	  in	  Figure	  4.4	  and	  described	  below.	  
	   	  





Figure	  4.6.	  ELA-­‐specific	  TIL	  population	  increases	  during	  in	  vitro	  culture	  with	  autologous	  tumour	  
FACS	  plots	  show	  the	  percentage	  of	  CD8+	  TILs	  that	  are	  stained	  with	  an	  A2–ELA	  (Melan-­‐A)	  tetramer.	  TILs	  were	  cultured	  for	  7	  days	  
in	  vitro	  with	  autologous	  tumour	  cells.	  No	  tumour	  cells	  were	  visible	  in	  culture	  or	  on	  FACS	  after	  48	  hours.	  Gates	  were	  set	  based	  
on	  staining	  with	  an	  irrelevant	  tetramer	  A2-­‐ALW	  (residues	  15-­‐24	  from	  preproinsulin)	  (not	  shown).	  All	  samples	  were	  treated	  with	  
Dasatinib	  (a	  protein	  kinase	  inhibitor,	  PKI)	  to	  prevent	  TCR	  triggering	  and	  internalisation	  of	  the	  TCR.	  Cells	  were	  tetramer	  stained	  
with	  a	  ‘boosted’	  protocol	  using	  both	  primary	  and	  secondary	  antibodies	  (Materials	  and	  Methods,	  section	  2.11.4).	  
	  
	  
Fifty	  cloning	  plates	  (~5000	  wells)	  were	  set	  up	  from	  MM909.24	  TIL	  cultures,	  and	  T-­‐cell	  clones	  isolated	  
by	  limiting	  dilution.	  More	  than	  one	  hundred	  clones	  were	  screened	  and	  selected	  based	  on	  specific	  lysis	  
of	  autologous	  tumour	  cells	  and	  ability	  to	  grow	  well	  in	  culture	  (Appendix:	  Table	  7.4).	  I	  opted	  for	  cloning	  
straight	   from	   the	   TIL	   infusion	   product	   to	   minimise	   further	   in	   vitro	   manipulation	   and	   potential	  
distortion.	   I	   later	   used	   flow	   cytometry	   based	  methods	   to	   sort	   viable	   T-­‐cells	   producing	   TNF-­‐α	   and	  
CD107a	  after	  co-­‐culture	  with	   tumour.	  Some	  clones	  did	  not	  grow	  after	   two	  passages	  and	  therefore	  
could	  not	  be	  used	  for	  further	  experiments.	  I	  also	  screened	  the	  clones	  with	  the	  peptides	  from	  Melan-­‐
A,	  gp100,	  TRAG-­‐3,	  p53	  and	  MG50	  (Figure	  4.5),	  which	  I	  previously	  identified	  by	  ELISpot	  performed	  on	  
bulk	  TILs.	  Overall	   five	  unique	  ELA	  specific	  clones	  were	   identified,	  some	  more	  than	  once.	  No	  clones	  
were	  procured	  from	  MM909.24	  TILs	  specific	  for	  gp100,	  TRAG-­‐3,	  p53	  or	  MG50,	  which	  may	  be	  due	  to	  
their	  relatively	  low	  frequency	  in	  the	  TILs	  and	  the	  cloning	  strategy	  I	  used.	  Peptide-­‐based	  methods	  could	  
have	  been	  used	  to	  specifically	  enrich	  these	  cells	  if	  desired,	  but	  I	  did	  not	  explore	  this	  any	  further	  due	  to	  
time	  constraints.	  	  
	  
Figure	   4.7	   displays	   the	   characterisation	   of	   the	   five	   unique	   ELA	   clones	   isolated.	   All	   T-­‐cell	   clones	  
specifically	  recognised	  and	  lysed	  the	  autologous	  melanoma	  (Figure	  4.7A),	  and	  showed	  higher	  cytotoxic	  
capability	  when	  target	  cells	  were	  pre-­‐treated	  with	  IFN-­‐γ	  for	  72	  hours.	  Enhanced	  tumour	  recognition	  is	  
likely	   to	   be	   associated	  with	   IFN-­‐γ	   induced	   expression	  of	  HLA	   complexes	   on	   the	   tumour	   surface	   as	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Figure	  4.7.	  Melan-­‐A	  specific	  clones	  from	  TILs	  MM909.24	  exhibit	  differing	  sensitivity	  to	  antigen	  and	  express	  unique	  TCRs	  
(A)	  Specific	  melanoma	  lysis	  (%)	  by	  T-­‐cell	  clones	  was	  determined	  in	  cytotoxicity	  assays	  with	  autologous	  target	  cells	  (E:T	  ratio	  5:1)	  
after	  4	  and	  18	  hours.	  Cytotoxicity	  of	  T-­‐cell	  clones	  VB6G4.24	  and	  ST8.24	  was	  titrated	  at	  different	  E:T	  ratios	  and	  is	  displayed	  after	  
24	  hours.	  Melanoma	  cells	  were	   left	  untreated	  or	   treated	  with	   low	  dose	  of	   IFN-­‐γ	   (100	   IU/mL)	   for	  72	  hours,	  as	   indicated	   (B)	  
Peptide	  sensitivity	  of	  Melan-­‐A	  specific	  CD8+	  CTL	  clones	  was	  determined	  by	  measuring	  MIP-­‐1β	  (pg/mL)	  release	  from	  peptide-­‐
stimulated	  T-­‐cells.	  T2	  cells	  were	   incubated	   in	  duplicate	  with	  titrated	  amounts	  of	  ELA	  (blue	  symbols)	  or	  EAA	  (black	  symbols)	  
peptide.	  (C)	  T-­‐cell	  clones	  were	  stained	  with	  PE-­‐conjugated	  A2-­‐ELA	  tetramer	  ±	  50	  nM	  Dasatinib	  (PKI)	  treatment.	  Unstained	  cells	  
and	  irrelevant	  tetramer	  staining	  (HLA-­‐A2	  ALWGPDPAAA:	  residues	  15-­‐24	  from	  pre-­‐proinsulin	  or	  HLA-­‐A2	  ILAKFLHWL:	  residues	  
540-­‐548	  from	  hTERT)	  were	  used	  as	  negative	  controls.	  ‘Boost’	  stands	  for	  tetramer	  staining	  followed	  by	  the	  addition	  of	  a	  primary	  
anti-­‐fluorochrome	  antibody.	  Mean	  fluorescence	  intensity	  (MFI)	  of	  PE	  is	  shown.	  (D)	  TCRα	  and	  TCRβ	  gene	  usage	  and	  CDR3	  amino	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The	  CTL	  clone	  VB6G4.24	  was	  the	  most	  sensitive	  killer	  among	  the	  T-­‐cell	  clones	  analysed,	  displaying	  an	  
average	  specific	  lysis	  of	  untreated	  tumour	  of	  37%	  at	  the	  lowest	  effector-­‐to-­‐target	  (E:T)	  ratio	  after	  18	  
hours.	  To	  further	  characterise	  the	  peptide	  sensitivity	  of	  Melan-­‐A	  specific	  clones	  they	  were	  tested	  in	  a	  
titration	  assay	  by	  MIP-­‐1β	  ELISA	  using	  T2	  cells	  pulsed	  with	  either	  the	  wild	  type	  EAA	  epitope	  or	  the	  ELA	  
analogue	  (Figure	  4.7B).	  This	  experiment	  was	  performed	  to	  ensure	  that	  the	  CTL	  clones	  recognised	  the	  
wild	  type	  epitope,	  which	  is	  actually	  processed	  and	  presented	  on	  melanoma	  cells.	  	  As	  shown	  in	  previous	  
studies	  (Kawakami	  et	  al.,	  1994c;	  Romero	  et	  al.,	  1997;	  Valmori	  et	  al.,	  1998)	  most	  of	  the	  Melan-­‐A	  clones	  
analysed	   displayed	   a	   pattern	   of	   recognition	   whereby	   the	   ELA	   analogue	   was	   recognised	   at	   lower	  
concentrations	  than	  the	  natural	  EAA	  decamer.	  The	  highest	  functional	  sensitivity	  (recognition	  at	  the	  
lowest	  peptide	  concentrations)	  was	  observed	  to	  both	  ELA	  and	  EAA	  peptides	  by	  T-­‐cell	  clone	  ST8.24.	  	  
	  
Finally,	   binding	   to	   A2-­‐ELA	   complexes	   was	   validated	   by	   tetramer	   staining	   of	   T-­‐cells	   (Figure	   4.7C).	  
Interestingly,	  despite	  all	  the	  clones	  recognising	  the	  ELA	  peptide	  in	  ELISA	  assays,	  three	  out	  of	  five	  clones	  
did	  not	  stain	  with	  the	  corresponding	  tetramer	  using	  standard	  protocols.	  With	  the	  exception	  of	  CTL	  
clone	  VB12H2.24,	  staining	  intensities	  were	  enhanced	  only	  when	  samples	  were	  pre-­‐treated	  with	  50	  nM	  
of	  the	  protein	  kinase	  inhibitor	  (PKI)	  Dasatinib.	  Tetramer	  staining	  is	  dependent	  on	  the	  TCR	  density	  at	  
the	  cell	  surface,	  therefore	  Dasatinib-­‐induced	  staining	  recovery	  is	  likely	  to	  be	  due	  to	  an	  inhibition	  of	  
tetramer-­‐induced	  TCR	  turnover	  (Dolton	  et	  al.,	  2015;	  Lissina	  et	  al.,	  2009).	  As	  previously	  reported	  by	  our	  
group	  (Tungatt	  et	  al.,	  2015;	  Dolton	  et	  al.,	  2015),	  addition	  of	  an	  anti-­‐tetramer	  primary	  antibody	  and	  
conjugated	  secondary	  antibody	  following	  A2-­‐ELA	  tetramer,	  is	  likely	  to	  boost	  the	  staining	  of	  the	  Melan-­‐
A	  clone	  VB12H2.24.	  
	  
Clonotypically,	  the	  five	  different	  Melan-­‐A	  clones	  shown	  here	  have	  unique	  αβ	  TCR	  sequences	  (Figure	  
4.7D).	  A	  TCR	  repertoire	  bias	  in	  human	  anti-­‐Melan-­‐A	  T-­‐cell	  responses	  has	  been	  reported	  by	  previous	  
studies.	   In	   particular,	   A2-­‐restricted	   CD8+	   T-­‐cells	   specific	   for	   the	   EAA	   antigen,	   were	   found	   to	  
predominantly	  express	  TRBV27/TRBJ2-­‐1/TRAV12/TRAJ34	  gene	  segments	  (Dietrich	  et	  al.,	  2003;	  Serana	  
et	  al.,	  2009;	  Wieckowski	  et	  al.,	  2009).	  Interestingly,	  only	  T-­‐cell	  clone	  VB16F1.24	  expresses	  the	  TRAV12-­‐
2	  gene	  segment,	  which	  is	  commonly	  used	  to	  encode	  the	  TCRα	  in	  more	  than	  80%	  of	  EAA-­‐specific	  T-­‐cells	  
across	   multiple	   individuals	   (Cole	   et	   al.,	   2009;	   Trautmann	   et	   al.,	   2002;	   Wieckowski	   et	   al.,	   2009).	  
Furthermore,	  despite	  having	  different	  peptide	  sensitivities,	  T-­‐cell	  clones	  VB6G4.24	  and	  VB12H2.24	  use	  
the	  TRBJ2-­‐1	  gene	  segment	  and	  also	  share	  the	  same	  CDR3β	  sequence.	  Taken	  together,	  these	  results	  
show	  that	  Melan-­‐A	  specific	  CTL	  clones	   isolated	  from	  the	  TIL	   infusion	  product	  of	  patient	  MM909.24	  
exhibit	  different	  sensitivity	  to	  the	  immunodominant	  ELA	  T-­‐cell	  epitope	  and	  express	  unique	  TCRs.	  My	  
experiments	  with	  one	  of	   these	   clones,	   ST8.24,	   indicated	   that	   it	  might	   recognise	  a	   further	   tumour-­‐
derived	  peptide	  and	  took	  my	  work	  in	  an	  unexpected	  direction.	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4.2.4   Unexpected	  cross-­‐recognition	  by	  MM909.24	  Melan-­‐A-­‐specific	  clone	  ST8.24	  
During	  my	  experiments	  with	  clone	  ST8.24,	  I	  found	  that	  this	  T-­‐cell	  clone	  repeatedly	  recognised	  the	  C1R-­‐
A2	  cell	  line	  I	  was	  using	  as	  a	  control.	  C1Rs	  are	  a	  lymphoblastoid	  cell	  line	  that	  also	  expresses	  some	  Epstein	  
Barr	  Virus	  (EBV)	  proteins,	  but	  not	  Melan-­‐A.	  Recognition	  of	  C1R-­‐A2,	  but	  not	  wild-­‐type	  C1Rs	  that	  lack	  
HLA-­‐A2	   expression,	   by	   clone	   ST8.24	   suggested	   that	   this	   clone	   might	   recognise	   a	   further	   HLA-­‐A2-­‐
resricted	  antigen	  (Figure	  4.8A).	  In	  order	  to	  test	  for	  recognition	  of	  EBV	  proteins,	  I	  tested	  ST8.24	  against	  
other	  EBV-­‐immortalised	  B-­‐cells	   to	  assess	  whether	   the	  observed	  cross-­‐reactivity	  was	  due	  to	  an	  EBV	  
epitope.	  Effector	  function	  was	  assessed	  by	  flow	  cytometry	  by	  measuring	  the	  expression	  of	  CD107a	  
and	  TNF-­‐α	  following	  5-­‐hour	  stimulation	  with	  target	  cells	  (Figure	  4.8B).	  ST8.24	  failed	  to	  recognise	  other	  
EBV-­‐immortalised	   B-­‐cell	   lines	   suggesting	   that	   this	   mechanism	   could	   not	   account	   for	   its	   reactivity	  




Figure	  4.8.	  ST8.24	  reacts	  towards	  C1R-­‐A2	  cells	  but	  fails	  to	  recognise	  EBV-­‐immortalised	  B-­‐cell	  lines	  
(A)	  ST8.24	  was	  tested	  against	  the	  human	  leukemic	  cell	  line	  C1R	  and	  its	  HLA-­‐A2+	  transfectant.	  Reactivity	  was	  measured	  as	  the	  
percentage	  of	  TNF-­‐α	  CD107a+	  T-­‐cells	  by	  flow	  cytometry.	  Cells	  were	  gated	  on	  live	  CD8+	  T-­‐cells.	  (B)	  ST8.24	  was	  tested	  against	  
EBV	   immortalised	   lymphoblastoid	   cell	   lines	   (LCL)	   that	   were	   either	   HLA-­‐A2+	   or	   HLA-­‐A2-­‐.	   Reactivity	   was	   measured	   as	   the	  




I	  next	  screened	  the	  ST8.24	  clone	  against	  a	  wide	  panel	  of	  HLA-­‐A2+	  tumour	  cell	  lines	  to	  test	  whether	  it	  
might	  recognise	  a	  further	  tumour	  antigen-­‐derived	  peptide	  in	  addition	  to	  Melan-­‐A.	  Effector	  function	  
was	  assessed	  by	  flow	  cytometry	  by	  measuring	  the	  expression	  of	  CD107a	  and	  TNF-­‐α	  following	  5-­‐hour	  
stimulation	  with	  target	  cells	  (Figure	  4.9).	  HLA-­‐A2+	  and	  HLA-­‐A2-­‐	  melanoma	  cell	  lines	  were	  also	  included	  
as	   positive	   and	   negative	   controls,	   respectively.	   Surprisingly,	   several	   non-­‐melanoma	   cell	   lines	  were	  
recognised	  by	  the	  ST8.24	  clone.	  





















Figure	  4.9.	  ST8.24	  recognises	  multiple	  cancer	  cell	  types	  
ST8.24	  T-­‐cell	  clone	  was	  tested	  against	  a	  panel	  of	  HLA-­‐A2+	  cell	  lines	  from	  tumour	  types	  other	  than	  melanoma.	  The	  tumour	  of	  
origin	  is	   indicated	  in	  brackets.	  The	  HLA-­‐A2+	  melanoma	  cell	   lines	  Mel-­‐526,	  Mel-­‐624	  and	  autologous	  tumour	  MM909.24	  were	  
added	  as	  positive	  control.	  The	  HLA-­‐A2-­‐	  melanoma	  cell	  lines	  FM-­‐2	  and	  FM-­‐56	  were	  added	  as	  negative	  control.	  Tumour	  reactivity	  
was	  measured	  as	  the	  percentage	  of	  TNF-­‐α	  CD107a+	  T-­‐cells	  by	  flow	  cytometry.	  Representative	  dot	  plots	  are	  shown	  in	  the	  bottom	  




The	   interaction	   between	   the	   TCR	   and	   pHLA	   can	   be	   highly	   degenerate,	   in	   that	   a	   single	   TCR	   may	  
recognise	  huge	  numbers	  of	  peptides	  in	  the	  context	  of	  a	  single	  HLA-­‐I	  molecule	  (Sewell,	  2012).	  T-­‐cell	  
cross-­‐reactivity	  in	  TILs,	  and	  its	  potential	  role	  in	  mediating	  in	  vivo	  tumour	  regression	  has	  never	  been	  
investigated.	   	   In	   order	   to	   address	   this,	   I	   took	   a	   systematic	   approach	   using	   combinatorial	   peptide	  
libraries	   (CPL)	   to	   screen	   the	   ST8.24	   clone.	   CPL	   libraries	   are	   composed	   a	   series	   of	   sub-­‐libraries	   in	  
positional-­‐scanning	  format;	  in	  particular,	  individual	  peptide	  sub-­‐libraries	  have	  an	  amino	  acid	  fixed	  in	  
each	  position	  and	  all	  other	  positions	  are	  made	  up	  of	  an	  equimolar	  mix	  of	  all	  remaining	  amino	  acids.	  A	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The	   ST8.24	   CD8+	   T-­‐cell	   clone	   was	   subjected	   to	   a	   decamer	   CPL	   library	   scan.	   Each	   sub-­‐library	   of	   a	  
decamer	  library	  is	  made	  of	  9.36	  x1012	  different	  decamer	  peptides.	  Using	  this	  approach,	  I	  was	  able	  to	  
scan	  every	  amino	  acid	  at	  every	  position	  of	  the	  peptide	  within	  a	  random	  residue	  “backbone”	  and	  obtain	  
a	   detailed	   picture	   of	   the	   amino	   acid	   landscape	   preferred	   by	   ST8.24	   the	   TCR.	   T-­‐cell	   activation	  was	  
measured	  by	  MIP-­‐1β	   ELISA	   (Figure	  4.10).	   The	  number	  of	  amino	  acids	   that	  were	   recognised	  by	   the	  
ST8.24	  TCR	  was	  limited	  to	  the	  index	  in	  the	  central	  region	  of	  the	  peptide	  (residues	  5-­‐6,	  corresponding	  
to	  I	  and	  G	  of	  EAAGIGILTV),	  suggesting	  that	  the	  TCR	  makes	  the	  majority	  of	   its	  peptide	  contacts	  with	  
these	  residues.	   In	  contrast,	  recognition	  was	  highly	  degenerate	  at	  the	  remaining	  positions	  at	  the	  N-­‐
term	  and	  C-­‐term	  of	  the	  peptide.	  The	  CPL	  scan	  results	  also	  suggested	  that	  the	  index	  Melan-­‐A	  peptide	  
(EAAGIGILTV)	  is	  suboptimal	  in	  positions	  1	  and	  2.	  Overall,	  positional	  peptide	  degeneracy	  is	  very	  high	  at	  
least	   at	   4	   out	   of	   10	   positions;	   these	   results	   suggest	   that	   ST8.24	   TCR	   can	   potentially	   recognise	   a	  
multitude	  of	  different	  amino	  acid	  combinations	   in	  addition	  to	   the	  EAA	  peptide.	   I	  was	   interested	   in	  
testing	  whether	  this	  TCR	  degeneracy	  was	  exclusive	  to	  the	  ST8.24	  clone	  or	  shared	  by	  the	  other	  ELA-­‐
specific	  CT	  clones	  isolated	  from	  MM909.24	  TILs.	  Unfortunately,	  I	  wasn’t	  able	  to	  grow	  the	  other	  clones	  
in	  high	  enough	  numbers	  to	  perform	  a	  full	  decamer	  CPL	  assay	  (approximately	  2x107	  cells	  are	  needed).	  
I	  was	  thus	  forced	  to	  continue	  my	  studies	  using	  only	  the	  ST8.24	  clone.	  
	  
I	   next	   sought	   to	   identify	   the	   sequence	   of	   decamer	   peptides	   from	   human	   proteins	   that	   could	   be	  
recognised	  by	  the	  ST8.24	  cytotoxic	  T-­‐cell	  clone.	  A	  novel	  webtool,	  developed	  by	  Dr	  Barbara	  Szomolay,	  
was	  used	  to	  link	  the	  raw	  data	  of	  the	  CPL	  scan	  to	  the	  likelihood	  of	  potential	  peptides	  from	  the	  human	  
proteasome	  to	  activate	  ST8.24	  T-­‐cells.	  During	  this	  bioinfomatic	  approach,	  the	  CPL	  scan	  data	  were	  used	  
to	   search	   collated	   human	   ‘self’	   protein	   database	   including	   proteins	   identified	   by	   Andersen	   et	   al.	  
(2012).	  A	  similar	  method	  was	  recently	  used	  to	  find	  the	  specificity	  of	  viral	  CD8+	  T-­‐cells	  (Szomolay	  et	  al.,	  
2016).	  This	  computational	  approach	  produced	  a	  ranked	  list	  of	  peptides	  that	  the	  ST8.24	  clone	  might	  
recognise.	   The	   top	   ranked	   peptides	   are	   listed	   in	   Table	   4.1,	   with	   colour	   coding	   depicting	   the	   sub-­‐
database	  each	  peptide	  was	  chosen	  from.	  The	  EAA	  index	  peptide	  and	  it	  ELA	  analogue	  were	  within	  the	  
top	   three	   scores.	   Interestingly,	   two	   peptides	   from	   the	   Insulin-­‐like	   growth	   factor	   2	   mRNA-­‐binding	  
protein	   family	   (IF2B2)	   resulted	   in	   a	   high	   score.	   IF2B2	   protein	   isoforms	   have	   been	   shown	   to	   be	  
expressed	  in	  several	  tumour-­‐derived	  and	  transformed	  cell	  lines,	  including	  the	  osteosarcoma-­‐derived	  
U2-­‐OS	  cells	  and	  melanoma	  (Bell	  et	  al.,	  2013).	  A	  decamer	  peptide	  LLLGIGILVL	  from	  the	  Bone	  marrow	  
stromal	  antigen	  2	  protein	  (BST2)	  also	  ranked	  highly	  in	  this	  bioinformatic	  analysis.	  Up-­‐regulation	  of	  this	  
interferon-­‐induced	  anti-­‐viral	  protein	  has	  been	  reported	  in	  the	  human	  MCF-­‐7	  breast	  cancer	  cell	   line	  
(Cai	   et	   al.,	   2009;	   Yi	   et	   al.,	   2013).	   Interestingly,	   the	   nonamer	   version	   of	   this	   BST2	   T-­‐cell	   epitope	  
(LLLGIGILV)	   was	   first	   published	   as	   an	   HLA-­‐A2	   restricted	   multiple	   myeloma-­‐associated	   antigen	  
(Hundemer	  et	  al.,	  2006).	  Peptides	  from	  other	  proteins	  that	  have	  been	  associated	  with	  melanoma,	  such	  
as	  MC1R	  and	  MAGE	  proteins	  also	  ranked	  highly	  (Table	  4.1).	  	  
	  
	  





Figure	  4.10.	  Decamer	  CPL	  scan	  of	  the	  ST8.24	  clone	  
In	  each	  well,	  6x104	  T2	  cells	  were	  pulsed	  in	  duplicate	  with	  each	  mixture	  from	  a	  decamer	  CPL	  library	  (100	  g/mL)	  at	  37°C.	  After	  2	  
hours,	  3x104	  ST8.24	  T-­‐cells	  were	  added	  and	  incubated	  overnight	  at	  37°C.	  Supernatants	  were	  harvested	  and	  assayed	  for	  MIP1-­‐β	  
(pg/mL)	  by	  ELISA.	  Results	  are	  displayed	  as	  histogram	  plots	  and	  SD	  from	  the	  mean	  of	  two	  replicates	  is	  shown.	  The	  index	  Melan-­‐
A	  peptide	  sequence	  (EAAGIGILTV)	  is	  shown	  in	  black	  bars.	  The	  L	  at	  position	  2	  in	  the	  	  ELAGIGILTV	  variant	  peptide	  is	  shown	  with	  a	  
hatched	  bar.	  























































































Rank	   	  Peptide	  	   Protein	   Abbrev.	   UniProt	  ID	  Organism	  
-­‐22.065	   	  ELAGIGILTV	   Melanoma	  antigen	  recognized	  by	  T-­‐cells	  1	  (analogue)	   Melan-­‐A	   	  Human	  
-­‐22.488	   	  NLAAVGLFPA	  	   Insulin-­‐like	  growth	  factor	  2	  mRNA-­‐binding	  protein	  1	   IF2B2	   Q9NZI8	   Human	  
-­‐22.659	   	  EAAGIGILTV	   Melanoma	  antigen	  recognized	  by	  T-­‐cells	  1	   Melan-­‐A	   Q16655	  	   Human	  
-­‐22.969	   	  LLLGIGILVL	  	   Bone	  marrow	  stromal	  antigen	  2	   BST2	   Q10589	   Human	  
-­‐23.128	   	  NLSALGIFST	  	   Insulin-­‐like	  growth	  factor	  2	  mRNA-­‐binding	  protein	  2	   IF2B2	   Q9Y6M1	   Human	  
-­‐23.301	   	  VYAALGILQG	  	   Canalicular	  multispecific	  organic	  anion	  transporter	  2	   MRP3	   O15438	   Human	  
-­‐23.373	   	  LILNIAIFFV	  	   Dermatan-­‐sulfate	  epimerase	   DSE	   Q9UL01	   Human	  
-­‐23.418	   	  ATSAMGTISI	  	   Mucin-­‐16	   MUC16	   Q8WXI7	   Human	  
-­‐23.435	   	  ISAVVGILLV	  	   Tyrosine	  Kinase-­‐Type	  Cell	  Surface	  Receptor	  HER2	   HER2	   P04626	   Human	  
-­‐23.477	   	  TSSAIPIMTV	  	   Mucin-­‐16	   MUC16	   Q8WXI7	   Human	  
-­‐23.530	   	  TYSCVGVFQH	  	   Heat	  shock	  70	  kDa	  1A	   HS71A	   P08107	   Human	  
-­‐23.530	   	  LRLALGLLQL	  	   G-­‐protein	  coupled	  receptor	  143	  	   GP143	   P51810	   Human	  
-­‐23.592	   	  MVSCIIFFFV	  	   Multidrug	  resistance-­‐associated	  protein	  1	   MRP8	   Q96J66	   Human	  
-­‐23.692	   	  QLLAEGVLSA	  	   Anoctamin-­‐7	  	   ANO7	   Q6IWH7	   Human	  
-­‐23.695	   	  TTLAICLLYV	  	   Canalicular	  multispecific	  organic	  anion	  transporter	  2	   MRP3	   O15438	   Human	  
-­‐23.794	   	  GVSGIGVTLF	  	   Tyrosine-­‐protein	  kinase	  Fgr	  	   FGR	   P09769	   Human	  
-­‐23.820	   	  LIAARGIFYG	  	   Canalicular	  multispecific	  organic	  anion	  transporter	  2	   MRP3	   O15438	   Human	  
-­‐23.836	   	  TSSAIPTLPV	  	   Mucin-­‐16	   MUC16	   Q8WXI7	   Human	  
-­‐23.840	   	  TIPSMGITSA	  	   Mucin-­‐16	   MUC16	   Q8WXI7	   Human	  
-­‐23.843	   	  TTQSLGVMSS	  	   Mucin-­‐16	   MUC16	   Q8WXI7	   Human	  
-­‐23.877	   	  VLNAVGVYAG	  	   Melanoma-­‐associated	  antigen	  C2	  	   MAGE-­‐C2	   Q9UBF1	   Human	  
-­‐23.893	   	  MISAIPTLAV	  	   Mucin-­‐16	   MUC16	   Q8WXI7	   Human	  
-­‐23.916	   	  AVAAIWVASV	  	   Melanocyte-­‐stimulating	  hormone	  receptor	   MC1R	   Q01726	   Human	  
-­‐23.917	   	  SVTWIGAAPL	  	   Prostate-­‐specific	  antigen	   PSA	   P07288	   Human	  
-­‐23.947	   	  LTSSKGQLQK	  	   Perilipin-­‐2	   PLIN2	   Q99541	   Human	  
-­‐23.957	   	  AASAIKVIPT	  	   Indoleamine	  2,3-­‐dioxygenase	  1	   IDO1	   P14902	   Human	  
-­‐23.984	   	  MVLGIGPVLG	  	   Solute	  carrier	  family	  45	  member	  3	   SLC45A3	   Q96JT2	   Human	  
-­‐23.985	   	  SAAGLGLVAI	  	   Solute	  carrier	  family	  45	  member	  3	   SLC45A3	   Q96JT2	   Human	  
-­‐24.014	   	  QTQAVPLLMA	  	   P	  protein	   P	  protein	   Q04671-­‐2	   Human	  
-­‐24.016	   	  STLNIDLFPA	  	   Peroxidasin	  homolog	   PXDN	   Q92626	   Human	  
-­‐24.019	   	  ILNGIKVLKL	  	   Multidrug	  resistance-­‐associated	  protein	  1	   MRP1	   P33527-­‐9	   Human	  
-­‐24.024	   	  VLTAMGLIGI	  	   Calcium-­‐activated	  chloride	  channel	  regulator	  2	  	   CLCA2	   Q9UQC9	   Human	  
	  
Key:	  	   Self	  protein	  database;	  	  
Tumour-­‐associated	  protein	  database	  (Andersen	  et	  al.,	  2012);	  	  
Known	  A2-­‐restricted	  melanoma-­‐associated	  T-­‐cell	  epitope	  database	  (Andersen	  et	  al.,	  2012)	  
	  
	  
Table	  4.1.	  Peptides	  sequences	  resulting	  from	  ST8.24	  CPL	  scan	  ranked	  in	  order	  of	  recognition	  likelihood	  
CPL	  scan	  data	  was	  used	  to	  search	  protein	  databases	  and	  rank	  peptides	  in	  order	  of	  likelihood	  recognition.	  Peptide	  ranking	  is	  
expressed	   on	   a	   natural	   logarithmic	   scale.	   For	   instance,	   a	   ranking	   value	   of	   -­‐22	   means	   that	   the	   corresponding	   peptide	   is	  
approximately	  three	  times	  more	  likely	  to	  be	  recognised	  than	  a	  peptide	  with	  ranking	  -­‐23.	  Computational	  analysis	  was	  performed	  
by	  Dr	  Barbara	  Szomolay	  (Cardiff).	  Protein	  names	  are	  colour	  coded	  according	  to	  the	  database	  of	  origin	  used	  for	  the	  computational	  













	  	  	  	  	  	  
	  
98	  
I	   next	   validated	   the	  bioinformatic	   data	   in	  Table	   4.1	   by	   examining	  whether	   the	   ST8.24	   clone	   could	  
recognise	   the	  predicted	  peptides	   in	  MIP-­‐1β	   	   ELISA	   (Figure	  4.11).	   ST8.24	   recognised	   the	  LLLGIGILVL	  
peptide	  from	  the	  Bone	  Marrow	  Stromal	  antigen	  2	  (BST2)	  with	  a	  similar	  sensitivity	  (-­‐LogEC50	  =	  8.4)	  to	  
the	  cognate	  EAAGIGILTV	  (Melan-­‐A)	  peptide	  (-­‐LogEC50	  =	  7.9).	  Peptide	  NLSALGIFST	  (IF2B2)	  resulted	  in	  
MIP-­‐1β	   production	   only	   at	   the	   highest	   peptide	   concentrations	   (10-­‐5	   and	   10-­‐6	  M),	   whereas	   peptide	  
NLAAVGLFPA	  from	  the	  same	  protein	  was	  not	  recognised.	  	  
	  
	  
Figure	  4.11.	  ST8.24	  peptide	  cross-­‐reactivity	  	  
Antigen	  sensitivity	  was	  measured	   in	  peptide	  titration	  assays	  by	  MIP-­‐1β	  ELISA.	  Briefly,	  6x104	  T2	  cells	  were	  pulsed	  with	  serial	  
dilutions	  of	  cognate	  peptide	  from	  10-­‐5	  to	  10-­‐10	  M	  in	  duplicate	  for	  1	  hour	  at	  37	  °C.	  ST8.24	  T-­‐cells	  were	  added	  and	   incubated	  
overnight	  at	  37°C.	  Supernatants	  were	  harvested	  and	  assayed	  for	  MIP-­‐1β	  production	  by	  ELISA. The	  mean	  ±	  SD	  of	  two	  replicate	  
assays	  is	  shown.	  
	  
	  
Taken	  together,	  the	  data	  obtained	  from	  the	  CPL	  decamer	  scan	  of	  T-­‐cell	  clone	  ST8.24,	  point	  towards	  
the	   possibility	   that	   this	   clone	   recognises	   other	   tumour-­‐associated	   peptides.	   However,	   further	  
experiments	  are	  required	  to	  validate	  the	  recognition	  of	  potential	  agonists.	  	  
	  
	  
4.2.5   Tumour-­‐reactive	  T-­‐cell	  clones	  persist	  in	  the	  patient’s	  blood	  after	  TIL-­‐therapy	  
Previous	  work	  indicates	  that	  the	  ability	  of	  tumour-­‐reactive	  TILs	  to	  persist	   in	  vivo	  following	  adoptive	  
infusion	  can	  have	  a	  significant	  impact	  on	  the	  clinical	  outcome	  of	  therapy	  (Dudley,	  2002;	  Huang	  et	  al.,	  
2004;	  Yee	  et	  al.,	  2002).	  To	  better	  understand	  which	  T-­‐cell	  clones	  are	  dominant	  in	  MM909.24	  TILs	  and	  
may	   be	   important	   in	  mediating	   in	   vivo	   tumour	   regression,	   I	   decided	   to	   analyse	   the	   presence	   and	  
persistence	  of	  individual	  tumour-­‐reactive	  T-­‐cell	  clones	  in	  the	  patient’s	  circulation	  after	  TIL	  therapy.	  In	  
order	  to	  address	  this,	  TCR	  clonotyping	  by	  sequence	  analysis	  was	  selected	  as	  the	  method	  of	  choice	  to	  
provide	  a	  complete	  analysis	  of	  TCRβ	  usage	  in	  TILs	  and	  PBMC	  samples.	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The	  experiment	  was	  performed	  directly	  on	  a	   thawed	  TIL	   infusion	  product	   sample	   to	  avoid	   in	   vitro	  
culture	   that	   could	   bias	   towards	   certain	   clonotypes.	   Briefly,	   tumour	   reactive	   T-­‐cells	   from	   the	   TIL	  
infusion	   product	   and	   PBMC	  were	   live-­‐sorted	   on	   their	   ability	   to	   produce	   TNF-­‐α	   and	   CD107a	  when	  
stimulated	  with	  autologous	  tumour	  (35.9%	  and	  2.6%	  of	  total	  CD3+	  cells,	  respectively)	  (Figure	  4.12A).	  
The	   TNF-­‐α	   Processing	   Inhibitor	   0	   (TAPI-­‐0)	   can	   directly	   prevent	   its	   release	   from	   the	   cell	   surface	  
therefore	  effectively	  ‘trapping’	  TNF	  on	  the	  surface	  of	  the	  effector	  T-­‐cell	  (Crowe	  et	  al.,	  1995;	  Hinrichs	  
et	  al.,	  2011).	  Total	  mRNA	  was	  isolated	  from	  sorted	  cells	  and	  used	  to	  analyse	  the	  TCRβ	  repertoire	  of	  
both	  samples	  by	  SMARTer™	  RACE	  technique.	  	  
	  
Figure	  4.12B	  shows	  the	  comparison	  of	  the	  TRBV	  gene	  segment	  usage	  between	  infused	  TILs	  and	  PBMC	  
(after	   therapy)	   from	   the	  patient	  MM909.24.	   TRBV20-­‐1	   and	  TRBV12-­‐4	   are	   the	  most	   frequent	   TCRβ	  
families	  amongst	  tumour	  reactive	  TILs	  (50%	  and	  14%	  respectively).	  These	  results	  are	   in	  accordance	  
with	   the	   data	   obtained	   by	   initial	   surface	   staining	   of	   total	   TILs	  with	   TRBV	   antibodies	   (Figure	   4.1B).	  
Interestingly,	  TRBV20-­‐1	  is	  still	  detected	  in	  the	  matched	  PBMC	  sample	  post	  TIL	  therapy,	  however	  it	  is	  
present	  at	  lower	  frequency	  (4.5%	  of	  total	  tumour	  reactive	  T-­‐cells).	  TRBV12-­‐4,	  on	  the	  other	  hand,	  is	  the	  
most	  frequent	  TCRβ	  family	  in	  circulation	  of	  patient	  MM909.24	  six	  months	  after	  therapy	  (51%	  of	  total	  
tumour	   reactive	   PBMC).	   TRBV24-­‐1,	   TRBV7-­‐9	   and	   TRBV4-­‐3	   are	   represented	   amongst	   the	   tumour-­‐
reactive	  cells	  in	  the	  TIL	  infusion	  product	  and	  the	  patient	  blood	  6	  months	  after	  treatment.	  In	  contrast,	  
TRBV5-­‐6	  and	  TRV6-­‐1	  (7.8%	  and	  3.5%	  in	  TIL	  infusion	  product,	  respectively)	  did	  not	  persist	  within	  the	  
tumour-­‐reactive	  T-­‐cell	  population	  in	  patient	  blood	  6	  months	  after	  treatment.	  
	  
The	  analysis	  of	  the	  composition	  of	  CDR3	  sequences,	  which	  are	  unique	  to	  each	  TCR-­‐β	  variant,	  was	  used	  
to	  further	  quantify	  TCR	  diversity	  in	  TILs	  and	  PBMC	  samples.	  The	  pie	  charts	  in	  Figure	  4.12C	  show	  the	  
distinct	   CDR3	   sequences	   detected	   in	   the	   TCRβ	   repertoire	   of	   the	   infusion	   product	   and	   blood	   from	  
patient	  MM909.24.	  Overall,	  both	  samples	  are	  characterised	  by	  a	  polyclonal	  T-­‐cell	   response	  against	  
autologous	  tumour.	  Strikingly,	  a	  single	  T-­‐cell	  clone	  represents	  34%	  of	  the	  total	  tumour-­‐reactive	  T-­‐cells	  
present	  in	  the	  original	  TIL	  infusion	  product,	  and	  is	  still	  present	  in	  the	  circulation	  after	  therapy	  (1.14%).	  
A	  second	  tumour-­‐specific	  T-­‐cell	  clone	  present	  at	  much	  lower	  frequency	  in	  the	  TILs	  (4.9%)	  persists	  in	  
the	  PBMC	  (1.13%).	  Interestingly,	  the	  clonotype	  that	  represents	  40%	  of	  the	  tumour-­‐reactivity	  in	  PBMC	  
was	  not	  present	  in	  the	  infusion	  product	  suggesting	  that	  this	  is	  a	  new	  T-­‐cell	  response.	  Deep	  sequencing	  
of	  all	  TCRβ	  in	  these	  samples	  will	  be	  required	  to	  confirm	  this	  finding.	  





Figure	  4.12	  CDR3	  sequences	  in	  the	  TCR	  beta	  repertoire	  of	  TILs	  and	  PBMC	  from	  patient	  MM909.24	  
(A)	  Tumour	  reactive	  T-­‐cells	  from	  TIL	  and	  PBMC	  were	  viably	  sorted	  based	  on	  the	  expression	  of	  both	  CD107a	  and	  TNF-­‐α	  (after	  
gating	  on	  live	  CD3+	  cells).	  T-­‐cells	  were	  stimulated	  with	  autologous	  tumour	  for	  5	  hours	  in	  the	  presence	  of	  TAPI-­‐0	  (30	  µM),	  anti-­‐
CD107a	  and	  anti-­‐TNF-­‐α	  mAb.	  Control	  cells	  were	  incubated	  with	  tumour.	  (B)	  Comparison	  of	  TCRBV	  gene	  usage	  between	  tumour	  
reactive	  T-­‐cells	  in	  TILs	  and	  PBMC.	  (C)	  Each	  pie	  chart	  represents	  the	  distribution	  of	  unique	  CDR3	  sequences	  detected	  in	  the	  TCRβ	  
repertoire	  of	  TIL	  infusion	  product	  and	  PBMC	  from	  patient	  MM909.24.	  Each	  pie	  segment	  represents	  the	  share	  of	  a	  distinct	  CDR3β	  
clonal	  sequence,	  thus	  reflects	  the	  respective	  frequency	  of	  each	  clonotype.	  Several	  grey	  scales	  are	  used	  repeatedly	  for	  different	  
sequences	  because	  of	  the	  high	  level	  of	  diversity.	  Shared	  CDR3	  amino	  acid	  sequences	  between	  matched	  TIL	  and	  PBMC	  samples	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Further	   experiments	   are	   ongoing	   aimed	   at	   cloning	   the	   dominant	   T-­‐cell	   from	   the	   infusion	   product	  
and/or	  the	  patient’s	  blood.	  If	  we	  can	  isolate	  these	  clones,	  we	  intend	  to	  dissect	  their	  antigen	  specificity	  
and	  HLA-­‐restriction.	  Preliminary	  studies	  were	  performed	  on	  the	  TRBV12-­‐4+	  T-­‐cell	  population	  that	  is	  
one	  of	  the	  dominant	  Vβ	  families	  in	  MM909.24	  TILs.	  I	  aimed	  at	  cloning	  tumour-­‐reactive	  T-­‐cells	  from	  
live-­‐sorted	  TRBV12-­‐4+	  TILs	  and	  map	  their	  antigen	  recognition.	  Tumour	  reactive	  TRBV12-­‐4+	  CD8+	  T-­‐
cells	  were	  sorted	  in	  bulk	  from	  TILs	  MM909.24	  based	  on	  TNF-­‐α	  and	  CD107a	  expression	  and	  cloned	  by	  
limiting	   dilution	   in	   96	  multi-­‐well	   plates.	   Individual	   clones	  were	   re-­‐tested	   for	   CD8+	   and	   TRBV12-­‐4+	  
expression	   (Figure	   4.13A).	   The	   tumour-­‐reactive	   T-­‐cell	   clone	   VB8#8	  was	   selected	   based	   on	   in	   vitro	  
expansion	  and	  used	  for	  further	  experiments.	  Figure	  4.13B	  shows	  that	  the	  clone	  recognizes	  many	  HLA-­‐
A2+	  melanomas.	  	  Unsurprisingly,	  VB8#8	  was	  found	  to	  be	  an	  HLA-­‐A2-­‐restricted	  Melan-­‐A-­‐specific	  clone,	  
as	  confirmed	  by	  ICS	  (Figure	  4.13C)	  and	  tetramer	  staining	  (Figure	  4.13D).	  
	   	  




Figure	  4.13	  T-­‐cell	  clone	  VB8#8	  from	  TILs	  MM909.24	  is	  ELA-­‐specific	  
(A)	  Tumour	  reactive	  and	  TRBV12-­‐4+	  CD8+	  T-­‐cells	  were	  sorted	  in	  bulk	  from	  TILs	  MM909.24	  (left	  panel)	  and	  cloned	  by	  limiting	  
dilution	  in	  96	  multi-­‐well	  plates.	   Individual	  clones	  were	  then	  re-­‐tested	  for	  CD8+	  and	  TRBV12-­‐4+	  expression	  (right	  panel).	  The	  
VB8.8	  clone	  is	  boxed	  in	  blue.	  (B)	  Partially	  matched	  HLA-­‐A2+	  melanoma	  cell	  lines	  are	  indicated	  by	  blue	  bars.	  Cells	  were	  gated	  on	  
live	  CD3+	  CD8+	  T-­‐cells.	  Co-­‐culture	  conditions	  with	  autologous	  tumour	  (black	  bar)	  and	  PHA	  (3	  µg/mL)	  (grey	  bar)	  were	  used	  as	  
positive	  controls.	   (C)	  Reactivity	  of	   the	  VB8#8	  T-­‐cell	   clone	   towards	   the	  Melan-­‐A	  analogue	  peptide	  ELA	  was	  assessed	  by	   flow	  
cytometry	  by	  measuring	  the	  production	  of	  TNF-­‐α	  and	  CD107a.	  T-­‐cell	  alone	  were	  used	  as	  negative	  control.	  Cells	  were	  gated	  on	  
viable	  CD3+	  CD8+	  T-­‐cells.	   (D)	   T-­‐cells	  were	   stained	  with	  PE-­‐conjugated	  A2-­‐ELA	   tetramer	  ±	   50	  nM	  Dasatinib	   (PKI)	   treatment.	  
Unstained	  cells	   and	   irrelevant	   tetramer	   staining	   (HLA-­‐A2	   ILAKFLHWL:	   residues	  540-­‐548	   from	  hTERT)	  were	  used	  as	  negative	  
controls.	   ‘Boost’	   stands	   for	   tetramer	   staining	   followed	   by	   the	   addition	   of	   a	   primary	   anti-­‐fluorochrome	   antibody.	  Mean	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4.3   Discussion	  
TIL-­‐ACT	  for	  stage	   IV	  melanoma	  is	  based	  on	  the	  re-­‐infusion	  of	  ex	  vivo	  expanded	  autologous	  tumour	  
reactive	  T-­‐cells.	  This	  relatively	  new	  form	  of	  immunotherapy	  provides	  onco-­‐immunology	  the	  proof	  of	  
principle	  that	  natural	  tumour	  specific	  CD8+	  T-­‐cells	  present	  within	  the	  tumour	  can	  mediate	  long-­‐lasting	  
cancer	  regression.	  TIL	  samples	  associated	  with	  in	  vivo	  tumour	  regression	  provide	  a	  good	  experimental	  
system	  to	  explore	  T-­‐cell	  reactivity	  and	  antigen	  specificity	  of	  successful	  T-­‐cell	  responses	  in	  melanoma.	  
In	   this	   chapter,	   I	   analysed	   naturally	   occurring	   T-­‐cell	   responses	   to	   melanoma-­‐associated	   peptide	  
antigens	   in	  TILs	  from	  an	  HLA-­‐A2+	  CR	  melanoma	  patient.	   I	  showed	  that	  TILs	  expanded	  from	  patient	  
MM909.24	   were	   mainly	   CD8+	   T-­‐cells.	   These	   results	   are	   in	   accordance	   with	   most	   of	   the	   existing	  
literature,	  which	  suggests	  that	  the	  clinical	  efficacy	  of	  TIL	  therapy	  is	  mainly	  associated	  with	  the	  CD8+	  T-­‐
cell	  subset	  of	  melanoma	  infiltrates	  (Dudley	  et	  al.,	  2011;	  Besser	  et	  al.,	  2012;	  Radvanyi	  et	  al.,	  2012).	  	  
4.3.1   Antigen	  specificity	  of	  tumour	  reactive	  TILs	  
The	  individual	  antigen	  specificity	  of	  T-­‐cell	  clones	  present	  in	  infused	  TIL	  populations	  is	  likely	  to	  vary	  and	  
could	   be	   another	   factor	   that	   influences	   clinical	   outcome.	  Melanoma	   TIL	   antigens	   that	   have	   been	  
identified	  to	  this	  date	  include	  both	  widely	  expressed	  non-­‐mutated	  antigens	  as	  well	  as	  neo-­‐antigens	  
derived	  from	  point	  mutations,	  which	  are	  generally	  expressed	  only	  by	  the	  autologous	  tumour.	  In	  this	  
chapter,	  I	  began	  to	  dissect	  the	  antigen	  reactivity	  of	  the	  TILs	  administrated	  to	  an	  HLA-­‐A2+	  patient,	  who	  
subsequently	  achieved	  a	  long-­‐lasting	  complete	  remission.	  My	  results	  show	  that	  CD8	  T-­‐cells	  specific	  for	  
the	  Melan-­‐A	   epitope	   (EAAGIGILTV,	   residues	   26-­‐35)	   dominate	   the	   anti-­‐melanoma	   response	   in	   this	  
patient.	   Melan-­‐A	   is	   a	   melanocyte-­‐expressed	   melanoma	   differentiation	   antigen	   that	   is	   also	   over-­‐
expressed	   in	  more	   than	   90%	   of	  melanomas	   (Kawakami	   et	   al.,	   1994c).	   Among	   the	   relatively	   large	  
number	  of	  known	  melanoma-­‐associated	  antigens	  recognised	  by	  human	  CD8	  T	  cells,	  Melan-­‐A	  is	  one	  of	  
the	  most	  immunodominant	  in	  HLA-­‐A2	  melanoma	  patients	  (Boon	  et	  al.,	  2006).	  The	  Melan-­‐A	  nonamer	  
(AAGIGILTV,	  residues	  27-­‐35)	  was	  originally	  described	  as	  the	  antigenic	  peptide	  (Kawakami	  et	  al.,	  1994);	  
however,	   it	  was	  subsequently	  shown	  that	   the	  ELA	   ‘heteroclitic’	  decamer	  bound	  more	  efficiently	   to	  
HLA-­‐A2	  and	  was	  substantially	  more	  immunogenic	  (Romero	  et	  al.,	  1997;	  Valmori	  et	  al.,	  1998).	  	  
	  
Overall,	  my	   results	   show	  that	  multiple	  clonotypes	  mediate	   the	  anti-­‐Melan-­‐A	   response	   in	  TILs	   from	  
patient	  MM909.24.	   I	  also	  showed	  that	   individual	  ELA-­‐specific	  CTL	  clones	  had	  different	  sensitivities.	  
Previous	  papers	  in	  the	  literature	  have	  shown	  that	  CD8+	  T-­‐cells	  specific	  for	  the	  A2-­‐EAA	  Melan-­‐A	  epitope	  
are	  characterised	  by	  a	  common	  TCR	  gene	  usage	  pattern	  (Miles	  et	  al.,	  2011a;	  Turner	  et	  al.,	  2006).	  In	  
particular,	  there	  is	  a	  remarkable	  bias	  in	  the	  TRAV	  segment	  usage,	  whereby	  more	  than	  80%	  of	  CD8+	  
EAA-­‐specific	  T-­‐cell	  isolated	  from	  multiple	  HLA-­‐A2+	  donors	  expressed	  a	  TRAV12-­‐2+	  TCR	  (Dietrich	  et	  al.,	  
2003).	  Interestingly,	  only	  one	  out	  of	  five	  of	  the	  unique	  Melan-­‐A	  clonotypes	  described	  in	  this	  chapter	  
used	  the	  TRAV12-­‐2	  gene	  segment.	  	  




I	   also	   examined	   the	   Melan	   A-­‐specific	   T-­‐cell	   response	   in	   patient	   MM909.24	   using	   standard	   pHLA	  
staining	  to	  detect	  antigen-­‐specific	  T-­‐cells.	  These	  experiments	  indicated	  that	  relevant	  clones	  could	  be	  
missed	  using	  standard	  staining	  protocols.	  Our	  group	  has	  recently	  shown	  that	  new	  improvements	  in	  
multimer	  staining	  protocols,	  including	  staining	  in	  the	  presence	  of	  PKI	  and	  boosting	  the	  staining	  with	  
anti-­‐tetramer	  antibodies	  (Tungatt	  et	  al.,	  2015),	  can	   increase	  staining	   intensity	  and	  the	   likelihood	  of	  
detecting	  relevant	  T-­‐cell	  clones.	  For	  instance,	  the	  VB6G4.24	  clone	  presented	  here,	  was	  cloned	  from	  
MM909.24	  TILs	  and	  is	  effective	  at	  killing	  the	  patient’s	  autologous	  tumour.	  However,	  VB6G4.24	  did	  not	  
stain	  with	  standard	  A2-­‐ELA	  tetramer	  staining	  alone;	  staining	  could	  be	  recovered	  when	  T-­‐cells	  were	  
pre-­‐treated	  with	  PKI.	  Tetramer	  staining	  intensity	  could	  be	  further	  enhanced	  with	  a	  boosted	  protocol	  
(Tungatt	  et	  al.,	   2015).	   In	  addition,	   in	  a	   recent	   review	  we	  have	  also	   shown	   the	   staining	  of	   the	  ELA-­‐
specific	  clone	  ST8.24	  presented	  here,	  using	  a	  different	  range	  of	  multimer	  conditions	   (Dolton	  et	  al.,	  
2015).	  Overall,	  staining	  with	  pHLA	  dextramers	  and	  PKI	  detected	  3-­‐fold	  more	  ELA-­‐specific	  T-­‐cells	  than	  
standard	  tetramer	  staining.	  In	  future,	  the	  ability	  to	  dissect	  additional	  T-­‐cell	  specificities	  in	  TIL	  infiltrates	  
will	  potentially	  help	  identifying	  the	  most	  relevant	  induced	  T-­‐cell	  responses	  and	  their	  correlation	  with	  
clinical	  outcome.	  	  
	  
During	  this	  work	  I	  also	  identified	  a	  number	  of	  other	  tumour-­‐specific	  CD8	  T-­‐cell	  clones	  that	  were	  not	  
Melan	  A-­‐specific.	  These	  clones	  did	  not	  respond	  to	  any	  of	  the	  known	  HLA-­‐A2-­‐restricted	  peptides	  listed	  
in	  Appendix	  (Table	  7.2).	  It’s	  possible	  that	  these	  clones	  responded	  to	  novel	  HLA	  A2-­‐restricted	  epitopes	  
including	   patient-­‐specific	   neo-­‐antigens,	   or	   that	   they	   are	   restricted	   by	   other	   HLA-­‐I	   molecules.	  
Unfortunately,	  I	  did	  not	  have	  the	  time	  to	  follow	  up	  with	  these	  clones.	  If	  I	  have	  had	  more	  time,	  I	  would	  
have	  liked	  to	  attempt	  to	  delineate	  the	  HLA-­‐restriction	  and	  peptide	  specificity	  of	  these	  tumour-­‐specific	  
‘orphan’	  clonotypes.	  Recently,	  my	  laboratory	  has	  devised	  a	  new	  way	  of	  determining	  HLA-­‐restriction	  in	  
such	  circumstances.	  This	   technique	   involves	  a	  complete	  knockout	  of	  HLA-­‐I	  genes	  expressed	  by	   the	  
autologous	  melanoma	  using	  CRISPR/Cas9	  gene	  editing	  technology	  (Sánchez-­‐Rivera	  and	  Jacks,	  2015).	  
Following	  HLA-­‐I	  knockout,	  individual	  patient-­‐autologous	  HLA-­‐I	  genes	  can	  be	  added	  back	  by	  lentiviral	  
transduction	   to	   test	   whether	   tumour	   recognition	   is	   restored.	   I	   would	   have	   also	   liked	   to	   explore	  
recognition	  of	  patient-­‐specific	  neo-­‐antigens.	  The	  MM909.24	  tumour	  is	  currently	  undergoing	  whole-­‐
genome	  exome	  sequencing	  for	  this	  purpose.	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4.3.2   Cross-­‐reactive	  potential	  of	  T-­‐cell	  responses	  in	  melanoma	  TILs	  
The	  notion	  of	  T-­‐cell	  cross	  reactivity	  is	  becoming	  increasingly	  clear	  from	  experimental	  evidence	  which	  
shows	  that	  a	  high-­‐degree	  of	  degeneracy	  is	  a	  normal	  feature	  of	  T-­‐cell	  recognition,	  in	  that	  a	  single	  TCR	  
may	  recognise	  more	  than	  one	  different	  peptide	  in	  the	  context	  of	  a	  single	  HLA-­‐I	  molecule	  (Wooldridge	  
et	  al.	  2012,	  Sewell,	  2012).	  Against	  this	  background,	  it	  is	  reasonable	  to	  hypothesise	  that	  T-­‐cell	  cross-­‐
reactivity	  may	  have	  a	  role	  in	  anti-­‐tumour	  immunity.	  Such	  cross-­‐reactivity	  might	  include	  recognition	  of	  
a	   tumour-­‐associated	   peptide	   by	   a	   pathogen-­‐specific	   T-­‐cell	   or	   recognition	   of	   multiple	   tumour-­‐
associated	  peptides	  by	  a	  single	  tumour-­‐specific	  T-­‐cell.	  I	  demonstrated	  that	  MM909.24	  TIL-­‐derived	  T-­‐
cell	  clone	  ST8.24	  might	  represent	  an	  example	  of	  this	  latter	  category	  by	  showing	  it	  could	  recognise	  the	  
BST2	   protein-­‐derived	   peptide	   LLLGIGILV	   with	   a	   similar	   sensitivity	   to	   the	   cognate	  Melan-­‐A-­‐derived	  
EAAGIGILTV	   peptide.	   I	   determined	   this	   cross-­‐reactivity	   via	   CPL	   scan	   and	   a	   computer	   algorithm	  
approach.	  A	  subsequent	  literature	  search	  showed	  that	  a	  previous	  study	  uncovered	  this	  same	  cross-­‐
reactivity	  in	  a	  different	  sample	  (Christensen	  et	  al.,	  2009).	  The	  finding	  of	  the	  same	  cross-­‐reactivity	  by	  
two	  different	  groups,	  using	  different	  samples,	  suggests	  that	  it	  might	  be	  a	  common	  occurrence.	  Further	  
validation	  work	  will	  be	  required	  to	  prove	  that	  ST8.24	  recognised	  tumour	  cells	  via	  both	  LLLGIGILV	  and	  
EAAGIGILTV	  peptides.	  The	  possibility	  of	   single	  anti-­‐tumour	  clones,	   recognising	   tumour	  via	  multiple	  
peptides,	  opens	  up	  some	  interesting	  possibilities	  that	  may	  explain	  some	  previous	  anomalies	  including	  
those	  within	  my	  own	  studies.	  Of	  particular	  relevance,	  dual	  recognition	  of	  LLLGIGILV	  and	  EAAGIGILTV	  
peptides	  by	  the	  ST8.24	  T-­‐cell	  clone	  (and	  perhaps	  other	  T-­‐cells	  clones)	  might	  offer	  an	  explanation	  for	  
how	  this	  T-­‐cell	  can	  simultaneously	  exhibit	  robust	  tumour	  lysis	  but	  poor	  staining	  with	  EAAGIGILTV	  pHLA	  
tetramer.	  Further	  work	  will	  be	  required	  to	  test	  this	  interesting	  possibility.	  
	  
Finally,	  it	  would	  be	  also	  worth	  exploring	  whether	  other	  CTLs	  isolated	  from	  TILs	  of	  complete	  regression	  
patients	   exhibit	   tumour-­‐reactive	   TCR	   degeneracy,	   and	   if	   this	   is	   correlated	   with	   in	   vivo	   tumour	  
regression.	  Interestingly,	  the	  recognition	  of	  multiple	  tumour	  antigens	  by	  individual	  T-­‐cells	  is	  likely	  to	  
make	   it	  much	  more	  difficult	   for	   the	  tumour	  to	  escape.	   It	   remains	  possible	   that	   those	  patients	   that	  
exhibit	  tumour	  regression	  after	  TIL	  therapy	  might	  have	  more	  cross-­‐reactive	  T-­‐cells	  than	  those	  where	  
the	  disease	  continues	  to	  progress.	  Unfortunately,	   testing	  of	  such	  a	  possibility	  was	  well	  beyond	  the	  
scope	  of	  what	  I	  could	  achieve	  during	  my	  PhD	  studies.	  Nevertheless,	  future	  studies	  on	  the	  potential	  
cross-­‐reactivity	  of	  anti-­‐cancer	  T-­‐cells	  are	  likely	  to	  be	  rewarding.	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4.3.3   Tracking	  the	  fate	  of	  tumour-­‐reactive	  TIL	  clones	  
The	  success	  of	  adoptive	  cell	  therapy	  for	  metastatic	  melanoma	  is	  likely	  to	  require	  long-­‐term	  persistence	  
of	  the	  adoptively	  transferred	  cells.	  Indeed,	  several	  studies	  have	  reported	  a	  correlation	  between	  the	  
persistence	  of	  TILs	  after	  adoptive	  transfer	  and	  the	  successful	  clinical	  response	  in	  patients	  (Robbins	  et	  
al.,	   2004;	   Zhou	  et	  al.,	   2005).	  However,	  existing	  TIL-­‐based	   studies	  have	  not	  generally	  examined	   the	  
ability	  of	  individual	  tumour-­‐specific	  clonotypes	  to	  persist.	  Against	  this	  background,	  I	  dissected	  the	  TCR	  
diversity	  in	  tumour-­‐reactive	  TILs	  associated	  with	  in	  vivo	  tumour	  clearance,	  and	  tracked	  the	  persistence	  
of	  dominant	  clonotypes	  in	  the	  patient’s	  blood	  after	  treatment.	  As	  part	  of	  this	  thinking,	  I	  reasoned	  that	  
the	  clonotypes	  that	  persist	  and	  dominate	  in	  the	  blood	  in	  a	  CR	  patient	  were	  most	  likely	  to	  be	  those	  
responsible	  for	  the	  advantageous	  clinical	  outcome.	  
	  
TCRβ	  clonotyping	  was	  the	  chosen	  method	  to	  assess	  TCR	  diversity	  within	  the	  two	  T-­‐cell	  populations	  
(infiltrating	   and	   circulating	   lymphocytes).	   Sequencing	   of	   hundreds	   of	   clones	   obtained	   by	   the	   PCR	  
amplification	  of	  individual	  cDNA	  sequences	  that	  include	  the	  CDR3β	  region,	  can	  provide	  a	  quantitative	  
survey	  of	  the	  frequency	  of	  individual	  T-­‐cell	  clonotypes.	  In	  this	  chapter,	  I	  analysed	  the	  composition	  and	  
persistence	   of	   tumour-­‐reactive	   T-­‐cell	   clones	   in	   TIL	   infusion	   products	   and	   peripheral	   blood	   of	   a	   CR	  
melanoma	  patient.	  In	  summary,	  two	  T-­‐cell	  clonotypes	  with	  tumour-­‐specific	  activities	  persisted	  in	  this	  
patient	   after	   treatment.	   The	   antigen	   specificity	   of	   the	   dominant	   clonotype	   detected	   in	   tumour-­‐
reactive	  TILs	   is	   yet	   to	  be	  been	   identified.	   I	   have	   shown	   that	   a	  CD8+	  T-­‐cell	   clone	   isolated	   from	   the	  
dominant	   population	   in	   the	   TILs	   is	   specific	   for	   the	   ELA	  Melan-­‐A	   peptide	   analogue.	   At	   the	   time	   of	  
writing,	  experiments	  are	  ongoing	  in	  order	  to	  clone	  other	  dominant	  clonotypes	  from	  the	  TIL	  infusion	  
product	  and	  dissect	  their	  antigen	  specificity	  by	  the	  use	  of	  known	  melanoma-­‐associated	  antigens	  and	  
CPL	   scans.	   I	   hope	   to	   be	   able	   to	   update	  my	   examiners	   on	   these	   interesting	   studies	   during	  my	  oral	  
examination.	  
	  
Interestingly,	  the	  most	  dominant	  clonotypes	  in	  the	  blood	  after	  TIL	  therapy	  were	  not	  detected	  in	  the	  
original	   TIL	   infusion	   product.	   This	   finding	   will	   be	   further	   discussed	   in	   Chapter	   5.	   Surprisingly,	   the	  
Melan-­‐A	  specific	  T-­‐cell	  clonotypes	  described	  at	  the	  beginning	  of	  this	  chapter	  were	  not	  detected	  in	  the	  
TILs	  by	  TCRβ	  sequencing.	  With	  the	  advent	  of	  next	  generation	  sequencing	  (NGS),	  further	  studies	  in	  our	  
group	  are	  ongoing	  in	  order	  to	  repeat	  these	  experiments	  with	  increased	  sensitivity.	  By	  deep	  sequencing	  
TCRVβ	   loci,	   sequences	   are	   decoded	   on	   arrays	   and	   many	   millions	   of	   sequences	   can	   be	   read	  
simultaneously	  (Metzker,	  2010).	  Deep	  sequencing	  the	  TCR	  clonotypes	  of	  TILs	  and	  PBMCs	  from	  patient	  
MM909.24	  will	  allow	  us	  to	  detect	  rare	  CDR3β	  sequences	  that	  have	  potentially	  been	  missed	  during	  the	  
standard	  TCRβ	  clonotyping	  shown	  above.	  Preliminary	  data	  suggest	  that	  there	  may	  be	  as	  many	  as	  300	  
different	  tumour-­‐specific	  clonotypes	  within	  the	  MM909.24	  TILs.	  I	  also	  hope	  to	  be	  able	  to	  update	  my	  
examiners	  on	  these	  studies	  during	  my	  viva.	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In	  addition,	  my	  group	  aims	  to	  extend	  my	  studies	  by	  dissecting	  TCR	  diversity	  in	  the	  patient’s	  blood	  at	  a	  
later	  time	  points	  (>	  12	  months	  after	  TIL	  therapy).	  There	  are	  also	  some	  PBMC	  stored	  from	  this	  patient	  
before	  therapy.	  A	  full	  understanding	  of	  the	  dynamics	  of	  T-­‐cell	  responses	  throughout	  TIL	  therapy,	  will	  
require	  a	  comparative	  analysis	  of	  tumour-­‐specific	  clonotypes	  before,	  during	  (TIL	  infusion	  product)	  and	  
multiple	  time	  points	  after	  treatment.	  These	  studies	  have	  now	  been	  initiated.	  The	  absence	  of	  tumour-­‐
reactive	   clonotypes	   in	   PBMC	   before	   treatment,	   would	   indicate	   that	   the	   T-­‐cells	   detected	   in	   the	  
circulation	  after	  cure	  are	  likely	  derived	  from	  ex	  vivo	  cultured	  and	  infused	  TILs.	  Theoretically,	  the	  TCR	  
repertoire	   in	   the	   patient’s	   original	   tumour	   sample	   (i.e.	   before	   infiltrating	   T-­‐cells	   are	   isolated	   and	  
expanded	  ex	  vivo)	  would	  also	  be	  informative,	  to	  test	  whether	  in	  vitro	  culture	  influences	  T-­‐cell	  clone	  
dominance.	  A	  published	  study	  has	  shown	  that	  in	  vitro	  culture	  can	  result	  in	  the	  preferential	  expansion	  
of	  certain	  clones	  from	  a	  relatively	  small	  number	  of	  T-­‐cells	  in	  the	  original	  tumour	  sample	  (Zhou	  et	  al.,	  
2004).	   A	   comprehensive	   understanding	   of	   how	   TIL	   therapy	   works	   will	   require	   study	   of	   multiple	  
patients.	  	  
	  
I	  next	  undertook	  to	  study	  the	  response	  in	  CR	  patient	  MM909.15.	  Unlike	  MM909.24,	  MM909.15	  is	  not	  
HLA-­‐A2+.	  The	  study	  of	  this	  patient	  allowed	  an	  examination	  of	  therapy	  in	  the	  absence	  of	  the	  known	  
numerical	   dominance	   of	   HLA-­‐A2	  Melan-­‐A-­‐specific	   T-­‐cells,	   and	   was	   reasoned	   to	   be	   more	   likely	   of	  
uncovering	  new	  epitopes	  and	  antigens.	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5   Dissection	  of	  T-­‐cell	  responses	  in	  a	  non-­‐HLA-­‐A2+	  melanoma	  
patient	  with	  complete	  remission	  after	  TIL-­‐therapy	  
5.1   Aims	  
Current	  knowledge	  regarding	  melanoma	  tumour	  antigens	  is	  still	  largely	  limited	  to	  T-­‐cell	  recognition	  in	  
the	   context	   of	   HLA-­‐A2.	   This	   skewing	   is	   apparent	   in	   the	   antigen	   list	   published	   by	   Andersen	   and	  
colleagues,	  where	  45%	  of	  the	  epitopes	  are	  restricted	  by	  HLA-­‐A2	  with	  the	  remaining	  spanning	  over	  36	  
different	  HLA-­‐I	  molecules	  (Andersen	  et	  al.,	  2012).	  The	  bias	  in	  HLA-­‐A2+	  patients	  is	  further	  distorted	  by	  
the	   known	   strong	   dominance	   of	   T-­‐cell	   responses	   specific	   for	   the	   HLA-­‐A2	   epitope	   EAAGIGILTV,	   as	  
described	   in	  the	  previous	  chapter.	   I	   thus	  thought	   it	  would	  be	   interesting	  to	  compare	  my	  studies	   in	  
HLA-­‐A2+	   patient	  MM909.24	  with	   those	   of	   a	   non-­‐HLA-­‐A2	   patient	   that	   underwent	   complete	   lasting	  
remission	  following	  TIL	  therapy.	  	  
	  
In	  this	  chapter,	  the	  overall	  aim	  was	  to	  dissect	  the	  successful	  anti-­‐melanoma	  T-­‐cell	  response	  in	  patient	  
MM909.15	  (HLA-­‐A3+,	  A31+;	  HLA-­‐B8+,	  -­‐B44+;	  HLA-­‐C7+).	  In	  particular,	  melanoma	  T-­‐cell	  responses	  were	  
studied	  in	  terms	  of	  the	  phenotype	  and	  antigen	  specificity	  of	  the	  tumour-­‐reactive	  populations.	  I	  also	  
hypothesised	   that	   the	   dominant	   anti-­‐melanoma	   responses	   in	   the	   patient’s	   circulation	   following	  
successful	  TIL	  therapy	  could	  be	  those	  responsible	  for	  in	  vivo	  tumour	  regression.	  Therefore,	  I	  also	  aimed	  
to	   examine	   the	   antigen	   specificity	   of	   the	   dominant	   clones	   in	   the	   patient’s	   blood	   after	   cure.	  
Experiments	  for	  this	  patient	  were	  performed	  in	  parallel	  with	  those	  for	  patient	  MM909.24,	  therefore	  
the	  experimental	  approach	  described	  at	  the	  beginning	  of	  Chapter	  4	  also	  applies	  here.	  	  
	  
5.2   Results	  
5.2.1   Anti-­‐tumour	  responses	  of	  MM909.15	  TILs	  
Figure	  5.1A	  provides	  information	  regarding	  the	  clinical	  outcome	  of	  patient	  MM909.15	  and	  TIL	  therapy	  
details.	  Data	  from	  our	  clinical	  collaborators	  showed	  the	  TIL	  infusion	  product	  received	  by	  this	  patient	  
was	  31.3%	  CD8+,	  54.9%	  CD4+	  and	  10%	  γδ	  TCR+.	  In	  contrast	  to	  patient	  MM909.24,	  the	  majority	  of	  the	  
TIL-­‐derived	  T-­‐cells	  infused	  into	  this	  CR	  patient	  were	  not	  CD8+	  T-­‐cells.	  The	  occurrence	  of	  a	  significant	  
proportion	  of	  γδ	  T-­‐cells	  was	  also	  interesting.	  A	  previous	  study	  by	  Donia	  and	  colleagues	  showed	  that	  
low	  levels	  of	  γδ	  T-­‐cells	  can	  be	  found	  in	  melanoma	  infiltrates,	  and	  that	  higher	  frequencies	  are	  detected	  
in	  Stage	  IV	  patients	  compared	  to	  Stage	  III	  melanoma	  (Donia	  et	  al.,	  2014a).	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While	  these	  unconventional	  T-­‐cells	  are	  very	  interesting,	  the	  study	  of	  this	  T-­‐cell	  subset	  in	  melanoma	  
infiltrates	  fell	  beyond	  the	  scope	  of	  my	  thesis.	  The	  role	  of	  TIL-­‐derived	  γδ	  T-­‐cells	  in	  ACT	  is	  the	  subject	  of	  





Figure	  5.1.	  Patient	  MM909.15	  characteristics,	  TIL	  composition	  and	  autologous	  tumour	  HLA	  expression.	  
(A)	  Patient	  characteristics,	   treatment	  details	  and	  clinical	  outcome.	  M1b	  stage,	  according	  to	  the	  AJCC	  classification,	   involves	  
metastasis	   to	   the	   lung	   (or	  with	  a	  combination	  of	   lung	  and	  skin	  or	  subcutaneous	  metastases)	   (Balch	  et	  al.,	  2009).	  Complete	  
response	  (CR)	  defined	  by	  RECIST	  guidelines	  as	  the	  “disappearance	  of	  all	  target	  lesions	  and	  any	  pathological	  lymph	  nodes	  must	  
have	  reduction	  to	  <10	  mm”	  (Eisenhauer	  et	  al.,	  2009).	  (B)	  TRBV	  antibody	  surface	  staining	  of	  MM909.15,	  gated	  on	  total	  CD3+	  
CD8+	  viable	  T-­‐cells.	  (C)	  Left	  panel	  shows	  the	  flow	  cytometric	  analysis	  of	  HLA-­‐I	  and	  HLA-­‐II	  expression	  of	  autologous	  melanoma	  
cells.	  Cells	  were	  untreated	  or	  treated	  with	  low	  dose	  IFN-­‐γ	   (100	  IU/mL)	  for	  72	  hours.	  Right	  panel	  shows	  full	  HLA-­‐I	  and	  HLA-­‐II	  
typing	  performed	  to	  the	  4-­‐digit	  level.	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The	   dominant	   TCR	   Vβ	   families	   in	  MM909.15	   TILs	   were	   initially	   analysed	   by	   flow	   cytometry	   using	  
labelled	   anti-­‐TRBV	   antibodies,	   as	   described	   in	   the	   previous	   chapter.	   	   Polyclonal	   TRBV	   usage	   was	  
observed	  in	  MM909.15	  TILs	  and	  TRBV9,	  TRBV20-­‐1,	  TRBV4-­‐1,	  TRBV4-­‐3,	  TRBV11-­‐2	  and	  TRBV2	  were	  the	  
most	   frequent	   TRBV	   gene	   segments	   (Figure	   5.1B).	   Unlike	   melanoma	   MM909.24,	   the	   MM909.15	  
tumour	   cell	   line	   constitutively	   express	   HLA-­‐II,	   and	   over-­‐expression	   is	   achieved	   by	   low	   dose	   IFN-­‐γ	  
treatment	  (Figure	  5.1C).	  Constitutive	  expression	  of	  HLA-­‐II	  by	  the	  MM909.15	  tumour	  may	  have	  been	  
responsible	  for	  the	  high	  CD4/CD8	  ratio	  of	  T-­‐cells	  observed	  within	  the	  TILs	  in	  this	  patient.	  
	  
The	  reactivity	  of	  MM909.15	  TILs	  to	  autologous	  tumour	  cells	  was	  initially	  assessed	  by	  flow	  cytometry	  
using	  intracellular	  TNF-­‐α,	  IFN-­‐γ	  and	  CD107a	  staining	  and	  CD3,	  CD4	  and	  CD8	  co-­‐labelling	  (Figure	  5.2B).	  
The	  CD8+	  subset	  within	  MM909.15	  TILs	  (38.1%	  of	  total	  CD3+	  TILs)	  expressed	  both	  IFN-­‐γ,	  TNF-­‐α	  and	  
CD107a	  upon	  stimulation	  with	  autologous	  tumour	  cells	  (1.97%,	  2.23%	  and	  3.7%,	  respectively).	  When	  
gated	  on	   total	  CD4+	  TILs	   (which	   represent	  59.6%	  of	  CD3+	  cells),	  only	  TNF-­‐α	   tumour	   reactivity	  was	  
detected	  (3.51%	  TNF-­‐α+	  CD4+)	  of	  the	  three	  markers	  analysed	  (Figure	  5.2C).	  The	  number	  of	  CD4+	  cells	  









Figure	  5.2.	  MM909.15	  TILs	  reactivity	  against	  autologous	  tumour	  (gated	  on	  CD8	  and	  CD4)	  
(A)	  	  TILs	  were	  gated	  on	  live	  CD3+	  T-­‐cells	  and	  CD8+	  and	  CD4+	  subsets	  were	  analysed	  separately.	  Gates	  were	  set	  on	  control	  sample	  
(unstimulated	  TILs)	  stained	  with	  surface	  markers	  only.	  (B)	  FACS	  plots	  of	  ICS	  of	  CD4+	  TILs	  expressing	  IFN-­‐γ,	  TNF-­‐α	  and	  CD107a	  
after	  5	  hour	  stimulation	  with	  autologous	  tumour	  cells	  (E:T	  ratio	  2:1).	  TILS	  alone	  were	  used	  as	  control.	  (C)	  ICS	  FACS	  plots	  of	  CD4+	  
TILs	  expressing	  IFN-­‐γ,	  TNF-­‐α	  and	  CD107a	  upon	  activation	  with	  autologous	  tumour	  cells.	  TILS	  alone	  were	  used	  as	  control.	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To	   further	   explore	   the	   HLA-­‐restriction	   of	   CD8+	   TILs	   from	   patient	  MM909.15,	   I	   used	   the	   panel	   of	  
partially	  matched	  melanoma	  cell	  lines	  (Appendix:	  Table	  7.1B).	  Tumour	  recognition	  was	  assessed	  by	  
measuring	  the	  percentage	  of	  TNF-­‐α	  and	  CD107a	  positive	  CD8+	  T-­‐cells	  upon	  stimulation	  with	   these	  
target	  cells.	  As	  shown	  in	  Figure	  5.3,	  MM909.15	  TILs	  recognised	  many	  melanoma	  cell	  lines	  in	  addition	  
to	  the	  autologous	  tumour.	  Overall,	  these	  data	  suggest	  that	  TIL	  tumour	  reactivity	  spans	  across	  several	  





Figure	  5.3.	  MM909.15	  TILs	  reactivity	  against	  partially	  matched	  panel	  of	  melanoma	  cell	  lines	  
Bar	  chart	  shows	  the	  percentage	  of	  CD107a+	  TNF-­‐α+	  TILs	  upon	  stimulation	  with	  semi-­‐matched	  melanoma	  cell	  lines	  (colour	  coded	  
depending	  on	  the	  allele	  shared	  with	  the	  autologous	  tumour).	  Coloured	  bars	  show	  cell	  lines	  sharing	  at	  least	  one	  HLA-­‐I	  allele	  with	  
the	   autologous	  MM909.15	   tumour.	   The	   colour-­‐code	   for	   HLA-­‐I	   expression	   is	   shown	   on	   top	   of	   the	   graph.	   Stimulation	   with	  
autologous	  melanoma	  MM909.15	  (black	  bar)	  and	  PHA	  (3	  µg/mL)	  (grey	  hatched	  bar)	  were	  used	  as	  positive	  controls.	  Gates	  were	  
set	  on	  unstimulated	  TILs	  samples	  (negative	  control).	  Representative	  FACS	  plots	  are	  shown	  in	  Appendix	  (Figure	  7.3).	  Cells	  were	  




I	  initiated	  my	  studies	  by	  looking	  for	  responses	  to	  known	  A3-­‐restricted	  melanoma	  T-­‐cell	  epitopes	  within	  
MM909.15	  TILs.	  A	  panel	  of	  16	  published	  A3-­‐restricted	  melanoma-­‐associated	  peptides	  were	  selected	  
from	  the	  paper	  described	   in	  Chapter	  4	   (Andersen	  et	  al.,	  2012).	  The	  other	  HLA	  alleles	  expressed	  by	  
patient	  MM909.15	  were	  not	  covered	  by	  the	  list	  of	  known	  melanoma	  T-­‐cell	  epitopes,	  therefore	  antigen	  
specificity	  was	  assessed	  only	  in	  the	  context	  of	  one	  out	  six	  possible	  HLA	  alleles.	  A	  full	  list	  of	  the	  16	  A3-­‐
restricted	  peptides	  used	  and	  proteins	  of	   origin	   can	  be	   found	   in	   the	  Appendix	   (Table	  7.3).	   Peptide	  
specific	  T-­‐cell	   responses	   in	  MM909.15	  TILs	  were	  quantified	  by	  an	   IFN-­‐γ	  ELISpot	  assay.	  As	  shown	   in	  
Figure	  5.4	   out	   of	   16	   known	  peptides	   tested,	   the	   TAG	  –derived	  peptide	  RLSNRLLLR	   (RLS	  hereafter)	  
elicited	  the	  highest	  TIL	  response	  (22	  ±	  7	  IFN-­‐γ	  SFU	  /	  5x105	  TILs).	  TAG	  protein	  isoforms	  are	  cancer-­‐testis	  

















































































































Figure	   5.4.	   ELISpot	   response	   to	   16	   known	   A3-­‐restricted	  
melanoma	  antigens	  
IFN-­‐γ	  ELISpot	  performed	  on	  5x105	  MM909.15	  TILs	  stimulated	  in	  
duplicate	  with	  known	  HLA-­‐A3	  restricted	  melanoma-­‐associated	  
peptides	  (10-­‐6	  M)	  for	  24	  hours.	  The	  number	  of	  IFN-­‐γ	  secreting	  
cells	  per	  5	  x105	  TILs	  is	  displayed	  on	  the	  X	  axis;	  peptide	  sequence	  
and	  protein	  of	  origin	  (in	  brackets)	  are	  displayed	  on	  the	  Y	  axis.	  
Each	   bar	   represents	   the	   mean	   spot	   count	   per	   well	   (±	   SD).	  
Representative	  images	  of	  ELISpot	  wells	  are	  shown	  in	  the	  bottom	  
panel.	   PHA	   (3	   µg/mL)	   was	   used	   as	   a	   positive	   control.	   PHA	  
control	   wells	   were	   fully	   saturated	   with	   spots,	   therefore	   not	  




Taken	  together,	  the	  results	  shown	  so	  far	  highlight	  the	  heterogeneous	  composition	  of	  TIL	  cultures	  from	  
the	  complete	  remission	  patient	  MM909.15.	  CD8+	  TILs	  recognise	  several	  partially	  matched	  melanomas,	  
including	  HLA-­‐A3+	  cell	  lines.	  In	  particular,	  TIL	  product	  MM909.15	  contained	  relatively	  low	  frequencies	  
of	  T-­‐cells	  specific	  for	  the	  shared	  tumour	  protein	  TAG.	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5.2.2   CD4+	  T-­‐cell	  response	  in	  TILs	  from	  patient	  MM909.15	  
Previous	  work	   by	   our	   collaborators	   and	   others	   have	   shown	   that	   some	   TIL	   infusion	   products	   from	  
melanoma	   patients	   achieving	   tumour	   regression	   after	   TIL	   therapy,	   are	   dominated	   by	   CD4+	   T-­‐cells	  
(Besser	  et	  al.,	  2009;	  Ellebæk	  et	  al.,	  2012;	  Pilon-­‐Thomas	  et	  al.,	  2012).	  It	  is	  known	  that	  CD4+	  T-­‐cells	  exert	  
anti-­‐tumour	   functions	   by	   producing	   type	   I	   cytokines	   or	   by	   directly	   recognising	   HLA-­‐II	   restricted	  
epitopes;	  however	  rare	  cytolytic	  CD4+	  T-­‐cells	  have	  been	  described	  in	  melanoma	  (Quezada	  et	  al.,	  2010).	  
Against	  this	  background,	  I	  decided	  to	  further	  explore	  the	  tumour	  reactivity	  of	  the	  CD4+	  TIL	  population	  
that	  represents	  more	  than	  50%	  of	  the	  total	  infusion	  product	  patient	  MM909.15	  was	  treated	  with.	  T-­‐
cells	  were	  gated	  on	  live	  CD3+	  CD4+	  T-­‐cells	  and	  reactivity	  against	  a	  panel	  of	  melanoma	  cell	  lines	  was	  
evaluated	   by	   measuring	   the	   percentage	   of	   TNF-­‐α	   and	   CD107a	   positive	   T-­‐cells	   following	   a	   5-­‐hour	  
stimulation	  (Figure	  5.5).	  Only	  3%	  of	  MM909.15	  CD4+	  TILs	  recognise	  the	  autologous	  tumour	  cells,	  and	  
reactivity	  against	  several	  melanoma	  cell	  lines	  tested	  in	  this	  experiment	  was	  similar.	  Melanoma	  cell	  line	  
FM-­‐2	  elicited	  the	  highest	  T-­‐cell	  response	  (6.6%	  of	  TNF-­‐α+	  CD107a+	  CD4+	  TILs).	  The	  full	  HLA-­‐II	  type	  of	  
the	  recognised	  melanoma	  cell	  lines	  would	  be	  worth	  exploring	  in	  order	  to	  further	  dissect	  the	  class-­‐II	  





Figure	  5.5.	  CD4+	  TILs	  reactivity	  against	  a	  panel	  of	  partially	  matched	  melanoma	  cell	  lines	  
Bar	  chart	  shows	  the	  percentage	  of	  CD107a+	  TNF-­‐α+	  TILs	  upon	  stimulation	  with	  semi-­‐matched	  melanoma	  cell	  lines	  (colour	  coded	  
depending	  on	  the	  allele	  shared	  with	  the	  autologous	  tumour).	  Stimulation	  with	  autologous	  melanoma	  (white	  bar)	  and	  PHA	  (3	  
µg/mL)	   (grey	   bar)	   were	   used	   as	   positive	   controls.	   Gates	   were	   set	   on	   unstimulated	   TILs	   samples	   (negative	   control).	  
Representative	  FACS	  plots	  are	  shown	  in	  Appendix	  (Figure	  7.4).	  Cells	  were	  gated	  on	  live	  CD3+	  CD4+	  TILs.	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A	   CD4+	   T-­‐cell	   clone	   (hereafter	   ML30.15)	   was	   isolated	   from	   TIL	   cultures	   of	   patient	   MM909.15.	  
Surprisingly,	  ML30.15	  showed	  specific	  cytolytic	  activity	  when	  tested	   in	  a	   51Chromium	  release	  assay	  
upon	  18-­‐hour	  co-­‐incubation	  with	  autologous	  tumour	  cells	  (Figure	  5.6A).	  Reactivity	  against	  autologous	  
melanoma	   was	   also	   assessed	   in	   preliminary	   experiments	   by	   flow	   cytometry	   by	   measuring	   the	  
intracellular	  expression	  of	  IFN-­‐γ,	  CD107a	  and	  TNF-­‐α	  upon	  5-­‐hour	  stimulation	  with	  target	  tumour	  cells	  
(Figure	   5.6B).	   Cytokine	   production	   was	   skewed	   towards	   TNF-­‐α	   (5.45%),	   whereas	   IFN-­‐γ	   and	   the	  
degranulation	  marker	  CD107a	  were	  detected	  at	  lower	  levels	  (1.97%	  and	  1.07%,	  respectively).	  A	  further	  
cytolytic	  CD4+	  T-­‐cell	  clone	  with	  a	  similar	  effector	  profile	  was	  isolated	  from	  TIL	  cultures	  from	  patient	  
MM909.24	   (data	   not	   shown).	   Characterisation	   of	   these	   rare	   cytotoxic	   CD4+	   cells	   in	   melanoma	  
infiltrates	   is	  worth	  exploring	   in	  terms	  of	  HLA	  restriction,	  killing	  mechanisms	  and	  antigen	  specificity,	  





Figure	  5.6.	  ML30.15	  CD4+	  cytotoxic	  clone	  
A)	  Specific	   lysis	  of	  autologous	  melanoma	  cells	  by	  ML30.15	  CD4+	  clone	  at	  different	  E:T	  ratios	  after	  18	  hour	  stimulation	   (left	  
panel).	  Full	  clonotyping	  and	  CDR3	  amino	  acid	  sequences	  are	  shown	  (right	  panel;	  courtesy	  of	  Mateusz	  Legut).	  B)	  FACS	  plots	  
showing	   intracellular	   staining	   of	   the	   CD4+	   clone	   ML30.15	   to	   measure	   IFN-­‐γ,	   TNF-­‐α	   and	   CD107a	   production	   after	   5-­‐hour	  
stimulation	  with	  autologous	  tumour	  cells	  (E:T	  ratio	  2:1).	  Unstimulated	  T-­‐cells	  were	  used	  as	  control.	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5.2.3   Peptide	  specificity	  of	  the	  dominant	  clone	  in	  the	  patient	  blood	  after	  cure	  
The	  clonal	  distribution	  of	  the	  TCR	  allows	  detection	  and	  tracking	  of	  tumour-­‐specific	  T-­‐cells	  based	  upon	  
their	  unique	  TCR.	  In	  light	  of	  the	  findings	  regarding	  T-­‐cell	  clonotype	  persistence	  in	  the	  peripheral	  blood	  
of	  patient	  MM909.24	  after	  TIL	  therapy	  in	  Chapter	  4,	  I	  used	  the	  same	  approach	  with	  patient	  MM909.15	  
using	   the	  TIL	   infusion	  product	   and	  patient	  PBMC	  six	  months	  after	   treatment.	   The	  experiment	  was	  
performed	  directly	  on	  thawed	  samples	  which	  were	  rested	  overnight	  prior	  incubation	  with	  autologous	  
melanoma	  cells.	  Tumour	  reactive	  T-­‐cells	  from	  the	  TIL	  infusion	  product	  and	  PBMC	  were	  live-­‐sorted	  on	  
their	  ability	  to	  produce	  TNF-­‐α	  and	  CD107a	  (5.94%	  and	  0.41%	  of	  total	  CD3+	  cells,	  respectively)	  upon	  5-­‐
hour	  stimulation	  with	  autologous	  melanoma	  cells	   (Figure	  5.7A).	  Total	  mRNA	  from	  sorted	  cells	  was	  
isolated	  and	  the	  TCRβ	  repertoire	  was	  amplified	  using	  the	  SMARTer™	  RACE	  approach	  and	  clonotyped.	  
TCRβ	  clonotyping	  results	  highlight	  a	  polyclonal	  TRBV	  usage	  in	  MM909.15	  TILs,	  where	  TRBV5-­‐5	  is	  the	  
most	  frequent	  among	  tumour	  reactive	  CD3+	  TILs	  (15.2%),	  followed	  by	  TRBV20-­‐1	  (10.13%),	  TRBV5-­‐1	  
(10.1%)	  and	  TRBV7-­‐9	  (7.6%)	  (Figure	  5.7B).	  TRBV7-­‐9	  is	  also	  expressed	  in	  the	  circulation	  six	  months	  post	  
TIL-­‐therapy	  (9.3%).	  Strikingly	  TRBV5-­‐1	  accounts	  for	  59.8%	  of	  total	  tumour-­‐reactive	  CD3+	  PBMC.	  	  
	  
Figure	   5.7C	   shows	   the	   comparison	   of	   the	   relative	   frequency	   of	   TCRβ	   CDR3	   sequences	   among	  
MM909.15	  TIL	  infusion	  product	  and	  the	  corresponding	  tumour-­‐reactive	  circulating	  T-­‐cell	  population.	  
Fewer	  clonotypes	  were	  detected	  in	  the	  blood	  compared	  to	  the	  infusion	  product	  (35	  and	  89	  unique	  
CDR3β	  sequences,	  respectively).	  Overall,	  five	  distinct	  TCRβ	  clonotypes	  from	  the	  original	  TIL	  infusion	  
product	  persisted	  in	  the	  patient’s	  blood	  six	  months	  after	  therapy.	  In	  particular,	  one	  of	  the	  persisting	  
T-­‐cells	  clones	  was	  found	  to	  be	  the	  dominant	  in	  the	  PBMC,	  representing	  58.3%	  of	  all	  CDR3β	  sequences	  
expressed	  in	  the	  circulating	  tumour-­‐reactive	  population.	  




Figure	  5.7.	  TCRβ	  repertoire	  diversity	  in	  tumour-­‐reactive	  TILs	  and	  PBMC	  from	  patient	  MM909.15	  
(A)	  Tumour	  reactive	  T-­‐cells	  from	  TIL	  and	  PBMC	  were	  viably	  sorted	  based	  on	  the	  expression	  of	  both	  CD107a	  and	  TNF-­‐α.	  Cells	  
were	  gated	  on	  live	  CD3+	  cells.	  T-­‐cells	  were	  stimulated	  with	  autologous	  tumour	  for	  5	  hours	  in	  the	  presence	  of	  TAPI-­‐0	  (30	  µM),	  
anti-­‐CD107a	  and	  anti-­‐TNF-­‐α	  mAb.	  Control	   cells	  were	  not	   stimulated.	   (B)	   Comparison	  of	  TCRV	  gene	  usage	  between	   tumour	  
reactive	   T-­‐cells	   in	   TILs	   and	   PBMC	   from	   patient	  MM909.15	   (C)	   Each	   pie	   chart	   represents	   the	   distribution	   of	   unique	   CDR3	  
sequences	  detected	  in	  TCRβ	  repertoire	  from	  the	  corresponding	  infusion	  product	  or	  blood	  sample	  from	  patient	  MM909.15.	  Each	  
pie	  segment	  represents	  the	  share	  of	  a	  distinct	  CDR3β	  clonal	  sequence,	  thus	  reflects	  the	  respective	  frequency	  of	  each	  clonotype.	  
Several	  grey	  scales	  are	  used	  repeatedly	  for	  different	  sequences	  because	  of	  the	  high	  level	  of	  diversity.	  The	  corresponding	  CDR3	  
amino	  acid	  sequences	  are	  listed	  in	  the	  order	  of	  frequency.	  Shared	  CDR3	  sequences	  between	  matched	  TIL	  and	  PBMC	  samples	  
are	  indicated	  by	  coloured	  pie	  segments.	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T-­‐cell	   cloning	   generated	   a	   clone	   with	   the	   same	   TCRβ	   chain	   that	   dominates	   the	   tumour-­‐specific	  
response	   in	  patient	  MM909.15	  after	   treatment	   (Figures	  5.8).	   This	   clone	  was	  named	  ML33.15.	   The	  
ML33.15	  CD8+	  TIL	  clone	  was	  highly	  cytolytic	  towards	  the	  MM909.15	  melanoma	  line	  even	  at	  low	  E:T	  
ratio	  in	  a	  4-­‐	  and	  18-­‐hour	  51Chromium	  release	  assay	  (Figure	  5.8B).	  To	  explore	  the	  antigen	  specificity	  
and	  HLA-­‐restriction	  of	  ML33.15,	  T-­‐cells	  were	   stimulated	  with	   the	  above-­‐mentioned	  known	  HLA-­‐A3	  
restricted	  melanoma	   epitopes	   (Table	   7.3)	   and	  MIP-­‐1β	   production	  was	  measured	   by	   ELISA	   (Figure	  
5.8C).	  ML33.15	  antigen	  specificity	  was	  mapped	  to	  the	  HLA-­‐A3	  restricted	  RLS	  peptide	  from	  the	  TAG	  
protein.	  Clone	  sensitivity	  to	  the	  TAG	  T-­‐cell	  epitope	  was	  tested	   in	  peptide	  titration	  assay	  by	  MIP-­‐1β	  
ELISA	  (Figure	  5.8D).	  
	  
In	   summary,	   I	   have	   shown	   that	   five	   different	   melanoma-­‐specific	   TIL	   clonotypes	   persist	   in	   the	  
circulation	  of	  a	  complete	   remission	  patient	  after	  TIL	   therapy.	  The	  dominant	  CD8+	  CTL	  clone	   in	   the	  
patient’s	   blood	   was	   clonotyped	   and	   its	   antigens	   specificity	   was	   mapped	   to	   an	   HLA-­‐A3-­‐restricted	  
cancer-­‐testis	  TAG	  T-­‐cell	  epitope	  (sequence	  RLSNRLLLR).	  
	   	  






Figure	  5.8.	  Dominant	  clone	  ML33.15	  (TRBV5-­‐1)	  is	  specific	  for	  a	  A3-­‐restricted	  TAG	  peptide	  (RLS)	  
(A)	  ML33.15	  is	  the	  dominant	  clone	  in	  MM909.15	  PBMC	  after	  therapy	  and	  fourth	  most	  frequent	  in	  the	  TIL	  infusion	  product.	  The	  
blue	  segment	  of	  each	  pie	  chart	  represents	  the	  share	  of	  the	  CDR3β	  sequence	  CASSLTGTSYNEQFF.	  The	  full	  clonotyping	  data	  for	  
the	  ML33.15	  T-­‐cell	  clone	  is	  shown	  below	  (courtesy	  of	  Mateusz	  Legut).	  (B)	  Specific	  lysis	  (%)	  of	  autologous	  tumour	  cells	  by	  the	  
CD8+	  T-­‐cell	  clone	  ML33.15	  (E/T	  ratio	  =	  5:1)	  after	  4h	  and	  18h,	  respectively.	  (C)	  MIP-­‐1β	  ELISA	  A3-­‐restricted	  peptides	  (10-­‐6	  M).	  (D)	  
Clone	  sensitivity	  (dose-­‐response)	  to	  A3-­‐TAG	  peptide	  RLSNRLLLR.	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5.3   Discussion	  
5.3.1   Heterogeneous	  cellular	  composition	  of	  TIL	  infusion	  products	  
In	   this	   chapter,	   I	   have	   highlighted	   that	  more	   than	   50%	  of	  αβ	   T-­‐cells	   in	   the	   patient	  MM909.15	   TIL	  
infusion	   product	   were	   CD4+	   T-­‐cells.	   Previous	   studies	   have	   shown	   that	   at	   least	   20%	   of	   Stage	   IV	  
melanomas	   contain	   infiltrating	   CD4+	   T-­‐cells	   with	   specific	   tumour	   recognition	   (Donia	   et	   al.,	   2012;	  
Friedman	  et	  al.,	  2012),	  suggesting	  a	  possible	  role	  for	  CD4+	  cells	  in	  tumour	  regression	  after	  adoptive	  
cell	   therapy.	   In	   addition,	   unlike	   most	   non-­‐haematopoietic	   tumours,	   melanomas	   including	   the	  
MM909.15	   tumour	   line,	   can	   constitutively	   express	  HLA-­‐II.	  Melanocytes	   are	   usually	  HLA-­‐II	   negative	  
(Fossati	  et	  al.,	  1986),	  suggesting	  that	  expression	  of	  HLA-­‐II	  is	  associated	  with	  the	  transformation	  process	  
and	   tumour	  progression	   (van	  Vreeswijk	  et	  al.,	  1988).	  Melanoma	  cells	  have	  been	  shown	  to	  process	  
antigen	  and	  present	  peptides	  efficiently	  to	  CD4+	  T	  cells,	  resulting	  in	  T-­‐cell	  proliferation	  (Brady	  et	  al.,	  
1996;	   Robila	   et	   al.,	   2008).	   However,	   the	   clinical	   significance	   of	   constitutive	   HLA-­‐II	   expression	   in	  
melanomas	  is	  still	  under	  debate,	  as	  HLA-­‐II	  expression	  has	  been	  associated	  with	  both	  longer	  and	  shorter	  
survival	  rates	  (Anichini	  et	  al.,	  2006;	  van	  Duinen	  et	  al.,	  1988;	  Zaloudik	  et	  al.,	  1988).	  In	  the	  context	  of	  TIL	  
therapy,	  work	  from	  Rosenberg	  and	  colleagues	  has	  shown	  that	  co-­‐infusion	  of	  CD8+	  and	  CD4+	  TILs	  is	  
more	  effective	  than	  the	  infusion	  of	  CD8+	  TILs	  alone	  (Dudley,	  2002).	  Furthermore,	  it	  has	  been	  reported	  
that	  the	  infusion	  of	   in	  vitro	  expanded	  autologous	  CD4+	  T-­‐cell	  clones	  specific	  for	  NY-­‐ESO-­‐1	  results	  in	  
long-­‐term	  tumour	  regression	  in	  advanced	  melanoma	  patients	  (Hunder	  et	  al.,	  2008).	  	  	  
	  
I	   also	   showed	   that	   CD4+	   TILs	   from	   patient	   MM909.15	   produce	   TNF-­‐α	   upon	   stimulation	   with	  
autologous	  tumour	  and	  several	  other	  other	  melanoma	  cell	  lines,	  suggesting	  the	  recognition	  of	  shared	  
T-­‐cell	  epitopes.	  Experiments	  using	  HLA-­‐II	  blocking	  antibodies	  were	  not	  conclusive	  (data	  not	  shown),	  
therefore	  further	  experiments	  are	  necessary	  to	  confirm	  the	  HLA-­‐II	  restriction	  of	  this	  anti-­‐melanoma	  
CD4+	   infiltrating	  population.	   In	  addition,	  a	  tumour-­‐reactive	  CD4+	  T-­‐cell	  clone	  was	   isolated	  from	  TIL	  
cultures	   of	   patient	   MM909.15	   was	   shown	   to	   be	   cytotoxic	   towards	   the	   autologous	   tumour	   line.	  
Cytotoxic	   CD4+	   T-­‐cell	   clones	   have	   been	   previously	   described	   in	   the	   context	   of	   anti-­‐viral	   immunity	  
(Hildemann	  et	  al.,	  2013;	  Marshall	  and	  Swain,	  2011),	  but	  their	  role	  in	  tumour	  immunosurveillance	  is	  
poorly	  understood	  and	  has	  only	  emerged	  in	  isolated	  papers	  (Perez-­‐Diez	  et	  al.,	  2007;	  Quezada	  et	  al.,	  
2010).	   It	   would	   have	   been	   interesting	   to	   study	   the	  mechanism	   by	   which	   cytolytic	   CD4	   T-­‐cells	   kill	  
tumour	  cells	  by	  determining	  whether	  cell	  lysis	  is	  dominated	  by	  perforin-­‐dependent,	  Fas-­‐dependent	  or	  
other	   mechanisms	   (Williams	   and	   Engelhard,	   1996;	   Yasukawa	   et	   al.,	   2000).	   In	   addition,	   TCR	   gene	  
transfer	  could	  be	  a	  strategy	  to	  address	  whether	  the	  anti-­‐melanoma	  cytotoxicity	  of	  the	  ML30.15	  clone	  
is	  mediated	  by	  the	  tumour-­‐reactive	  TCR.	  Cytokine	  profiling	  of	  the	  ML30.15	  clone,	  was	  only	  undertaken	  
for	  IFN-­‐γ,	  TNF-­‐α	  and	  CD107a	  upon	  stimulation	  with	  autologous	  tumour	  cells.	  However,	  other	  Th1	  and	  
Th2	  cytokines	  should	  be	  measured	  to	  provide	  a	  full	  cytokine	  profiling	  of	  effector	  tumour-­‐specific	  CD4+	  
T-­‐cells	   in	  melanoma	  TILs.	  Previous	  work	  revealed	  that	  the	  proportions	  of	  different	   infiltrating	  CD4+	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subtypes	  varies	  depending	  on	  the	  thickness	  and	  characteristics	  of	  the	  melanoma	  lesion	  (Conrad	  et	  al.,	  
1999;	  Wagner	  et	  al.,	  1998).	  It	  is	  unclear	  whether	  this	  variation	  is	  cause	  or	  effect.	  An	  additional	  recent	  
paper	  published	  by	  our	  collaborators	  analysed	  the	  functional	  patterns	  of	  anti-­‐melanoma	  CD4+	  TILs	  of	  
melanoma	  patients	  in	  comparison	  to	  CD8+	  TILs	  (Donia	  et	  al.,	  2015).	  Results	  showed	  that	  CD4+	  tumour-­‐
specific	   T-­‐cells	   were	   skewed	   towards	   TNF-­‐α	   production	   in	   all	   the	   melanoma	   patients	   analysed	  
(including	   patient	   MM909.15),	   with	   comparable	   IFN-­‐γ	   and	   MIP-­‐1β	   production.	   Regulatory	   T-­‐cells	  
(Treg)	  are	  also	  generally	  CD4+	  (Viguier	  et	  al.,	  2004).	  A	  higher	  percentage	  of	  Treg	  has	  been	  shown	  in	  
TILs	   from	   metastatic	   melanoma	   lesions	   and	   can	   be	   associated	   with	   a	   higher	   risk	   of	   recurrence	  
(Mourmouras	   et	   al.,	   2007;	   Viguier	   et	   al.,	   2004).	   It	   would	   be	   worth	   exploring	   if	   the	   CD4+	   T-­‐cell	  
population	  that	  dominates	  MM909.15	  TILs	  presented	  here	  express	  markers	  typically	  associated	  with	  
this	   immune-­‐suppressive	  Treg	  subtype,	  such	  as	  FoxP3	  (Sakaguchi	  et	  al.,	  2001).	  In	  analysing	  CD4+	  T-­‐
cells,	  it	  is	  important	  to	  remember	  that	  these	  cells	  can	  represent	  a	  broad	  population	  of	  cells	  that	  can	  
have	   wide	   ranging	   immunosuppressive	   or	   immunostimulatory	   functions.	   It	   would	   therefore	   be	  
worthwhile	   undertaking	   a	   full	   CD4+	   T-­‐cell	   profiling	   of	   the	   TILs	   present	   in	   the	   MM909.15	   patient	  
samples.	  
	  
The	   heterogenic	   composition	   of	   melanoma	   TIL	   infusion	   products	   is	   highlighted	   not	   only	   by	   the	  
different	   ratios	  of	  CD4+	  and	  CD8+	  conventional	  αβ	   T-­‐cells	   subset	   seen	   in	  patients,	  but	  also	  by	   the	  
presence	  of	  a	  population	  of	  γδ	  T-­‐cells,	  with	  a	  prevalence	  of	  the	  Vδ1+	  subset	  (Donia	  et	  al.,	  2012).	  This	  
unconventional	  T-­‐cell	  fraction	  can	  be	  significant	  (more	  than	  1x109),	  as	  for	  the	  patient	  presented	  in	  this	  
chapter	   (10%	   of	   infused	   TILs).	   The	   contribution	   of	   γδ	   T-­‐cells	   to	   anti-­‐melanoma	   TILs	   has	   not	   been	  
explored	   until	   recently.	   Our	   collaborators	   have	   described	   Vδ1+	   T-­‐cells	   derived	   from	   metastatic	  
melanomas	  and	  characterized	  by	  an	  effector	  tumour-­‐reactive	  phenotype	  (Donia	  et	  al.,	  2012).	  Similar	  
findings	  from	  a	  cultured	  polyclonal	  Vδ1+	  TIL	   line	  with	   in	  vitro	  cytotoxic	  capability	  were	  reported	  by	  
another	  group	   (Cordova	  et	  al.,	   2012).	  Of	  note,	  other	   immune	  cells	   infiltrating	  melanomas,	   such	  as	  
natural	  killer	  (NK)	  cells,	  usually	  do	  not	  expand	  using	  REP	  expansion	  methods	  and	  are	  therefore	  not	  
commonly	   detected	   among	   clinical	   grade	   infusion	   products	   (Donia	   et	   al.,	   2012).	   Overall,	   these	  
observations	   point	   towards	   interesting	   heterogeneity	   within	   melanoma	   infiltrating	   T-­‐cell	   subsets.	  
Detailed	  characterisation	  of	  these	  subsets	  awaits	  further	  experimentation.	  
5.3.2   T-­‐cell	  responses	  to	  the	  TAG	  cancer-­‐testis	  antigen	  
The	  analysis	  of	  known	  HLA-­‐A3-­‐restricted	  antigen	  specificities	  present	  in	  TILs	  from	  patient	  MM909.15	  
revealed	   T-­‐cell	   reactivity	   against	   the	   TAG	   T-­‐cell	   epitope	   RLSNRLLLR.	   TAG	   protein	   isoforms	   encode	  
cancer-­‐testis	  epitopes	  known	  to	  be	  overexpressed	   in	  melanoma	  cell	   lines	  and	  other	  solid	  tumours,	  
including	   breast,	   ovarian	   and	   colorectal	   cancer	   (Adair	   et	   al.,	   2008).	   The	   TAG-­‐derived	   peptide	  
RLSNRLLLR	  is	  encoded	  by	  multiple	  TAG	  isoforms	  and	  is	  naturally	  immunogenic.	  Spontaneous	  T-­‐cells	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responses	   in	   melanoma	   patients	   against	   the	   RLSNRLLLR	   peptide	   have	   been	   previously	   described	  
(Hogan	  et	  al.,	  2004;	  Linnemann	  et	  al.,	  2013;	  Yamshchikov	  et	  al.,	  2001).	  	  
Interestingly,	  T-­‐cell	  reactivity	  against	  the	  same	  TAG	  peptide	  was	  detected	  in	  TIL	  cultures	  from	  a	  third	  
complete	   remission	  melanoma	   patient	   analysed	   during	  my	   PhD	   project.	   Details	   on	   TILs	   from	   this	  
patient	  (MM909.11;	  HLA-­‐A3+,	  HLA-­‐A1+)	  and	  a	  summary	  of	  melanoma	  reactivity	  are	  shown	  in	  Figure	  
7.5	  in	  the	  Appendix.	  TILs	  from	  patient	  MM909.11	  were	  tested	  by	  IFN-­‐γ	  ELISpot	  against	  known	  HLA-­‐A1	  
and	   HLA-­‐A3-­‐restricted	   peptides.	   Only	   a	   response	   to	   RLS	   HLA-­‐A3	   restricted	   peptide	   was	   detected	  
(Appendix:	  Table	  7.3).	  TAG	  specific	  T-­‐cell	   responses	  have	  also	  been	  detected	   in	  melanoma	  TILs	  by	  
other	   groups	   (Linnemann	   et	   al.,	   2013;	   Kvistborg	   et	   al.,	   2012;	   Donia,	   personal	   communication).	  
Strikingly,	  the	  dominant	  tumour-­‐reactive	  clonotype	  in	  the	  PBMC	  of	  patient	  MM909.15	  is	  specific	  for	  
the	  RLSNRLLLR	  T-­‐cell	  epitope.	  An	  identical	  RLSNRLLLR-­‐specific	  clonotype	  has	  been	  found	  in	  another	  
melanoma	  patient	  (Linnemann	  et	  al.,	  2013),	  suggesting	  that	  this	  αβ	  TCR	  could	  be	  a	  ‘public’.	  Public	  TCR	  
CDR3	  amino	  acid	  sequences	  have	  been	  reported	  in	  the	  literature	  (Ely	  et	  al.,	  2005;	  Venturi	  et	  al.,	  2008;	  
2006)	  but	  have	  not	  been	  described	  in	  the	  context	  of	  T-­‐cell	  based	  adoptive	  cell	  therapy.	  
	  
Overall,	  the	  dissection	  of	  the	  antigen	  specificity	  of	  the	  two	  melanoma	  TILs	  (MM909.15	  and	  MM909.11)	  
as	   presented	   here	   has	   an	   obvious	   limitation.	   T-­‐cell	   reactivity	   against	   known	   epitopes	   was	   only	  
measured	  for	  one	  out	  of	  the	  six	  possible	  HLA	  alleles.	  This	  also	  relates	  to	  the	  limited	  published	  panel	  of	  
non	   HLA-­‐A2	   restricted	   T-­‐cell	   epitopes	   (Andersen	   et	   al.,	   2012).	   However,	  my	   data	   suggest	   that	   TIL	  
reactivities	  against	  known	  melanoma-­‐associated	  antigens,	  such	  as	  shared	  cancer-­‐testis	  epitopes,	  only	  
account	   for	   a	   small	   fraction	   of	   the	   total	   tumour	   reactivity.	   This	   observation	   is	   in	   accordance	  with	  
preliminary	  deep	  sequencing	  of	  tumour-­‐reactive	  TILs	  from	  these	  patients,	  that	  indicates	  the	  tumour-­‐
specific	  T-­‐cell	  population	  is	  made	  up	  of	  hundreds	  of	  individual	  clonotypes.	  Taken	  together,	  my	  results	  
point	   towards	   the	   notion	   that	   T-­‐cell	   responses	   against	   TAG	   cancer-­‐testis	   melanoma	   antigens	   are	  
shared	  between	  patients	  and,	  given	  their	  long-­‐term	  persistence	  after	  therapy	  they	  could	  contribute	  
to	  explain	   tumour	   clearance	   in	   vivo.	  Based	  on	  my	  data,	   I	   hypothesise	   that	   raising	  of	   a	   therapeutic	  
response	  to	  HLA-­‐A3-­‐RLSNRLLLR	  in	  HLA-­‐A3+	  melanoma	  patients	  could	  result	  in	  beneficial	  responses.	  	  
5.3.3   Persistence	  of	  T-­‐cell	  clones	  in	  the	  blood	  after	  cure	  	  
The	  activation	  of	  tumour-­‐specific	  T-­‐cells	  leads	  to	  clonal	  expansions	  and	  elevated	  numbers	  of	  mRNA	  
encoding	  a	  particular	  TCRα	   and	  TCRβ	   chain.	   Therefore,	   the	  detection	  of	  dominant	   clonotypes	   in	  a	  
patient’s	  blood	  after	  TIL	  therapy	  can	  be	  a	  marker	  of	  an	  ongoing	  HLA-­‐restricted	  T-­‐cell	  response	  and,	  
indirectly,	  of	  the	  anti-­‐tumour	  effect	  of	  adoptive	  TIL	  therapy.	  Against	  this	  background,	  I	  studied	  the	  TCR	  
repertoire	  of	  reactive	  T-­‐cells	  in	  both	  TILs	  and	  PBMC	  of	  three	  complete	  remission	  patients	  (Figures	  4.11,	  
5.7	  and	  7.6),	  and	  made	  the	  following	  observations:	  (i)	  the	  TCR	  repertoire	  of	  tumour	  reactive	  cells	  in	  
TIL	  infusion	  products	  and	  PBMC	  is	  broad	  and	  diverse;	  ii)	  in	  all	  three	  patients	  analysed	  at	  least	  two	  T-­‐
cell	   clones	  persisted	   in	   the	  blood	  after	   treatment;	   and	   iii)	   tumour	   reactive	  T-­‐cells	   in	   the	  blood	  are	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dominated	  by	  few	  clonotypes,	  possibly	  following	  in	  situ	  expansion	  after	  encounter	  with	  the	  tumour-­‐
antigen.	  	  
Previous	   studies	   have	   begun	   to	   explore	   the	   expansion	   and	   diversity	   of	   T-­‐cell	   clones	   in	  melanoma	  
patients	  and	  their	  role	   in	  clinical	  responses	  to	  TIL	  transfer	  (Berger	  et	  al.,	  2004;	  Straten	  et	  al.,	  1999;	  
2004).	  However,	  recent	  technological	  advances,	  such	  as	  deep	  next	  generation	  sequencing	  (Clemente	  
et	  al.,	  2013;	  Mamedov	  et	  al.,	  2013)	  now	  allow	  tracking	  of	  tumour-­‐specific	  T-­‐cell	  clonotypes	  infiltrating	  
the	  tumour	  before	  and	  after	  TIL	  therapy	  and	  monitoring	  of	  individual	  T-­‐cell	  fate	  during	  treatment.	  	  
	  
Of	   note,	   in	   the	   complete	   remission	   patients	   analysed,	   the	   TCR	   repertoire	   in	   the	   blood	   contained	  
tumour-­‐reactive	  clonotypes	  that	  were	  not	  detected	  in	  the	  original	  TIL	  infusion	  product.	  In	  particular,	  
the	  number	  of	  CDR3β	  sequences	  in	  the	  PBMC	  of	  patient	  MM909.11	  was	  far	  more	  after	  than	  in	  TILs	  
(22	  and	  7	  unique	  CDR3β	  sequences,	  respectively)	  (Appendix:	  Figure	  7.6B).	  These	  observations	  may	  
indirectly	  point	  towards	  epitope	  spreading,	  where	  T-­‐cells	  with	  antigen	  specificity	  other	  than	  the	  one	  
induced	  by	  adoptive	  therapy	  appear	  after	  tissue	  damage	  caused	  by	  the	  initial	  clone	  (Ribas	  et	  al.,	  2003).	  
As	   has	   been	   reported	   in	   autoimmune	   diseases,	   this	   initial	   tissue	   destruction	   could	   lead	   to	   the	  
expansion	   of	   T	   cells,	  with	   specificity	   for	   other	  melanoma	   antigens	   (Ma	   et	   al.,	   2013).	   There	   is	   also	  
evidence	  of	  epitope	  spreading	   in	  some	  vaccination	  studies	   (Butterfield	  et	  al.,	  2003;	  Corbière	  et	  al.,	  
2011).	  In	  order	  to	  validate	  this	  hypothesis,	  I	  would	  have	  to	  map	  the	  epitope	  that	  clone(s)	  recognises	  
in	  the	  circulation	  and	  demonstrate	  via	  PCR	  specific	  amplification	  that	  these	  T-­‐cell	  reactivities	  were	  not	  
in	  the	  original	  infusion	  product.	  Taken	  together,	  my	  data	  highlights	  that	  a	  deeper	  knowledge	  of	  the	  
key	   antigen-­‐specificities	   within	   TIL	   TCR	   repertoires	   should	   allow	   a	   better	   understanding	   the	  
mechanisms	  and	  complexities	  of	  tumour	  regression	   in	  vivo	  and	  improve	  the	  efficacy	  of	  T-­‐cell	  based	  
therapies	  for	  melanoma.	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6   General	  Discussion	  and	  Conclusions	  
6.1   Discussion	  
The	  work	  outlined	  in	  my	  thesis	  is	  united	  by	  the	  common	  theme	  of	  immunotherapies	  for	  the	  treatment	  of	  
advanced	  melanoma.	   Indeed,	  both	  peptide	   vaccination	  and	  TIL-­‐based	   therapies	  have	  been	  among	   the	  
most	  extensively	  studied	  strategies	  in	  both	  preclinical	  and	  clinical	  settings.	  In	  Chapter	  3,	  I	  have	  explored	  
the	  X-­‐ray	  crystal	  structure	  of	  a	  TCR	  in	  complex	  with	  HLA-­‐A2	  and	  the	  gp100280-­‐288	  epitope,	  a	  common	  target	  
of	  melanoma	  vaccination	  platforms.	  I	  also	  undertook	  a	  thorough	  alanine	  mutagenesis	  study	  of	  the	  gp100	  
epitope,	   and	   performed	   functional	   analyses	   to	   assess	   if	   peptide	   analogues	   induce	   a	   specific	   T-­‐cell	  
response.	  From	  structural	  and	  functional	  analyses,	  I	  found	  that	  mutation	  of	  residue	  Glu3	  into	  an	  alanine	  
generated	   a	  molecular	   switch	   that	  was	   transmitted	   to	   neighbour	   residues,	   completely	   abolishing	   TCR	  
binding	  and	  antigenic	  responses.	  The	  findings	  of	  this	  project	  have	  convinced	  me	  about	  the	  importance	  of	  
taking	   into	   account	   the	   detailed	   structural	   information	   available	   from	   crystallography,	   combined	  with	  
biophysical	  and	  binding	  data,	  when	  studying	  TCR-­‐pHLA	  interactions.	  While	  sensitivity	  of	  certain	  TCRs	  to	  
HLA	   and/or	   peptide	   changes	   in	   buried	   sites	   has	   been	   long	   appreciated,	   this	   study	   provides	   a	  
comprehensive	   analysis	   of	   this	   phenomenon	   extending	   over	   a	   relatively	   long	  molecular	   distance	   in	   a	  
cancer	  system	  of	  considerable	  current	  interest.	  
	  
In	  Chapters	  4	  and	  5,	  I	  dissected	  the	  anti-­‐melanoma	  T-­‐cell	  responses	  in	  long-­‐term	  melanoma-­‐free	  patients	  
after	  adoptive	  TIL	  transfer.	  In	  the	  two	  CR	  patients	  studied	  in	  this	  thesis,	  I	  began	  by	  analysing	  the	  overall	  
tumour-­‐reactivity	  of	  TIL	  cultures	  against	  autologous	  melanoma	  by	  flow	  cytometry.	   I	   then	  proceeded	  to	  
dissect	  a	  panel	  of	  TIL	  clones	  and	  investigate	  the	  persistence	  of	  tumour-­‐reactive	  clonotypes	  in	  the	  patient’s	  
blood	  after	  cure	  and	  was	  able	  to	  map	  cognate	  T-­‐cell	  specificities.	  I	  believe	  that	  the	  composition	  of	  T-­‐cell	  
clones	  over	  time,	  based	  on	  the	  detection	  of	  unique	  CDR	  sequences,	  offers	  a	  means	  to	  track	  specific	  T-­‐cell	  
reactivities	  that	  persist	  after	  TIL	  therapy.	  We	  are	  now	  in	  a	  prime	  position	  to	  understand	  the	  key	  antigen-­‐
specificities	   associated	  with	   cancer	   regression	   following	   TIL	   therapy.	   Gaining	   an	   understanding	   of	   the	  
patient-­‐specific	  and/or	  shared	  T-­‐cell	  epitopes	  that	  mediate	  in	  vivo	  tumour	  clearance	  will	  allow	  important	  
further	  investigation	  that	  may	  pave	  the	  way	  to	  replication	  of	  these	  successes	  in	  other	  patients	  and	  other	  
tumour	  types.	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My	   research	   group	   are	   exploring	   whether	   CPL	   scans	   combined	   with	   computational	   analysis	   can	   be	  
integrated	  in	  an	  overall	  strategy	  to	  track	  T-­‐cell	  clonotypes	  in	  TILs	  and	  PBMC,	  and	  map	  the	  specificities	  of	  
‘orphan’	   cancer-­‐specific	   T-­‐cells	   (Figure	   6.1).	   Regardless	   of	   their	   HLA-­‐restriction,	   T-­‐cell	   clones	   can	   be	  
screened	   using	   autologous	   LCL	   lines	   and	   CPL	   scans	   to	   study	   the	   peptide	   landscape	   recognised	   by	   the	  
cognate	  TCR.	  	  Cross-­‐reactive,	  public	  or	  novel	  anti-­‐melanoma	  TCRs	  can	  be	  then	  examined	  from	  a	  structural	  
and	  biophysical	  point	  of	  view	  in	  order	  to	  study	  the	  TCR-­‐pHLA	  molecular	  interaction	  (as	  shown	  in	  Chapter	  
3,	   for	  a	  gp100-­‐specific	  TCR).	  Knowledge	  of	   the	  T-­‐cell	   responses	   that	  persist	   in	  patients	   that	   clear	   their	  
cancer	  will	  be	  highly	  informative	  for	  designing	  future	  therapeutic	  strategies	  and	  may	  allow	  these	  successes	  
to	  be	  replicated	  in	  other	  patients.	  
	  
	  
Figure	  6.1.	  A	  strategy	  for	  dissecting	  unknown	  T-­‐cell	  clones	  from	  anti-­‐melanoma	  TIL	  and	  PBMC	  samples	  
	  
In	  addition,	  we	  are	  exploring	  a	  new	  application	  of	  the	  cutting-­‐edge	  CRISPR	  gene	  editing	  technology,	  which	  
allows	   generation	   of	   tailored	   RNA-­‐guided	   nucleases	   (such	   as	   Cas9)	   that	   induce	   DNA	   double-­‐breaks	   at	  
specific	  genomic	  sites	  (Cong	  et	  al.,	  2013;	  Mali	  et	  al.,	  2013;	  Sander	  and	  Joung,	  2014).	  Whole-­‐genome	  CRISPR	  
libraries	  have	  been	  published	  and	  consist	  of	   a	  mixed	  population	  of	   lentiviral	   vectors	   containing	  guide-­‐
RNAs,	  each	  targeting	  a	  specific	  gene	  of	  the	  genome	  (Parnas	  et	  al.,	  2015;	  Wang	  et	  al.,	  2014).	  Whole-­‐genome	  
CRISPR	  libraries	  could	  be	  used	  to	  screen	  anti-­‐melanoma	  TIL	  clones	  with	  unknown	  specificity	  to	   identify	  
cognate	  T-­‐cell	  epitope	  candidates.	  The	  screening	  process	  relies	  on	  the	  ability	  of	  cytotoxic	  T-­‐cell	  clones	  to	  
specifically	  lyse	  their	  target.	  	  


















a) TIL infusion products from melanoma patients; b) Dissection of
TIL anti5tumour reactivity; c) Tracking of persisting anti5melanoma
T5cell clones; d) Characterisation of individual killer clones; e) CPL
scan; f) Computational approach for T5cell epitope mapping; g) X5
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Briefly,	   the	   whole-­‐genome	   CRIPSR	   library	   is	   used	   to	   deliver	   a	   pool	   of	   lentiviral	   guide-­‐RNAs	   to	   target	  
melanoma	  cells,	  prior	  to	  incubation	  with	  the	  autologous	  TIL	  clone.	  Melanoma	  cells	  in	  which	  an	  essential	  
gene	  for	  cognate	  peptide	  expression,	  processing	  or	  presentation	  has	  been	  knocked	  out,	  will	  fail	  to	  activate	  
the	  specific	  T-­‐cells	  and	  therefore	  will	  not	  be	  lysed.	  The	  CRISPR	  guide-­‐RNAs	  in	  surviving	  cells	  can	  be	  simply	  
amplified	  and	  sequenced	  to	  identify	  the	  genes	  that	  have	  been	  targeted,	  and	  ultimately	  the	  T-­‐cell	  epitope	  
candidate.	  
	  
6.2   Future	  perspectives	  in	  melanoma	  immunotherapy	  
6.2.1   The	  role	  of	  the	  tumour	  microenvironment	  	  
Tumours	  have	  been	  traditionally	  studied	  as	  isolated	  entities	  of	  transformed	  cells,	  but	  increasing	  evidence	  
supports	  the	  idea	  that	  cancer	  cells	  rather	  interact	  with	  the	  surrounding	  microenvironment	  (Steeg,	  2016;	  
Turley	  et	  al.,	  2015).	  Indeed,	  melanomas	  are	  composed	  not	  only	  of	  transformed	  melanocytes	  but	  also	  of	  
the	  supporting	  stroma,	  which	  includes	  fibroblasts,	  endothelial	  cells,	  immune	  cells,	  soluble	  molecules,	  and	  
the	  extracellular	  matrix.	  Extensive	  research	   in	   this	   field	   reveals	  a	  bidirectional	  and	  dynamic	   interaction	  
between	   tumour	   cells	   and	   the	   microenvironment	   that	   can	   influence	   the	   malignant	   phenotype,	   and	  
ultimately	  modulate	  the	  success	  of	  immunotherapy.	  Multiple	  immunosuppressive	  mechanisms	  can	  coexist	  
in	  melanoma	  to	  reduce	  the	  effectiveness	  of	  T-­‐cell	  immunity.	  	  These	  mechanisms	  include:	  expression	  of	  co-­‐
inhibitory	  molecules,	  down-­‐regulation	  of	  co-­‐stimulatory	  or	  HLA	  molecules,	  and	  increased	  regulatory	  T-­‐cell	  
activity	   (Ferrone	  and	  Marincola,	   1995;	  Ostrand-­‐Rosenberg,	   2008;	  Polak	  et	   al.,	   2007;	  Real	   et	   al.,	   2001).	  
Against	  this	  background,	  current	  clinical	  trial	  protocols	  are	  now	  trying	  to	  tip	  the	  balance	  towards	  a	  lower	  
immunosuppressive	   microenvironment,	   by	   including	   antibody	   blockade	   of	   co-­‐inhibitory	   molecules	   or	  
targeting	  immune	  suppressive	  cells.  
6.2.2   The	  future	  of	  peptide	  cancer	  vaccines	  
Therapeutic	   peptide	   cancer	   vaccines	   have	   generally	   been	   disappointing.	   Over	   the	   years	   several	   anti-­‐
melanoma	  vaccination	  platforms	  have	  been	  tested	  through	  clinical	  trials,	  showing	  a	  variety	  of	  success	  rates	  
and	  highlighting	  issues	  to	  be	  addressed	  (Berzofsky	  et	  al.,	  2015;	  Slingluff,	  2011;	  Tsang	  et	  al.,	  2015).	  One	  of	  
the	  main	  concerns	  is	  the	  choice	  of	  appropriate	  T-­‐cell	  antigens	  to	  be	  incorporated	  in	  the	  vaccine.	  The	  lack	  
of	   selectivity	   of	   tumour-­‐associated	   antigens	   can	   lead	   to	   autoimmunity,	   such	   as	   severe	   vitiligo,	   in	  
immunised	  patients	  (Amos	  et	  al.,	  2011).	  Another	  major	  issue	  is	  the	  choice	  of	  the	  adjuvant	  used	  to	  boost	  
the	  immunogenicity	  of	  the	  tumour-­‐associated	  antigen.	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Adjuvants	  are	  key	  for	  vaccine	  efficacy,	  but	  a	  fine	  balance	  must	  be	  found	  between	  eliciting	  the	  desired	  T-­‐
cell	  response	  and	  adverse	  reactions	  (Reed	  et	  al.,	  2013).	  Finally,	  data	  from	  other	  tumour	  models	  suggests	  
that	  the	  use	  long	  peptides	  (30-­‐mer),	  which	  include	  short	  minimal	  epitopes,	  may	  overcome	  some	  of	  the	  
limitations	  of	  short	  peptide	  vaccines,	  in	  that	  they	  induce	  both	  CD4+	  and	  CD8+	  anti-­‐tumour	  T-­‐cell	  responses	  
and	  better	  antigen	  presentation	  (Bijker	  et	  al.,	  2008;	  Sercarz	  and	  Maverakis,	  2003).	  	  
	  
Even	   if	   the	   selected	   antigen	   and	   the	   delivery	   platform	   have	   been	   optimised,	   therapeutic	   vaccination	  
protocols	   may	   fail	   because	   of	   tumour-­‐associated	   immune	   evasion	   mechanisms	   mentioned	   above.	  
Therefore,	  the	  future	  of	  therapeutic	  peptide	  vaccines	  could	  lie	  in	  their	  combination	  with	  other	  reagents,	  
such	  as	  immunomodulators.	  A	  promising	  combination	  is	  the	  use	  of	  a	  peptide	  vaccine	  administered	  with	  
an	   anti-­‐CTLA4	   antibody.	   In	   a	   clinical	   trial	   in	   metastatic	   melanoma	   patients,	   a	   peptide	   vaccine	   in	  
combination	  with	   IFN-­‐α	  and	  anti-­‐CTLA4	  significantly	  down-­‐regulated	   immunosuppression	  and	  achieved	  
significant	  clinical	  activity	   (Tarhini	  et	  al.,	  2012).	  A	  phase	   III	   trial	   in	  advanced	  melanoma	  patients	  used	  a	  
combination	  of	  ipilimumab	  and	  gp100	  peptide	  vaccine;	  results	  showed	  that	  ipilimumab	  with	  or	  without	  
the	  peptide	  vaccine	  improved	  the	  overall	  survival	  when	  compared	  to	  the	  peptide	  alone	  (Hodi	  et	  al.,	  2010).	  
Dissection	  of	  successful	  TIL	  therapy,	  as	  I	  have	  done	  in	  my	  studies,	  will	  provide	  signposts	  to	  tumour	  antigens	  
and	  peptide-­‐HLA	  associated	  with	  success.	  These	  antigens	  will	  then	  make	  promising	  candidates	  for	  future	  
vaccine	  trials.	  
6.2.3   Improvement	  of	  TIL	  therapy	  and	  future	  questions	  
Despite	  the	  overall	  clinical	  efficacy	  achieved	  with	  TIL-­‐based	  immunotherapy,	  several	  questions	  remain	  to	  
be	  addressed	  before	  this	  technology	  is	  routinely	  implemented	  into	  clinical	  practice.	  Firstly,	  the	  technical	  
aspects	  of	  TIL	  therapy	  have	  room	  for	  improvement.	  TIL	  production	  is	  still	  a	  complex,	  laborious	  procedure	  
that	  requires	  highly	  specialised	  cancer	  centres	  and	  a	  minimum	  of	  3-­‐4	  weeks	  in	  order	  to	  expand	  T-­‐cells	  to	  
sufficient	  numbers	   for	   infusion.	  This	   time	   frame	  often	  results	   in	  significant	  patient	  dropout	  because	  of	  
rapid	  disease	  progression	  or	  failure	  to	  culture	  and	  expand	  autologous	  T-­‐cells	  to	  the	  numbers	  required	  for	  
treatment	  (Svane	  and	  Verdegaal,	  2014).	  	  
	  
Secondly,	  a	  deeper	  understanding	  of	  the	  factors	  influencing	  clinical	  outcome	  is	  critical.	  	  As	  pointed	  out	  in	  
Chapters	  4	  and	  5,	  an	  important	  goal	  of	  current	  TIL	  investigation	  is	  to	  identify	  the	  subsets	  and	  phenotypes	  
within	  the	   initial	  mixed	  TIL	   infiltrate	  that	  are	  associated	  with	   in	  vivo	  tumour	  regression.	  For	  example,	  a	  
matter	   of	   controversy	   has	   been	  which	   CD8+	   T-­‐cell	   differentiation	   stage	   better	   correlates	  with	   clinical	  
outcome	  by	  contributing	  to	  immediate	  melanoma	  killing.	  Several	  protocols	  for	  TIL	  generation	  include	  a	  
two-­‐step	   in	   vitro	   expansion	   (pre-­‐REP	   and	   REP	   phase)	   which	   can	   drive	   further	   differentiation	   and	  
phenotypic	  changes	  in	  the	  anti-­‐melanoma	  T-­‐cell	  population	  (Li	  et	  al.,	  2010;	  Rosenberg	  et	  al.,	  2008).	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The	  use	  of	  alternative	  cytokines	  besides	  IL-­‐2	  (such	  as	  IL-­‐15,	  IL-­‐21	  and	  TGF-­‐β)	  are	  also	  under	  investigation	  
in	  order	  to	  determine	  the	  most	  effective	  lymphokine	  combination	  for	  supporting	  anti-­‐tumour	  T-­‐cells	  over	  
regulatory	  T-­‐cells	  (Liu	  et	  al.,	  2006;	  Zeng	  et	  al.,	  2005).	  Understanding	  the	  role	  and	  efficacy	  of	  anti-­‐melanoma	  
T-­‐cell	  subsets	  in	  patients	  could	  lead	  to	  their	  preferential	  in	  vitro	  expansion	  and	  selective	  administration	  of	  
more	  effective	  cell	  combinations.	  In	  addition,	  immune	  correlates	  of	  successful	  anti-­‐melanoma	  responses	  
in	  TILs	  might	  also	  help	  as	  biomarkers	  for	  identifying	  which	  patients	  to	  treat.	  	  This	  would	  allow	  treatment	  
of	   only	   those	   patients	   most	   likely	   to	   respond	   to	   TIL	   therapy;	   sparing	   those	   unlikely	   to	   respond	   from	  
treatment-­‐associated	  toxicities.	  
	  
Thirdly,	  preconditioning	  of	  the	  patient	  is	  currently	  required	  to	  achieve	  high	  levels	  of	  T-­‐cell	  engraftment	  by	  
eradicating	  the	  patient’s	  own	  immune	  system	  and	  making	  ‘space’	  for	  the	  adoptively	  infused	  TILs.	  Despite	  
being	  associated	  with	  better	   response	  rates	   (Dudley	  et	  al.,	  2008),	  non-­‐myeloablative	  regimens	  used	  to	  
precondition	  patients	  before	  TIL	   infusion,	   still	   carry	  significant	   toxicity	   (Dudley,	  2005;	  Rosenberg	  et	  al.,	  
2011).	   Major	   toxicities	   resulting	   from	   current	   ACT	   regimens	   are	   also	   related	   to	   the	   high-­‐dose	   IL-­‐2	  
administered	  after	  TIL	  infusion	  in	  order	  to	  support	  in	  vivo	  proliferation	  and	  persistence	  of	  the	  transferred	  
T-­‐cells.	  	  
	  
Finally,	  the	  improvement	  of	  TIL	  therapy	  by	  enhancing	  T-­‐cell	  function	  in	  vivo	  is	  another	  area	  of	  interest.	  TILs	  
can	  either	  be	  coupled	  with	  blocking	  antibodies	  against	  negative	  co-­‐stimulatory	  molecules	  overexpressed	  
on	  tumour-­‐specific	  T-­‐cells	  (such	  as	  PD-­‐1)	  (Chen	  and	  Han,	  2015),	  or	  genetically-­‐modified	  ex	  vivo	  in	  order	  to	  
improve	  their	  persistence	  and	  anti-­‐tumour	  reactivity	  in	  vivo.	  For	  example,	  an	  important	  aspect	  is	  whether	  
transferred	  autologous	  T-­‐cells	  migrate	  efficiently	  to	  the	  tumour	  site.	  Tumour	  homing	  has	  been	  improved	  
in	   a	  preclinical	  murine	  melanoma	  model	   in	  which	   tumour-­‐specific	   T-­‐cells	  were	   transduced	  with	  a	   viral	  
vector	  expressing	  a	  homing	  chemokine	  receptor	  (Kershaw	  et	  al.,	  2002;	  Peng	  et	  al.,	  2010).	  Besides	  improved	  
trafficking,	   direct	   genetic	   manipulation	   of	   TIL	   effector	   function	   or	   apoptotic	   machinery	   can	   also	   be	  
investigated	  (Charo	  et	  al.,	  2005;	  Cheng	  et	  al.,	  2002;	  Foster	  et	  al.,	  2008;	  Zhang	  et	  al.,	  2011).	  	  
	  
6.2.3.1   Extension	  to	  other	  tumour	  types	  
TIL	  therapy	  is	  gradually	  transforming	  the	  current	  state	  of	  melanoma	  treatment.	  The	  challenge	  now	  is	  to	  
extend	  TIL	  therapy	  to	  other	  solid	  tumour	  types	  beyond	  skin	  cancer.	  The	  reason	  why	  T-­‐cell	  infiltrates	  are	  
present	   in	   some	   tumour	   types	   more	   than	   others	   is	   not	   entirely	   known	   (Yannelli	   et	   al.,	   1996).	  
Immunogenicity	  of	  a	  given	  tumour	  may	  be	  related	  to	  the	  expression	  of	  HLA-­‐I	  and	  HLA-­‐II	  molecules	  by	  a	  
given	  tumour.	  Another	  influencing	  factor	  is	  the	  cancer	  mutational	  load.	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Exome	   analysis	   of	   lung	   carcinoma	   in	   smokers,	   for	   example,	   has	   shown	   a	   high	   frequency	   of	   somatic	  
mutations	  (Alexandrov	  et	  al.,	  2013;	  Lee	  et	  al.,	  2010).	  Overall,	  T-­‐cell	  infiltration	  in	  several	  cancer	  types	  (such	  
as	  head	  and	  neck	  cancer,	  breast	  cancer	  and	  colon	  cancer)	  is	  associated	  with	  an	  improved	  clinical	  outcome	  
(Jochems	  and	  Schlom,	  2011),	  suggesting	  that	  anti-­‐tumour	  T-­‐cells	  may	  have	  a	  therapeutic	  role.	  
	  
6.3   Concluding	  remarks	  
Immunotherapy	  for	  cancer	  treatment	  is	  a	  rapidly	  growing	  field	  and	  has	  rightly	  earned	  its	  place	  in	  Science’s	  
top	  scientific	  breakthrough	  for	  2013.	  It	  is	  clear	  that	  the	  adaptive	  immune	  system	  offers	  a	  viable	  approach	  
to	   eradicating	   tumour	   cells.	   A	   key	   focus	   of	  my	   research	  was	   to	   study	   human	   T-­‐cell	   responses	   against	  
melanoma	   from	  both	   a	  molecular	   and	   cellular	   point	   of	   view.	   It	   is	   hoped	   that	   such	   knowledge	  will	   aid	  
strategies	  to	  enhance	  current	  T-­‐cell	  based	   immunotherapies	  by	  maximizing	  the	   in	  vivo	  specific	  effector	  
function	  of	  anti-­‐melanoma	  T-­‐cell	  responses.	  	  As	  research	  on	  the	  role	  of	  the	  tumour	  microenvironment	  and	  
the	  genetic	  makeup	  of	  the	  patient	  continues,	  several	  immunotherapeutic	  approaches	  have	  already	  shown	  
the	  potential	  to	  provide	  real	  clinical	  benefit.	  The	  challenge	  for	  tumour	  immunologists	  is	  now	  to	  translate	  
the	   technology	   into	   approved	   clinical	   practice	   for	   melanoma	   and,	   ultimately,	   to	   extend	   T-­‐cell	   based	  
treatment	  options	  to	  other	  tumours.	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7   Appendix	  
Figure	  7.1.	  Density	  plot	  analysis	  
The	  observed	  map	  at	  1.0	   sigma	   (shown	  as	  grey	  mesh	  around	  stick	   representations	  of	   the	  protein	  chains)	  after	   subsequent	  
refinement	  using	  automatic	  non-­‐crystallographic	  symmetry	  restraints	  applied	  by	  REFMAC5.	  (A)	  The	  model	  for	  PMEL17	  TCR-­‐A2-­‐
YLE-­‐9V	  with	  the	  TCR	  CDR3	  loops	  coloured	  blue	  (α	  chain)	  and	  orange	  (β	  chain)	  and	  the	  green	  peptide,	  (B)	  the	  model	  for	  A2-­‐YLE	  
with	  the	  peptide	  coloured	  dark	  green,	  (C)	  the	  model	  for	  A2-­‐YLE-­‐3A	  with	  the	  orange	  peptide,	  and	  (D)	  the	  model	  for	  A2-­‐YLE-­‐5A	  
with	  the	  pink	  peptide.	  
	  
	  
	   	  




Table	  7.1.	  Panel	  of	  melanoma	  cell	  lines	  
The	  melanoma	  cell	  line	  panel	  was	  kindly	  provided	  by	  Marco	  Donia	  (CCIT,	  Copenhagen).	  HLA	  class-­‐I	  typing	  of	  the	  A	  and	  B	  locus	  
is	  shown	  where	  available.	  Typing	  was	  performed	  at	  the	  Herlev	  Hospital	  by	  standard	  PCR	  on	  selected	  HLA-­‐alleles.	  The	  autologous	  
tumour	  cell	  lines	  of	  patient	  MM909.24	  (A)	  and	  patient	  MM909.15	  (B)	  are	  boxed.	  Colour	  code	  indicates	  HLA-­‐A	  and	  HLA-­‐B	  alleles	  
shared	  with	  the	  corresponding	  autologous	  tumour	  cell	  line.	  	  
A	   B	  
Cell	  line	   HLA-­‐A	   HLA-­‐B	  
FM-­‐2	   A1,	  A29	   B5,	  B40	  
FM-­‐3	   A2,	  A3	   B7,	  B44	  
FM-­‐6	   A1,	  A2	   B7,	  B8	  
FM-­‐28	   A1,	  A2	   B8,	  B15	  
FM-­‐45	   A23,	  A28	   B17,	  B35	  
FM-­‐48	   A28,	  A33	   B15,	  B40	  
FM-­‐55P	   A1,	  A2	   B8,	  B15	  
FM-­‐56	   A28,	  A31	   B27,	  B44	  
FM-­‐57	   A2	   B5,	  B7	  
FM-­‐72	   A2	   B7,	  B18	  
FM-­‐74	   A24,	  A31	   B15,	  B35	  
FM-­‐78	   A3,	  A31	   B15,	  B17	  
FM-­‐79	   A25,	  A32	   B18,	  B44	  
FM-­‐81	   A2,	  A28	   B15,	  B44	  
FM-­‐82	   A1,	  A2	   B8,	  B15	  
FM-­‐86	   A2	   B15,	  B44	  
FM-­‐88	   A2	   B27,	  B49	  
FM-­‐92	   A1,	  A2	   B8,	  B44	  
FM-­‐93/2	   A2	   -­‐	  
FM-­‐95	   A3,	  A19	   B5,	  B51	  
SK-­‐Mel-­‐3	   A24,	  A24	   B13,	  B44	  
SK-­‐Mel-­‐28	   A11,	  A26	   B40	  
Mel-­‐526	   A2,	  A3	   B50,	  B62	  
Mel-­‐624	   A2,	  A3	   B7,	  B14	  
MM909.11	   A1,	  A3	   -­‐	  
MM909.15	   A3,	  A31	   B8,	  B44	  
MM909.24	   A2,	  A30	   B40	  
MM909.37	   A2	   -­‐	  
MM909.09	   A2,	  A3	   -­‐	  
MM909.12	   A1,	  A24	   B8,	  B55	  
	  
Cell	  line	   HLA-­‐A	   HLA-­‐B	  
FM-­‐2	   A1,	  A29	   B5,	  B40	  
FM-­‐3	   A2,	  A3	   B7,	  B44	  
FM-­‐6	   A1,	  A2	   B7,	  B8	  
FM-­‐28	   A1,	  A2	   B8,	  B15	  
FM-­‐45	   A23,	  A28	   B17,	  B35	  
FM-­‐48	   A28,	  A33	   B15,	  B40	  
FM-­‐55P	   A1,	  A2	   B8,	  B15	  
FM-­‐56	   A28,	  A31	   B27,	  B44	  
FM-­‐57	   A2	   B5,	  B7	  
FM-­‐72	   A2	   B7,	  B18	  
FM-­‐74	   A24,	  A31	   B15,	  B35	  
FM-­‐78	   A3,	  A31	   B15,	  B17	  
FM-­‐79	   A25,	  A32	   B18,	  B44	  
FM-­‐81	   A2,	  A28	   B15,	  B44	  
FM-­‐82	   A1,	  A2	   B8,	  B15	  
FM-­‐86	   A2	   B15,	  B44	  
FM-­‐88	   A2	   B27,	  B49	  
FM-­‐92	   A1,	  A2	   B8,	  B44	  
FM-­‐93/2	   A2	   -­‐	  
FM-­‐95	   A3,	  A19	   B5,	  B51	  
SK-­‐Mel-­‐3	   A24,	  A24	   B13,	  B44	  
SK-­‐Mel-­‐28	   A11,	  A26	   B40	  
Mel-­‐526	   A2,	  A3	   B50,	  B62	  
Mel-­‐624	   A2,	  A3	   B7,	  B14	  
MM909.11	   A1,	  A3	   -­‐	  
MM909.15	   A3,	  A31	   B8,	  B44	  
MM909.24	   A2,	  A30	   B40	  
MM909.37	   A2	   -­‐	  
MM909.09	   A2,	  A3	   -­‐	  
MM909.12	   A1,	  A24	   B8,	  B55	  
	  
	  
	   	  




Figure	  7.2.	  MM909.24	  TIL	  reactivity	  against	  a	  panel	  of	  semi-­‐matched	  HLA-­‐A2+	  melanoma	  cell	  lines	  
FACS	  plots	  show	  the	  percentage	  of	  CD107a+	  TNF-­‐α+	  TILs	  upon	  stimulation	  with	  semi-­‐matched	  HLA-­‐A2+	  melanoma	  cell	   lines	  
(blue).	  Melanomas	  that	  share	  the	  HLA-­‐B40	  allele	  with	  tumour	  cells	  MM909.24	  were	  also	  included	  (aqua).	  Cells	  were	  gated	  on	  
live	  CD3+	  CD8+	  TILs.	  Stimulation	  with	  autologous	  tumour	  and	  PHA	  (3	  µg/mL)	  (bold)	  were	  used	  as	  positive	  controls.	  Stimulation	  
with	  ELA	  peptide	  (10-­‐6M)	  was	  also	  included	  in	  the	  experiment.	  Gates	  were	  set	  on	  unstimulated	  TILs	  (negative	  control).	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Table	  7.2.	  List	  of	  A2-­‐restricted	  melanoma-­‐associated	  peptides	  (from	  Andersen	  et	  al.,	  2012)	  
#	   sequence	   protein	  
1	   MVYDLYKTL	   ATIC	  (AICRT)	  
2	   RLDFNLIRV	   	  	  
3	   GLQHWVPEL	   BA46	  (MFGE8)	  
4	   NLFETPVEA	   	  	  
5	   PLFDFSWLSL	   Bcl-­‐2	  
6	   WLSLKTLLSL	   	  	  
7	   YLNDHLEPWI	   Bcl-­‐xL	  
8	   CQWGRLWQL	   BING-­‐4	  
9	   LATEKSRWS	   B-­‐RAF	  
10	   LATEKSRWSG	   	  	  
11	   FIIENLKAA	   Cadherin	  3/P-­‐cadherin	  
12	   FILPVLGAV	   	  	  
13	   YMMPVNSEV	   CDCA1/NUF2	  
14	   KLATAQFKI	   	  	  
15	   ACDPHSGHFV	   CDK4	  
16	   ALVDAGVPM	   CML28	  (EXOSC5)	  
17	   FMTRKLWDL	   COA-­‐1	  (UBXN11)	  
18	   RLLASLQDL	   	  	  
19	   LMLQNALTTM	   CPSF	  
20	   KVHPVIWSL	   	  	  
21	   LLDRFLATV	   Cyclin	  I	  
22	   AKYLMELTM	   cyclin	  B1	  
23	   AGYLMELCC	   	  
24	   ILIDWLVQV	   	  	  
25	   LLGATCMFV	   cyclin	  D1	  
26	   VLEGMEVV	   cyclophilin	  B	  (Cyp-­‐B)	  
27	   KLKHYGPGWV	   	  	  
28	   FLWGPRAYA	   DAM-­‐6,	  -­‐10	  (MAGE-­‐B1)	  
29	   TLADFDPRV	   EphA2	  
30	   IMNDMPIYM	   	  
31	   VLLLVLAGV	   	  
32	   VLAGVGFFI	   	  	  
33	   FMVEDETVL	   EZH2	  
34	   FINDEIFVEL	   	  	  
35	   VLPDVFIRCV	   GnTV	  
36	   VLPDVFIRC	   	  	  
37	   YLEPGPVTA	   gp100	  /	  Pmel17	  
38	   VLYRYGSFSV	   	  
39	   SLADTNSLAV	   	  
40	   MLGTHTMEV	   	  
41	   RLMKQDFSV	   	  
42	   KTWGQYWQV	   	  
43	   ITDQVPFSV	   	  
44	   IMDQVPFSV	   	  
45	   AMLGTHTMEV	   	  
46	   LLDGTATLRL	   	  
47	   RLPRIFCSC	   	  	  
48	   MLAVISCAV	   HERV-­‐K-­‐MEL	  
49	   LLDVAPLSL	   hsp70	  
50	   LLLLDVAPL	   	  	  
51	   ALLEIASCL	   IDO1	  
52	   SLLMWITQC	   LAGE-­‐1	  
53	   MLMAQEALAFL	   	  	  
54	   QLCPICRAPV	   Livin	  (ML-­‐IAP)	  
55	   RLASFYDWLP	   	  
56	   SLGSPVLGL	   	  	  
57	   RIDITLSSV	   M2BP	  
58	   KVLEYVIKV	   MAGE-­‐A1	  
59	   KMVELVHFL	   MAGE-­‐A2	  
60	   LVHFLLLKY	   	  
61	   LVQENYLEY	   	  
62	   YLQLVFGIEV	   	  	  
63	   KVAELVHFL	   MAGE-­‐A3	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64	   LVFGIELMEV	   	  	  
65	   GVYDGREHTV	   MAGE-­‐A4	  
66	   YLEYRQVPV*	   MAGE-­‐A6	  
67	   GLMDVQIPT	   MAGE-­‐A8	  
68	   KVAELVRFL	   	  	  
69	   ALSVMGVYV	   MAGE-­‐A9	  
70	   GLYDGMEHL	   MAGE-­‐A10	  
71	   FLWGPRALV**	   MAGE-­‐A12	  
72	   KVLEFLAKL	   MAGE-­‐C2	  
73	   TLDEKVAELV	   	  
74	   ALKDVEERV	   	  
75	   LLFGLALIEV	   	  
76	   VIWEVLNAV	   	  	  
77	   TILLGIFFL	   MC1R	  
78	   ELAGIGILTV	   Melan-­‐A	  /	  MART-­‐1	  
79	   ILTVILGVL	   	  	  
80	   TLNDECWPA	   Meloe-­‐1	  
81	   RCPPKPPLA	   Meloe-­‐2	  
82	   RLPPKPPLA	   	  	  
83	   WLPKILGEV	   MG50	  
84	   VLSVNVPDV	   	  
85	   TLKCDCEIL	   	  
86	   RLGPTLMCL	   	  
87	   LLLEAVPAV	   	  
88	   CMHLLLEAV	   	  	  
89	   MLMAQEALAFL	   NY-­‐ESO-­‐1	  /	  LAGE-­‐2	  
90	   QLSLLMWIT	   	  
91	   SLLMWITQA	   	  
92	   SLLMWITQC	   	  
93	   SLLMWITQCFL	   	  	  
94	   IMLCLIAAV	   P	  Polypeptide	  
95	   YLGSYGFRL	   p53	  
96	   KLCPVQLWV	   	  
97	   KTCPVQLWV	   	  
98	   LLGRNSFEV	   	  
99	   LLPENNVLSPV	   	  
100	   RMPEAAPPV	   	  
101	   SLPPPGTRV	   	  
102	   SMPPPGTRV	   	  
103	   VVPCEPPEV	   	  
104	   GLAPPQHLIRV	   	  	  
105	   IIGGGMAFT	   PGK1	  
106	   SLLQHLIGL	   PRAME	  
107	   SLYSFPEPEA	   	  
108	   ALYVDSLFFL	   	  
109	   VLDGLDVLL	   	  	  
110	   AMAPIKVRL	   PRDX5	  
111	   LLLDDLLVSI	   	  	  
112	   VLHWDPETV	   RAB38	  /	  NY-­‐MEL-­‐1	  
113	   LKLSGVVRL	   RAGE-­‐1	  
114	   PLPPARNGGL	   	  	  
115	   YLMDTSGKV	   Replication	  protein	  A	  
116	   RLAEYQAYI	   SART-­‐3	  
117	   LLQAEAPRL	   	  	  
118	   KMDAEHPEL	   secernin	  1	  
119	   AWISKPPGV	   SOX10	  
120	   SAWISKPPGV	   	  	  
121	   KASEKIFYV	   SSX-­‐2	  
122	   RLQGISPKI	   	  	  
123	   KLQELNYNL	   STAT1-­‐alpha/ß	  
124	   FLYTLLREV	   STEAP1	  
125	   LLLGTIHAL	   	  
126	   MIAVFLPIV	   	  	  
127	   LMLGEFLKL	   Survivin	  
128	   ELTLGEFLKL	   	  
129	   TLPPAWQPFL	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130	   SLGWLFLLL	   TAG-­‐1	  
131	   ILAKFLHWL	   Telomerase	  
132	   RLVDDFLLV	   	  
133	   RLFFYRKSV	   	  	  
134	   FLYDDNQRV	   Topoisomerase	  II	  
135	   ILLRDAGLV	   TRAG-­‐3	  
136	   TLDSQVMSL	   TRP-­‐2	  
137	   FVWLHYYSV	   	  
138	   SLDDYNHLV	   	  
139	   VYDFFVWLHY	   A1,	  A2	  
140	   SVYDFFVWL	   	  	  
141	   ATTNILEHY	   TRP2-­‐6b	  
142	   MLLAVLYCL	   tyrosinase	  
143	   YMDGTMSQV	   	  
144	   CLLWSFQTSA	   	  	  
145	   LLSGQPASA	   XBP-­‐1	  
*Sequence	  is	  shared	  for	  MAGE-­‐A1,	  A2,	  A2,	  A4,	  A6,	  A10	  and	  A12	  




Table	  7.3	  List	  of	  A1-­‐	  or	  A3-­‐restricted	  melanoma	  associated	  peptides	  (from	  Andersen	  et	  al.,	  2012)	  
TAA	  resulting	  from	  mutations:	  The	  residues	  modified	  by	  the	  mutation	  are	  indicated	  in	  red.	  
	  
#	   sequence	   protein	   HLA-­‐‑restriction	  
1	   RSDSGQQARY	   AIM-­‐2	   A1	  
2	   KILDAVVAQK	   EFTUD2	   A3	  
3	   LIYRRRLMK	   gp100	  /	  Pmel17	   A3	  
4	   ALNFPGSQK	   	   A3	  
5	   IALNFPGSQK	   	   A3	  
6	   ALLAVGATK	   	  	   A3	  
7	   EADPTGHSY	   MAGE-­‐A1	   A1	  
8	   SLFRAVITK	   	  	   A3	  
9	   EVDPIGHLY	   MAGE-­‐A3	   A1	  
10	   EVDPASNTY	   MAGE-­‐A4	   A1	  
11	   FLEGNEVGKTY	   MART2	   A1	  
12	   FLALIICNA	   MC1R	   A3	  
13	   ILDTAGREEY	   N-­‐ras	   A1	  
14	   RLGLQVRKNK	   RhoC	   A3	  
15	   WLEYYNLER	   SART-­‐3	   A3	  
16	   QIRPIFSNR	   	  	   A3	  
17	   ILDSSEEDK	   Sp17	   A1	  
18	   RLSNRLLLR	   TAG	   A3	  
19	   KLFGVLRLK	   Telomerase	   A3	  
20	   VYDFFVWLHY	   TRP-­‐2	   A1,	  A2	  
21	   DSDPDSFQDY	   tyrosinase	   A1	  
22	   KCDICTDEY	   	   A1	  
23	   SSDYVIPIGTY	   	  	   A1	  
24	   KINKNPKYK	   Myosin	  class	  I	   A3	  
25	   KILDAVVAQK	   EFTUD2	   A3	  
26	   TLDWLLQTPK	   GPNMB	   A3	  
27	   KIFSEVTLK	   SIRT2	   A3	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Table	  7.4.	  Overview	  of	  T-­‐cell	  clones	  isolated	  from	  MM909.24	  TIL	  cultures	  
T-­‐cell	  clones	  isolated	  from	  MM909.24	  TILs	  were	  screened	  and	  selected	  based	  on	  specific	  lysis	  and	  recognition	  of	  autologous	  
tumour	  cells	  and	  ability	  to	  grow	  well	   in	  culture.	  T-­‐cells	  were	  co-­‐incubated	  overnight	  with	  autologous	  tumour	  cells	  (+/-­‐	  IFN-­‐γ	  
treated	  for	  72	  hours)	  and	  supernatants	  were	  tested	  in	  a	  51Chromium	  release	  assay	  and	  MIP-­‐1β	  ELISA.	  The	  selection	  criteria	  for	  
each	  T-­‐cell	   clone	   is	   schematically	   colour	   coded.	   T-­‐cell	   clones	  highlighted	   in	   the	   table	   correspond	   to	   those	   selected	   for	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Figure	  7.3.	  CD8+	  TILs	  MM909.15	  reactivity	  against	  a	  panel	  of	  melanoma	  cell	  lines	  
FACS	  plots	  show	  the	  percentage	  of	  CD107a+	  TNF-­‐α+	  TILs	  upon	  stimulation	  with	  semi-­‐matched	  melanoma	  cell	  lines.	  Cells	  were	  
gated	  on	  live	  CD3+	  CD8+	  TILs.	  Stimulation	  with	  autologous	  tumour	  and	  PHA	  (3	  µg/mL)	  (bold)	  were	  used	  as	  positive	  controls.	  
Gates	  were	  set	  on	  unstimulated	  TILs	  (negative	  control).	  	  
	  
	  
FM#2 FM#3 FM#6 FM#28 FM#45
FM#48 FM#55p FM#56 FM#57 FM#72
FM#74 FM#78 FM#79 FM#81 FM#82
FM#86 FM#88 FM#92 FM#93/2 FM#95
SKMel#3 SKMel#28 MM909.11 MM909.15 MM909.24
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Figure	  7.4.	  CD4+	  TILs	  MM909.15	  reactivity	  against	  a	  panel	  of	  melanoma	  cell	  lines	  
FACS	  plots	  show	  the	  percentage	  of	  CD107a+	  TNF-­‐α+	  TILs	  upon	  stimulation	  with	  semi-­‐matched	  melanoma	  cell	  lines.	  Cells	  were	  
gated	  on	  live	  CD3+	  CD4+	  TILs.	  Stimulation	  with	  autologous	  tumour	  and	  PHA	  (3	  µg/mL)	  (bold)	  were	  used	  as	  positive	  controls.	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Figure	  7.5.	  TAG	  T-­‐cell	  reactivity	  detected	  in	  a	  complete	  remission	  HLA-­‐A3,	  HLA-­‐A1+	  melanoma	  patient	  (MM909.11)	  
(A)	  Patient	  MM909.11	  characteristics,	  TIL	  therapy	  details	  and	  clinical	  outcome.	  M1a	  stage	  (AJCC,	  Balch	  et	  al.,	  2009)	  involves	  
distant	  metastasis	  in	  the	  skin,	  subcutaneous	  tissue,	  or	  distant	  lymph	  nodes.	  	  (B)	  HLA-­‐I	  and	  HLA-­‐II	  typing	  was	  kindly	  provided	  by	  
Marco	  Donia	  (CCIT,	  Copenhagen).	  (C)	  CD8+	  TILs	  MM909.11	  reactivity	  against	  autologous	  tumour	  was	  measured	  by	  intracellular	  
staining	  with	  IFN-­‐γ,	  CD107a	  and	  TNF-­‐α.	  T-­‐cells	  were	  gated	  on	  live	  CD3+	  and	  unstimulated	  TILs	  were	  used	  as	  control.	  	  (D)	  IFN-­‐γ	  
ELISpot	  performed	  on	  5x105	  MM909.11	  TILs	   stimulated	   in	  duplicate	  with	  known	  HLA-­‐A3	  and	  HLA-­‐A1	   restricted	  melanoma-­‐
associated	  peptides	  (10-­‐6	  M)	  for	  24	  hours.	  The	  number	  of	  IFN-­‐γ	  secreting	  cells	  per	  5	  x105	  TILs	  is	  displayed	  on	  the	  x	  axis;	  peptide	  
sequence	  and	  protein	  of	  origin	  (in	  brackets)	  are	  displayed	  on	  the	  y	  axis.	  Each	  bar	  represents	  the	  mean	  spot	  count	  per	  well	  (±	  
SD).	  Representative	  images	  of	  ELISpot	  wells	  are	  shown	  in	  the	  bottom	  panel.	  PHA	  (3	  µg/mL)	  was	  used	  as	  a	  positive	  control.	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Figure	  7.6.	  CDR3	  sequences	  in	  the	  TCR	  beta	  repertoire	  of	  TILs	  and	  PBMC	  MM909.11	  
(A)	  Tumour	  reactive	  T-­‐cells	  from	  TIL	  and	  PBMC	  were	  viably	  sorted	  based	  on	  the	  expression	  of	  both	  CD107a	  and	  TNF-­‐α	  (after	  
gating	  on	  live	  CD3+	  cells).	  T-­‐cells	  were	  stimulated	  with	  autologous	  tumour	  for	  5	  hours	   in	  the	  presence	  of	  TAPI-­‐0	  (µM),	  anti-­‐
CD107a	  and	  anti-­‐TNF-­‐α	  mAb.	  Control	  cells	  were	  not	  stimulated.	  (B)	  Each	  pie	  chart	  represents	  the	  distribution	  of	  unique	  CDR3	  
sequences	  detected	  in	  TCRβ	  repertoire	  from	  the	  corresponding	  infusion	  product	  or	  blood	  sample	  from	  patient	  MM909.15.	  Each	  
pie	  segment	  represents	  the	  share	  of	  a	  distinct	  CDR3β	  clonal	  sequence,	  thus	  reflects	  the	  respective	  frequency	  of	  each	  clonotype.	  
Several	  grey	  scales	  are	  used	  repeatedly	  for	  different	  sequences	  because	  of	  the	  high	  level	  of	  diversity.	  The	  corresponding	  CDR3	  
amino	  acid	  sequences	  are	  listed	  in	  the	  order	  of	  frequency.	  Shared	  CDR3	  sequences	  between	  matched	  TIL	  and	  PBMC	  samples	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